<SEC-DOCUMENT>0001125345-22-000047.txt : 20220503
<SEC-HEADER>0001125345-22-000047.hdr.sgml : 20220503
<ACCEPTANCE-DATETIME>20220503160427
ACCESSION NUMBER:		0001125345-22-000047
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		51
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220503
DATE AS OF CHANGE:		20220503

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		22886763

	BUSINESS ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>mgnx-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:1bd791be-5155-40b4-b9a0-bccec8bc4c7f,g:90cbb752-e1e3-4609-a8e8-bbefff2b5852,d:da709811ef604d5ea772a19a8a9c1dfd--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mgnx="http://macrogenics.com/20220331" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mgnx-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80L2ZyYWc6YzBhYTcxMGQxZmRlNDdjMDg1M2M2ZTY2Yjk3ZmFiMzkvdGFibGU6N2UyNjZiZjlkMTQ1NDU5YThhZjFlMDc3NTg4N2NjOTQvdGFibGVyYW5nZTo3ZTI2NmJmOWQxNDU0NTlhOGFmMWUwNzc1ODg3Y2M5NF8yLTEtMS0xLTM2OTIx_c773a9e6-f346-4fa8-87c1-67717465317b">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80L2ZyYWc6YzBhYTcxMGQxZmRlNDdjMDg1M2M2ZTY2Yjk3ZmFiMzkvdGFibGU6N2UyNjZiZjlkMTQ1NDU5YThhZjFlMDc3NTg4N2NjOTQvdGFibGVyYW5nZTo3ZTI2NmJmOWQxNDU0NTlhOGFmMWUwNzc1ODg3Y2M5NF80LTEtMS0xLTM2OTIx_44765d51-3276-496b-8f6f-c7bed67fde66">2022</ix:nonNumeric><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80L2ZyYWc6YzBhYTcxMGQxZmRlNDdjMDg1M2M2ZTY2Yjk3ZmFiMzkvdGFibGU6N2UyNjZiZjlkMTQ1NDU5YThhZjFlMDc3NTg4N2NjOTQvdGFibGVyYW5nZTo3ZTI2NmJmOWQxNDU0NTlhOGFmMWUwNzc1ODg3Y2M5NF81LTEtMS0xLTM2OTIx_6f37ea51-c629-474b-b67c-469d53fdde42">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80L2ZyYWc6YzBhYTcxMGQxZmRlNDdjMDg1M2M2ZTY2Yjk3ZmFiMzkvdGV4dHJlZ2lvbjpjMGFhNzEwZDFmZGU0N2MwODUzYzZlNjZiOTdmYWIzOV8xMzA_a38d055c-8b6c-4c92-bb09-e81c3d1c4e8f">0001125345</ix:nonNumeric><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80L2ZyYWc6YzBhYTcxMGQxZmRlNDdjMDg1M2M2ZTY2Yjk3ZmFiMzkvdGV4dHJlZ2lvbjpjMGFhNzEwZDFmZGU0N2MwODUzYzZlNjZiOTdmYWIzOV8xMzE_b8b72687-3ac1-4742-8085-23f7029aad10">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i950e359d634d41aeb9e7dcdaf238a1ec_D20170501-20170531" name="mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfMzg0ODI5MDcwNDU3Ng_27cd901d-e912-415a-9df7-55d3c46ad18f">P6M</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mgnx-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9c7ce63000148a1940f679036069716_I20220429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i48bdd36e5bfa487081b635f45c9c8141_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i4d6180f7949d43fd94d47d00066fc533_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2b41ef23b1644f8bf8a1ab64aa91c4e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if51dfe4d455b420781d382a10b0128c6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8052edef0e8142a0aae1084562aec9a8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c66c701c256418fb52b049e4ebc9d9a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i607d6d4b7a0b4a269b66b704af5c7980_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42f32c13c8944d9ba988f770f28210b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7ab8dc2df2542edb9cf3ade797023cf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5a1fda27e1b42518702a64371c3ffbf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie29fa966142d4809926b4fce9ac47d66_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e82a89c57234ca2a3478adaa271fec3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21ac8ecb1ef74bb188581735307623a4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i782fb333be73427da78999262075f9f1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic759253504a2492db7e2ee3ad72992da_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26a9072466f44863844deebde8ebd435_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba667f5b561d48d8a13c95cd18dd77d0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cd82a548e734c0b80d9b7adbea03f44_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13caa53ffc1749ee85d3f04baf65b8e2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12a5fd8f1ac64b25a36c35f490310693_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i514431b860214fa08d26900f9bc8809f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c1fe4be954c4a76a3462acae2e52d25_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fb34feb7d82479fa90e51ee903d7fc5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61850671ea5c46908f41ccc8bad84475_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i765ca9da243a400f9b9eda52bf592847_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d29335a8b4d442d847dc74d97919490_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b13a8a2d938497f94da21f2db99b34d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30760bd2ed9f4522bde9a72f4d193433_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39336f55686d443a9f9bb2e7f5368a75_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5672f6e735064f58bfdfcc331c3ac673_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7646821245c2453e910c16b5b8ae12a4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2c7a9bb638f4f09a965e4cc3541bc2b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5da4e28ca474a05a3dd215f637ca9a6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id95d122f09ba4d2abee62f84fae879ac_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87b87bbcaef644248cdf6ccd14a1dceb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e70e3df18ab41f78be816bc2ec224ad_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38dae976f1074d01ade570e63f5432e2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11d98d66595a4e23a7412ce37ac28a09_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic38615f63b384c709ab9bb249a259668_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1679ec57ed840b4ba3621b23001f423_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i134315721b8b4bc8b6ad9a64c9dca944_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01b2c1f07c9a491abfb73f67bfdfee33_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84a8b67fd745449695ca7b9bb8d32b55_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b8362beacc0443ebef61473a9dccbea_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec177ca29fe3450a851669d85c7c44bc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadf67bfafee04b0e8f19076f8b5ba241_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c87ec43f73d49438e33596695e0f16a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6211e35b2594407c9f7301938b926647_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74c05f3a658142a898bc4958d7248bad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc78708aeb344bafbf36d06b7e3268c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if85bdb5b035f43b884ce2ecf0893b353_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ad8e34e86da4770904f35743caf98ac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4152da960bb40088ebf5bc56b742e61_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ec75cded8dd44b088006c06d9e3b597_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id74359d02a6a4da78e3f2fc132eb4559_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdf424220c884f50be1e050499baaa2e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6db79bbb4d648b889a9b1cb12bcc873_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib90bb549405247818bd658fcfc5dbb02_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2a9ffd7eb2944f7a2b80b1417657841_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdf1d14d8fc0481c9792632139822db0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic793e546189e40c692e374b70b7656d3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib77cf447ac3c41209a584a715a1efc6e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1670779e18c400db0676422bc94c22e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ce219c82bc1424b9f3d36c9e3956c15_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3b3f430d68b497f825e77b9e6f604da_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1f6c9125c0b45aab207a0111b790111_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7afc4d905b84b94add195a76efd0e03_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied0c021681ab444cb45099fb32ff4b98_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i543d462b4fb941c3b7c489c116e8bf4f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee6c657f52bd4f23bd0bf6abce303d78_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46cfcfe1a61845d48ac67642abb7f911_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if06926cd9b2147e88810d44763baa9ce_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d0c61251f464c44a32c131af591406f_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0aca00030b84821a220040e1894b4ed_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53817096bacf40229bf71a7348ab1def_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5527acf5cf248e5ac690d183c18549f_I20210615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b909bf9e4ae42208ed813d9676eadb7_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a2c1fb5405243d38e27f09c198a5915_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dabbd2bdcd948c59b80f6888528ba3b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica1236dc56be456dadbe35007ebd92bc_D20180101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie34522f6d1964d318f94e89b4a7854b2_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i02d8186b9ed94687aa3108cc69312fbd_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="performanceobligation"><xbrli:measure>mgnx:performanceObligation</xbrli:measure></xbrli:unit><xbrli:context id="i94127aa94aa2402086ac95e5ef578edd_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54eb455b76a2472aae844a12fa08813e_D20170101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c7b19308ad740b49d92d38c4aa6390d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43cf385ec61546e2885724e6c7c3177a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3c00bc643434efbbf8833b77153ad2d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0adbde0716db4da29d82fc8ba600273b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8d7471a9a78429b9f892ec0cc71150c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012SupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifba4c7039c924aa5b223417e6cf78e36_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a199c459cc44adc89979956653b5201_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a9c376486b84ec3b165f5f033a1fd8d_D20200701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c95d8da85da4d78b72fd3032fd7f680_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9c86092c7f8459fa95d28f361b3564a_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i605a7292ff3f44c383e3d95959a523b0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51a097abe2f346a8bea4a1a0e880968a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia36f2c15a9ed480fb6dfd60b54cdb774_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29c3c82f97234786bc2f333cf100ce5f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a06e176aa5944de902c9e6384aa45bf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3025bab32fb46cd9d6da9f324ce3688_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36440f83cc204cf1996dbfe7485383bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76399d6c1802415b90c08bf9c69f7100_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie55d7a52498740cc96d51ad5658ea4c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc75ade1173842ff87ee4dbbac9daeb5_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib49d110aa2b04f54ad540230e16f5db5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6925c66d0d90474cabcbca044e7bb353_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecc8c23d2f2f46e295c148fe79e31e39_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61fd77fcf6144f8f852769a79d64119a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia548adfe30414a9f9d0fd63c315589d5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e56061fef8544908e67631567510f9d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1514a61deb464837bf8bb0f50659cd2b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5ec03c4a3794d77bfafe5617533f80a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8da3009f9f94f879c4bf206e40f1cc4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic49edb54de2c4ae4a6d757a5b491be58_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedfb3cdeb7214224a72fce2beb8e46d1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0157b8cec1ad4b9a9b95f37868dd31e3_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4e2cd3790dd4e78a153c3c1da4940aa_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaec489dac35b477286b66bb36de621fc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1337d1949d0643488c0089eab0614890_D20150915-20150915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-15</xbrli:startDate><xbrli:endDate>2015-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="molecule"><xbrli:measure>mgnx:Molecule</xbrli:measure></xbrli:unit><xbrli:context id="i7e37fc50bcd44ac683c40725c776294b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic750b1bc388a426a9377427e21e4fe52_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ba225f70b5e431a996b967e49bfb1c8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad1e5d2adfa44b97a1de1c2f673de3f3_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i909599960cbd4d01a402618a5680f14c_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i950e359d634d41aeb9e7dcdaf238a1ec_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83ac7c613bf04ee3a7d8345a36323be1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86806d0d26194ccda0c95e062fc00349_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:A2003StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ded582f69f04d0aaaf29d8dddc272a5_I20131031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib91bd3b003bd40c9b8460d6c1e8f8f10_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0a7f8632e7f42d5ad0ae052ddb56492_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35c13a3e3a224d948c4a2fe4b9fa5d99_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59db3d1311064ab88fb9f88769f9da7b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i010ad6f9a1c640caa25d8015911a45d6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacae1a7b3e1f4879bf90a88d717407ae_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia47224cd15db4935927f150937cfc761_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2e3c0ef64b149e285c3286cfaaaefa7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1675839c45fe4c938d0aaa356a3df94c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11689de0548a42dba1fc04b3de566926_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66614c40c0e14c88b42fd0af30436dfc_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dc396f12757461e9c5b3a86b51821a5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa66c46429f947848a8668ce68165b60_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id18c2d3f95654745b74930d2f8ea04b0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ida709811ef604d5ea772a19a8a9c1dfd_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGV4dHJlZ2lvbjo2ZThhZTQ0ZjQ0Y2E0NTA4OTZlYzFhNTgwY2M2ZTJjYV84Mg_9966ec78-3b97-4d35-821d-44bfa4b7227d">10-Q</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.337%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGFibGU6OTY5OGQzNTk2NGQ1NDU3OWJlYTZiNjk5OGY4MGUyNTYvdGFibGVyYW5nZTo5Njk4ZDM1OTY0ZDU0NTc5YmVhNmI2OTk4ZjgwZTI1Nl8wLTAtMS0xLTM2OTIx_29e2d212-52e2-499b-840b-086c83868e09">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGV4dHJlZ2lvbjo2ZThhZTQ0ZjQ0Y2E0NTA4OTZlYzFhNTgwY2M2ZTJjYV8xMTc_c6763240-9d07-4591-a4cf-b1f3a7decf1d">March 31, 2022</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.337%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGFibGU6MTlmNjI1MDAyYmJmNDg3ODlkMmRiN2YwODUzZDZmYzkvdGFibGVyYW5nZToxOWY2MjUwMDJiYmY0ODc4OWQyZGI3ZjA4NTNkNmZjOV8wLTAtMS0xLTM2OTIx_94b19076-8320-4944-aceb-603b90707722">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGV4dHJlZ2lvbjo2ZThhZTQ0ZjQ0Y2E0NTA4OTZlYzFhNTgwY2M2ZTJjYV8yMDg_87bd563c-b5fc-4af5-8775-302655fc26b6">001-36112</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGV4dHJlZ2lvbjo2ZThhZTQ0ZjQ0Y2E0NTA4OTZlYzFhNTgwY2M2ZTJjYV8yMTE_a628ef95-b1c8-4d6e-96f0-6303727c8357">MACROGENICS, INC.</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGFibGU6MTBkYzBhNGEwZGIzNDg5MWJkM2MzM2NmODI5YTFmZmUvdGFibGVyYW5nZToxMGRjMGE0YTBkYjM0ODkxYmQzYzMzY2Y4MjlhMWZmZV8wLTAtMS0xLTM2OTIx_689ac431-8864-4244-8f1d-286e671f362f">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGFibGU6MTBkYzBhNGEwZGIzNDg5MWJkM2MzM2NmODI5YTFmZmUvdGFibGVyYW5nZToxMGRjMGE0YTBkYjM0ODkxYmQzYzMzY2Y4MjlhMWZmZV8wLTEtMS0xLTM2OTIx_3e3b992b-881f-450c-8f91-a459aa295cad">06-1591613</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGFibGU6MTBkYzBhNGEwZGIzNDg5MWJkM2MzM2NmODI5YTFmZmUvdGFibGVyYW5nZToxMGRjMGE0YTBkYjM0ODkxYmQzYzMzY2Y4MjlhMWZmZV8zLTAtMS0xLTM2OTIxL3RleHRyZWdpb246ZmZhOTFiOTk1OWVkNDI3ZjgxM2ZiN2Q0Y2U3NGE5YWRfNQ_f51c23a9-c4bb-4427-bea9-5ee73398bbd4">9704 Medical Center Drive</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGFibGU6MTBkYzBhNGEwZGIzNDg5MWJkM2MzM2NmODI5YTFmZmUvdGFibGVyYW5nZToxMGRjMGE0YTBkYjM0ODkxYmQzYzMzY2Y4MjlhMWZmZV8zLTAtMS0xLTM2OTIxL3RleHRyZWdpb246ZmZhOTFiOTk1OWVkNDI3ZjgxM2ZiN2Q0Y2U3NGE5YWRfOA_bec6d39a-9651-40b5-9849-1b02e873d20f">Rockville</ix:nonNumeric>, <ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGFibGU6MTBkYzBhNGEwZGIzNDg5MWJkM2MzM2NmODI5YTFmZmUvdGFibGVyYW5nZToxMGRjMGE0YTBkYjM0ODkxYmQzYzMzY2Y4MjlhMWZmZV8zLTAtMS0xLTM2OTIxL3RleHRyZWdpb246ZmZhOTFiOTk1OWVkNDI3ZjgxM2ZiN2Q0Y2U3NGE5YWRfMTI_c15f7b90-55cc-4d99-8ac0-108da904502c">Maryland</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGFibGU6MTBkYzBhNGEwZGIzNDg5MWJkM2MzM2NmODI5YTFmZmUvdGFibGVyYW5nZToxMGRjMGE0YTBkYjM0ODkxYmQzYzMzY2Y4MjlhMWZmZV8zLTEtMS0xLTM2OTIx_c745d6de-3d30-45dd-bb15-c469eea62106">20850</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Zip code)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGV4dHJlZ2lvbjo2ZThhZTQ0ZjQ0Y2E0NTA4OTZlYzFhNTgwY2M2ZTJjYV8yNzA_b4541644-37fb-40cb-ab9a-c9f9d2b62002">301</ix:nonNumeric>-<ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGV4dHJlZ2lvbjo2ZThhZTQ0ZjQ0Y2E0NTA4OTZlYzFhNTgwY2M2ZTJjYV8yNzM_5f5b7fd7-f544-4079-b74a-d5e64e987f16">251-5172</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant's telephone number, including area code)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:36.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGFibGU6NDhhM2RiYmU1ZTBhNDRmNDgyNDA2MWM4ZDFmNzhjOGUvdGFibGVyYW5nZTo0OGEzZGJiZTVlMGE0NGY0ODI0MDYxYzhkMWY3OGM4ZV8xLTAtMS0xLTM2OTIx_011da034-69e0-498d-8563-b3bcde6efb8e">Common Stock, par value $0.01 per share</ix:nonNumeric></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGFibGU6NDhhM2RiYmU1ZTBhNDRmNDgyNDA2MWM4ZDFmNzhjOGUvdGFibGVyYW5nZTo0OGEzZGJiZTVlMGE0NGY0ODI0MDYxYzhkMWY3OGM4ZV8xLTEtMS0xLTM2OTIx_86ef4578-0c50-41d8-9ad7-73dab1a1b140">MGNX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGFibGU6NDhhM2RiYmU1ZTBhNDRmNDgyNDA2MWM4ZDFmNzhjOGUvdGFibGVyYW5nZTo0OGEzZGJiZTVlMGE0NGY0ODI0MDYxYzhkMWY3OGM4ZV8xLTItMS0xLTM2OTIx_252e8763-e3ca-4e34-aa4a-4aa625ac576b">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGV4dHJlZ2lvbjo2ZThhZTQ0ZjQ0Y2E0NTA4OTZlYzFhNTgwY2M2ZTJjYV8xOTE1_017e62c2-b27f-45a3-a994-0622aa0ffe4e">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGV4dHJlZ2lvbjo2ZThhZTQ0ZjQ0Y2E0NTA4OTZlYzFhNTgwY2M2ZTJjYV8xOTE2_ca48009c-2be1-40f8-821e-d5d10128c85a">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "accelerated filer," "large accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:23.301%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGFibGU6Yjc0NzUzNDk2OWYzNGZhNjljODViM2VkYTYyM2RkMjcvdGFibGVyYW5nZTpiNzQ3NTM0OTY5ZjM0ZmE2OWM4NWIzZWRhNjIzZGQyN18wLTAtMS0xLTM2OTIx_52061ec4-1a3e-4a88-8ec0-061eff16513a">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGFibGU6Yjc0NzUzNDk2OWYzNGZhNjljODViM2VkYTYyM2RkMjcvdGFibGVyYW5nZTpiNzQ3NTM0OTY5ZjM0ZmE2OWM4NWIzZWRhNjIzZGQyN18yLTMtMS0xLTM2OTIx_1fe62421-ffed-46a3-ae30-531b96901669">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGFibGU6Yjc0NzUzNDk2OWYzNGZhNjljODViM2VkYTYyM2RkMjcvdGFibGVyYW5nZTpiNzQ3NTM0OTY5ZjM0ZmE2OWM4NWIzZWRhNjIzZGQyN180LTEtMS0xLTM2OTIx_53738ecf-bf94-46eb-9cf6-2cbb19ef549a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160; &#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGV4dHJlZ2lvbjo2ZThhZTQ0ZjQ0Y2E0NTA4OTZlYzFhNTgwY2M2ZTJjYV8xOTE3_d276b98a-d656-4614-bc8d-0c2cd8043e2e">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;No&#160;&#160;&#9746;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;29, 2022, <ix:nonFraction unitRef="shares" contextRef="id9c7ce63000148a1940f679036069716_I20220429" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGV4dHJlZ2lvbjo2ZThhZTQ0ZjQ0Y2E0NTA4OTZlYzFhNTgwY2M2ZTJjYV8xODI4_752c22ce-e369-4ee7-a52f-9a27f6ed534a">61,333,500</ix:nonFraction> shares of the registrant's common stock, par value $0.01 per share, were outstanding.</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ida709811ef604d5ea772a19a8a9c1dfd_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:23.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.707%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida709811ef604d5ea772a19a8a9c1dfd_13">FINANCIAL INFORMATION</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida709811ef604d5ea772a19a8a9c1dfd_16">Financial Statements</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida709811ef604d5ea772a19a8a9c1dfd_19">Consolidated Balance Sheets at</a> March&#160;31, 2022 (unaudited) and December&#160;31, 2021</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida709811ef604d5ea772a19a8a9c1dfd_22">Consolidated Statements of Operations and Comprehensive Loss for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida709811ef604d5ea772a19a8a9c1dfd_22">months ended</a> March&#160;31, 2022<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida709811ef604d5ea772a19a8a9c1dfd_22"> and </a>March&#160;31, 2021<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida709811ef604d5ea772a19a8a9c1dfd_22"> (unaudited)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida709811ef604d5ea772a19a8a9c1dfd_25">Consolidated Statements of Stockholders' Equity for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida709811ef604d5ea772a19a8a9c1dfd_25">months </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida709811ef604d5ea772a19a8a9c1dfd_25">ended </a>March&#160;31, 2022<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida709811ef604d5ea772a19a8a9c1dfd_25"> and </a>March&#160;31, 2021<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida709811ef604d5ea772a19a8a9c1dfd_25"> (unaudited)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida709811ef604d5ea772a19a8a9c1dfd_28">Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida709811ef604d5ea772a19a8a9c1dfd_28">t</a>hree<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida709811ef604d5ea772a19a8a9c1dfd_28"> months ended </a>March&#160;31, 2022<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida709811ef604d5ea772a19a8a9c1dfd_28"> and </a>March&#160;31, 2021<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida709811ef604d5ea772a19a8a9c1dfd_28"> (unaudited)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida709811ef604d5ea772a19a8a9c1dfd_31">Notes to Consolidated Financial Statements (unaudited)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida709811ef604d5ea772a19a8a9c1dfd_61">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida709811ef604d5ea772a19a8a9c1dfd_82">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida709811ef604d5ea772a19a8a9c1dfd_85">Controls and Procedures</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;II.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida709811ef604d5ea772a19a8a9c1dfd_88">OTHER INFORMATION</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida709811ef604d5ea772a19a8a9c1dfd_91">Legal Proceedings</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida709811ef604d5ea772a19a8a9c1dfd_94">Risk Factors</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida709811ef604d5ea772a19a8a9c1dfd_100">Exhibits</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida709811ef604d5ea772a19a8a9c1dfd_103">Signatures</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ida709811ef604d5ea772a19a8a9c1dfd_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in this Quarterly Report on Form 10-Q. Forward-looking statements can often be identified by the use of terminology such as "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. The following uncertainties and factors, among others (including those set forth under "Item 1A. Risk Factors" of our Annual Report on Form 10-K for the year ended December&#160;31, 2021), could affect future performance and cause actual results to differ materially from those matters expressed in or implied by forward-looking statements:</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to develop and commercialize our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcomes of our ongoing and planned clinical trials and the timing of those outcomes, including when clinical trials will be initiated or completed, and when data will be reported or regulatory filings will be made;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates and the labeling for any approved products;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise additional capital through the capital markets or through one or more corporate partnerships, equity offerings, debt financings, collaborations, licensing arrangements or asset sales and the availability of financing to fund the development of our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding commercial prospects of or product revenues from MARGENZA and our product candidates if approved;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the severity and duration of the impact of the COVID-19 global pandemic on our business, operations, clinical programs, manufacturing, financial results and other aspects of our business;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding product candidates currently being developed by our collaborators;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into new collaborations or to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential benefits and future operation of our existing collaborations; </span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to recover the investment in our manufacturing capabilities;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our products;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our commercialization, marketing and manufacturing capabilities and strategy;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant competition in our industry;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of litigation and the failure to successfully defend lawsuits and other claims against us and our expectations regarding the outcome of any regulatory or legal proceedings;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic, political and other risks associated with our international operations;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to receive research funding and achieve anticipated milestones under our collaborations;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect and enforce patents and other intellectual property;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of compliance and our failure to comply with new and existing governmental regulations including, but not limited to, tax regulations;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss or retirement of key members of management;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to successfully execute our growth strategy, including any delays in our planned future growth; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to maintain effective internal controls.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. You should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance or achievements. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ida709811ef604d5ea772a19a8a9c1dfd_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="ida709811ef604d5ea772a19a8a9c1dfd_16"></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div id="ida709811ef604d5ea772a19a8a9c1dfd_19"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfNC0xLTEtMS0zNjkyMQ_c3796104-c16e-477e-b2fd-599b2b31f5ec">47,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfNC0zLTEtMS0zNjkyMQ_e8e489ea-03f9-45e8-befb-964bf4a568c1">123,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfNS0xLTEtMS0zNjkyMQ_2d86e9cb-9e94-4413-b0eb-ee1b1f529fe8">136,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfNS0zLTEtMS0zNjkyMQ_437a3171-681d-4703-a886-ebab9adc75d3">120,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfNi0xLTEtMS0zNjkyMQ_bde98caa-0bba-459a-af82-4fd4da55ebdc">14,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfNi0zLTEtMS0zNjkyMQ_e83c41c9-583e-43bf-866a-43b399f22f4b">10,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, net </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfNy0xLTEtMS0zNjkyMQ_b7ea1cad-0813-4295-95a0-51b780521771">4,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfNy0zLTEtMS0zNjkyMQ_83630d54-4451-42ab-9d72-e110822af0cc">4,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfOC0xLTEtMS0zNjkyMQ_6b7a31b5-0f5a-49a9-813f-faf2a450a95f">14,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfOC0zLTEtMS0zNjkyMQ_9a9a5766-930e-47c9-a2e0-1a6462575725">21,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMTAtMS0xLTEtMzY5MjE_dffa818c-479c-464a-aa18-e435c8bdcec5">218,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMTAtMy0xLTEtMzY5MjE_9c813880-5a6a-4679-897b-062b038d2cad">279,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMTEtMS0xLTEtMzY5MjE_eef1cf70-a3cb-44cc-b96d-6090628e2284">36,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMTEtMy0xLTEtMzY5MjE_cb4305eb-e7b3-4fdc-ab7c-ba8380c9e0dc">37,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMTMtMS0xLTEtMzY5MjE_c1fc2d54-7580-4c89-920a-e7b3a157cbb6">17,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMTMtMy0xLTEtMzY5MjE_74eb49e8-5967-4106-b44d-267e820919b9">18,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMTQtMS0xLTEtMzY5MjE_5bf711f5-c03d-4874-beba-484e3c633551">271,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMTQtMy0xLTEtMzY5MjE_d0f7737d-c254-45b2-bca5-7c8a713a1160">335,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMTgtMS0xLTEtMzY5MjE_28dbcccb-3de6-46a8-8684-10fa80080d34">3,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMTgtMy0xLTEtMzY5MjE_a28d158f-0458-4abd-ab54-336e29af3a21">15,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMTktMS0xLTEtMzY5MjE_1d1fefc2-07e4-4140-ab30-8b9d74f641b9">32,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMTktMy0xLTEtMzY5MjE_973e9df4-27e8-490e-9405-12776c37b115">33,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjAtMS0xLTEtMzY5MjE_d76ec88c-de29-4e45-a701-e300a322ac36">25,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjAtMy0xLTEtMzY5MjE_640aae50-88f8-4906-8566-c8fa36cab9fa">20,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjEtMS0xLTEtMzY5MjE_1516aa59-178b-49d5-96b2-40ffdb38f952">4,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjEtMy0xLTEtMzY5MjE_d40e3be8-205c-41b6-8d11-5e3cbccb4133">4,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjMtMS0xLTEtMzY5MjE_ebd6c123-7890-417b-9650-2ebec90940bc">67,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjMtMy0xLTEtMzY5MjE_98b25cae-17ea-4ebe-842f-b018329700c6">74,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjQtMS0xLTEtMzY5MjE_3ce20489-71ad-441a-bb82-28e5c5658097">6,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjQtMy0xLTEtMzY5MjE_503bacd6-cbf5-4c55-8b7f-45a10cd4de27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjUtMS0xLTEtMzY5MjE_4cda3893-38e7-404c-a9f7-9ac7aecc53b8">19,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjUtMy0xLTEtMzY5MjE_53cce398-ca63-4b5c-a6a0-e0a0526b2b6c">20,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjYtMS0xLTEtMzY5MjE_e78658ae-ace1-4970-9965-2958b8154f4c">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjYtMy0xLTEtMzY5MjE_2c5b7b1c-184f-4fe5-a315-89c4eb91cbfb">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjctMS0xLTEtMzY5MjE_17385441-cd7f-4a09-ba7e-9858cc4b8d44">93,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjctMy0xLTEtMzY5MjE_2cdffe78-ef93-46f5-8abb-c522a2b43a02">95,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjktMC0xLTEtMzY5MjEvdGV4dHJlZ2lvbjo5ZTgzNzk1NzZhMmE0ZmNkYTY2ODZmZmFhMjY3OTIxMF8xOA_cab2090c-c45b-4897-9cac-aecdc0f3f393"><ix:nonFraction unitRef="usdPerShare" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjktMC0xLTEtMzY5MjEvdGV4dHJlZ2lvbjo5ZTgzNzk1NzZhMmE0ZmNkYTY2ODZmZmFhMjY3OTIxMF8xOA_e5dbf4e5-f90f-4c11-8b60-ca9fd9674306">0.01</ix:nonFraction></ix:nonFraction> par value -- <ix:nonFraction unitRef="shares" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjktMC0xLTEtMzY5MjEvdGV4dHJlZ2lvbjo5ZTgzNzk1NzZhMmE0ZmNkYTY2ODZmZmFhMjY3OTIxMF8zNA_11b71daf-b4e7-4394-b9b3-9a258d840fca"><ix:nonFraction unitRef="shares" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjktMC0xLTEtMzY5MjEvdGV4dHJlZ2lvbjo5ZTgzNzk1NzZhMmE0ZmNkYTY2ODZmZmFhMjY3OTIxMF8zNA_5d82cec3-27e8-41e1-bbb4-bc80e445978c">125,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjktMC0xLTEtMzY5MjEvdGV4dHJlZ2lvbjo5ZTgzNzk1NzZhMmE0ZmNkYTY2ODZmZmFhMjY3OTIxMF81Ng_a8f3db47-db12-403f-9aff-7fb0e2cad4e8">61,333,074</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjktMC0xLTEtMzY5MjEvdGV4dHJlZ2lvbjo5ZTgzNzk1NzZhMmE0ZmNkYTY2ODZmZmFhMjY3OTIxMF82Mw_bc87032c-aee1-476d-9a75-21787d6696d0">61,307,428</ix:nonFraction> shares outstanding at March&#160;31, 2022 and December&#160;31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjktMS0xLTEtMzY5MjE_a88c2979-9ab4-4939-982c-b9b21c76a217">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjktMy0xLTEtMzY5MjE_31d67701-d7d3-4afb-ae1a-38a7e05fdc34">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMzAtMS0xLTEtMzY5MjE_848fc7cd-7b47-4a08-804f-0862863101f3">1,218,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMzAtMy0xLTEtMzY5MjE_af759337-e182-474e-b7b0-2a6e5c9373d8">1,213,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMzEtMS0xLTEtMzY5MjE_57862124-2920-4bd7-9678-8059e70a02e1">283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMzEtMy0xLTEtMzY5MjE_a722bcfb-f5a5-452d-ba31-42cba3f1d594">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMzItMS0xLTEtMzY5MjE_edc9e84c-2ede-4ca5-8950-0a60ca61aba8">1,040,379</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMzItMy0xLTEtMzY5MjE_86f52264-0cce-495d-945d-0a94cec00946">973,936</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMzMtMS0xLTEtMzY5MjE_969aa288-1f31-48cb-96aa-a548e8cad457">178,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMzMtMy0xLTEtMzY5MjE_55032aeb-7f70-4429-a2ef-d12e3f89f75b">239,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMzQtMS0xLTEtMzY5MjE_6e531f46-7237-45b3-863c-313d32f701cc">271,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMzQtMy0xLTEtMzY5MjE_0eac3eaf-d230-40d0-b385-c1e731f2f2fa">335,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ida709811ef604d5ea772a19a8a9c1dfd_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.200%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from collaborative and other agreements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d6180f7949d43fd94d47d00066fc533_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMy0xLTEtMS0zNjkyMQ_732e3132-78b6-431a-82e8-51b87b2c5121">7,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2b41ef23b1644f8bf8a1ab64aa91c4e_D20210101-20210331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMy0zLTEtMS0zNjkyMQ_fb81854b-b088-4a09-9062-a4247fb903a5">15,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if51dfe4d455b420781d382a10b0128c6_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfNC0xLTEtMS0zNjkyMQ_27902a22-5bae-40b7-93d0-ddb3dfdd5875">3,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8052edef0e8142a0aae1084562aec9a8_D20210101-20210331" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfNC0zLTEtMS0zNjkyMQ_2d68b2f1-1eaf-4425-9863-b328a75ce586">887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from government agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c66c701c256418fb52b049e4ebc9d9a_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfNS0xLTEtMS0zNjkyMQ_bce2bbe1-00f2-4ef6-b077-9ef6161cf36f">428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i607d6d4b7a0b4a269b66b704af5c7980_D20210101-20210331" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfNS0zLTEtMS0zNjkyMQ_2a7b153a-0f9d-41b4-9af4-d10755960f9f">810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfNi0xLTEtMS0zNjkyMQ_5f7968f6-b361-4769-9db3-8a11e76b155c">11,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfNi0zLTEtMS0zNjkyMQ_f46ac26b-12ab-4df8-86fe-0f4e9d512956">16,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfOC0xLTEtMS0zNjkyMQ_95ba5096-59b1-4611-8c4e-08b3e9716223">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfOC0zLTEtMS0zNjkyMQ_8e799efa-aaee-4193-aaf3-f2943e06e416">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfOS0xLTEtMS0zNjkyMQ_982cfc39-c519-4be0-a636-9ce342feaa97">61,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfOS0zLTEtMS0zNjkyMQ_40e85584-fe75-47cf-8c58-93549fea2899">53,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTAtMS0xLTEtMzY5MjE_4ca211ca-002f-46f3-bec5-014a1b99ce47">16,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTAtMy0xLTEtMzY5MjE_6b2b0750-a34e-4913-a29f-bc8193ad6fee">15,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTEtMS0xLTEtMzY5MjE_25655669-4d43-44b8-9e8b-0ecc09be1f0a">77,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTEtMy0xLTEtMzY5MjE_659559e5-cb1a-4589-8266-fba74096eb28">68,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTItMS0xLTEtMzY5MjE_cbda1aac-8262-4dc0-b3d4-844ec05fae66">66,638</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTItMy0xLTEtMzY5MjE_b665232a-85da-4ead-9354-37e146daf4d8">51,293</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTMtMS0xLTEtMzY5MjE_7a57d40b-f2aa-483f-8768-78de100d0a16">195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTMtMy0xLTEtMzY5MjE_48ba2f9c-28be-472a-b4fe-35dab6390379">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTQtMS0xLTEtMzY5MjE_1cd7a942-0e43-4e5c-b52a-2c90491c5db7">66,443</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTQtMy0xLTEtMzY5MjE_57c266ab-f6ba-4d07-a5e7-4c38eacaf9f5">51,272</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTYtMS0xLTEtMzY5MjE_32646731-2d78-4aed-8f72-952aadfd4c5c">222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTYtMy0xLTEtMzY5MjE_ed7403e9-dae9-425c-84d7-bbf0a80cf440">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTctMS0xLTEtMzY5MjE_f4965456-ba05-440d-bda5-9c76b17e2256">66,665</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTctMy0xLTEtMzY5MjE_468f8108-11e7-42d3-a559-fff6288a4302">51,254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTktMS0xLTEtMzY5MjE_839d86af-c8e4-45c9-8f87-752c5f38f89b"><ix:nonFraction unitRef="usdPerShare" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTktMS0xLTEtMzY5MjE_b8bc4af0-dea2-4fa6-a604-28832ca54d85">1.08</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTktMy0xLTEtMzY5MjE_3a9c6df0-24b3-443f-a8b7-a26133a76d38"><ix:nonFraction unitRef="usdPerShare" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTktMy0xLTEtMzY5MjE_ba972ea1-9625-4d63-8538-376580936141">0.90</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMjAtMS0xLTEtMzY5MjE_028c7c7b-2377-4a7b-95c1-537ce2945182"><ix:nonFraction unitRef="shares" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMjAtMS0xLTEtMzY5MjE_1a9f6405-12c8-4bfd-86d8-49d2041d9b01">61,324,163</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMjAtMy0xLTEtMzY5MjE_794c0189-d280-4209-a652-2fd209825c73"><ix:nonFraction unitRef="shares" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMjAtMy0xLTEtMzY5MjE_bbad41d7-7e48-4d0a-8c8d-8385afd5ba6d">57,202,846</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ida709811ef604d5ea772a19a8a9c1dfd_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.563%"><tr><td style="width:1.0%"></td><td style="width:33.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.727%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.546%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i42f32c13c8944d9ba988f770f28210b3_I20211231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfMi0xLTEtMS0zNjkyMQ_068fecb6-31a1-4b6d-9ea8-3d1af610104c">61,307,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42f32c13c8944d9ba988f770f28210b3_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfMi0zLTEtMS0zNjkyMQ_cf984e2e-6805-4bfc-9fe7-7e786d29e515">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7ab8dc2df2542edb9cf3ade797023cf_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfMi05LTEtMS0zNjkyMQ_d67a51e5-045c-41df-80a5-fea372866ae0">1,213,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5a1fda27e1b42518702a64371c3ffbf_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfMi0xMS0xLTEtMzY5MjE_91054390-e26f-41b9-b7ec-2d9e799de745">973,936</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie29fa966142d4809926b4fce9ac47d66_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfMi0xMy0xLTEtMzY5MjE_41d57d60-fcc7-4622-bdea-fc0e80358b8b">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfMi0xNS0xLTEtMzY5MjE_ed6d4163-4055-41cb-a03a-de167e946955">239,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e82a89c57234ca2a3478adaa271fec3_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfMy05LTEtMS0zNjkyMQ_d7223631-ee10-458c-bbfc-3d1717b0ebf4">5,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfMy0xNS0xLTEtMzY5MjE_c54c484c-eef0-454a-ae0b-4331360b2152">5,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21ac8ecb1ef74bb188581735307623a4_D20220101-20220331" decimals="INF" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfNS0xLTEtMS0zNjkyMQ_a5b28331-30d0-4e1a-8224-76835603434c">25,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e82a89c57234ca2a3478adaa271fec3_D20220101-20220331" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfNS05LTEtMS0zNjkyMQ_555c9d50-7d10-4670-97fd-87127f71ab5b">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfNS0xNS0xLTEtMzY5MjE_865e292b-2583-4a62-b508-a82d4fcb69d9">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i782fb333be73427da78999262075f9f1_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfNi0xMy0xLTEtMzY5MjE_8dfcf484-44d6-4d12-9ce7-5b9c2e95e719">222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfNi0xNS0xLTEtMzY5MjE_8bdc82db-5397-4e6c-b60d-d412112fa850">222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic759253504a2492db7e2ee3ad72992da_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfNy0xMS0xLTEtMzY5MjE_b9e2c1fc-87af-4901-8f31-d667eda97506">66,443</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfNy0xNS0xLTEtMzY5MjE_c9671f5a-5a61-403a-9d17-fc45db310fb0">66,443</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i26a9072466f44863844deebde8ebd435_I20220331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfOC0xLTEtMS0zNjkyMQ_29dd4ed8-ed57-4585-a694-de64d93af2aa">61,333,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a9072466f44863844deebde8ebd435_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfOC0zLTEtMS0zNjkyMQ_859de3d7-13df-450d-880c-90be922daf26">613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba667f5b561d48d8a13c95cd18dd77d0_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfOC05LTEtMS0zNjkyMQ_b925f17c-9a50-45fb-b284-d1834a58535b">1,218,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd82a548e734c0b80d9b7adbea03f44_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfOC0xMS0xLTEtMzY5MjE_1eb30a3d-e949-4d88-9f57-0649c20d0a13">1,040,379</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13caa53ffc1749ee85d3f04baf65b8e2_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfOC0xMy0xLTEtMzY5MjE_eefc2b63-8596-44b3-a680-595f34cf7c13">283</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfOC0xNS0xLTEtMzY5MjE_35d69b24-2419-42fb-b4ab-2e96c0f33b13">178,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:37.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.540%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.238%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.266%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.264%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12a5fd8f1ac64b25a36c35f490310693_I20201231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfMi0xLTEtMS0zNjkyMQ_8900e5cb-9818-4570-98a2-2bbecb7cbd5a">56,244,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a5fd8f1ac64b25a36c35f490310693_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfMi0zLTEtMS0zNjkyMQ_ae95475a-2d1e-4f90-9824-b11b7b8dd377">562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i514431b860214fa08d26900f9bc8809f_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfMi05LTEtMS0zNjkyMQ_693489b0-b7e1-47b9-9c3e-f1dfcca88de7">1,067,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c1fe4be954c4a76a3462acae2e52d25_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfMi0xMS0xLTEtMzY5MjE_8018c083-1a71-4940-8075-3ffff7629a92">771,821</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fb34feb7d82479fa90e51ee903d7fc5_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfMi0xMy0xLTEtMzY5MjE_895c2176-c4a6-4000-ae16-fe6fe55fe656">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61850671ea5c46908f41ccc8bad84475_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfMi0xNS0xLTEtMzY5MjE_06078917-7646-44d5-94ae-443c6aa29d28">295,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i765ca9da243a400f9b9eda52bf592847_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfMy05LTEtMS0zNjkyMQ_234dc913-9060-4730-b078-b887fc3e1974">5,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfMy0xNS0xLTEtMzY5MjE_8a5c70f1-6c8a-4890-ab94-7988f95798bc">5,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d29335a8b4d442d847dc74d97919490_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNC0xLTEtMS0zNjkyMQ_2ff67551-65b5-40f1-ac07-6b6feed4510a">3,622,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d29335a8b4d442d847dc74d97919490_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNC0zLTEtMS0zNjkyMQ_14ea17d4-6c10-4c35-aaa2-d8f0ae6b6520">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i765ca9da243a400f9b9eda52bf592847_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNC05LTEtMS0zNjkyMQ_ddf23747-bbde-4079-9d17-baf82115decb">98,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNC0xNS0xLTEtMzY5MjE_5e366129-15eb-4e5d-91b9-b01bcca09a0d">98,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d29335a8b4d442d847dc74d97919490_D20210101-20210331" decimals="INF" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNS0xLTEtMS0zNjkyMQ_e40c3895-a6dd-44f8-8737-f2b4087e0d8d">144,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d29335a8b4d442d847dc74d97919490_D20210101-20210331" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNS0zLTEtMS0zNjkyMQ_eb8a9deb-9f27-4d29-a4b5-943799286cec">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i765ca9da243a400f9b9eda52bf592847_D20210101-20210331" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNS05LTEtMS0zNjkyMQ_851de4ff-d4b8-4cba-ad0c-75f1f83a058b">2,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNS0xNS0xLTEtMzY5MjE_0b23e886-3f00-458a-8344-3bc97b5c2655">2,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b13a8a2d938497f94da21f2db99b34d_D20210101-20210331" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNi0xMy0xLTEtNDExOTE_0405f719-b14e-4a19-a9e3-8fcb4d42de6b">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNi0xNS0xLTEtMzY5MjE_b6c61a78-443e-40fc-9389-529e6f8fd2e7">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30760bd2ed9f4522bde9a72f4d193433_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNy0xMS0xLTEtMzc4ODQ_5e073c20-2a3a-459a-9baf-6f40aab74471">51,272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNy0xNS0xLTEtMzc4ODQ_0fe6fbc9-933f-4192-8e76-173ccdf2f7c2">51,272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i39336f55686d443a9f9bb2e7f5368a75_I20210331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNy0xLTEtMS0zNjkyMQ_98735b54-053f-440a-ae56-e47402efd8c2">60,011,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39336f55686d443a9f9bb2e7f5368a75_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNy0zLTEtMS0zNjkyMQ_7b42cda1-fc44-4dc3-87b2-af23550b9b75">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5672f6e735064f58bfdfcc331c3ac673_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNy05LTEtMS0zNjkyMQ_6b965364-a104-48e3-bbdd-8624770c0164">1,173,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7646821245c2453e910c16b5b8ae12a4_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNy0xMS0xLTEtMzY5MjE_e1021602-775d-4236-b11a-124826ebc255">823,093</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2c7a9bb638f4f09a965e4cc3541bc2b_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNy0xMy0xLTEtMzY5MjE_31f1bb1b-bf20-40f5-b173-5d0c9aa2a2f7">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5da4e28ca474a05a3dd215f637ca9a6_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNy0xNS0xLTEtMzY5MjE_e209aa8f-6ec6-449f-b39d-43aa2796af3c">350,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ida709811ef604d5ea772a19a8a9c1dfd_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.275%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMy0xLTEtMS0zNjkyMQ_fab4e09e-d0a7-4d86-bc71-65b41d5f681c">66,443</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMy0zLTEtMS0zNjkyMQ_868dfaea-6674-48a7-9e67-ff1a7d35310e">51,272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfNS0xLTEtMS0zNjkyMQ_d83cc3a5-b878-451d-b2ec-61b6add9b324">2,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfNS0zLTEtMS0zNjkyMQ_938b0d93-012c-4497-8d96-66cbd5ce8aa1">2,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums and discounts on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfNi0xLTEtMS0zNjkyMQ_36d458ec-8570-45c4-a302-6dc6d06c9db9">334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfNi0zLTEtMS0zNjkyMQ_4e82b425-e17e-49c7-a812-5a899c5d9ea5">367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfNy0xLTEtMS0zNjkyMQ_9a0b5857-ac75-467b-b822-f2f7cedc50c1">5,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfNy0zLTEtMS0zNjkyMQ_e70f6c0d-a5a0-4e22-af4c-6f8fe8a9637a">5,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTAtMS0xLTEtMzY5MjE_4b51c290-63da-4aa4-872d-ef3b7c40e006">4,520</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTAtMy0xLTEtMzY5MjE_0d982ac2-114e-421f-9e64-e8315eb09862">15,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTEtMS0xLTEtMzY5MjE_f3b6f9a2-08a2-4727-a5a0-d403673f0048">210</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTEtMy0xLTEtMzY5MjE_e9af757e-ecf2-4fdc-b231-47b7fa502a84">6,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTItMS0xLTEtMzY5MjE_f1cf9146-ad5f-40b6-94f3-83199654e0e4">6,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTItMy0xLTEtMzY5MjE_3675fe46-d658-487b-b2de-dc473d6109df">1,239</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTMtMS0xLTEtMzY5MjE_8c9117b3-f9a6-40f1-8404-ddcd89860fb1">801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTMtMy0xLTEtMzY5MjE_4aa547fb-d19b-4a7b-96cd-cdcc6931bcd5">3,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTQtMS0xLTEtMzY5MjE_60b2698c-8553-4233-8041-efe1327d401b">11,920</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTQtMy0xLTEtMzY5MjE_649fd75e-2cc7-42ce-ad7f-6793e997a425">1,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTUtMS0xLTEtMzY5MjE_a17b2569-dc3b-49dc-a7fe-d1a6cad5a2c2">543</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTUtMy0xLTEtMzY5MjE_b375df4f-67ff-4d84-bbec-404146ca0eeb">855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTYtMS0xLTEtMzY5MjE_adcd7cca-2e62-4d48-90bf-95fee9037be1">1,119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTYtMy0xLTEtMzY5MjE_0355db91-7b73-41c5-b4bf-ff5698503c12">683</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTctMS0xLTEtMzY5MjE_514c924d-521a-4075-9197-b1e814b0c6b1">11,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTctMy0xLTEtMzY5MjE_216a019b-42fb-4c00-b680-03b4603d3bd8">601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTgtMS0xLTEtMzY5MjE_56fdaf43-db7a-41b2-81b6-7a5445680b23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTgtMy0xLTEtMzY5MjE_172ee86f-7673-4101-89db-95c963cb8d81">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTktMS0xLTEtMzY5MjE_beba9931-29a3-4c0f-9f69-a401e103feda">57,696</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTktMy0xLTEtMzY5MjE_4ba6e3a8-8635-44e8-b17e-63d65a51b7b6">29,036</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMjEtMS0xLTEtMzY5MjE_74fbb39c-5b58-4295-9561-b006330933bc">54,077</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMjEtMy0xLTEtMzY5MjE_cc9502de-5b8c-42a5-a92d-0502b448a4ee">93,881</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale and maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMjItMS0xLTEtMzY5MjE_97c71f61-4003-47e2-bca6-7f1f7e7cef92">37,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMjItMy0xLTEtMzY5MjE_d65bbd6c-28b5-481e-821d-083c330b73bf">60,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMjMtMS0xLTEtMzY5MjE_3e8a8918-aa43-4f7d-be14-2e086396ef9d">1,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMjMtMy0xLTEtMzY5MjE_260ff8f1-e275-4f61-9f3e-c15496292f9f">626</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMjQtMS0xLTEtMzY5MjE_759eecfb-e720-47a2-8433-65b5e72cf704">18,482</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMjQtMy0xLTEtMzY5MjE_ca9538b5-2950-4386-82e4-1e501288dd2d">34,257</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMjYtMS0xLTEtMzY5MjE_6194a695-9649-4898-bef4-1f032e618415">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMjYtMy0xLTEtMzY5MjE_203a448e-b918-4659-8b52-311556eb7c31">98,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMjctMS0xLTEtMzY5MjE_49f983f6-fa69-432e-adab-c92b0c1edfbf">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMjctMy0xLTEtMzY5MjE_bc958e4a-4f46-488b-b272-b61e055fbcbd">2,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMjktMS0xLTEtMzY5MjE_4c6619c1-9e5c-48f8-8884-278da34c68c6">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMjktMy0xLTEtMzY5MjE_5ff90320-1f65-4288-b33f-e03d07ede920">100,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMzAtMS0xLTEtMzY5MjE_137e9130-d9af-4903-aaba-7d9e4d5e56a2">76,141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMzAtMy0xLTEtMzY5MjE_1636368d-c238-478a-a441-c17751518b92">37,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMzEtMS0xLTEtMzY5MjE_c9bad031-bfce-4d76-9dae-adc94cde39d3">123,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61850671ea5c46908f41ccc8bad84475_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMzEtMy0xLTEtMzY5MjE_4a532c95-15d4-4156-a4d5-9b63851347bf">181,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMzItMS0xLTEtMzY5MjE_a0b12490-8275-4bc6-9259-5d20aeb47e2e">47,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5da4e28ca474a05a3dd215f637ca9a6_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMzItMy0xLTEtMzY5MjE_07bd7e11-9dba-4669-a1ad-d9b58e297fd6">218,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software included in accounts payable or accruals</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMzUtMS0xLTEtMzY5MjE_d28fd493-a8a4-485c-9eb2-68eb5565b211">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMzUtMy0xLTEtMzY5MjE_5eb521ee-fe09-4f33-94f2-22f2c4cee9b1">486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ida709811ef604d5ea772a19a8a9c1dfd_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div id="ida709811ef604d5ea772a19a8a9c1dfd_34"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8zNC9mcmFnOjQwZTVmNzkzNDQ1NjRlNzc4OWQ2ZDMxYTE4NzE4ZmQ2L3RleHRyZWdpb246NDBlNWY3OTM0NDU2NGU3Nzg5ZDZkMzFhMTg3MThmZDZfNTEyOQ_b4698dd6-4352-4f62-894b-9fc63cfb7e81" continuedAt="if8800273594d4d43a9a21173631fa5ee" escape="true">Nature of Operations</ix:nonNumeric></span></div><ix:continuation id="if8800273594d4d43a9a21173631fa5ee"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of the business</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The Company has a pipeline of product candidates being evaluated in clinical trials sponsored by MacroGenics or its collaborators.  These product candidates include multiple immuno-oncology programs, some of which were created primarily using the Company&#8217;s proprietary, antibody-based technology platforms. The Company believes its product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.  In March 2021, the Company and its commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.  </span></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biotechnology company, the Company has primarily funded its operations with proceeds from the sale of its common stock in equity offerings, revenue from its multiple collaboration agreements, and contracts and grants from the National Institute of Allergy and Infectious Diseases (NIAID).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews the Company&#8217;s available liquidity relative to its operating budget and forecast to monitor the sufficiency of the Company&#8217;s working capital.  Based on the Company&#8217;s most recent cash flow forecast, the Company believes its current resources are sufficient to fund its operating plans for a minimum of twelve months from the date that this Quarterly Report on Form 10-Q was filed. The Company plans to meet its future operating requirements by generating revenue from current and future strategic collaborations or other arrangements, and product sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support its product development activities.  If the Company is unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate one or more of its product research and development programs or clinical studies, reduce other operating expenses, and/or downsize its organization.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the other risk factors pertinent to the Company's business, the COVID-19 pandemic and geopolitical tensions, including the ongoing military conflict between Russia and Ukraine and the related sanctions imposed against Russia, might unfavorably impact the Company's ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to the COVID-19 pandemic and geopolitical tensions, the Company will continue to evaluate the nature and extent of the impact of these uncertainties on its business and financial position.</span></div><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8zNC9mcmFnOjQwZTVmNzkzNDQ1NjRlNzc4OWQ2ZDMxYTE4NzE4ZmQ2L3RleHRyZWdpb246NDBlNWY3OTM0NDU2NGU3Nzg5ZDZkMzFhMTg3MThmZDZfNTEzMA_f1d778b3-6d2c-4366-8933-20542e6f1750" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2021 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 24, 2022.</span></div></ix:nonNumeric></ix:continuation><div id="ida709811ef604d5ea772a19a8a9c1dfd_37"></div><div style="margin-bottom:9pt;margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 2. <ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8zNy9mcmFnOmZlNTM1MjFjYWEzMjRjMjJiZWIwNjJjZjY3NzBjOTk4L3RleHRyZWdpb246ZmU1MzUyMWNhYTMyNGMyMmJlYjA2MmNmNjc3MGM5OThfOTI3NA_23a113a2-3785-43ae-8be4-ddbaddd7e82b" continuedAt="ia5af7fade2ac44d49011d6c9ece9041b" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ia5af7fade2ac44d49011d6c9ece9041b"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, there have been no material changes to the significant accounting policies previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021. </span></div><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8zNy9mcmFnOmZlNTM1MjFjYWEzMjRjMjJiZWIwNjJjZjY3NzBjOTk4L3RleHRyZWdpb246ZmU1MzUyMWNhYTMyNGMyMmJlYjA2MmNmNjc3MGM5OThfOTI3Mw_2aeab123-680d-4e1d-8013-84ba3715858a" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements that were issued or became effective since the issuance of the Company&#8217;s 2021 Annual Report on Form 10-K that had, or are expected to have, a material impact on its consolidated financial position, results of operations or cash flows.</span></div></ix:nonNumeric></ix:continuation><div id="ida709811ef604d5ea772a19a8a9c1dfd_40"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RleHRyZWdpb246YmU4YzFlNzExYzYxNGRiNGJlZjIzOTdkYmRkMzJlNjBfMzE2NQ_35b6fbd3-4ae9-4bd4-b594-890506eaa72a" continuedAt="i43c521c915b84b3f996fed87809c90ae" escape="true">Fair Value of Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i43c521c915b84b3f996fed87809c90ae" continuedAt="ic9344df8b00b499fa29448b7c5b291ab"><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RleHRyZWdpb246YmU4YzFlNzExYzYxNGRiNGJlZjIzOTdkYmRkMzJlNjBfMzE2Ng_cc92de24-681b-4b33-84aa-6687548ba173" continuedAt="i75abb061c40849f3b1cb8989187e73be" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i75abb061c40849f3b1cb8989187e73be" continuedAt="i6bd4b8b98234412fbbde82d5bf414fbb">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. </ix:continuation></span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6bd4b8b98234412fbbde82d5bf414fbb">There were no transfers between levels during the periods presented.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ic9344df8b00b499fa29448b7c5b291ab"><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RleHRyZWdpb246YmU4YzFlNzExYzYxNGRiNGJlZjIzOTdkYmRkMzJlNjBfMzE2Nw_025c7a06-f1cf-4015-8ce1-ce76615209d0" escape="true"><div style="margin-bottom:15pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:15pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id95d122f09ba4d2abee62f84fae879ac_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfMy0xLTEtMS0zNjkyMQ_81fbbafc-1091-43a6-8769-018dd88b73a2">352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87b87bbcaef644248cdf6ccd14a1dceb_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfMy0zLTEtMS0zNjkyMQ_e1719ba4-3d80-4521-929f-d39ea7960918">352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e70e3df18ab41f78be816bc2ec224ad_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfMy01LTEtMS0zNjkyMQ_bebe9b81-eed3-4c47-b06c-e8047fcb78c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38dae976f1074d01ade570e63f5432e2_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfNC0xLTEtMS0zNjkyMQ_0d6a70fa-7349-4299-8f35-a36f1d14c8a1">127,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11d98d66595a4e23a7412ce37ac28a09_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfNC0zLTEtMS0zNjkyMQ_8d9f4fb4-c335-48bf-bd18-313d6a3ca871">127,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic38615f63b384c709ab9bb249a259668_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfNC01LTEtMS0zNjkyMQ_e91025dd-91ff-41e3-ad83-bd2279b4ef12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1679ec57ed840b4ba3621b23001f423_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfNS0xLTEtMS0zNjkyMQ_e1166ba8-f180-48fb-9cd9-1897004d1868">7,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i134315721b8b4bc8b6ad9a64c9dca944_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfNS0zLTEtMS0zNjkyMQ_c2255212-8a14-499f-bb1e-19ae8b24db21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01b2c1f07c9a491abfb73f67bfdfee33_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfNS01LTEtMS0zNjkyMQ_cdddce70-6fe8-4e92-b5cc-342e75b4abac">7,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84a8b67fd745449695ca7b9bb8d32b55_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfNi0xLTEtMS0zNjkyMQ_710bc205-4387-495d-af8c-1683b8d80e11">6,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b8362beacc0443ebef61473a9dccbea_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfNi0zLTEtMS0zNjkyMQ_3ad99f4f-3673-49cc-9fd5-38222991b286">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec177ca29fe3450a851669d85c7c44bc_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfNi01LTEtMS0zNjkyMQ_81fb7ad0-207e-43b6-9b89-8a862ac2f9a1">6,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf67bfafee04b0e8f19076f8b5ba241_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfOC0xLTEtMS0zNjkyMQ_39bf17b0-1282-43b5-8d38-4045661f6955">143,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c87ec43f73d49438e33596695e0f16a_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfOC0zLTEtMS0zNjkyMQ_95642b6d-62d5-4e4b-bbd3-77a2f636ae68">128,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6211e35b2594407c9f7301938b926647_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfOC01LTEtMS0zNjkyMQ_433bad67-53b6-4204-a0ca-0dd7215dcdc2">14,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c05f3a658142a898bc4958d7248bad_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfMy0xLTEtMS0zNjkyMQ_d14164b0-67e8-4c2f-8bcc-78bb0b934e68">17,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc78708aeb344bafbf36d06b7e3268c0_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfMy0zLTEtMS0zNjkyMQ_9a57518b-3bea-4c56-b756-7b1174ccc51c">17,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if85bdb5b035f43b884ce2ecf0893b353_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfMy01LTEtMS0zNjkyMQ_eff0f481-128b-403e-acc8-124766fa39fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ad8e34e86da4770904f35743caf98ac_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfNC0xLTEtMS0zNjkyMQ_1a7f6c1c-2a0d-40b8-81ac-fea39acbd389">81,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4152da960bb40088ebf5bc56b742e61_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfNC0zLTEtMS0zNjkyMQ_59b8e11d-fe4d-408f-9b84-9fde1bb35e54">81,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ec75cded8dd44b088006c06d9e3b597_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfNC01LTEtMS0zNjkyMQ_89d47500-b888-4141-999b-bf57cb6e71a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id74359d02a6a4da78e3f2fc132eb4559_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfNS0xLTEtMS0zNjkyMQ_901f0420-7d01-4f3f-ab96-c62ff098d544">7,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdf424220c884f50be1e050499baaa2e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfNS0zLTEtMS0zNjkyMQ_5d5c8420-dd23-442a-9c07-322ac5f5eff5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6db79bbb4d648b889a9b1cb12bcc873_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfNS01LTEtMS0zNjkyMQ_690b2d75-25fd-494d-9b2c-2f447e55d326">7,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib90bb549405247818bd658fcfc5dbb02_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfNi0xLTEtMS0zNjkyMQ_1a78d421-c97a-4976-bfc1-8b2a28923bcf">37,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2a9ffd7eb2944f7a2b80b1417657841_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfNi0zLTEtMS0zNjkyMQ_d61e0a0d-2713-4fdc-820d-f9d7fcd8fd42">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdf1d14d8fc0481c9792632139822db0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfNi01LTEtMS0zNjkyMQ_524bce04-9501-46b5-8ecd-4fa4034e4565">37,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic793e546189e40c692e374b70b7656d3_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfOC0xLTEtMS0zNjkyMQ_d0cd6e9c-1e0e-467a-8866-86412f340220">143,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib77cf447ac3c41209a584a715a1efc6e_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfOC0zLTEtMS0zNjkyMQ_968d59b8-f67d-408b-873f-9d05658b36b5">98,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1670779e18c400db0676422bc94c22e_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfOC01LTEtMS0zNjkyMQ_32568477-3b0d-4f65-b3d5-d24d556805fe">45,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at March&#160;31, 2022 includes approximately $<ix:nonFraction unitRef="usd" contextRef="iadf67bfafee04b0e8f19076f8b5ba241_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RleHRyZWdpb246YmU4YzFlNzExYzYxNGRiNGJlZjIzOTdkYmRkMzJlNjBfMjUwNA_b33fb832-041c-46b7-9147-0df755788f60">6.3</ix:nonFraction> million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2021 includes approximately $<ix:nonFraction unitRef="usd" contextRef="ic793e546189e40c692e374b70b7656d3_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RleHRyZWdpb246YmU4YzFlNzExYzYxNGRiNGJlZjIzOTdkYmRkMzJlNjBfMjY0OQ_f1a55d0e-87ee-4e33-bd26-70e5b6e0ed54">23.2</ix:nonFraction> million reported in cash and cash equivalents on the consolidated balance sheet.</span></div></ix:nonNumeric></ix:continuation><div id="ida709811ef604d5ea772a19a8a9c1dfd_43"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RleHRyZWdpb246ZWVmYWRiYjY3MWU3NGJlNTgzNDBmYmRhMWI4ZDQzYzdfMTAyOQ_882918ae-fae5-43ac-82e2-b29583a16a8e" continuedAt="i5e9766a3bdbf4a78bee1d3bbb445d15f" escape="true">Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="i5e9766a3bdbf4a78bee1d3bbb445d15f" continuedAt="i761dc21d0dce40ffae5d653f26440df4"><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RleHRyZWdpb246ZWVmYWRiYjY3MWU3NGJlNTgzNDBmYmRhMWI4ZDQzYzdfMTAzMQ_8d17bc94-ca93-4ed6-976b-f0cba4a4da3a" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's marketable debt securities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.724%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce219c82bc1424b9f3d36c9e3956c15_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfMi0xLTEtMS0zNjkyMQ_e53e42ca-1f79-40de-9064-96dde38bac39">128,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce219c82bc1424b9f3d36c9e3956c15_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfMi0zLTEtMS0zNjkyMQ_495ca726-f1e1-4d4e-a5ff-772c301464a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ce219c82bc1424b9f3d36c9e3956c15_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfMi01LTEtMS0zNjkyMQ_aeedbf50-a52a-42ba-8e75-fa38fe919099">274</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce219c82bc1424b9f3d36c9e3956c15_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfMi03LTEtMS0zNjkyMQ_41553352-2287-4f80-a485-043ad71649bf">127,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b3f430d68b497f825e77b9e6f604da_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfMy0xLTEtMS0zNjkyMQ_ba909171-3cf9-41d4-946e-f343989f3bea">7,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b3f430d68b497f825e77b9e6f604da_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfMy0zLTEtMS0zNjkyMQ_f54de1e0-697e-4145-9fe6-04c4ea1cbd97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3b3f430d68b497f825e77b9e6f604da_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfMy01LTEtMS0zNjkyMQ_5ef3d545-3328-46ee-8728-4d7ef6c22462">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b3f430d68b497f825e77b9e6f604da_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfMy03LTEtMS0zNjkyMQ_e5e959bd-015a-4445-8421-f2c8f1418082">7,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1f6c9125c0b45aab207a0111b790111_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfNC0xLTEtMS0zNjkyMQ_897b4b0b-87d0-42f5-b5cc-ca7a15e8f052">1,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1f6c9125c0b45aab207a0111b790111_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfNC0zLTEtMS0zNjkyMQ_8656f156-6ea2-4876-a738-1a3bf7764140">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1f6c9125c0b45aab207a0111b790111_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfNC01LTEtMS0zNjkyMQ_6d743b11-b1a6-4b2f-ad80-a9a6b4a76354">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1f6c9125c0b45aab207a0111b790111_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfNC03LTEtMS0zNjkyMQ_a61bd5e3-351f-4a82-baee-d8ae5a3480aa">1,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfNS0xLTEtMS0zNjkyMQ_a9dcff1a-51f2-4fed-a05d-48e3d201d983">136,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfNS0zLTEtMS0zNjkyMQ_a74b2e06-3cbc-463a-91b8-d0be31ac50a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfNS01LTEtMS0zNjkyMQ_3306f2ff-a77f-4894-b2c5-41e6396c3bc5">282</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfNS03LTEtMS0zNjkyMQ_0c729747-5f0b-4b40-b233-ba975daebbd8">136,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.724%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7afc4d905b84b94add195a76efd0e03_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfMi0xLTEtMS0zNjkyMQ_9b411349-125f-48fe-b807-621ffe7d7c24">81,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7afc4d905b84b94add195a76efd0e03_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfMi0zLTEtMS0zNjkyMQ_7a464c71-1efb-4ffb-9372-174ecb551edf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7afc4d905b84b94add195a76efd0e03_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfMi01LTEtMS0zNjkyMQ_7eaca07c-f117-4356-b836-1537c2946551">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7afc4d905b84b94add195a76efd0e03_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfMi03LTEtMS0zNjkyMQ_455130fb-d9f8-4223-80f9-dace6ae3389c">81,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied0c021681ab444cb45099fb32ff4b98_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfMy0xLTEtMS0zNjkyMQ_8e3fbc9d-0159-4c3b-a7d6-206fd196c8d9">7,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied0c021681ab444cb45099fb32ff4b98_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfMy0zLTEtMS0zNjkyMQ_6897f98c-e645-4596-8e49-92931cbfeeb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied0c021681ab444cb45099fb32ff4b98_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfMy01LTEtMS0zNjkyMQ_bd3cc693-cc32-42cf-8bae-29dd3e48e51c">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied0c021681ab444cb45099fb32ff4b98_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfMy03LTEtMS0zNjkyMQ_b01f152a-1a77-4d49-a2fd-20fc9a235c81">7,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i543d462b4fb941c3b7c489c116e8bf4f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfNC0xLTEtMS0zNjkyMQ_6c460eb5-46f7-495b-90ef-6b17881a45b5">31,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i543d462b4fb941c3b7c489c116e8bf4f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfNC0zLTEtMS0zNjkyMQ_d216a948-e2d9-4bfa-a6a3-f40fd1aec0fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i543d462b4fb941c3b7c489c116e8bf4f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfNC01LTEtMS0zNjkyMQ_708ae6a4-d0cd-4ed0-8197-714643961872">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i543d462b4fb941c3b7c489c116e8bf4f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfNC03LTEtMS0zNjkyMQ_dd8d51d7-db2c-43d7-a431-eff94aac7d05">31,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfNS0xLTEtMS0zNjkyMQ_4f8ad779-a514-4122-855c-0c91a28b9a4e">120,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfNS0zLTEtMS0zNjkyMQ_8dd1343a-8f67-4c58-80ed-ec73a21f1853">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfNS01LTEtMS0zNjkyMQ_91753d43-1bb3-422b-96de-3234c8beae49">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfNS03LTEtMS0zNjkyMQ_fb9b798e-3c24-4982-b59d-d4b6e08a3430">120,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All available-for-sale marketable debt securities held as of March&#160;31, 2022 and December&#160;31, 2021 had contractual maturities of less than one year.  All of the Company's available-for-sale marketable debt securities in an unrealized loss position as of March&#160;31, 2022 and December&#160;31, 2021 were in a loss position for less than twelve months.&#160; Unrealized losses on </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i761dc21d0dce40ffae5d653f26440df4">available-for-sale debt securities as of March&#160;31, 2022 and December&#160;31, 2021 were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities.  Accordingly, <ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RleHRyZWdpb246ZWVmYWRiYjY3MWU3NGJlNTgzNDBmYmRhMWI4ZDQzYzdfNjc2_a5592eb7-35c3-4dc2-a6d2-c1c75ec31551"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RleHRyZWdpb246ZWVmYWRiYjY3MWU3NGJlNTgzNDBmYmRhMWI4ZDQzYzdfNjc2_c65dabef-596d-44ef-922d-b7a0df93dc21">no</ix:nonFraction></ix:nonFraction> allowance for credit losses related to the Company's available-for-sale debt securities was recorded for any periods presented. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</ix:continuation> </span></div><div id="ida709811ef604d5ea772a19a8a9c1dfd_46"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80Ni9mcmFnOjRlYTE4YWQyMmQ3NjQ2ODBhMTk3ODAzMzY3ZmNjZDIwL3RleHRyZWdpb246NGVhMThhZDIyZDc2NDY4MGExOTc4MDMzNjdmY2NkMjBfNjA5_b168b2ea-22d2-48d8-b59b-0dd71cee496b" continuedAt="i19d27fb9ae9e4f82811aa82e8474eede" escape="true">Inventory, Net</ix:nonNumeric></span></div><ix:continuation id="i19d27fb9ae9e4f82811aa82e8474eede" continuedAt="iac0568b8160842d48aeadafa842ee68e"><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80Ni9mcmFnOjRlYTE4YWQyMmQ3NjQ2ODBhMTk3ODAzMzY3ZmNjZDIwL3RleHRyZWdpb246NGVhMThhZDIyZDc2NDY4MGExOTc4MDMzNjdmY2NkMjBfNjA4_7ed6bca3-5f72-4ce7-bb6b-b1526e72a24c" escape="true"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's net inventory (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80Ni9mcmFnOjRlYTE4YWQyMmQ3NjQ2ODBhMTk3ODAzMzY3ZmNjZDIwL3RhYmxlOjVlYTViZjE1ZjJiZDQyMjU4NzI3ODkyZGM0MTM3YmQwL3RhYmxlcmFuZ2U6NWVhNWJmMTVmMmJkNDIyNTg3Mjc4OTJkYzQxMzdiZDBfMy0xLTEtMS0zNjkyMQ_81e140b4-a398-4af4-a8d8-fffea26d0a45">3,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80Ni9mcmFnOjRlYTE4YWQyMmQ3NjQ2ODBhMTk3ODAzMzY3ZmNjZDIwL3RhYmxlOjVlYTViZjE1ZjJiZDQyMjU4NzI3ODkyZGM0MTM3YmQwL3RhYmxlcmFuZ2U6NWVhNWJmMTVmMmJkNDIyNTg3Mjc4OTJkYzQxMzdiZDBfMy0zLTEtMS0zNjkyMQ_79eb708b-1c3a-45de-9c4f-c684289dde4c">3,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80Ni9mcmFnOjRlYTE4YWQyMmQ3NjQ2ODBhMTk3ODAzMzY3ZmNjZDIwL3RhYmxlOjVlYTViZjE1ZjJiZDQyMjU4NzI3ODkyZGM0MTM3YmQwL3RhYmxlcmFuZ2U6NWVhNWJmMTVmMmJkNDIyNTg3Mjc4OTJkYzQxMzdiZDBfNC0xLTEtMS0zNjkyMQ_b7707c24-f4c6-4fd6-9b85-f2696745275f">874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80Ni9mcmFnOjRlYTE4YWQyMmQ3NjQ2ODBhMTk3ODAzMzY3ZmNjZDIwL3RhYmxlOjVlYTViZjE1ZjJiZDQyMjU4NzI3ODkyZGM0MTM3YmQwL3RhYmxlcmFuZ2U6NWVhNWJmMTVmMmJkNDIyNTg3Mjc4OTJkYzQxMzdiZDBfNC0zLTEtMS0zNjkyMQ_42c60680-fe70-48c0-9cf5-8be104fe4f37">459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80Ni9mcmFnOjRlYTE4YWQyMmQ3NjQ2ODBhMTk3ODAzMzY3ZmNjZDIwL3RhYmxlOjVlYTViZjE1ZjJiZDQyMjU4NzI3ODkyZGM0MTM3YmQwL3RhYmxlcmFuZ2U6NWVhNWJmMTVmMmJkNDIyNTg3Mjc4OTJkYzQxMzdiZDBfNS0xLTEtMS0zNjkyMQ_c1b51d8e-96fb-48d4-affa-585b3405defb">4,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80Ni9mcmFnOjRlYTE4YWQyMmQ3NjQ2ODBhMTk3ODAzMzY3ZmNjZDIwL3RhYmxlOjVlYTViZjE1ZjJiZDQyMjU4NzI3ODkyZGM0MTM3YmQwL3RhYmxlcmFuZ2U6NWVhNWJmMTVmMmJkNDIyNTg3Mjc4OTJkYzQxMzdiZDBfNS0zLTEtMS0zNjkyMQ_2912b86d-2328-4c01-a0fd-ddabf5792348">4,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:31.5pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iac0568b8160842d48aeadafa842ee68e">Prior to U.S. Food and Drug Administration (FDA) approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA. The inventory balance as of March&#160;31, 2022 and December&#160;31, 2021 is net of a reserve of $<ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80Ni9mcmFnOjRlYTE4YWQyMmQ3NjQ2ODBhMTk3ODAzMzY3ZmNjZDIwL3RleHRyZWdpb246NGVhMThhZDIyZDc2NDY4MGExOTc4MDMzNjdmY2NkMjBfMTA5OTUxMTYzMDE2MQ_3cf3f404-66cb-452d-aa9b-5072aa1e40a9"><ix:nonFraction unitRef="usd" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80Ni9mcmFnOjRlYTE4YWQyMmQ3NjQ2ODBhMTk3ODAzMzY3ZmNjZDIwL3RleHRyZWdpb246NGVhMThhZDIyZDc2NDY4MGExOTc4MDMzNjdmY2NkMjBfMTA5OTUxMTYzMDE2MQ_5a2e173f-debd-46ab-b0b0-b31fd7975c99">2.0</ix:nonFraction></ix:nonFraction> million for unsaleable inventory.</ix:continuation> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="ida709811ef604d5ea772a19a8a9c1dfd_49"></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80OS9mcmFnOjI1MmZiMWNiODMwNzRkMDY5MjIyYzI3Yjc1ZGU0NmU1L3RleHRyZWdpb246MjUyZmIxY2I4MzA3NGQwNjkyMjJjMjdiNzVkZTQ2ZTVfMTgxNA_745da55b-ccf1-4874-b277-c626aa7cd45e" continuedAt="i5ca16b1fc3aa4e8e9de4eec1fb6e6c3e" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="i5ca16b1fc3aa4e8e9de4eec1fb6e6c3e"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Company entered into a sales agreement (Sales Agreement) with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $<ix:nonFraction unitRef="usd" contextRef="iee6c657f52bd4f23bd0bf6abce303d78_D20201101-20201130" decimals="-5" name="mgnx:CommonStockMaximumAmountAvailableForIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80OS9mcmFnOjI1MmZiMWNiODMwNzRkMDY5MjIyYzI3Yjc1ZGU0NmU1L3RleHRyZWdpb246MjUyZmIxY2I4MzA3NGQwNjkyMjJjMjdiNzVkZTQ2ZTVfMjE4_ed2161e6-f7e4-4805-9ef1-dac4f700b205">100.0</ix:nonFraction> million through an &#8220;at the market offering&#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. The shares that were sold under the Sales Agreement were issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on November 4, 2020.  During the three months ended March 31, 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="i46cfcfe1a61845d48ac67642abb7f911_D20210701-20210930" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80OS9mcmFnOjI1MmZiMWNiODMwNzRkMDY5MjIyYzI3Yjc1ZGU0NmU1L3RleHRyZWdpb246MjUyZmIxY2I4MzA3NGQwNjkyMjJjMjdiNzVkZTQ2ZTVfNTk0_d065b0bb-1be0-4764-b557-62e167966e05">3,622,186</ix:nonFraction> shares of common stock at a weighted average price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="if06926cd9b2147e88810d44763baa9ce_I20210930" decimals="2" name="us-gaap:SaleOfStockPricePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80OS9mcmFnOjI1MmZiMWNiODMwNzRkMDY5MjIyYzI3Yjc1ZGU0NmU1L3RleHRyZWdpb246MjUyZmIxY2I4MzA3NGQwNjkyMjJjMjdiNzVkZTQ2ZTVfNjYx_bd6c58dc-63ed-4736-84b6-b4c5c45fde2a">27.60</ix:nonFraction>, resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i46cfcfe1a61845d48ac67642abb7f911_D20210701-20210930" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80OS9mcmFnOjI1MmZiMWNiODMwNzRkMDY5MjIyYzI3Yjc1ZGU0NmU1L3RleHRyZWdpb246MjUyZmIxY2I4MzA3NGQwNjkyMjJjMjdiNzVkZTQ2ZTVfNzA4_8e74dab5-de3b-4a65-8760-bd40eb8bc54e">98.2</ix:nonFraction> million, net of underwriting discounts and commissions and other offering expenses. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company entered into Amendment No. 1 to the Sales Agreement which increases the amount of the Company&#8217;s common stock that can be sold by the Company through its agent under the ATM Offering, from an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="iee6c657f52bd4f23bd0bf6abce303d78_D20201101-20201130" decimals="-5" name="mgnx:CommonStockMaximumAmountAvailableForIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80OS9mcmFnOjI1MmZiMWNiODMwNzRkMDY5MjIyYzI3Yjc1ZGU0NmU1L3RleHRyZWdpb246MjUyZmIxY2I4MzA3NGQwNjkyMjJjMjdiNzVkZTQ2ZTVfMTA0MA_f616cf45-6bc4-402b-b663-73b0f15da22e">100.0</ix:nonFraction>&#160;million to an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i7d0c61251f464c44a32c131af591406f_D20210401-20210430" decimals="-5" name="mgnx:CommonStockMaximumAmountAvailableForIssuanceIncrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80OS9mcmFnOjI1MmZiMWNiODMwNzRkMDY5MjIyYzI3Yjc1ZGU0NmU1L3RleHRyZWdpb246MjUyZmIxY2I4MzA3NGQwNjkyMjJjMjdiNzVkZTQ2ZTVfMTA4Mw_9b461833-af04-4796-bda4-036174d94e83">300.0</ix:nonFraction>&#160;million.  The Company has not sold any shares of common stock related to Amendment No. 1 to the Sales Agreement as of March&#160;31, 2022.  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the consideration for the rights granted to Zai Lab US LLC under the collaboration and license agreement described more fully in Note 7, Revenue, the Company and Zai Lab US LLC entered into a separate stock purchase agreement (Stock Purchase Agreement) in June 2021.  Under this Stock Purchase Agreement, Zai Lab US LLC paid the Company approximately $<ix:nonFraction unitRef="usd" contextRef="ie0aca00030b84821a220040e1894b4ed_D20210601-20210630" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80OS9mcmFnOjI1MmZiMWNiODMwNzRkMDY5MjIyYzI3Yjc1ZGU0NmU1L3RleHRyZWdpb246MjUyZmIxY2I4MzA3NGQwNjkyMjJjMjdiNzVkZTQ2ZTVfMTU3Mg_13da2f7f-c8b7-4eee-86ab-7a8bab3042c3">30.0</ix:nonFraction> million to purchase <ix:nonFraction unitRef="shares" contextRef="i53817096bacf40229bf71a7348ab1def_D20210601-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80OS9mcmFnOjI1MmZiMWNiODMwNzRkMDY5MjIyYzI3Yjc1ZGU0NmU1L3RleHRyZWdpb246MjUyZmIxY2I4MzA3NGQwNjkyMjJjMjdiNzVkZTQ2ZTVfMTU4Nw_17dc35f7-957d-49b1-a846-6d9dd4613fa7">958,467</ix:nonFraction> newly issued shares of the Company's common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80OS9mcmFnOjI1MmZiMWNiODMwNzRkMDY5MjIyYzI3Yjc1ZGU0NmU1L3RleHRyZWdpb246MjUyZmIxY2I4MzA3NGQwNjkyMjJjMjdiNzVkZTQ2ZTVfMTY1MQ_56024c2b-b020-47c8-86c1-8a9eb7f763e1">0.01</ix:nonFraction>, at a fixed price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib5527acf5cf248e5ac690d183c18549f_I20210615" decimals="2" name="us-gaap:SaleOfStockPricePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80OS9mcmFnOjI1MmZiMWNiODMwNzRkMDY5MjIyYzI3Yjc1ZGU0NmU1L3RleHRyZWdpb246MjUyZmIxY2I4MzA3NGQwNjkyMjJjMjdiNzVkZTQ2ZTVfMTY3NQ_76bcf053-9a6a-49e6-af12-6b505178d5fb">31.30</ix:nonFraction> which represented a $<ix:nonFraction unitRef="usd" contextRef="i1b909bf9e4ae42208ed813d9676eadb7_D20210601-20210630" decimals="-5" name="mgnx:PremiumReceivedOnStockPurchase" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80OS9mcmFnOjI1MmZiMWNiODMwNzRkMDY5MjIyYzI3Yjc1ZGU0NmU1L3RleHRyZWdpb246MjUyZmIxY2I4MzA3NGQwNjkyMjJjMjdiNzVkZTQ2ZTVfMTcwOQ_380086a2-6639-44dc-b429-2fe69d0ddcdc">10.4</ix:nonFraction> million premium over the share price on the Stock Purchase Agreement date.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="ida709811ef604d5ea772a19a8a9c1dfd_52"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMzA3Mjg_11b979ca-833d-43c4-b994-9428c0b9d01c" continuedAt="i30181eeab0fc4a6593d22a27b3a4f53e" escape="true">Revenue </ix:nonNumeric></span></div><ix:continuation id="i30181eeab0fc4a6593d22a27b3a4f53e" continuedAt="i9fc8e12fc60c44e79d64f566d36f2fa9"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborative and Other Agreements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte Corporation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte License Agreement</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for retifanlimab, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab.  Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i3a2c1fb5405243d38e27f09c198a5915_D20180101-20180630" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNzE0_af82bfc4-bbda-4917-8624-7c7a02820f8c">150.0</ix:nonFraction> million in 2017. In July 2021, Incyte announced that the FDA had issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for retifanlimab as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal. Incyte&#8217;s announcement indicated that the FDA determined that additional data are needed to demonstrate the clinical benefit of retifanlimab for the submitted indication, and that Incyte was reviewing the CRL </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i9fc8e12fc60c44e79d64f566d36f2fa9" continuedAt="i8401883c501145fd86d53e720f5713af"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and would discuss next steps with the FDA. Incyte subsequently withdrew its European application for marketing authorization of retifanlimab for the treatment of squamous carcinoma of the anal canal. Incyte has stated it is pursuing development of retifanlimab in potentially registration-enabling studies beyond squamous cell carcinoma of the anal canal, including in patients with MSI-high endometrial cancer, Merkel cell carcinoma and non-small cell lung cancer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, Incyte will lead global development of retifanlimab.  Assuming successful development and commercialization by Incyte, the Company could receive up to approximately $<ix:nonFraction unitRef="usd" contextRef="i1dabbd2bdcd948c59b80f6888528ba3b_I20181231" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTY0Nw_b525e32a-c340-4b42-90a3-d527f1384a88">420.0</ix:nonFraction> million in development and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i1dabbd2bdcd948c59b80f6888528ba3b_I20181231" decimals="-5" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTcwMQ_7f95c03d-0d34-43eb-b96d-e79e4b885545">330.0</ix:nonFraction> million in commercial milestones. From the inception of the Incyte License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has recognized $<ix:nonFraction unitRef="usd" contextRef="ica1236dc56be456dadbe35007ebd92bc_D20180101-20220331" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTgyMA_26f2052f-7f4e-466e-8f8a-41ca7e42d84e">70.0</ix:nonFraction> million in development milestones under the Incyte License Agreement.  If retifanlimab is approved and commercialized, the Company would be eligible to receive tiered royalties of <ix:nonFraction unitRef="number" contextRef="ie34522f6d1964d318f94e89b4a7854b2_D20180101-20180630" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTk5NQ_0a535f7f-b426-42a0-9ffa-d3c1f1cd6817">15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i02d8186b9ed94687aa3108cc69312fbd_D20180101-20180630" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjAwMQ_c824c480-e7cf-4586-bea4-0f3df712669d">24</ix:nonFraction>% on any global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte License Agreement under the provisions of Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606) and identified the following <ix:nonFraction unitRef="performanceobligation" contextRef="i1dabbd2bdcd948c59b80f6888528ba3b_I20181231" decimals="INF" name="mgnx:NumberOfPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjU0Mw_003efec8-927f-4ad2-877f-7bfcd66f163e">two</ix:nonFraction> performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period.  The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience.  The Company determined that the transaction price of the Incyte License Agreement at inception was $<ix:nonFraction unitRef="usd" contextRef="i1dabbd2bdcd948c59b80f6888528ba3b_I20181231" decimals="-5" name="mgnx:CollaborativeAgreementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMzMzMA_7ce9937d-58c0-468c-994e-9fcae09eb7e5">154.0</ix:nonFraction> million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed.  The transaction price was allocated to each performance obligation based on their relative standalone selling price.  The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The standalone selling price for the agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. From 2018 through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, it became probable that a significant reversal of cumulative revenue would not occur for development milestones totaling $<ix:nonFraction unitRef="usd" contextRef="ica1236dc56be456dadbe35007ebd92bc_D20180101-20220331" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNDkwOQ_26f2052f-7f4e-466e-8f8a-41ca7e42d84e">70.0</ix:nonFraction> million related to </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical and regulatory activities related to the further advancement of retifanlimab, including Incyte&#8217;s initiation of a Phase 3 clinical trial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Therefore, the associated consideration was added to the estimated transaction price and was recognized as revenue</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the $<ix:nonFraction unitRef="usd" contextRef="i94127aa94aa2402086ac95e5ef578edd_D20180101-20180630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNTE4NQ_bab0350c-58ed-436e-94a9-aa931dd25995">150.0</ix:nonFraction> million allocated to the license when it satisfied its performance obligation and transferred the license to Incyte in 2017. The $<ix:nonFraction unitRef="usd" contextRef="i54eb455b76a2472aae844a12fa08813e_D20170101-20181231" decimals="-5" name="mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNTMxMA_a3636d75-96bd-49f8-92a8-0eebaee3af88">4.0</ix:nonFraction> million allocated to the clinical activities was recognized ratably as services were performed during 2017 and 2018. <ix:nonFraction unitRef="usd" contextRef="i8c7b19308ad740b49d92d38c4aa6390d_D20220101-20220331" decimals="INF" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNTcyNA_2ef9230e-badf-43cb-810e-44e82f746b29"><ix:nonFraction unitRef="usd" contextRef="i8c7b19308ad740b49d92d38c4aa6390d_D20220101-20220331" decimals="INF" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNTcyNA_8c0ee3c8-ccab-4291-9a1e-9e881b240157">No</ix:nonFraction></ix:nonFraction> revenue was recognized under the Incyte License Agreement during the three months ended March 31, 2022.  During the three months ended March 31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i43cf385ec61546e2885724e6c7c3177a_D20210101-20210331" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNTgzNg_45859cff-6d85-47fd-bb86-dc4be67b92c5"><ix:nonFraction unitRef="usd" contextRef="i43cf385ec61546e2885724e6c7c3177a_D20210101-20210331" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNTgzNg_bd0bc0c0-60f9-4ff9-8dc6-8c50bff58648">10.0</ix:nonFraction></ix:nonFraction> million in milestone revenue was recognized under the Incyte License Agreement.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte Clinical Supply Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into an agreement with Incyte, under which the Company is to perform development and manufacturing services for Incyte&#8217;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement).  The Company evaluated the Incyte Clinical Supply Agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab.  The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services.  During the three months ended March 31, 2022 and 2021, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="if3c00bc643434efbbf8833b77153ad2d_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNjk5MQ_b4ed1642-dde9-4137-9f73-bd93305432bc">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0adbde0716db4da29d82fc8ba600273b_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNjk5OA_663d114f-8fd5-4910-8843-f346fa9076d3">0.1</ix:nonFraction> million, respectively, for services performed under the Incyte Clinical Supply Agreement.  </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i8401883c501145fd86d53e720f5713af" continuedAt="iac572cc3caab4fe99f9f6719440a0911"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte Commercial Supply Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company entered into an agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#8217;s obligation to pay royalties under the Incyte License Agreement.  The Company evaluated the Incyte Commercial Supply Agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the commercial supply of retifanlimab. The transaction price is based on a fixed price per batch of bulk drug substance to be manufactured and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor costs incurred) related to the manufacturing services.  During the three months ended March 31, 2022 , the Company recognized de minimis revenue and during the three months ended March 31, 2021 the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ic8d7471a9a78429b9f892ec0cc71150c_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTA5OTUxMTY2MzQyMg_63ad2ec1-357d-4d1b-b245-d581deb8c284">3.1</ix:nonFraction>&#160;million for services performed under the Incyte Commercial Supply Agreement.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zai Lab Limited</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Zai Lab Agreement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab)  under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#8217;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab, a bispecific DART&#174; molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development of these molecules in its territory. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2018 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ifba4c7039c924aa5b223417e6cf78e36_D20190101-20190630" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfOTQxOA_a861e5a8-7463-4495-80a6-6ce7b4735c43">25.0</ix:nonFraction> million ($<ix:nonFraction unitRef="usd" contextRef="ifba4c7039c924aa5b223417e6cf78e36_D20190101-20190630" decimals="-5" name="mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfOTQyMg_c7c23e43-19bb-436b-b7d8-3c7f48c98851">22.5</ix:nonFraction> million after netting value-added tax withholdings of $<ix:nonFraction unitRef="usd" contextRef="ifba4c7039c924aa5b223417e6cf78e36_D20190101-20190630" decimals="-5" name="mgnx:NonrefundablePaymentTaxWithholding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfOTQ3MQ_aba8ceb3-1dd2-45ad-9abd-960949d9aa9b">2.5</ix:nonFraction> million). Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, the Company could receive up to $<ix:nonFraction unitRef="usd" contextRef="i8a199c459cc44adc89979956653b5201_I20200930" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfOTYxNw_83251b24-58c1-4988-9adc-28f181ca19ee">140.0</ix:nonFraction> million in development and regulatory milestones, of which the Company has earned $<ix:nonFraction unitRef="usd" contextRef="i6a9c376486b84ec3b165f5f033a1fd8d_D20200701-20220331" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfOTY2Mg_7db23f76-95c4-4380-8c6e-56cbefb207fb">9.0</ix:nonFraction> million through March&#160;31, 2022. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-teens to <ix:nonFraction unitRef="number" contextRef="i0c95d8da85da4d78b72fd3032fd7f680_D20190101-20190630" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfOTg4MQ_f471d8ed-d5af-49e3-b2ce-573d24b1f27f">20</ix:nonFraction>% for net sales of margetuximab in Zai Lab&#8217;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#8217;s territory and <ix:nonFraction unitRef="number" contextRef="ib9c86092c7f8459fa95d28f361b3564a_D20190101-20190630" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTAwMDQ_a1770e87-9c0b-4107-af6e-509cae4da3bb">10</ix:nonFraction>% for net sales of the TRIDENT molecule in Zai Lab&#8217;s territory, which may be subject to adjustment in specified circumstances. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2018 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and tebotelimab:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#8217;s territory and (ii) certain research and development activities. The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate. Activities related to margetuximab and tebotelimab are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract. The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule. The Company determined that the net $<ix:nonFraction unitRef="usd" contextRef="ifba4c7039c924aa5b223417e6cf78e36_D20190101-20190630" decimals="-5" name="mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTEzMDk_c7c23e43-19bb-436b-b7d8-3c7f48c98851">22.5</ix:nonFraction> million upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.  From 2020 through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, it became probable that a significant reversal of cumulative revenue would not occur for development and regulatory milestones totaling $<ix:nonFraction unitRef="usd" contextRef="i6a9c376486b84ec3b165f5f033a1fd8d_D20200701-20220331" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNDM5ODA0NjU5ODk2MA_7db23f76-95c4-4380-8c6e-56cbefb207fb">9.0</ix:nonFraction> million.  Therefore, the associated consideration was added to the estimated transaction price and was recognized as revenue</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Of this </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i6a9c376486b84ec3b165f5f033a1fd8d_D20200701-20220331" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNDM5ODA0NjU5OTcxMA_7db23f76-95c4-4380-8c6e-56cbefb207fb">9.0</ix:nonFraction> million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i605a7292ff3f44c383e3d95959a523b0_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNDM5ODA0NjU5OTcxOA_f8a94e09-9e38-456d-a50b-4fe08de7f975">5.0</ix:nonFraction> million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was recognized as revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the three months ended March 31, 2022.  <ix:nonFraction unitRef="usd" contextRef="i51a097abe2f346a8bea4a1a0e880968a_D20210101-20210331" decimals="-5" name="mgnx:RevenuesNetOfTaxWithholding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTA5OTUxMTY2NjYxMw_02f7a468-8c96-44d0-95b4-3794cdb83a10">No</ix:nonFraction> revenue was recognized during the three months ended March 31, 2021 under the 2018 Zai Lab Agreement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="iac572cc3caab4fe99f9f6719440a0911" continuedAt="i3b3f4d7902984e8b893d52c7c4f2a3ae"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zai Lab Clinical Supply Agreements</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#8217;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements). The Company evaluated the agreements under ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: to perform services related to manufacturing the clinical supply of each of margetuximab and tebotelimab.  The transaction price is based on the costs incurred to manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing service. During the three months ended March 31, 2022 and 2021, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="ia36f2c15a9ed480fb6dfd60b54cdb774_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTQ0MjQ_ffc58507-40bc-46ae-ab67-741aa5514ef6">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i29c3c82f97234786bc2f333cf100ce5f_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTQ0MzE_a4a2ad4e-e8cf-420c-a390-d5dbc16584d5">1.1</ix:nonFraction> million, respectively, related to the Zai Lab Clinical Supply Agreements. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Zai Lab Agreement</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates the Company&#8217;s DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be designated by the Company. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while the Company receives commercial rights in all other territories. Under the Lead Program, Zai Lab received an option upon reaching a predefined clinical milestone to convert the regional arrangement into a global 50/50 profit share. If Zai Lab elects such option, Zai Lab is to pay the Company $<ix:nonFraction unitRef="usd" contextRef="ib5527acf5cf248e5ac690d183c18549f_I20210615" decimals="-5" name="mgnx:OptInFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTU2Mzc_b569c591-7178-4a28-9a1f-ead118417de4">85.0</ix:nonFraction>&#160;million plus any research costs incurred by both parties as of the option election date. Zai Lab also obtained exclusive, global licenses from the Company to develop, manufacture and commercialize two additional molecules. Zai Lab granted the Company a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to the Company.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2021 Zai Lab Agreement, the Lead Program includes joint research and development services by both the Company and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with the Company to perform research and development services in the future. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ie0aca00030b84821a220040e1894b4ed_D20210601-20210630" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTYzOTc_f504cddb-a8bd-4c78-8f2a-2e72b166fe52">25.0</ix:nonFraction>&#160;million. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, the Company and Zai Lab entered into the Stock Purchase Agreement whereby Zai Lab paid the Company approximately $<ix:nonFraction unitRef="usd" contextRef="ie0aca00030b84821a220040e1894b4ed_D20210601-20210630" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTY2MjU_13da2f7f-c8b7-4eee-86ab-7a8bab3042c3">30.0</ix:nonFraction> million to purchase shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTY2ODg_eb1ec008-c6b3-46ab-b812-0408c7c9c119">0.01</ix:nonFraction>, at a fixed price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib5527acf5cf248e5ac690d183c18549f_I20210615" decimals="2" name="us-gaap:SaleOfStockPricePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTY3MTI_76bcf053-9a6a-49e6-af12-6b505178d5fb">31.30</ix:nonFraction> which represented a $<ix:nonFraction unitRef="usd" contextRef="i1b909bf9e4ae42208ed813d9676eadb7_D20210601-20210630" decimals="-5" name="mgnx:PremiumReceivedOnStockPurchase" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTY3MzU_380086a2-6639-44dc-b429-2fe69d0ddcdc">10.4</ix:nonFraction> million premium over the share price on the Stock Purchase Agreement date. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful development and commercialization of the Programs, the Company could receive up to approximately $<ix:nonFraction unitRef="usd" contextRef="ib5527acf5cf248e5ac690d183c18549f_I20210615" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTY5MjM_9a4c038d-4891-4bee-811d-87a6735aab43">800.0</ix:nonFraction>&#160;million in development and regulatory milestones and $<ix:nonFraction unitRef="usd" contextRef="ib5527acf5cf248e5ac690d183c18549f_I20210615" decimals="-5" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTY5NzE_c7cd5534-9d53-401b-bd6b-e325c56fb156">600.0</ix:nonFraction>&#160;million in commercial milestones. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of low double digit teens on annual net sales of certain specified products and of mid-single digits to low double digit teens on annual net sales of other specified products in Zai Lab&#8217;s territory, which may be subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, the Company may also receive reimbursements from Zai Lab for certain research and development costs incurred by the Company. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2021 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises: (i) exclusive licenses to develop, manufacture and commercialize the products in Zai Lab&#8217;s territory for each Program and (ii) certain research and development activities for the Lead Program. The Company determined that for the Lead Program, the license is not distinct from the related research and development activities, considering the early stage of development of the molecule and the Company&#8217;s significant expertise in this area and as such, the research and development services are expected to significantly modify and customize the license. Therefore, for the Lead Program, the license and the services were combined into a single performance obligation. Since the other programs each represent distinct intellectual property and there are no other services included in the 2021 Zai Lab Agreement related to these licenses, each license is considered to be a distinct performance obligation. As such, there are four performance obligations included in the 2021 Zai Lab Agreement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the estimated transaction price is $<ix:nonFraction unitRef="usd" contextRef="ib5527acf5cf248e5ac690d183c18549f_I20210615" decimals="-5" name="mgnx:CollaborativeAgreementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTg3MjQ_f62f4703-c6a1-4f8c-91e6-cc32d245a03e">40.4</ix:nonFraction> million, consisting of the $<ix:nonFraction unitRef="usd" contextRef="ie0aca00030b84821a220040e1894b4ed_D20210601-20210630" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTg3NDY_f44bd440-0417-4c28-9086-50af09ac2801">25.0</ix:nonFraction> million upfront payment, the $<ix:nonFraction unitRef="usd" contextRef="i1b909bf9e4ae42208ed813d9676eadb7_D20210601-20210630" decimals="-5" name="mgnx:PremiumReceivedOnStockPurchase" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTg3NzA_4437a49a-7422-42a2-9c0c-e5f0345606f0">10.4</ix:nonFraction> million premium related to the purchase of the Company&#8217;s common stock, and the $<ix:nonFraction unitRef="usd" contextRef="ie0aca00030b84821a220040e1894b4ed_D20210601-20210630" decimals="-5" name="mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTg4NTQ_4f60626e-fda5-4057-b2e5-0dad5485b2ad">5.0</ix:nonFraction> million estimated reimbursement by Zai Lab for research and development activities for the Lead Program. The potential milestone payments </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i3b3f4d7902984e8b893d52c7c4f2a3ae" continuedAt="i931e450df372494f9d2330948758e350"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were deemed to be fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company will re-assess the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price of $<ix:nonFraction unitRef="usd" contextRef="ib5527acf5cf248e5ac690d183c18549f_I20210615" decimals="-5" name="mgnx:CollaborativeAgreementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTk3Mjg_64c0bae8-eb2a-4a74-89e3-7d268da519f0">40.4</ix:nonFraction> million was then allocated to the four performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was not directly observable; therefore, the Company estimated the standalone selling price using an adjusted market assessment approach, representing the amount that the Company believes a market participant is willing to pay for the product or service. The estimate was based on consideration of observable inputs, such as, values of other preclinical collaboration arrangements adjusted for the Company&#8217;s estimate of the probability of success for each Program. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue related to the Lead Program license and related research and development services performance obligation is being recognized over time as the research and development activities are performed. The Company will utilize a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations. The Company recognized revenue allocated to the other programs at a point in time upon transfer of the licenses to Zai Lab in June 2021. During the three months ended March 31, 2022, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i3a06e176aa5944de902c9e6384aa45bf_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjEwMzQ_2902fd2e-b525-4a31-97d9-b621d5bc0bd6">0.3</ix:nonFraction> million under the 2021 Zai Lab Agreement. As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="ic3025bab32fb46cd9d6da9f324ce3688_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjExMTQ_55ab3d41-3004-445b-b26c-b41fe7b6e5d1">16.2</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenue was deferred under the agreement, all of which was current. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i36440f83cc204cf1996dbfe7485383bc_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNDM5ODA0NjU1NjI1Nw_fa8ff00e-90d3-4f67-bbed-87eb316c4933">16.1</ix:nonFraction> million in revenue was deferred, all of which was current.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Biotech, Inc.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company entered into a research collaboration and license agreement with Janssen Biotech, Inc. (Janssen) to develop a novel DART molecule (Janssen Agreement).  The research collaboration will incorporate the Company&#8217;s proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the Janssen Agreement, Janssen paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i76399d6c1802415b90c08bf9c69f7100_D20201201-20201231" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjE2OTQ_f5a7f711-4fa2-4170-970a-b617462c4f08">20.0</ix:nonFraction>&#160;million and will be responsible for funding all research and development expenses. The Company will also be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ie55d7a52498740cc96d51ad5658ea4c5_I20211231" decimals="-5" name="mgnx:PotentialMilestonePaymentsAndRoyaltiesOnProductSales" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjE4MjM_b02bf858-2933-4226-ac20-2fd6fabd9e2f">312.0</ix:nonFraction>&#160;million in potential milestone payments and tiered royalties of up to <ix:nonFraction unitRef="number" contextRef="i76399d6c1802415b90c08bf9c69f7100_D20201201-20201231" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjE4ODg_2bd3dde2-ff88-4916-a80a-9cd8485a4df9">10</ix:nonFraction>% on worldwide product sales. </span><span style="color:#58585a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Janssen an exclusive, royalty-bearing license to develop, manufacture and commercialize the preclinical bispecific molecule and the Company will perform certain research and development activities during a specified research term. The Company evaluated the Janssen Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i)  a license to develop the preclinical bispecific molecule and (ii) performing certain research and development activities during the research term. The Company determined that the license and research and development activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as Janssen could benefit from the license on its own without the Company&#8217;s involvement during the research term.  The Company determined that the transaction price of the Janssen Agreement at inception was $<ix:nonFraction unitRef="usd" contextRef="ie55d7a52498740cc96d51ad5658ea4c5_I20211231" decimals="-5" name="mgnx:CollaborativeAgreementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjI5Njc_adee61a0-752a-47e1-bc08-ce4e91fdd703">22.2</ix:nonFraction>&#160;million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for research and development activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements as well as current market conditions. The standalone selling price for agreed-upon research and development activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. This variable consideration is fully constrained until the Company begins its work under the performance obligation.  The potential milestone payments are </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Janssen and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the $<ix:nonFraction unitRef="usd" contextRef="ibc75ade1173842ff87ee4dbbac9daeb5_D20201201-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjQ1ODI_6f1f846c-8a9e-4b8b-9d5e-342139e32cd5">20.0</ix:nonFraction>&#160;million allocated to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license when it satisfied its performance obligation and transferred the license to Janssen in December 2020. The $<ix:nonFraction unitRef="usd" contextRef="i76399d6c1802415b90c08bf9c69f7100_D20201201-20201231" decimals="-5" name="mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjQ3MTY_359547c0-969b-4961-8309-3ca7c0362895">2.2</ix:nonFraction>&#160;million allocated to the research and development activities is being recognized over the Company&#8217;s involvement in the research term, which is estimated to be less than two years.  The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="ib49d110aa2b04f54ad540230e16f5db5_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjQ5NTA_286e4511-1bac-4f52-b157-9ee1116d5021"><ix:nonFraction unitRef="usd" contextRef="i6925c66d0d90474cabcbca044e7bb353_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjQ5NTA_3d27a6bf-634b-49c8-9d0a-2a6797f8f726">0.3</ix:nonFraction></ix:nonFraction>&#160;million for each of the three-month periods ended March&#160;31, 2022 and 2021 for research and development activities performed under the Janssen Agreement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i931e450df372494f9d2330948758e350" continuedAt="i5c8f597e19c24355bd42bef0e0f3fb5f"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">I-Mab Biopharma</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">I-Mab License Agreement</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the Company's proprietary Fc Optimization technology platform (I-Mab License Agreement).  I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the I-Mab License Agreement, I-Mab paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="iecc8c23d2f2f46e295c148fe79e31e39_D20200101-20200630" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjU3MTk_3b13d44d-285c-411a-be53-8cfdff6b01c3">15.0</ix:nonFraction> million.  Assuming successful development and commercialization of enoblituzumab, the Company could receive up to $<ix:nonFraction unitRef="usd" contextRef="i61fd77fcf6144f8f852769a79d64119a_I20201231" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjU4Mjg_46b5e836-b146-46dd-968f-99cbf91177d4">135.0</ix:nonFraction> million in development and regulatory milestones, of which $<ix:nonFraction unitRef="usd" contextRef="ia548adfe30414a9f9d0fd63c315589d5_D20220101-20220331" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTA5OTUxMTY2MzQ4NQ_c3fcde91-fb1b-4e71-88a8-de872ed4a773">5.0</ix:nonFraction>&#160;million has been earned from the inception of the I-Mab License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, I-Mab would pay the Company tiered royalties ranging from mid-teens to <ix:nonFraction unitRef="number" contextRef="i0e56061fef8544908e67631567510f9d_D20200101-20200630" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjYwNDk_674fb337-5f81-4647-9a21-c5e9a9d859f4">20</ix:nonFraction>% on annual net sales in I-Mab's territory.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the I-Mab License Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i) an exclusive license to develop and commercialize enoblituzumab in I-Mab&#8217;s territories, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation. The Company determined that the $<ix:nonFraction unitRef="usd" contextRef="iecc8c23d2f2f46e295c148fe79e31e39_D20200101-20200630" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjY4NTA_3b13d44d-285c-411a-be53-8cfdff6b01c3">15.0</ix:nonFraction> million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities. The Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $<ix:nonFraction unitRef="usd" contextRef="iecc8c23d2f2f46e295c148fe79e31e39_D20200101-20200630" decimals="-5" name="mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjcyNjU_178c03af-b1e8-43a4-be00-3b7d61c8d175">1.0</ix:nonFraction> million. I-Mab paid the Company for the cost of this study as the costs were incurred and I-Mab received a one-time credit of eighty percent of the total amount of such costs against the milestone achieved during 2021. The Company reassessed the transaction price as it became probable that a significant reversal of cumulative revenue would not occur for a $<ix:nonFraction unitRef="usd" contextRef="i1514a61deb464837bf8bb0f50659cd2b_D20210101-20211231" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNDM5ODA0NjU1MTU5MA_11ae6530-519e-4091-9688-3695296337cf">5.0</ix:nonFraction>&#160;million milestone ($<ix:nonFraction unitRef="usd" contextRef="ib5ec03c4a3794d77bfafe5617533f80a_I20211231" decimals="-5" name="mgnx:OneTimeMillstoneCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNDM5ODA0NjU1MTYwNQ_e61cc15e-fb19-4a9f-91c6-feffbc47ba16">4.5</ix:nonFraction>&#160;million after netting a one-time credit as described above) related to development progress of enoblituzumab, therefore the associated consideration was added to the estimated transaction price and was recognized as revenue during 2021. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to I-Mab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Revenue under the I-Mab License Agreement is being recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations.  During the three months ended March 31, 2022 and 2021, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="ia548adfe30414a9f9d0fd63c315589d5_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjg4MTk_e89785b1-6dc1-4f2d-819b-16241535e213">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if8da3009f9f94f879c4bf206e40f1cc4_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjg4MjY_988bbd83-c470-49a3-8fbc-46b4139eee7b">0.6</ix:nonFraction> million, respectively, under the I-Mab License Agreement. As of March&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="ic49edb54de2c4ae4a6d757a5b491be58_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTA5OTUxMTY2MzYxNw_08bf238b-4cf3-4a29-94b7-fa787112df5c">4.4</ix:nonFraction> million in revenue was deferred under the I-Mab License Agreement, all of which was current. As of December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="ib5ec03c4a3794d77bfafe5617533f80a_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNDM5ODA0NjU1NjQ4NA_0ccc3106-aa9d-4a73-9ef3-3d0db41a14ac">4.5</ix:nonFraction> million in revenue was deferred under the I-Mab License Agreement, all of which was current.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">I-Mab Clinical Supply Agreement</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into an agreement under which the Company is to perform development and manufacturing services for I-Mab&#8217;s clinical needs of enoblituzumab (I-Mab Clinical Supply Agreement). The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of enoblituzumab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the three months ended March 31, 2022, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="iedfb3cdeb7214224a72fce2beb8e46d1_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTA5OTUxMTY2MzY0Mw_c911c791-6e7e-4a57-a6ca-1d6ed089e63e">0.9</ix:nonFraction> million for research and development activities performed under the I-Mab Clinical Supply Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing Services Agreement</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i5c8f597e19c24355bd42bef0e0f3fb5f" continuedAt="ifac951a1a0a64086974e0302289373d4"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into a Manufacturing and Clinical Supply Agreement with Incyte (Incyte Manufacturing and Clinical Supply Agreement) to provide manufacturing services to produce certain Incyte bulk drug substance over a three-year period at one of the Company&#8217;s manufacturing facilities. Under the terms of the Incyte Manufacturing and Clinical Supply Agreement, the Company received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i0157b8cec1ad4b9a9b95f37868dd31e3_D20220101-20220131" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTA5OTUxMTcxNjc2MQ_45b28e16-767f-443d-9083-cbb5714be7dc">10.0</ix:nonFraction>&#160;million and is eligible to receive annual fixed payments paid quarterly over the term of the contract totaling $<ix:nonFraction unitRef="usd" contextRef="ia4e2cd3790dd4e78a153c3c1da4940aa_I20220331" decimals="-5" name="mgnx:TotalAnnualFixedPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTA5OTUxMTcxNjc2OQ_ce1bd774-926f-4b22-89dd-b79e6c162565">14.4</ix:nonFraction>&#160;million. The Company will also be reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing services.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte Manufacturing and Clinical Supply Agreement under the provisions of ASC 606 and identified one performance obligation to provide manufacturing runs to Incyte, as and when requested by Incyte, over the term of the contract that is part of a series of goods and services. The Company determined that the transaction price at inception consists of the upfront payment received of $<ix:nonFraction unitRef="usd" contextRef="i0157b8cec1ad4b9a9b95f37868dd31e3_D20220101-20220131" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMzg0ODI5MDc4NjI4MQ_4ee1170c-68e4-4b75-8999-ec1c6d177d33">10.0</ix:nonFraction>&#160;million and the annual fixed payments totaling $<ix:nonFraction unitRef="usd" contextRef="ia4e2cd3790dd4e78a153c3c1da4940aa_I20220331" decimals="-5" name="mgnx:TotalAnnualFixedPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMzg0ODI5MDc4NjI5Ng_d299dce3-4be7-433b-ba62-07a1a506f825">14.4</ix:nonFraction>&#160;million.   The Company will recognize revenue over time on a straight-line basis as the manufacturing services are provided to Incyte, as the Company determined that its efforts in providing the manufacturing services will be incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product for Incyte will be allocated to the related manufacturing activities and will be recognized as revenue as those activities occur.  Materials purchased by the Company to manufacture the product for Incyte are considered costs to fulfill a contract and will be capitalized and expensed as the materials are used to provide the manufacturing services.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was <ix:nonFraction unitRef="usd" contextRef="iaec489dac35b477286b66bb36de621fc_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMzg0ODI5MDc4NzMyOQ_3015badf-4863-40db-bae7-90c717779af0">no</ix:nonFraction> revenue recognized under the Incyte Manufacturing and Clinical Supply Agreement during the three months ended March 31, 2022. As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ia4e2cd3790dd4e78a153c3c1da4940aa_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTA5OTUxMTcxNjc3OQ_cc2b3378-75e3-4e99-8b36-687673518316">11.2</ix:nonFraction>&#160;million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was deferred under this agreement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ia4e2cd3790dd4e78a153c3c1da4940aa_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTA5OTUxMTcxNjc4Nw_b9c80d93-ca23-4744-8f78-b13783b4fa82">4.8</ix:nonFraction>&#160;million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was current and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ia4e2cd3790dd4e78a153c3c1da4940aa_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTA5OTUxMTcxNjgyMw_f76413f8-82eb-4a64-a56c-e9ee1c46059c">6.4</ix:nonFraction>&#160;million </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of which was non-current.  </span></div><div style="margin-bottom:6pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NIAID Contract</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a contract with National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to <ix:nonFraction unitRef="molecule" contextRef="i1337d1949d0643488c0089eab0614890_D20150915-20150915" decimals="INF" name="mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjk2NDg_fd05a877-32be-4cf2-bcfd-753ad7f9891b">two</ix:nonFraction> DART molecules, MGD014 and MGD020 (NIAID Contract). Under the NIAID Contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.</span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifac951a1a0a64086974e0302289373d4">Since the inception of the NIAID Contract, NIAID has exercised the two options contemplated in the original contract and executed modifications such that the total funded contract value as of March&#160;31, 2022 is $<ix:nonFraction unitRef="usd" contextRef="i7e37fc50bcd44ac683c40725c776294b_D20220101-20220331" decimals="-5" name="mgnx:TotalPotentialValueUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTA5OTUxMTY2MzY1Ng_58930f79-68d9-45dd-9372-9ab57b2af267">25.1</ix:nonFraction>&#160;million. In addition, the most recent modification changed the period of performance under the NIAID Contract to end in July 2023. During the three months ended March 31, 2022 and 2021, the Company recognized revenue under the NIAID Contract of $<ix:nonFraction unitRef="usd" contextRef="ic750b1bc388a426a9377427e21e4fe52_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMzA3MDA_2208fa48-522a-4a3f-aa2b-37fe8cae64cb">0.4</ix:nonFraction> million and    $<ix:nonFraction unitRef="usd" contextRef="i0ba225f70b5e431a996b967e49bfb1c8_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMzA3MDc_a4e7a85f-c92e-424d-806b-126670016b7a">0.8</ix:nonFraction> million, respectively.</ix:continuation>  </span></div><div id="ida709811ef604d5ea772a19a8a9c1dfd_55"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNTQ3Mw_50cd4d43-a455-4b6b-91a8-59cabd658b9f" continuedAt="i6b7437c534f04cc19dcd4aa8e2dbb210" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i6b7437c534f04cc19dcd4aa8e2dbb210" continuedAt="i22117815f1394105aa63ff9cdb281dd5"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended (IRC), and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company reserved <ix:nonFraction unitRef="shares" contextRef="iad1e5d2adfa44b97a1de1c2f673de3f3_I20170531" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNDI3_e8b81636-ff05-4394-a424-fe6f3e94f396">800,000</ix:nonFraction> shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="i909599960cbd4d01a402618a5680f14c_D20170501-20170531" decimals="INF" name="mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNjI2_f33a287f-1143-44bd-a9c0-03f87ca62509">10</ix:nonFraction>% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfMzg0ODI5MDcwNDU3Ng_27cd901d-e912-415a-9df7-55d3c46ad18f">six</span>-month offering periods ending on May 31 and November 30 of each year.  At the end of each offering period, employees are able to purchase shares at <ix:nonFraction unitRef="number" contextRef="i909599960cbd4d01a402618a5680f14c_D20170501-20170531" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfODcz_4e09d451-88bc-4879-8aae-95eb96c220fd">85</ix:nonFraction>% of the fair market value of the Company&#8217;s common stock on the last day of the offering period.  During the three months ended March&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="i83ac7c613bf04ee3a7d8345a36323be1_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfMTAwMw_c1463417-bff9-4a3a-a54b-e9aeb544e349">no</ix:nonFraction> shares of common stock were purchased under the 2016 ESPP.   </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Option Plans</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the IRC, or non-qualified stock options.  In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan.  Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i22117815f1394105aa63ff9cdb281dd5" continuedAt="i2701ee0f443f4bd0bbb37a20a7c1e2ec"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160; As of March&#160;31, 2022, under the 2003 Plan, there were options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i86806d0d26194ccda0c95e062fc00349_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfMTkyNQ_389c5072-0b92-484d-9550-bcbd214fe85c">160,357</ix:nonFraction> shares of common stock outstanding.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2013, the Company implemented the 2013 Plan.&#160;&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards.&#160;&#160;The number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) <ix:nonFraction unitRef="shares" contextRef="i1ded582f69f04d0aaaf29d8dddc272a5_I20131031" decimals="INF" name="mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfMjQxNQ_ca874aab-f1eb-42f4-aacd-6636f1c3e46a">1,960,168</ix:nonFraction> shares, (b) <ix:nonFraction unitRef="number" contextRef="ib91bd3b003bd40c9b8460d6c1e8f8f10_D20220101-20220331" decimals="3" name="mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfMjQzMA_77bf5ceb-cfb6-4ba6-be7c-91137705b212">4.0</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Company's Board of Directors. During the three months ended March&#160;31, 2022, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to <ix:nonFraction unitRef="shares" contextRef="if0a7f8632e7f42d5ad0ae052ddb56492_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfMjc4Mg_f751fc65-1a79-41a1-8ee8-d1411a3464dc">15,816,949</ix:nonFraction>.&#160;&#160; If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards.  As of March&#160;31, 2022, there were options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="if0a7f8632e7f42d5ad0ae052ddb56492_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfMzM1OA_834b61ca-dcd8-433a-8a0c-9de325b7aa77">10,346,223</ix:nonFraction> shares of common stock outstanding.</span></div><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNTQ3MQ_2e7ac549-4c3b-4129-99db-f28b83c607e1" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation expense was recognized for the periods indicated (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.375%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35c13a3e3a224d948c4a2fe4b9fa5d99_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmYzYmI0YzkxMDhjMDQ0ZTU4NmE0OTYwNWE4NmMyMjhlL3RhYmxlcmFuZ2U6ZjNiYjRjOTEwOGMwNDRlNTg2YTQ5NjA1YTg2YzIyOGVfMi0xLTEtMS0zNjkyMQ_ddaaab7e-8e6b-4d12-9717-cea6cd1e5360">2,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59db3d1311064ab88fb9f88769f9da7b_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmYzYmI0YzkxMDhjMDQ0ZTU4NmE0OTYwNWE4NmMyMjhlL3RhYmxlcmFuZ2U6ZjNiYjRjOTEwOGMwNDRlNTg2YTQ5NjA1YTg2YzIyOGVfMi0zLTEtMS0zNjkyMQ_84f6eaf8-cacb-46a0-92fb-1403a8cdad10">2,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i010ad6f9a1c640caa25d8015911a45d6_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmYzYmI0YzkxMDhjMDQ0ZTU4NmE0OTYwNWE4NmMyMjhlL3RhYmxlcmFuZ2U6ZjNiYjRjOTEwOGMwNDRlNTg2YTQ5NjA1YTg2YzIyOGVfMy0xLTEtMS0zNjkyMQ_c1f046e1-6fd7-48c1-a701-e349a75dfe32">2,882</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacae1a7b3e1f4879bf90a88d717407ae_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmYzYmI0YzkxMDhjMDQ0ZTU4NmE0OTYwNWE4NmMyMjhlL3RhYmxlcmFuZ2U6ZjNiYjRjOTEwOGMwNDRlNTg2YTQ5NjA1YTg2YzIyOGVfMy0zLTEtMS0zNjkyMQ_f9b5bd1a-a5f4-423c-987a-2e0c426da350">2,559</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmYzYmI0YzkxMDhjMDQ0ZTU4NmE0OTYwNWE4NmMyMjhlL3RhYmxlcmFuZ2U6ZjNiYjRjOTEwOGMwNDRlNTg2YTQ5NjA1YTg2YzIyOGVfNC0xLTEtMS0zNjkyMQ_24a91346-45f6-4e9b-8f3e-c302eabdd0b9">5,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmYzYmI0YzkxMDhjMDQ0ZTU4NmE0OTYwNWE4NmMyMjhlL3RhYmxlcmFuZ2U6ZjNiYjRjOTEwOGMwNDRlNTg2YTQ5NjA1YTg2YzIyOGVfNC0zLTEtMS0zNjkyMQ_75473bbf-e40d-475f-8503-9ea4aca61107">5,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNTQ3Ng_291a4652-c11c-4f82-92ea-c45004ebe704" escape="true"><div style="margin-bottom:9pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:</span></div><div style="margin-bottom:9pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.837%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjlkMDk3ZDFjZDE3OTRiNzU5MGFmODA3YzU3OTAxMDg0L3RhYmxlcmFuZ2U6OWQwOTdkMWNkMTc5NGI3NTkwYWY4MDdjNTc5MDEwODRfMi0xLTEtMS0zNjkyMQ_6afbdd35-f582-4f1e-bc95-2a9f03af77c3">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjlkMDk3ZDFjZDE3OTRiNzU5MGFmODA3YzU3OTAxMDg0L3RhYmxlcmFuZ2U6OWQwOTdkMWNkMTc5NGI3NTkwYWY4MDdjNTc5MDEwODRfMi0zLTEtMS0zNjkyMQ_a8070723-09e1-4cbe-9c7a-82c4dfbd2cbb">0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia47224cd15db4935927f150937cfc761_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjlkMDk3ZDFjZDE3OTRiNzU5MGFmODA3YzU3OTAxMDg0L3RhYmxlcmFuZ2U6OWQwOTdkMWNkMTc5NGI3NTkwYWY4MDdjNTc5MDEwODRfMy0xLTEtMS0zNjkyMS90ZXh0cmVnaW9uOjg3YmM5MTcwNjg1MzQ4MjZhNmE0MzY5MTgxYWY4MjA0XzEwOTk1MTE2Mjc4MzQ_74872302-cc01-4e8d-8744-85cd53f05ab1">87.9</ix:nonFraction>% -<ix:nonFraction unitRef="number" contextRef="ib2e3c0ef64b149e285c3286cfaaaefa7_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjlkMDk3ZDFjZDE3OTRiNzU5MGFmODA3YzU3OTAxMDg0L3RhYmxlcmFuZ2U6OWQwOTdkMWNkMTc5NGI3NTkwYWY4MDdjNTc5MDEwODRfMy0xLTEtMS0zNjkyMS90ZXh0cmVnaW9uOjg3YmM5MTcwNjg1MzQ4MjZhNmE0MzY5MTgxYWY4MjA0XzEwOTk1MTE2Mjc4MDg_f0ae5370-6fe2-4cf1-83e8-4a1b7d72615e">88.3</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1675839c45fe4c938d0aaa356a3df94c_D20210101-20210331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjlkMDk3ZDFjZDE3OTRiNzU5MGFmODA3YzU3OTAxMDg0L3RhYmxlcmFuZ2U6OWQwOTdkMWNkMTc5NGI3NTkwYWY4MDdjNTc5MDEwODRfMy0zLTEtMS0zNjkyMS90ZXh0cmVnaW9uOjY4ZmFhYTExY2RjNjQ0YTJhMjlhZjkxMDM5MGM0OGU2XzQ_15aa9277-30c5-44be-9703-7009c75e1dd0">86.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i11689de0548a42dba1fc04b3de566926_D20210101-20210331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjlkMDk3ZDFjZDE3OTRiNzU5MGFmODA3YzU3OTAxMDg0L3RhYmxlcmFuZ2U6OWQwOTdkMWNkMTc5NGI3NTkwYWY4MDdjNTc5MDEwODRfMy0zLTEtMS0zNjkyMS90ZXh0cmVnaW9uOjY4ZmFhYTExY2RjNjQ0YTJhMjlhZjkxMDM5MGM0OGU2Xzk_7bed92f6-f05d-4d82-b33d-44cc8cb29ce1">86.7</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia47224cd15db4935927f150937cfc761_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjlkMDk3ZDFjZDE3OTRiNzU5MGFmODA3YzU3OTAxMDg0L3RhYmxlcmFuZ2U6OWQwOTdkMWNkMTc5NGI3NTkwYWY4MDdjNTc5MDEwODRfNC0xLTEtMS0zNjkyMS90ZXh0cmVnaW9uOmYwMjJjOTMyMmRmNTRjNWJiNzliZWM1ODc2NDA0ZWVhXzQ_589ad9e6-2b2a-43f6-a369-91a4fbdceb87">1.5</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ib2e3c0ef64b149e285c3286cfaaaefa7_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjlkMDk3ZDFjZDE3OTRiNzU5MGFmODA3YzU3OTAxMDg0L3RhYmxlcmFuZ2U6OWQwOTdkMWNkMTc5NGI3NTkwYWY4MDdjNTc5MDEwODRfNC0xLTEtMS0zNjkyMS90ZXh0cmVnaW9uOmYwMjJjOTMyMmRmNTRjNWJiNzliZWM1ODc2NDA0ZWVhXzk_b9910dff-cc05-44a7-9b91-2632a7175184">2.4</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1675839c45fe4c938d0aaa356a3df94c_D20210101-20210331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjlkMDk3ZDFjZDE3OTRiNzU5MGFmODA3YzU3OTAxMDg0L3RhYmxlcmFuZ2U6OWQwOTdkMWNkMTc5NGI3NTkwYWY4MDdjNTc5MDEwODRfNC0zLTEtMS0zNjkyMS90ZXh0cmVnaW9uOjdjY2VmM2M0ZGZiYjQwNDM4ZDk5MzE1OTIzNDBiMjZlXzQ_67aa602c-1c92-4bdb-a37e-ff4e45d234c3">0.6</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i11689de0548a42dba1fc04b3de566926_D20210101-20210331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjlkMDk3ZDFjZDE3OTRiNzU5MGFmODA3YzU3OTAxMDg0L3RhYmxlcmFuZ2U6OWQwOTdkMWNkMTc5NGI3NTkwYWY4MDdjNTc5MDEwODRfNC0zLTEtMS0zNjkyMS90ZXh0cmVnaW9uOjdjY2VmM2M0ZGZiYjQwNDM4ZDk5MzE1OTIzNDBiMjZlXzk_d8d136a6-537b-4231-9ec0-c3714ab75e79">1.4</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjlkMDk3ZDFjZDE3OTRiNzU5MGFmODA3YzU3OTAxMDg0L3RhYmxlcmFuZ2U6OWQwOTdkMWNkMTc5NGI3NTkwYWY4MDdjNTc5MDEwODRfNS0xLTEtMS0zNjkyMQ_1388b050-4068-49ef-9569-81aafb676823">5.95</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjlkMDk3ZDFjZDE3OTRiNzU5MGFmODA3YzU3OTAxMDg0L3RhYmxlcmFuZ2U6OWQwOTdkMWNkMTc5NGI3NTkwYWY4MDdjNTc5MDEwODRfNS0zLTEtMS0zNjkyMQ_55110493-9a10-410d-b3de-48d5d1451adf">6.25</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNTQ3OA_fde801f1-1ecc-4d81-bc2f-e6bc0e7b0b1f" escape="true"><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the three months ended March&#160;31, 2022:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>&#160;(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfMS0xLTEtMS0zNjkyMQ_c395ef94-1cfe-4005-a86d-774b5404fdc8">8,373,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfMS0zLTEtMS0zNjkyMQ_072c2889-db79-42d3-afba-74dca3a34af2">21.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i66614c40c0e14c88b42fd0af30436dfc_D20210101-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfMS01LTEtMS0zNjkyMQ_65be54fc-645f-4431-b0b3-9f348376d1df">6.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfMi0xLTEtMS0zNjkyMQ_5433da44-d480-4ec7-96f0-7c1b2b5f79c0">2,349,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfMi0zLTEtMS0zNjkyMQ_ed08a85a-b729-483c-8e7a-21955306edcb">10.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfMy0xLTEtMS0zNjkyMQ_76e4c781-cef8-44fe-84a6-cb14ca425090">25,646</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfMy0zLTEtMS0zNjkyMQ_3d34c25b-502a-43d3-b9d8-504a659a61d6">1.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfNC0xLTEtMS00MzU2MA_7d69e0af-5727-44e9-90d9-d096d57ce45e">157,197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfNC0zLTEtMS00MzU2MA_d5867045-a16c-4cfa-86bc-692381e192a9">16.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfNC0xLTEtMS0zNjkyMQ_346d2fdc-71d3-472d-9c0a-25a5a0413dc7">33,695</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfNC0zLTEtMS0zNjkyMQ_24a8b526-4a15-49b8-8683-cda0b89f9b61">21.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfNS0xLTEtMS0zNjkyMQ_da840f7a-c3a8-45c5-97eb-69b8f79be9d4">10,506,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfNS0zLTEtMS0zNjkyMQ_fdca0ee2-622a-455d-a442-9f89e9aca0f6">19.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfNS01LTEtMS0zNjkyMQ_1b4b13a6-c523-4f46-83e5-3213202d69ae">7.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfNS03LTEtMS0zNjkyMQ_fd0c376d-bd70-4ed5-be97-e67bb14b5e86">904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of March 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfNy0xLTEtMS0zNjkyMQ_4ead658f-1f9a-425e-8dca-91615058f8ab">5,853,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfNy0zLTEtMS0zNjkyMQ_af25b1c9-fa00-475b-a9f1-272e410921f3">22.61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfNy01LTEtMS0zNjkyMQ_993c4377-9a9d-4085-a9a7-a44500ecd2e2">5.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfNy03LTEtMS0zNjkyMQ_29ebb8ed-233a-4405-93cf-bbbc1ab27e8f">898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfOC0xLTEtMS0zNjkyMQ_55eba5d8-ee34-40bd-9f55-8cb9fdc41b82">9,693,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfOC0zLTEtMS0zNjkyMQ_1c46d758-8c86-4202-b32c-79ff9ae021df">19.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfOC01LTEtMS0zNjkyMQ_8df43233-c92e-4abc-b356-faa612f11b66">7.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfOC03LTEtMS0zNjkyMQ_8886dc4c-fa18-4afd-8ae8-6f7e5a57177e">903</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of options granted during the three months ended March&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfMzk3Mg_8c017583-949c-4b61-af3f-e85744eb9b9d">7.48</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfMzk3OQ_0c5f8340-c59e-4efc-8722-93d9180b301c">14.23</ix:nonFraction>, respectively. The total intrinsic value of options exercised during the three months ended March&#160;31, 2022 and 2021 was approximately $<ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNDA5OQ_0879cbb6-f1d6-4884-9cec-d29289d3448e">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNDEwNg_2494de2a-422e-4a45-a548-531c7ca9ab9d">1.4</ix:nonFraction> million, respectively.  The total cash received for options </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i2701ee0f443f4bd0bbb37a20a7c1e2ec"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercised during the three months ended March&#160;31, 2022 was de minimis, and $<ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNDIzMw_14bcc18e-d51a-46f8-ac58-0577799b699d">2.5</ix:nonFraction> million was received for options exercised during the three months ended March 31, 2021.  The total fair value of shares vested in the three months ended March&#160;31, 2022 and 2021 was approximately $<ix:nonFraction unitRef="usd" contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNDM0MQ_d9c08261-20bb-4b29-9058-799485d8abbe">5.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNDM0OA_4db7962c-7bdb-4137-b566-bef65fbc97b6">4.1</ix:nonFraction> million, respectively. As of March&#160;31, 2022, the total unrecognized compensation expense related to unvested stock options, net of related forfeiture estimates, was approximately $<ix:nonFraction unitRef="usd" contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNDUxMA_cb97d24a-c596-47f5-94b4-dd81e45f2559">38.4</ix:nonFraction> million, which the Company expects to recognize over a weighted-average period of approximately <ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNDYwMQ_512704fa-efba-43db-ab93-81fd66f6c694">1.6</ix:nonNumeric> years.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants restricted stock units (RSUs) under the 2013 Plan to employees from time to time as a component of their compensation. During the three months ended March 31, 2022, the Company awarded RSUs to employees in conjunction with the annual performance review process. Each RSU vests over a <ix:nonNumeric contextRef="i0dc396f12757461e9c5b3a86b51821a5_D20220101-20220331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfMzg0ODI5MDcwNDYwMA_1daa5e50-3dd4-4983-9109-72486bf0e9ae">two-year</ix:nonNumeric> period and entitles the holder to receive <ix:nonFraction unitRef="shares" contextRef="i0dc396f12757461e9c5b3a86b51821a5_D20220101-20220331" decimals="INF" name="mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfMzg0ODI5MDcwNDU4NQ_cf19c22f-ffd3-4c6a-9851-02d156f95633">one</ix:nonFraction> share of the Company's common stock when the RSU vests. Compensation expense is recognized on a straight-line basis over the vesting period. </span></div><ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNTQ3Mg_b980e999-53c1-47b6-9342-0489d0742ed8" escape="true"><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the three months ended March&#160;31, 2022:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa66c46429f947848a8668ce68165b60_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjE4ZDdhYzA5MDAxNzQ3NThiMjk5MDZjMTIxNTRkNDM5L3RhYmxlcmFuZ2U6MThkN2FjMDkwMDE3NDc1OGIyOTkwNmMxMjE1NGQ0MzlfMS0xLTEtMS0zNjkyMQ_dd614cf0-ea44-4fa6-9b41-0699da8ff5a1">21,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifa66c46429f947848a8668ce68165b60_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjE4ZDdhYzA5MDAxNzQ3NThiMjk5MDZjMTIxNTRkNDM5L3RhYmxlcmFuZ2U6MThkN2FjMDkwMDE3NDc1OGIyOTkwNmMxMjE1NGQ0MzlfMS0zLTEtMS0zNjkyMQ_d16ff12c-26fa-4afe-b832-eadb879958dc">25.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0dc396f12757461e9c5b3a86b51821a5_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjE4ZDdhYzA5MDAxNzQ3NThiMjk5MDZjMTIxNTRkNDM5L3RhYmxlcmFuZ2U6MThkN2FjMDkwMDE3NDc1OGIyOTkwNmMxMjE1NGQ0MzlfMi0xLTEtMS0zNjkyMQ_3ed51ae8-e559-4091-9595-dfb1c0548b7e">309,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0dc396f12757461e9c5b3a86b51821a5_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjE4ZDdhYzA5MDAxNzQ3NThiMjk5MDZjMTIxNTRkNDM5L3RhYmxlcmFuZ2U6MThkN2FjMDkwMDE3NDc1OGIyOTkwNmMxMjE1NGQ0MzlfMi0zLTEtMS0zNjkyMQ_be9ee6f3-b44c-40a2-874b-eba2a0b90828">10.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0dc396f12757461e9c5b3a86b51821a5_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjE4ZDdhYzA5MDAxNzQ3NThiMjk5MDZjMTIxNTRkNDM5L3RhYmxlcmFuZ2U6MThkN2FjMDkwMDE3NDc1OGIyOTkwNmMxMjE1NGQ0MzlfNC0xLTEtMS0zNjkyMQ_bf16a194-abcd-40b8-9c35-5a7681aad2bd">5,428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0dc396f12757461e9c5b3a86b51821a5_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjE4ZDdhYzA5MDAxNzQ3NThiMjk5MDZjMTIxNTRkNDM5L3RhYmxlcmFuZ2U6MThkN2FjMDkwMDE3NDc1OGIyOTkwNmMxMjE1NGQ0MzlfNC0zLTEtMS0zNjkyMQ_52f4a564-d285-4039-984f-a78d6e73b805">10.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id18c2d3f95654745b74930d2f8ea04b0_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjE4ZDdhYzA5MDAxNzQ3NThiMjk5MDZjMTIxNTRkNDM5L3RhYmxlcmFuZ2U6MThkN2FjMDkwMDE3NDc1OGIyOTkwNmMxMjE1NGQ0MzlfNS0xLTEtMS0zNjkyMQ_b9e7b859-e782-4e0e-9c7c-8736cb278e07">325,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id18c2d3f95654745b74930d2f8ea04b0_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjE4ZDdhYzA5MDAxNzQ3NThiMjk5MDZjMTIxNTRkNDM5L3RhYmxlcmFuZ2U6MThkN2FjMDkwMDE3NDc1OGIyOTkwNmMxMjE1NGQ0MzlfNS0zLTEtMS0zNjkyMQ_e6e43f01-41df-4c53-bc21-faf1f7b8435c">11.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="id18c2d3f95654745b74930d2f8ea04b0_I20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNTMwMg_7c651423-9f63-48c6-ab1b-1c5b30c6bab5">2.9</ix:nonFraction> million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of approximately <ix:nonNumeric contextRef="i0dc396f12757461e9c5b3a86b51821a5_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNTQ2OA_55cece12-2701-49d6-9c2a-1d9d45f6cbb4">1.4</ix:nonNumeric> years.</span></div></ix:continuation><div id="ida709811ef604d5ea772a19a8a9c1dfd_58"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 9. <ix:nonNumeric contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81OC9mcmFnOjU2OThkNDlmODY4YjQ1OWM4ZGRkZGJiYWUxZGMyZjhkL3RleHRyZWdpb246NTY5OGQ0OWY4NjhiNDU5YzhkZGRkYmJhZTFkYzJmOGRfMTA2Mg_2c7f9602-85ca-4bc2-b8b1-197a8ba10079" continuedAt="i7013e251d5444a6999afdfa7c43e9a93" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7013e251d5444a6999afdfa7c43e9a93">On September 13, 2019, a securities class action complaint was filed in the U.S. District Court for the District of Maryland (District Court) by Todd Hill naming the Company, its Chief Executive Officer, Dr. Koenig, and its Chief Financial Officer, Mr. Karrels, as defendants for allegedly making false and materially misleading statements regarding the Company&#8217;s SOPHIA trial. On August 17, 2020, the Employees&#8217; Retirement System of the City of Baton Rouge and Parish of East Baton Rouge was appointed as Lead Plaintiff, and on October 16, 2020, the Lead Plaintiff filed an amended complaint. The amended complaint asserts a putative class period stemming from February 6, 2019 to June 4, 2019. The Company filed a Motion to Dismiss on November 30, 2020. On September 29, 2021, the District Court issued an Order dismissing the case, with prejudice. On October 28, 2021 the Lead Plaintiff filed a Notice of Appeal.  The appeal is now pending in the Fourth Circuit. The Company intends to vigorously defend against this action. However, the outcome of this legal proceeding is uncertain at this time and the Company cannot reasonably estimate a range of loss, if any. Accordingly, the Company has not accrued any liability associated with this action.</ix:continuation></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="ida709811ef604d5ea772a19a8a9c1dfd_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations is based upon our unaudited consolidated financial statements included in this Quarterly Report on Form 10-Q, which have been prepared by us in accordance with U.S. generally accepted accounting principles (GAAP), for interim periods and with Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended. This discussion and analysis should be read in conjunction with these unaudited consolidated financial statements and the notes thereto as well as in conjunction with our audited consolidated financial statements and related notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-indent:45pt"><span><br/></span></div><div id="ida709811ef604d5ea772a19a8a9c1dfd_64"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer.  We have a pipeline of product candidates being evaluated in clinical trials sponsored by us or our collaborators.  These product candidates include multiple immuno-oncology programs, some of which were created primarily using our proprietary, antibody-based technology platforms. We believe our product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.  In March 2021, we and our commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We commenced active operations in 2000, and have since devoted substantially all of our resources to staffing our company, developing our technology platforms, identifying potential product candidates, undertaking preclinical studies, conducting clinical trials, developing collaborations, business planning and raising capital. We only began generating revenues from the sale of products in 2021. We have financed our operations primarily through the public and private offerings of our securities, collaborations with other biopharmaceutical companies, and government grants and contracts.&#160;Although it is difficult to predict our funding requirements, we anticipate that our cash, cash equivalents and marketable securities as of March&#160;31, 2022, combined with anticipated and potential collaboration payments and product revenues, should enable us to fund our operations through 2023. Our expected funding requirements do not reflect anticipated expenditures related to the full Phase 2/3 development of MGC018 in metastatic castration-resistant prostate cancer (mCRPC) anticipated to begin by year-end 2022, or further expansion of our other studies currently ongoing. However, we believe that we can reasonably obtain funding for the planned Phase 2 portion of the MGC018 mCRPC study through a combination of existing financial resources, a variety of external funding or potential revenue sources, and project prioritization.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through March&#160;31, 2022, we had an accumulated deficit of $1.0 billion. We expect that over the next several years this deficit will increase as we increase our expenditures in research and development in connection with our ongoing activities with several clinical trials, and incur costs related to commercial product sales.&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has negatively impacted the global economy, created significant financial market volatility, disrupted global supply chains, and resulted in a significant number of infections and deaths worldwide.  In addition, several national, state and local governments have placed restrictions on people from gathering in groups or interacting within a certain physical distance. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, although there has been some negative impact on our business and operations, including, for example, slowed clinical trial enrollment, we have been able to mitigate against more severe impacts of the COVID-19 pandemic on our business and operations.  However, the COVID-19 pandemic could have a more significant negative impact on our business in the future depending on the depth of the effects and the duration of the crisis. In response to the COVID-19 pandemic, we have been focused on keeping our employees safe, continuing patients on trials, and maintaining our manufacturing capabilities and research efforts.  The COVID-19 pandemic and its variants continue to evolve and we continue to monitor our business very closely to try and mitigate any potential impacts. We expect the pandemic to continue to have some near-term impact on the initiation of new studies and on clinical trial enrollment.  Significant delays in the timing of our clinical trials and in regulatory reviews could adversely affect our ability to commercialize the product candidates in our pipeline. We are classified as a government contractor and are required to comply with Executive Order 14042. The contract terms include the requirement that all our employees that may be on site at the same location as any employee supporting the government contract be fully vaccinated against COVID-19, unless legally entitled to an accommodation due to a disability or religious belief, practice or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">observance. In anticipation of deadlines associated with the contract terms and Executive Order 14042, we implemented a company-wide vaccination requirement by the end of 2021, with certain exceptions.  To date, we do not believe our vaccination requirement has resulted in workforce attrition nor will it result in material difficulty securing future labor needs. If attrition is significant, our business could be adversely affected.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, we cannot precisely predict the impact that the COVID-19 pandemic will have in the future due to numerous uncertainties, including the severity, duration and resurgences of the disease and new variants, actions that may be taken by governmental authorities, the impact to the business of potential variations or disruptions in our supply chain, and other factors identified in Part II, Item 1A. &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2021. Given these uncertainties, the COVID-19 pandemic could disrupt the business of certain of our collaborators and impact our business operations and our ability to execute on our associated business strategies and initiatives, and adversely impact our consolidated results of operations and/or our financial condition in the future. We will continue to closely monitor and evaluate the nature and extent of the impact of the COVID-19 pandemic to our business, consolidated results of operations, and financial condition. </span></div><div><span><br/></span></div><div id="ida709811ef604d5ea772a19a8a9c1dfd_67"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborations</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pursue a balanced approach between product candidates that we develop ourselves and those that we develop with our collaborators. Under our strategic collaborations to date, we have received significant non-dilutive funding and continue to have rights to additional funding upon completion of certain research, achievement of key product development milestones and royalties and other payments upon the commercial sale of products. Our current collaborations include the following:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Incyte. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for retifanlimab, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while we retain the right to develop our pipeline assets in combination with retifanlimab. Incyte paid us an upfront payment of $150.0 million under the terms of the agreement. In July 2021, Incyte announced that the U.S. Food and Drug Administration (FDA) had issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for retifanlimab as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal.  Incyte&#8217;s announcement indicated that the FDA determined that additional data were needed to demonstrate the clinical benefit of retifanlimab for the submitted indication, and that Incyte was reviewing the CRL and would discuss next steps with the FDA. Incyte subsequently withdrew its European application for marketing authorization of retifanlimab for the treatment of squamous carcinoma of the anal canal. Incyte has stated it is pursuing development of retifanlimab in potentially registration-enabling studies beyond squamous cell carcinoma of the anal canal, including in patients with MSI-high endometrial cancer, Merkel cell carcinoma and non-small cell lung cancer.  Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline.   </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, Incyte leads global development of retifanlimab. Assuming successful development and commercialization of retifanlimab by Incyte, we could receive total development and regulatory milestones of up to approximately $420.0 million and up to $330.0 million in commercial milestones. We received $70.0 million of the total development milestones through March&#160;31, 2022. If retifanlimab is approved and commercialized, we would be eligible to receive tiered royalties of 15% to 24% on any global net sales and we have the option to co-promote retifanlimab with Incyte. We retain the right to develop our pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and us commercializing our asset(s), if any such potential combinations are approved. We also have an agreement with Incyte under which we are to perform development and manufacturing services for Incyte's clinical needs of retifanlimab (Incyte Clinical Supply Agreement) and another agreement under which we are entitled to manufacture a portion of Incyte&#8217;s global commercial supply of retifanlimab (Incyte Commercial Supply Agreement). </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Zai Lab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In 2018, we entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#8217;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab, a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development in its territory. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2018 Zai Lab Agreement, Zai Lab paid us an upfront payment of $25.0 million less foreign withholding tax of $2.5 million. Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, we could receive up to $140.0 million in development and regulatory milestones, of which we have already earned $9.0 million. In addition, Zai Lab would pay us tiered royalties at percentage rates of mid-teens to 20% for net sales of margetuximab in Zai Lab&#8217;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#8217;s territory and 10% for net sales of the TRIDENT molecule in Zai Lab&#8217;s territory, which may be subject to adjustment in specified circumstances.</span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into two agreements under which we are to perform manufacturing services for Zai Lab&#8217;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements).  </span></div><div style="padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates our DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be designated by us. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while we receive commercial rights in all other territories. Under the Lead Program, Zai Lab received an option upon reaching a predefined clinical milestone to convert the regional arrangement into a global 50/50 profit share. If Zai Lab elects such option, Zai Lab is to pay us $85.0 million plus any research costs incurred by both parties as of the option election date. Zai Lab also obtained exclusive, global licenses from us to develop, manufacture and commercialize two additional molecules (license-only programs). Zai Lab granted us a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to us.</span></div><div style="padding-left:54pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2021 Zai Lab Agreement, the Lead Program includes joint research and development services by both us and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with us to perform research and development services in the future. </span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab paid us an upfront payment of $25.0 million. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, we and Zai Lab entered into a separate stock purchase agreement (Stock Purchase Agreement) whereby Zai Lab paid us approximately $30.0 million to purchase 958,467 newly issued shares of our common stock, par value $0.01, at a fixed price of $31.30 which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date. </span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful development and commercialization of the Programs under the 2021 Zai Lab Agreement, we could receive up to $1.4 billion in development, regulatory and commercial milestones. In addition, Zai Lab would pay us tiered royalties at percentage rates of low double digit teens on annual net sales of certain specified products and of mid-single digits to low double digit teens on annual net sales of other specified products in Zai's territory, subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, we may also receive reimbursements from Zai Lab for certain research and development costs incurred by us. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">I-Mab Biopharma.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2019, we entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates our proprietary Fc Optimization technology platform (I-Mab License Agreement). I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by us. <br/> <br/>Under the terms of the agreement, I-Mab paid us an upfront payment of $15.0 million. Assuming successful development and commercialization of enoblituzumab, we could receive up to $135.0 million in development and regulatory milestones of which $5.0 million has been earned from the inception of the I-Mab License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, I-Mab would pay us tiered royalties ranging from mid-teens to 20% on annual net sales in its territories.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       In October 2021, we entered into an agreement under which we are to perform development and manufacturing services for I-Mab&#8217;s clinical needs of enoblituzumab</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Janssen. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we entered into a research collaboration and global license agreement to develop a preclinical bispecific molecule with Janssen Biotech, Inc. (Janssen). The research collaboration will incorporate our proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the agreement, Janssen paid us an upfront payment of $20.0 million and will be responsible for funding all expenses. We will also be eligible to receive up to $312.0 million in potential milestone payments and tiered royalties of up to 10% on worldwide product sales.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="ida709811ef604d5ea772a19a8a9c1dfd_70"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="text-indent:39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting estimates are policies which require the most significant judgments and estimates in the preparation of our consolidated financial statements. A summary of our critical accounting estimates is presented in Part II, Item&#160;7, of our Annual Report on Form 10-K for the year ended December&#160;31, 2021.  There have been no material changes with respect to our critical accounting estimates during the three months ended March 31, 2022. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:39pt"><span><br/></span></div><div id="ida709811ef604d5ea772a19a8a9c1dfd_73"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a comparison of our revenue for the three months ended March&#160;31, 2022 and 2021 (dollars in millions):</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:43.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.431%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from collaborative and other agreements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from government agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in revenue of $5.8 million for the three months ended March 31, 2022 compared to the three months ended March 31, 2021 was primarily due to:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of $10.0 million in development milestones recognized under the</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Incyte License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of $3.0 million in revenue recognized under the Incyte Commercial Supply Agreement due to timing of manufacturing activities.  </span></div><div style="margin-bottom:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreases were partially offset by:  </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognition of a $5.0 million milestone under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2018 Zai Lab Agreement during the three months ended March 31, 2022</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $2.7 million in net product revenue from sales of MARGENZA.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Sales</span></div><div style="margin-bottom:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales for the three months ended March 31, 2022 and 2021 consisted primarily of product royalties and fill finish costs. Product sold during these periods consisted of drug product that was previously charged to research and development expense prior to FDA approval of MARGENZA, which favorably impacted our gross margin for the three months ended March 31, 2022 and 2021. We expect cost of product sales to continue to be positively impacted as we sell through this drug product.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a comparison of our research and development expense for the three months ended March&#160;31, 2022 and 2021 (dollars in millions):</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.859%"><tr><td style="width:1.0%"></td><td style="width:45.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.513%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.336%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.338%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGC018</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Margetuximab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flotetuzumab</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lorigerlimab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enoblituzumab</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tebotelimab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IMGC936</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retifanlimab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGD024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DART molecules under HIV government contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other programs (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)  Includes research and discovery projects, as well as early preclinical and terminated molecules.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expense for the three months ended March 31, 2022 increased by $8.3 million compared to the three months ended March 31, 2021 primarily due to:</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased development, manufacturing and clinical trial costs related to MGC018;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased development of discovery projects and preclinical molecules; and</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased clinical trial enrollment costs related to lorigerlimab.</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These increases were partially offset by:</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">decreased development, manufacturing and clinical trial costs related to flotetuzumab, which development has been discontinued;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased margetuximab manufacturing costs related to the Zai Lab Clinical Supply Agreement; and</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">decreased retifanlimab manufacturing costs related to the Incyte Commercial Supply Agreement.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect our research and development expense will continue to increase as we progress our pipeline of product candidates. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expense</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased by $1.2 million for the three months ended March 31, 2022 compared to the three months ended March 31, 2021 primarily due to MARGENZA selling costs, as well as increased stock-based compensation and consulting expenses.  </span></div><div><span><br/></span></div><div id="ida709811ef604d5ea772a19a8a9c1dfd_76"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use. As a biotechnology company, we have primarily funded our operations with proceeds from the sale of our common stock in equity offerings, revenue from our multiple collaboration agreements, and contracts and grants from the National Institute of Allergy and Infectious Diseases.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews our available liquidity relative to our operating budget and forecast to monitor the sufficiency of our working capital, and anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support our product development activities. There can be no assurances that new sources of capital will be available to us on commercially acceptable terms, if at all. Also, any future collaborations, strategic alliances and marketing, distribution or licensing arrangements may require us to give up some or all rights to a product or technology at less than its full potential value. If we are unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, we will assess our capital resources and may be required to delay, reduce the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">scope of, or eliminate one or more of our product research and development programs or clinical studies, and/or downsize our organization</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although it is difficult to predict our funding requirements, we anticipate that our cash, cash equivalents and marketable securities as of March&#160;31, 2022, as well as anticipated and potential collaboration payments, and product revenues should enable us to fund our operations through 2023. Our expected funding requirements do not reflect anticipated expenditures related to the full Phase 2/3 development of MGC018 in mCRPC anticipated to begin by year-end 2022, or further expansion of our other studies currently ongoing. However, we believe that we can reasonably obtain funding for the planned Phase 2 portion of the MGC018 mCRPC study through a combination of existing financial resources, a variety of external funding or potential revenue sources, and project prioritization.</span></div><div style="margin-bottom:6pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Material Cash Requirements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, there were no significant changes to our material cash requirements, including contractual and other obligations, as presented in Part II, Item 7, Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a summary of our cash flows for the three months ended March&#160;31, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:64.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.494%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net change in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(76.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities consists of our net loss adjusted for non-cash items such as depreciation and amortization expense and stock-based compensation and changes in working capital.  Cash used in operating activities for the three months ended March&#160;31, 2022 benefited from the $11.2 million received from Incyte under the Incyte Manufacturing and Clinical Supply Agreement, and cash used in operating activities for the three months ended March 31, 2021 benefited from the $10.0 million milestone payment received under the Incyte License Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Investing Activities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities during the three months ended March 31, 2022 and 2021 is primarily due to purchases of marketable securities, partially offset by maturities of marketable securities.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the three months ended March 31, 2021 reflects net cash proceeds from our securities offerings of approximately $98.2 million. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="ida709811ef604d5ea772a19a8a9c1dfd_82"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;As of March&#160;31, 2022, our exposure to market risk has not changed materially since December&#160;31, 2021. For more information on financial market risks related to changes in interest rates, reference is made to Item 7A. Quantitative and Qualitative Disclosures About Market Risk contained in Part II of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, filed with the SEC on February 24, 2022. </span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="ida709811ef604d5ea772a19a8a9c1dfd_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONTROLS AND PROCEDURES</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of March&#160;31, 2022. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in our periodic reports filed with the SEC (such as this Quarterly Report on Form 10-Q) has been appropriately recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Based on their evaluation of our disclosure controls and procedures as of March&#160;31, 2022, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective at the reasonable assurance level.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the three months ended March 31, 2022 that materially affected, or are reasonably likely to materially effect, our internal control over financial reporting.</span></div><div id="ida709811ef604d5ea772a19a8a9c1dfd_88"></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="ida709811ef604d5ea772a19a8a9c1dfd_91"></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.  Legal Proceedings</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are or may be involved in various legal or regulatory proceedings, claims or  class actions related to alleged patent infringements and other intellectual property rights, or alleged violation of commercial, corporate, securities, labor and employment, and other matters incidental to our business. We do not currently, however, expect such legal proceedings to have a material adverse effect on our business, financial condition or results of operations. However, depending on the nature and timing of a given dispute, an eventual unfavorable resolution could materially affect our current or future results of operations or cash flows.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 9, Commitments and Contingencies, to the consolidated financial statements of this Quarterly Report on Form 10-Q for more information.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ida709811ef604d5ea772a19a8a9c1dfd_94"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:7.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.008%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk Factors</span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There have been no material changes in the risk factors described in &#8220;Item 1A. Risk Factors&#8221; of our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="ida709811ef604d5ea772a19a8a9c1dfd_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"><tr><td style="width:1.0%"></td><td style="width:6.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibits</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:14.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.468%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex101spitznagelemploymenta.htm">Employment Agreement between the Company and Thomas Spitznagel Ph.D. </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31-1q12022.htm">Rule 13a-14(a) Certification of Principal Executive Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31-2q12022.htm">Rule 13a-14(a) Certification of Principal Financial Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32-1q12022.htm">Section 1350 Certification of Principal Executive Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32-2q12022.htm">Section 1350 Certification of Principal Financial Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Schema Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Calculation Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Definition Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Labels Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Presentation Linkbase Document</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data (formatted as Inline XBRL and contained in Exhibit 101 filed herewith)</span></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+  Indicates management contract or compensatory plan.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ida709811ef604d5ea772a19a8a9c1dfd_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURES</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MACROGENICS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BY:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Scott Koenig</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Koenig, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BY:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ James Karrels</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Karrels</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: May 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex101spitznagelemploymenta.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib88268b88f3f483ca532957840d32233_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EMPLOYMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This Employment Agreement (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) is entered into as of November 1, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), by and between MacroGenics, Inc., a Delaware corporation, together with its successors and assigns (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employer'' </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">or</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, and Thomas Spitznagel </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Executive&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In consideration of the promises and the respective undertakings of Employer and Executive set forth below, Employer and Executive hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt;text-decoration:underline">Employment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Employer hereby employs Executive, and Executive hereby accepts such employment and agrees to perform services for Employer, for the period and on the other terms and subject to the conditions set forth in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Executive is employed &#8220;at-will&#8221; which means that Executive's employment is not for any defined term and may be terminated by either Executive or the Company at any time, with or without cause, for any or no reason, subject to the notice provisions herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt;text-decoration:underline">Position and Duties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.01</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Service with Employer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Employer hereby employs Executive in an executive capacity with the title of Sr. Vice President, BioPharmaceutical Development and Manufacturing (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) reporting directly to the President and Chief Executive Officer (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CEO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), and Executive hereby accepts such employment and undertakes and agrees to serve in such capacity. Subject to the overall policy directives of the Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), CEO, and applicable law, in Executive's capacity as, Sr. Vice President, BioPharmaceutical Development and Manufacturing, Executive shall have such powers, perform such duties and fulfill such responsibilities as are typically associated with such position in other similarly situated companies.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.02</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Performance of Duties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Executive agrees to&#58; (i) devote substantially all of Executive's business time, attention and efforts to the business and affairs of Employer while employed&#59; and (ii) adhere to all Employer's written employment policies and procedures as shall be in force from time to time. Executive shall perform Executive's duties primarily at the Company's headquarters in Rockville, Maryland, but is expected to travel as Company business necessitates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.03</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Outside Activities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. During the term of Executive's employment with the Company pursuant to this Agreement, Executive shall not&#58; (i) accept other employment&#59; (ii) render or perform services for compensation to any Person (as hereinafter defined) other than Employer and its Affiliates (as defined below)&#59; (iii) serve as an officer or on the board of directors (or similar governing body) of any entity other than Employer or an Affiliate of Employer, whether or not for compensation&#59; or (iv) engage in any other business enterprise or activity without prior approval from the CEO and Board of Directors. Executive may engage in personal investments without disclosure to or written approval from the Board provided (1) such investment is passive and Executive is not required or expected to, and does not, serve as a board member, advisor or consultant, (2) at all times Executive owns beneficially less than 5 % of the outstanding securities of any issuer, and (3) and such personal investment shall not otherwise interfere with Executive's performance of duties hereunder and&#47;or the other provisions of this Agreement or any other of Executive's written agreements with Employer. Executive may engage in charitable and community activities without disclosure to or written approval from the Board provided such activities do not interfere with Executive's responsibilities, duties and obligations to Employer. Nothing herein is intended to limit or waive Executive's fiduciary duties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.04</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Executive Representations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Executive represents that Executive is not subject to any restrictive covenant, confidentiality, or any other agreement that would interfere in any way with Executive's employment with Employer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt;text-decoration:underline">Compensation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Employer shall pay to Executive an annual base salary for all services to be rendered by Executive under this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Base Salary</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), which Base Salary shall be paid in accordance with Employer's normal payroll schedule, procedures and policies (which schedule, procedures and policies may be modified from time to time) and subject to applicable deductions as required by law. As of the date hereof, the Base Salary is $385,000. Employer shall review Executive's </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">salary on an annual basis and may, in its discretion, consider and declare from time to time increases in the Base Salary.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.02</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Annual Bonus</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Executive shall also be eligible to receive, in addition to the Base Salary, an annual bonus (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bonus</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) having a target amount equal to a percent of Executive's Base Salary (''</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Target Bonus</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). The Target Bonus will be determined by the Compensation Committee of the Board (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compensation Committee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) from time to time based on Executive's position and title. The actual dollar amount of any Bonus payable for any particular year will be determined by the Compensation Committee in its discretion taking into account the Company's performance and Executive's individual performance. In order to receive a Bonus, Executive must be employed by Employer on the date the Bonus is paid, except as set forth below in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.03</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.04</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.03</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Participation in Benefit Plans</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Executive shall be entitled to participate in all employee benefit plans or programs offered to other senior executives from time to time (to the extent that Executive meets the requirements for each such plan or program), including participation in any health insurance plan, disability insurance plan, dental plan, eye care plan, 401(k) plan, life insurance plan, or other similar plans (all such benefits, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit Plans</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), in accordance with the terms and conditions of such Benefit Plans in effect from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.04</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Employer shall reimburse Executive for all ordinary and necessary business expenses reasonably incurred by him in the performance of Executive's duties under this Agreement, subject to the presentment and approval of appropriate itemized expense statements, receipts, vouchers or other supporting documentation in accordance with Employer's normal policies for expense verification in effect from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.05</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Vacation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Executive shall be entitled to twenty (20) vacation days per calendar year, accruing in accordance with the Company's vacation policy. Executive may carry over up to a maximum of 200 hours of annual leave at any time, and any unused vacation time beyond that will be forfeited.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.06</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Total Compensation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Other than as may be approved by the Compensation Committee or Board, Executive shall not receive any other compensation or benefits from the Company other than as provided in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt;text-decoration:underline">Termination and Payments Upon Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.01</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Voluntary Resignation without Good Reason</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Executive may terminate Executive's employment by providing Employer with 30 days' advance written notice. Employer may waive some or all of such notice period and accelerate the Termination Date, or request that Executive not report to work for some of all such notice period notice, neither of which will be deemed a termination by Employer or a Good Reason event. If Executive terminates Executive's employment (other than for Good Reason (as defined below) or by reason of death or Disability (as defined below))&#58; (i) Employer shall pay to Executive the Accrued Obligations (as defined below), (ii) Executive's participation in the Benefit Plans shall terminate as of the Termination Date, and (iii) Employer shall have no other obligations to Executive under this Agreement, other than those provided in this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.01</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.11pt">For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued Obligations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means&#58; (i) Executive's earned and unpaid Base Salary through the Termination Date&#59; (ii) reimbursement for any reimbursable business expenses incurred by Executive through the Termination Date in accordance with </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.05</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#59; and (iii) Executive's accrued but unused vacation time as of the Termination Date. The amounts payable hereunder shall be paid no later than sixty (60) days following Executive's Termination Date..</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.11pt">For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Termination Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means&#58; the effective date of Executive's &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">separation from service</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; as defined in Section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.02</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Termination by Employer For Cause. Employer may terminate Executive with or without Cause upon written notice to Executive. If Executive is terminated for Cause&#58; (i) Employer shall pay to Executive the Accrued Obligations, (ii) Executive's participation in the Benefit Plans shall terminate as of the Termination Date, and (iii) Employer shall have no further obligations to Executive under this Agreement, other than those provided in this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.02</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cause</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means&#58; (a) Executive's failure to substantially perform Executive's duties with the Company (if Executive </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">has not cured such failure to substantially perform, if curable, within thirty (30) days after Executive's receipt of written notice thereof from the Board that specifies the conduct constituting Cause under this clause (a))&#59; (b) Executive's willful misconduct, or gross negligence in the performance of Executive's duties hereunder&#59; (c) the conviction of Executive, or the entering by Executive of a guilty plea or plea of no contest with respect to, any crime that constitutes a felony or involves fraud, dishonesty or moral turpitude&#59; (d) Executive's commission of an act of fraud, embezzlement or misappropriation against the Company&#59; (e) Executive's material breach of the fiduciary duty owed by Executive to Company&#59; (f) Executive's engaging in any improper conduct (including conduct that occurred within ten (10) years prior to the date of this Agreement that has not been previously disclosed to the Company) that has or is likely to have an adverse economic or reputational impact on the Company&#59; (g) Executive engaging in sexual or other harrasment in the workplace or with respect to any employees, consultants, customers, vendors or business relations of Employer and its Affiliates or violating any Company policies regarding harassment&#59; or (h) Executive's material breach of this Agreement (if Executive has not cured such breach, if curable, within thirty (30) days after Executive's receipt of written notice thereof from the Board that specifies the conduct constituting Cause under this clause (h)).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.03</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Termination by Employer Without Cause or by Executive for Good Reason. If Executive is terminated by Employer without Cause or by Executive for Good Reason&#58; (i) Employer shall pay to Executive the Accrued Obligations, (ii) Executive shall be entitled to receive the Severance Benefits (as defined below in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.05</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and subject to the conditions described therein and in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.06</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">). (iii) Employer shall pay to Executive any earned, but unpaid, bonus obligation relating to the prior fiscal year payable at the same time as bonuses are paid to the senior management team (but not later than March 15 of the calendar year following the year for which the bonus is payable), and (iv) Employer shall have no further obligations to Executive under this Agreement, other than those provided in this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.03</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Executive's rights to the Severance Benefits under this Agreement shall be in lieu of, and not in addition to, any severance under any other policy, plan or arrangement of Employer. For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Good Reason</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the occurrence of any of the following events (without Executive's consent)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">a material adverse change in Executive's functions, duties, or responsibilities as Sr. Vice President, Biopharmaceutical Development &#38; Manufacturing with the Company, which change would cause Executive's position to become one of materially lesser responsibility, importance, or scope&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">a material change in the geographic location at which Executive must perform services to the Company of 50 miles or more from the Company's headquarters in Rockville, Maryland (unless Executive is permitted to telecommute rather than work at the Company's new headquarters)&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">a material breach of this Agreement by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, (1) no such event shall constitute &#8220;Good Reason&#8221; unless (a) Executive shall have given written notice of such event to the Company within ninety (90) days after the initial occurrence thereof, (b) the Company shall have failed to cure the condition constituting Good Reason within thirty (30) days following the delivery of such notice (or such longer cure period as may be agreed upon by the parties), and (c) Executive terminates employment within thirty (30) days after expiration of such cure period, and (2) there shall not be &#8220;Good Reason&#8221; under clause (i) above if the Company puts Executive on a paid leave of absence or similar arrangement in order to investigate whether there has been a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cause</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; event as long as the Board has determined in good faith that such investigation is warranted.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.04</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Termination by Employer due to Executive's Death or Disability. If Executive's employment is terminated by reason of death or Disability (as defined below)&#58; (i) Employer shall pay to Executive the Accrued Obligations, (ii) Employer shall pay to Executive any earned, but unpaid, bonus obligation relating to the prior fiscal year payable at the same time as bonuses are paid to the senior management team (but not later than March 15 of the calendar year following the year for which the bonus is payable), (iii) Executive's participation in the Benefit Plans shall terminate as of the Termination Date (except to the extent Executive is eligible for continued disability benefits under the applicable Employer plan), and (iv) Employer shall have no further obligations to Executive under this Agreement, other than those provided in this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.04</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Disability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means Executive being determined to be totally disabled by the Social Security Administration or Executive's inability to engage in any substantial gainful activity by reason of any medically determinable physical or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than twelve months.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.05</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Severance Benefits&#58; &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severance Benefits</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.11pt">The payment to Executive of the Severance Amount in substantially equal installments over one year (with the first payment commencing on the first payroll date that occurs at least 28 days following the Termination Date), in accordance with Employer's normal payroll practices (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severance Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). If the Executive's termination occurs as of or in the twelve (12) months following a Change of Control, then &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severance Amount</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means (i) one year of Executive's then-current Base plus (ii) the Target Bonus multiplied by the Executive's then-current Base Salary. If the Executive's termination occurs prior to, or more than twelve (12) months following, a Change of Control, then &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severance Amount</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means one year of Executive's then-current Base Salary.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.11pt">The continuation of Executive's participation in the Company's medical, dental, and vision benefit plans at the same premium cost to Executive as charged to Executive immediately prior to the Termination Date for a period of twelve (12) months immediately following the Termination Date, or if earlier, until Executive obtains other employment which provides the same type of benefit&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">however,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that (i) it is understood and agreed that such continued medical, dental and vision benefits may at the election of the Company be provided by Executive electing the continuation of such coverage pursuant to COBRA with the Company reimbursing Executive for COBRA premiums to the extent required so that Executive's premium cost for the coverage in effect for Executive prior to the Termination Date is substantially the same as immediately prior to the Termination Date, and (ii) if the Company determines, in its reasonable judgment, that providing medical, dental, and&#47;or vision benefits in accordance with the preceding provisions of this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.05(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> would result in a violation of applicable law, the imposition of any penalties under applicable law, or adverse tax consequences for participants covered by the Company's medical, dental, and&#47;or vision plans, the Company may terminate such coverage (or reimbursement) with respect to Executive and instead pay to Executive taxable cash payments at the same time and in the same amounts as the Company would have paid as premiums (or as COBRA premium reimbursements) to provide such coverage.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">If the Termination Date occurs upon or within one year after the occurrence of a Change in Control, each stock option granted by the Company to Executive that is outstanding as of the Termination Date and is not fully vested as of the date of the Termination Date shall, as of the date Executive provides the Company with the Irrevocable Release (as defined below) provided for in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.06</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (but only if the Irrevocable Release is provided within the 60 day period provided for by </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.06</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), become vested with respect to 100% of the shares with respect to which the stock option is not vested as of the Termination Date&#59; provided, however that in no event shall any such option vest to the extent the option has expired prior to the date Executive provides the Company with the Irrevocable Release. For the avoidance of doubt, in the event that any of Executive's unvested stock options are to be terminated in connection with a Change of Control, Executive shall nonetheless be entitled to the accelerated vesting described in and subject to the conditions of this clause (c).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change of Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, and shall be deemed to have occurred, if&#58;</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">any Person, excluding employee benefit plans of the Company or any of its Affiliates, is or becomes the &#8220;beneficial owner'' (as defined in Rules 13d-3 and 13d-5 under the Securities and Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exchange Act</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), which Rules shall apply for purposes of this clause (a) whether or not the Company is subject to the Exchange Act), directly or indirectly, of Company securities representing more than fifty percent (50%) of the combined voting power of the Company's then outstanding securities (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Voting Power</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">the Company consummates a merger, consolidation, share exchange, division or other reorganization or transaction of the Company (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fundamental Transaction</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) with any other corporation, other than a Fundamental Transaction that results in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) at least fifty percent (50%) of the combined Voting Power immediately after such Fundamental Transaction of (i) the Company's outstanding securities, (ii) the surviving entity's outstanding securities, or (iii) in the case of a division, the outstanding securities of each entity resulting from the division&#59;</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.23pt">the stockholders of the Company approve a plan of complete liquidation or winding-up of the Company or the consummation of the sale or disposition (in one transaction or a series of transactions) of all or substantially all of the Company's assets&#59; or</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">during any period of 24 consecutive months, individuals who at the beginning of such period constituted the Board (including for this purpose any new director whose election or nomination for election by the Company's stockholders was approved by a vote of at least two-thirds (2&#47;3) of the directors then still in office who were directors at the beginning of such period or whose appointment, election or nomination was previously so approved or recommended) cease for any reason to constitute at least a majority of the Board.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.06</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Required Delivery of Irrevocable Release</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58; Compliance with </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Obligations. Notwithstanding the provisions of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.05</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, as a condition to entitlement to the Severance Benefits, Executive must provide to the Company an Irrevocable Release (as defined below) not later than the twenty-first (21st) day after the Date of Termination (or such later deadline as is specified by the Employer), and any statutory period pursuant to which Executive may revoke such release, as set forth in the Irrevocable Release, has lapsed without any such revocation. The Severance Benefits will not be paid or provided until the Irrevocable Release has been executed and delivered and the revocation period lapsed without revocation, and any Severance Benefits otherwise payable with respect to such waiting period shall be paid or provided with the first payment following the end of such waiting period. &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Irrevocable Release</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a confidential separation agreement and release of claims, in form and substance substantially similar to the attached </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. that has been executed by Executive, delivered to the Company, and become irrevocable by Executive. In addition, in the event that Executive breaches the obligations under </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> at any time during the Severance Period, Executive will cease to be entitled to any further Severance Benefits.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt;text-decoration:underline">Promises and Covenants Regarding Confidential Information and Goodwill&#59; Inventions and Assignment&#59; Restrictive Covenants</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.01</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Confidential Information and Goodwill</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. In consideration of Executive's promises and covenants contained in this Agreement, including Executive's promise and covenant not to disclose Confidential Information (as defined below), Employer will provide Executive with Confidential Information. In further consideration of Executive's promises and covenants contained in this Agreement, including Executive's promise and covenant to utilize the Goodwill (as defined below) exclusively for the benefit of Employer, Employer will allow Executive to receive Confidential Information concerning the Company's customers, labs, vendors and employees and, to the extent required to fulfill Executive's duties, the Company will permit Executive to represent the Company on its behalf with such persons. To the extent that Executive's duties involve sales or customer relations, the Company will permit Executive to utilize the Goodwill in Executive's sales efforts and will provide sales support to Executive similar to that which it provides to its sales representatives.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.02</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Duties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. While employed by Company, Executive shall perform the duties required of Executive hereunder and shall devote Executive's best efforts and exclusive business time, energy and skill to performing such duties&#59; not make any disparaging remarks regarding Company to any person with whom Company has business relations, including any employee or vendor of Company&#59; use the Goodwill solely for the benefit of Company&#59; and not interfere in such Goodwill.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.03</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Non-Disclosure Obligation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Executive will not at any time or in any manner, whether during or after the termination of employment, for any reason whatsoever (other than as required for the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">performance of Executive's authorized employment duties to Company), directly or indirectly disclose or make accessible to any person or entity (both commercial and non-commercial) any of the trade secrets, proprietary, technical and&#47;or confidential business information concerning the Company and its affiliates (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Confidential Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), including&#58; its research and development activities, including results and insights&#59; biological materials, products, designs, prototypes, methods, techniques, systems, processes, and technical specifications&#59; inventions (whether patentable or not), show-how and know-how&#59; potential or actual collaborations, partnerships or other arrangements with third parties&#59; regulatory and marketing plans, proposals and strategies&#59; pricing and costing policies&#59; sales&#59; customer and supplier lists and accounts&#59; employee information&#59; nonpublic financial information of the Company&#59; or information received by the Company from others under an obligation of confidentiality. This restriction shall not apply to&#58; (i) information that is in the public domain through no fault of the Executive&#59; (ii) information approved for release by written authorization of the Company but only to the extent of such authorization&#59; or (iii) information to the extent required by law or an order of any court, agency or proceeding to be disclosed, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that the Executive shall provide the Company with prompt notice of such disclosure so that the Company may seek an appropriate protective order or other relief and the Executive shall cooperate with the Company in any efforts by the Company to obtain a protective order or any other appropriate remedy restricting the disclosure. In addition, under the U.S. Defend Trade Secrets Act (18 U.S.C. Section 1833(b)(1)), Executive will not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (i) is made (A) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney&#59; and (B) solely for the purpose of reporting or investigating a suspected violation of law&#59; or (ii) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Executive shall comply with Company's policies pertaining to the management and protection of Confidential Information, as may be updated from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.04</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Company Property</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Executive agrees that during Executive's employment with the Company, the Executive shall not use or permit to be used any Company Property (as hereinafter defined) otherwise than for the purpose of performing services pursuant to Executive's employment with the Company. The term &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company Property</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall include all Company Confidential Information, notes, memoranda, files, reports, lists, agreements, records, drawings, sketches, designs, specifications, software programs, software codes, data, computers, network infrastructure, supplies, equipment (including lab equipment), assays, biological materials, cellular telephones and other devices, credit and&#47;or calling cards, keys, access cards, all means of access to any account, database, or computer system of the Company (whether personal to the Executive or public, published or unpublished, standard or backdoor, including all account names, passwords, access codes, unique personal identification numbers, any code kept secret and any other means allowing employee access to Company data or documentation), documentation or other materials of any nature and in any form, whether written, printed, electronic or in digital format or otherwise, relating to any matter within the scope of the business or reasonably anticipated business of the Company and its affiliates or concerning any of its dealings or affairs and any other Company property in Executive's possession, custody or control. The Executive further agrees that Executive shall not, after the termination of Executive's employment with the Company, possess, use or permit others to possess or use any such Company Property. The Executive acknowledges and agrees that all Company Property shall be and remain the sole and exclusive property of the Company. At any time and from time to time upon the request of the Company, the Executive shall deliver immediately to the Company all or any part of the Company Property in Executive's possession, and all copies thereof (including electronic copies), specified by the Company in such request. In addition, immediately upon the termination of Executive's employment with the Company, the Executive shall deliver to the Company all Company Property in Executive's possession, and all copies thereof (including electronic copies). Upon request, Executive shall deliver to Company a signed certification stating that Executive has complied with the terms of this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.04</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.05</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Assignment of Inventions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.11pt">The Executive expressly agrees to assign and does hereby assign to Company Executive's entire right, title, and interest in and to any designs, developments, trade secrets, technical specifications and technical data, methods, techniques, systems, processes, know-how and show-how, customer and supplier lists, marketing plans, pricing policies, inventions, concepts, ideas, works of authorship, expressions, discoveries, documentation, formulas, software, and improvements, derivatives, or modifications in any of the foregoing, (whether or not patentable or registerable under copyright, trademark or similar statutes, or subject to analogous protection) authored, created, made, conceived and&#47;or reduced to practice, in whole or in part by the Executive, solely or jointly with others, during Executive's employment with the Company (or initiated during Executive's employment and substantially completed during the six (6) months following Executive's termination of employment for any reason), and which (i) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">relate to or arise out of Executive's employment with the Company or the business or reasonably anticipated business of the Company, (ii) are developed using the Company Property, or (iii) are based on or derived from the Company Confidential Information (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inventions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) together with all intellectual property rights in and to such Inventions throughout the world, in each case, free and clear of any liens and other encumbrances and without reservations of any kind. The Executive agrees that all Inventions consisting of copyrightable subject matter are &#8220;works made for hire&#8221; as defined in in the Copyright Act of 1976 (17 U.S.C. &#167;101), as amended) and therefore the copyrights in such Inventions are solely owned by the Company. Executives waives any and all moral rights in or with respect to the Inventions that Executive may retain under law despite the foregoing assignment.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.11pt">The Executive agrees that Executive will promptly disclose to the Company any and all Inventions, and that during the Executive's employment or at any time thereafter, upon request of the Company, the Executive will sign, execute and deliver any and all documents or instruments, including applications, registrations, oaths, declarations, affidavits, invention assignments and copyright assignments, and will take any other action which the Company shall deem necessary to (i) procure or register trademark, copyright or patent rights with respect to Inventions, or to otherwise protect the Company's intellectual property and proprietary interests, (ii) enforce or defend Company's intellectual property rights in and to such Inventions, or (iii) perfect or demonstrate the Company's ownership of such Inventions and any intellectual property rights in and to such Inventions. The Company agrees to pay reasonable fees and expenses or other costs incurred by the Executive for any assistance rendered to the Company pursuant to this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.05(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">In the event the Company is unable, after reasonable effort, to secure the Executive's signature on any document required for the filing, prosecution or granting of an application (whether foreign or domestic) for patent, copyright or other analogous protection relating to the Inventions, whether because of the Executive's physical or mental incapacity, inability to locate Executive, failure of Executive to respond to reasonable requests or for any other reason whatsoever, the Executive hereby irrevocably designates and appoints the Company and its duly authorized officer and agent as the Executive's agent and attorney-in-fact (which designation and appointment is irrevocable and shall be deemed coupled with an interest and shall survive the Executive's death or incapacity), to act for and in the Executive's behalf and stead to execute and file any such documents and to do all other lawfully permitted acts to further the prosecution and issuance of patent, copyright or other analogous protection in the name of the Company with the same legal force and effect as if executed by the Executive.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.11pt">The Executive's obligation to assign Inventions shall not apply to any invention that the Executive can demonstrate through contemporaneous written records&#58; (i) was developed entirely on the Executive's own time and effort without using the Company's equipment, supplies, facilities, trade secrets or confidential information or other Company Property&#59; (ii) does not relate to the business of the Company or to the Company's actual or anticipated research and development activities&#59; and (iii) did not result from any work performed by the Executive for the Company. The obligations of the Executive under this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.05</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> shall continue beyond the termination of the Executive's employment with respect to Inventions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.06</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Pre-Existing Intellectual Property</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Executive has attached hereto as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> a complete list of all existing inventions (including patents and patent applications) and works of authorship (including publications) to which Executive claims ownership (whether partial or in its entirety) as of the date of this agreement and which relate, directly or indirectly, to Company's existing or proposed business, products, or research and development activities (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pre-Existing Intellectual Property</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). If no list is attached to this Agreement, Executive represents and warrants that there is no such Pre-Existing Intellectual Property. Executive will inform Company in writing, and obtain Company's express written permission, before incorporating any Pre-Existing Intellectual Property into any Invention or otherwise utilizing such Pre-Existing Intellectual Property in the course of Executive's employment with the Company. To the extent any Invention includes, is based on, or is a derivative or improvement of, or cannot reasonably be made, used, imported, sold, reproduced, distributed, modified, adapted, displayed, performed or otherwise exploited without using or violating any Pre Existing Intellectual Property or any other intellectual property rights that Executive owns or controls that have not been assigned hereunder, Executive hereby grants to Company a worldwide, royalty-free, fully paid-up, perpetual, irrevocable, transferable, non-exclusive right and license (with the right to sublicense through multiple tiers) to exploit and exercise all such Pre-Existing Intellectual Property and other intellectual property rights in connection with such Invention.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.07</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Other Promises and Covenants</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.11pt">During Executive's employment with Company and for a period of 12 months following termination of employment for any reason (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Competition Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), Executive shall not either directly or indirectly, on Executive's own or another's behalf, engage in or assist others in any of the following activities (except on behalf of Company)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">(whether as principal, agent, partner or otherwise) engage in, own, manage, operate, control, finance, invest in, participate in, or otherwise carry on, or be employed by, associated with, or in any manner connected with, lend such Executive's name to, lend Executive's credit to, or render services or advice to a Competing Business anywhere in the Geographic Area&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">provide or develop any products, technology or services that are the same or Substantially Similar to the products, technology and services provided or developed by the Company or any of its Affiliates&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">induce or attempt to induce any customer, agent, supplier, licensee, or business relation of the Company or any of its Affiliates to cease doing business with the Company or any of its Affiliates, or in any way interfere with the relationship between any customer, supplier, licensee, or business relation of the Company or any of its Affiliates or the Goodwill of the Company&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">on behalf of a Competing Business, solicit or attempt to solicit the business or patronage of any Person who is a customer or agent of the Company or any of its Affiliates, whether or not Executive had personal contact with such Person&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that nothing set forth in this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.06(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> shall prohibit Executive from owning, as a passive investment, not in excess of &#91;five percent (5% in the aggregate of any class of capital stock of any corporation if such stock is publicly traded and listed on any national or regional stock exchange or reported on the Nasdaq Stock Market</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.11pt">During Executive's employment with Company and for a period of 12 months following termination of employment for any reason (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Solicitation Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), Executive shall not either directly or indirectly, on Executive's own or another's behalf, engage in or assist others in any of the following activities&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">solicit, encourage, or take any other action which is intended to induce any employee, independent contractor or agent of the Company or any of its Affiliates to terminate employment or other business relationship with the Company or such Affiliate&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">in any way interfere in any manner with the employment or other business relationship between the Company and&#47;or any of its Affiliates, on the one hand, and any employee, independent contractor or agent of the Company or such Affiliate, on the other hand&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">employ, or otherwise engage as an employee, independent contractor or otherwise, any individual who was an employee or was otherwise affiliated with the Company or any of its Affiliates from the period beginning one year prior to Executive's last day of employment and continuing through the expiration of the Non-Solicitation Period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.08</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. For purposes hereof&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.11pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Entity, any Entity that, directly or indirectly through one or more intermediaries, controls, is controlled by or under common control with, such Entity.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.11pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Company Business</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the research, development, testing and&#47;or marketing&#47;sales of pharmaceutical products or processes that are, rely on, target or rely upon (a) monoclonal antibodies directed against HER2 or B7-H3, (b) any bi-specific or multi-specific antibody-based protein targeting any of the Company's product candidates that are in active </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">clinical development (meaning that an IND has been filed and accepted by the FDA or EMA with respect to that product candidate and the Company is developing the protocol, enrolling sites or patients or analyzing patients with respect to a human clinical trial for such product candidate), or (c) any target or combination of targets that is the subject of pre-clinical research and for which the Company intends to file an IND for a product candidate with such specificity or specificities in the 24 months following Termination.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Competing Business</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any other Entity engaged in the Company Business, other than the Company and its Affiliates.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:27.11pt">&#8220;Entity&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means and includes any person, partnership, association, corporation, limited liability company, trust, unincorporated organization or any other business entity or enterprise.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.11pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Geographic Area</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; mean those states in which the Company or any of its Affiliates conducts business or in which its products are being sold or marketed at the time of the termination of Executive's employment.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:29.9pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Goodwill</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the value of the relationships between the Company and its agents, customers, vendors, labs, and employees.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.11pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any Entity or individual.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.11pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Substantially Similar</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means substantially similar in function or capability or otherwise competitive to the products or services being developed, manufactured or sold by the Company during and&#47;or at the end of Executive's employment, or are marketed to substantially the same type of user or customer as that to which the products and services of the Company are marketed or proposed to be marketed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.09</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Acknowledgements Regarding Other Promises and Covenants</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. With regard to the promises and covenants set forth herein, Executive acknowledges and agrees that&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.11pt">the restrictions are ancillary to an otherwise enforceable agreement including the provisions of this Agreement regarding the disclosure, ownership and use of the Confidential Information and Goodwill of Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.11pt">the limitations as to time, geographical area, and scope of activity to be restricted are reasonable and acceptable to Executive, and do not impose any greater restraint than is reasonably necessary to protect the Goodwill and other legitimate business interests of Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">the performance by Executive, and the enforcement by Company, of such promises and covenants will cause no undue hardship on Executive&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.11pt">Executive will play a key business role for the Company in which Executive will have access to the Company's Confidential Information and Goodwill&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.11pt">the time periods covered by the promises and covenants will not include any period(s) of violation of, or any period(s) of time required for litigation brought by Company to enforce any such promise or covenant, it being understood that the extension of time provided in this paragraph may not exceed two (2) years.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Duty to Give Notice of Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. During employment by Company and the period of any post-employment obligation applicable hereunder, Executive shall provide written notice to any prospective employer of Executive's obligations under this Agreement and shall provide to it a true copy of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> of this Agreement before accepting employment with such prospective employer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Independent Elements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The parties acknowledge that the promises and covenants contained in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> above are essential independent elements of this Agreement and that, but for Executive agreeing to comply with them, Company would not employ Executive. Accordingly, the existence or assertion of any claim by Executive against Company, whether based on this Agreement or otherwise, shall not operate as a defense to Company's enforcement of the promises and covenants in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. An alleged or actual breach of the Agreement by Company will not be a defense to enforcement of any such promise or covenant, or other obligations of Executive to Company. The promises and covenants in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> will remain in full force and effect whether Executive is terminated by Company or voluntarily resigns.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Remedies for Breach of Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Executive acknowledges that Executive's breach of any promise or covenant contained in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> will result in irreparable injury to Company and that Company's remedies at law for such a breach will be inadequate. Accordingly, Executive agrees and consents that Company, in addition to all other remedies available at law and in equity, shall be entitled to both preliminary and permanent injunctions to prevent and&#47;or halt a breach or threatened breach by Executive of any such promise or covenant, and Executive waives the requirement of the posting of any bond in connection with such injunctive relief. Executive further acknowledges and agrees that the promises and covenants contained in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> are enforceable, reasonable, and valid.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt;text-decoration:underline">Directors and Officers Insurance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Company shall cause Executive to be covered under a director and officer's liability insurance policy that provides insurance coverage for Executive on substantially the same terms and conditions as the other senior executives of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.01</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Governing Law&#59; Arbitration</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.11pt">This Agreement is made under and shall be governed by and construed in accordance with the laws of Maryland, without regard to its conflicts of law principles.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.11pt">With respect to claims by the Company against Executive related to Executive's threatened or actual breach of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> of this Agreement, each Party hereby irrevocably agrees that all actions or proceedings concerning such disputes may be brought by the Company in (a) the United States District Court for the District of Maryland&#59; or (b) in any court of the State of Maryland sitting in Montgomery County, provided that the United States District Court. lacks subject matter jurisdiction over such action or proceeding. Executive consents to jurisdiction of and venue in the courts in the State of Maryland set forth in this Section, and hereby waives to the maximum extent permitted by applicable law any objection which Executive may have based on improper venue or</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> forum non conveniens</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">Except to the extent provided for in subsection (b) above, the Company and Executive agree that any claim, dispute or controversy arising under or in connection with this Agreement, or otherwise in connection with Executive's employment by the Company or termination of his employment (including any such claim, dispute or controversy arising under any federal, state or local statute, regulation or ordinance or any of the Company's employee benefit plans, policies or programs) shall be resolved solely and exclusively by binding, confidential, arbitration. The arbitration shall be held in Rockville, MD (or at such other location as shall be mutually agreed by the parties). The arbitration shall be conducted in accordance with the Commercial Rules of the American Arbitration Association (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AAA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) in effect at the time of the arbitration, including the Expedited Procedures. All fees and expenses of the arbitration, including a transcript if either requests them, shall be borne equally by the parties. Each party is responsible for the fees and expenses of its own attorneys, experts, witnesses, and preparation and presentation of proofs and post-hearing briefs (unless the party prevails on a claim for which attorney's fees are recoverable under law). In rendering a decision, the arbitrator shall apply all legal principles and standards that would govern if the dispute were being heard in court. This includes the availability of all remedies that the parties could obtain in court. In addition, all statutes of limitation and defenses that would be applicable in court, will apply to the arbitration proceeding. The decision of the arbitrator shall be set forth in writing and be binding and conclusive on all parties. Any action to enforce or vacate the arbitrator's award shall be governed by the Federal Arbitration Act, if applicable, and otherwise by applicable state law. If either the Company or Executive improperly pursues any claim, dispute or controversy against the other in a proceeding other than the arbitration provided for herein, the responding party shall be entitled to dismissal or injunctive relief regarding such action and recovery of all costs, losses and attorney's fees related to such action.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.02</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Agreement and the documents referenced herein contain the entire agreement of the parties relating to the employment of Executive by Employer and the ancillary matters discussed herein and supersedes all prior agreements, negotiations and understandings with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">respect to such matters, including any term sheet between the parties hereto with respect to such matters, and the parties hereto have made no agreements, representations or warranties relating to such employment or ancillary matters which are not set forth herein. To the extent that work product, intellectual property rights, Inventions, Company Property and&#47;or Company Confidential Information are owned by the Company on the date hereof as a result of prior agreement or under law, this Agreement shall not derogate such ownership.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.03</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Taxes and Withholding</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. All compensation and benefits will be subject to applicable taxes. Employer may withhold from any compensation and Benefits payable under this Agreement all federal, state, city or other taxes as shall be required pursuant to any law or governmental regulation or ruling or as authorized by Executive.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.04</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Golden Parachute Limit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Notwithstanding any other provision of this Agreement, in the event that any portion of the Severance Benefits or any other payment or benefit received or to be received by Executive (whether pursuant to the terms of this Agreement or any other plan, arrangement or agreement) (collectively, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Benefits</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) would be subject to the excise tax imposed under Section 4999 of the Code (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Excise Tax</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), the Total Benefits shall be reduced to the extent necessary so that no portion of the Total Benefits is subject to the Excise Tax&#59; provided, however, that no such reduction in the Total Benefits shall be made if by not making such reduction, Executive's Retained Amount (as hereinafter defined) would be more than ten percent (10%) greater than Executive's Retained Amount if the Total Benefits are so reduced. All determinations required to be made under this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.04</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> shall be made by tax counsel selected by the Company and reasonably acceptable to Executive (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax Counsel</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), which determinations shall be conclusive and binding on Executive and the Company absent manifest error. All fees and expenses of Tax Counsel shall be borne solely by the Company. Prior to any reduction in Executive's Total Benefits pursuant to this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.04</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Tax Counsel shall provide Executive and the Company with a report setting forth its calculations and containing related supporting information. In the event any such reduction is required, the Total Benefits shall be reduced in the following order&#58; (i) the Severance Amount (in reverse order of payment), (iii) any other portion of the Total Benefits that are not subject to Section 409A of the Code (other than Total Benefits resulting from any accelerated vesting of equity awards), (iv) other Total Benefits that are subject to Section 409A of the Code in reverse order of payment, and (v) Total Benefits that are not subject to Section 409A and arise from any accelerated vesting of any equity awards. &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retained Amount</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean the present value (as determined in accordance with Sections 280G(b)(2)(A)(ii) and 280G(d)(4) of the Code) of the Total Benefits net of all federal, state and local taxes imposed on Executive with respect thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.05</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Compliance With Section 409A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Agreement is intended to comply with the requirements of Section 409A of the Code (including the exceptions thereto), to the extent applicable, and shall be interpreted accordingly, but nothing in this Agreement shall transfer liability for any tax, including under Section 409A of the Code, from Executive to the Company or any other Person. Notwithstanding anything to the contrary herein, for purposes of determining Executive's entitlement to the Severance Benefits under </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> hereof, (a) Executive's employment shall not be deemed to have terminated unless and until Executive incurs a &#8220;separation from service&#8221; as defined in Section 409A of the Code, and (b) the effective date of any termination or resignation of employment (or any similar term) shall be the effective date of Executive's separation from service. Reimbursement of any expenses provided for in this Agreement shall be made in accordance with the Company's policies (as applicable) with respect thereto as in effect from time to time, provided that, with respect to taxable reimbursements, no reimbursement .shall be paid later than the end of calendar year following the year such expenses were incurred) and in no event shall (i) the amount of expenses eligible for reimbursement hereunder during a taxable year affect the expenses eligible for reimbursement in any other taxable year or (ii) the right to reimbursement be subject to liquidation or exchange for another benefit. Notwithstanding anything to the contrary herein, if a payment or benefit under this Agreement is due to a &#8220;separation from service&#8221; for purposes of the rules under Treas. Reg.&#167; 1.409A-3(i)(2) (payments to specified employees upon a separation from service) and Executive is determined to be a &#8220;specified employee&#8221; (as determined under Treas. Reg.&#167; 1.409A-1(i)), such payment shall, to the extent necessary to comply with the requirements of Section 409A of the Code, be made on the later of (x) the date specified by the foregoing provisions of this Agreement or (y) the date that is six (6) months after the date of Executive's separation from service (or, if earlier, the date of Executive's death). Any installment payments that are delayed pursuant to the provisions of this section shall be accumulated and paid in a lump sum on the first day of the seventh month following Executive's separation from service (or, if earlier, upon Executive's death) and the remaining installment payments shall begin on such date in accordance with the schedule provided in this Agreement. To the extent permitted by Section 409A, each payment hereunder shall be deemed to be a separate payment for purposes of Section 409A of the Code. Notwithstanding anything to the contrary in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. if the period during which the Executive has discretion to execute or revoke a release straddles two calendar years, the Company shall make the payments that are conditioned upon the release no </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">earlier than January 1st of the second of such calendar years, regardless of which taxable year the Executive actually delivers the executed release to the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.06</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Amendments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. No amendment or modification of the terms of this Agreement shall be valid unless made in writing and signed by both Executive and Employer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.07</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Severability&#58; Reformation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Whenever possible, each provision of this Agreement shall be interpreted in such a manner as to be effective and valid under applicable Law but if any provision of this Agreement is held to be invalid, illegal or unenforceable under any applicable Law or rule, the validity, legality and enforceability of the other provisions of this Agreement will not be affected or impaired thereby. If any provision of this Agreement is found invalid, illegal or unenforceable because it is too broad in scope, too lengthy in duration or violates any law or regulation, it shall be reformed by limiting its scope, limiting its duration or construing it to avoid such violation (as the case may be) while giving the greatest effect to the intent of the parties as is legally permissible.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.08</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">No Waiver</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. No waiver of any provision of this Agreement shall in any event be effective unless the same shall be in writing and signed by the party against whom such waiver is sought to be enforced, and any such waiver shall be effective only in the specific instance and for the specific purpose for which given.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.09</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Assignment&#58; No Third Party Beneficiary</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Agreement is a personal service contract, and shall not be assignable by Executive. This Agreement shall be assignable by Employer to any successor to the business of Employer, without the written consent of Executive&#59; provided, however, that the assignee or transferee is the successor to all or substantially all of the business assets of Employer and such assignee or transferee expressly assumes all the obligations, duties, and liabilities of Employer set forth in this Agreement. Any purported assignment of this Agreement in violation of this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.09</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> shall be null and void. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns, and no other Person shall have any right, benefit or obligation hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Counterparts&#59; Facsimile Signatures</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Agreement may be executed in separate counterparts, each of which will be an original and all of which taken together shall constitute one and the same agreement, and any party hereto may execute this Agreement by signing any such counterpart. A facsimile signature by any party on a counterpart of this Agreement shall be binding and effective for all purposes. Such party shall subsequently deliver to the other party an original, executed copy of this Agreement&#59; provided, however, that a failure of such party to deliver an original, executed copy shall not invalidate Executive's or its signature.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. All notices and other communications relating to this Agreement will be in writing and will be deemed to have been given when personally delivered, three (3) days following mailing by certified or registered mail, return receipt requested, and one (1) Business Day following delivery to a reliable overnight courier or immediately following transmission by electronic facsimile. All notices to Employer shall be addressed and delivered to&#58;</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MacroGenics, Inc.</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9704 Medical Center Drive</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rockville, MD 20850</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attn&#58; Chief Executive Officer</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">or to such other address and facsimile number as designated by Employer in a written notice to Executive. All notices to Executive shall be addressed and delivered to&#58;</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tom Spitznagel</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">or to such other address and facsimile number as Executive has designated in a written notice to Employer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Interpretation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The headings contained in this Agreement are for reference purposes only and shall not in any way affect the meaning or interpretation of this Agreement. The words &#8220;include,&#8221; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;includes&#8221; and &#8220;including,&#8221; when used in this Agreement, will be deemed to be followed by the phrase &#8220;but not limited to&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.13</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Cumulative Remedies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The rights and remedies of the parties hereunder are cumulative and not exclusive of any rights or remedies any party hereto may otherwise have.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.14</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt;text-decoration:underline">Expenses Relating to this Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Each party shall pay its or Executive's own expenses incident to the negotiation, preparation and execution of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Remainder of the Page Intentionally Left Blank&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Executive and Employer have executed this Employment Agreement as of the date set forth in the first paragraph.</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">EMPLOYER</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;</font></div><div style="margin-bottom:24pt;padding-left:180pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MacroGenics, Inc.</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Koenig</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; Scott Koenig</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;President and CEO</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font><br></font></div><div style="margin-bottom:24pt;padding-left:180pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">EXECUTIVE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Thomas Spitznagel, Ph.D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br>Thomas Spitznagel, Ph.D.</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sr. Vice President, BioPharmaceutical Development &#38; Manufacturing</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#93;</font></div><div style="margin-bottom:12pt;padding-left:216pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT B</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIST OF PRE-EXISTING INTELLECTUAL PROPERTY</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit B </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PUBLICATIONS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PATENTS</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exhibit31-1q12022.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if80fd02a74a24033bca0e3a1e9287d89_1"></div><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 31.1</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott Koenig, certify that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended March&#160;31, 2022 of MacroGenics, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Scott Koenig</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scott Koenig, M.D., Ph.D.</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; May&#160;3, 2022 </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exhibit31-2q12022.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i71cdf852a7134e25af269bd435f60108_1"></div><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James Karrels, certify that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended March&#160;31, 2022 of MacroGenics, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; James Karrels</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">James Karrels</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Vice President and Chief Financial Officer</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; May&#160;3, 2022 </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exhibit32-1q12022.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="idf307eb3533143e091dbc754c19de96d_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 32.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to 18 U.S.C. 1350</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Section 906 of the Sarbanes-Oxley Act of 2002</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott Koenig, President and Chief Executive Officer (principal executive officer) of MacroGenics, Inc. (the Registrant), certify, to the best of my knowledge, based upon a review of the Quarterly Report on Form 10-Q for the period ended&#160;March&#160;31, 2022&#160;of the Registrant (the Report), that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div style="padding-left:22pt;text-indent:-22pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Scott Koenig</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Scott Koenig, M.D., Ph.D.</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;3, 2022 </font></div><div style="padding-left:252pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>exhibit32-2q12022.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i9e81fa426bcf4ebd935d871e7259ce03_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 32.2</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Financial Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to 18 U.S.C. 1350</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Section 906 of the Sarbanes-Oxley Act of 2002)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James Karrels, Senior Vice President and Chief Financial Officer (principal financial officer) of MacroGenics, Inc. (the Registrant), certify, to the best of my knowledge, based upon a review of the Quarterly Report on Form 10-Q for the period ended&#160;March&#160;31, 2022&#160;of the Registrant (the Report), that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; James Karrels</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; James Karrels</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;3, 2022 </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>mgnx-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:1bd791be-5155-40b4-b9a0-bccec8bc4c7f,g:90cbb752-e1e3-4609-a8e8-bbefff2b5852-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mgnx="http://macrogenics.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://macrogenics.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://macrogenics.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofOperations" roleURI="http://macrogenics.com/role/NatureofOperations">
        <link:definition>2101101 - Disclosure - Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2102102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstruments" roleURI="http://macrogenics.com/role/FairValueofFinancialInstruments">
        <link:definition>2104103 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsTables" roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables">
        <link:definition>2305301 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsDetails" roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails">
        <link:definition>2406401 - Disclosure - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://macrogenics.com/role/MarketableSecurities">
        <link:definition>2107104 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://macrogenics.com/role/MarketableSecuritiesTables">
        <link:definition>2308302 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetails" roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails">
        <link:definition>2409402 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNet" roleURI="http://macrogenics.com/role/InventoryNet">
        <link:definition>2110105 - Disclosure - Inventory, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNetTables" roleURI="http://macrogenics.com/role/InventoryNetTables">
        <link:definition>2311303 - Disclosure - Inventory, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNetDetails" roleURI="http://macrogenics.com/role/InventoryNetDetails">
        <link:definition>2412403 - Disclosure - Inventory, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://macrogenics.com/role/StockholdersEquity">
        <link:definition>2113106 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://macrogenics.com/role/StockholdersEquityDetails">
        <link:definition>2414404 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://macrogenics.com/role/Revenue">
        <link:definition>2115107 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsIncyteCorporationDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails">
        <link:definition>2416405 - Disclosure - Collaboration and Other Agreements - Incyte Corporation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsZaiLabDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails">
        <link:definition>2417406 - Disclosure - Collaboration and Other Agreements - Zai Lab (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsJanssenDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails">
        <link:definition>2418407 - Disclosure - Collaboration and Other Agreements - Janssen (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsIMabBiopharmaDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails">
        <link:definition>2419408 - Disclosure - Collaboration and Other Agreements - I-Mab Biopharma (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsNIAIDContractDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails">
        <link:definition>2420409 - Disclosure - Collaboration and Other Agreements - NIAID Contract (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://macrogenics.com/role/StockBasedCompensation">
        <link:definition>2121108 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://macrogenics.com/role/StockBasedCompensationTables">
        <link:definition>2322304 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>2423410 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationOptionPricingAssumptionsDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails">
        <link:definition>2424411 - Disclosure - Stock-Based Compensation - Option Pricing Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>2425412 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationRestrictedStockUnitActivityDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails">
        <link:definition>2426413 - Disclosure - Stock-based Compensation - Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://macrogenics.com/role/CommitmentsandContingencies">
        <link:definition>2127109 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" abstract="false" name="NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" abstract="false" name="CollaborationAndOtherAgreementsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" abstract="true" name="RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandSixteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_PremiumReceivedOnStockPurchase" abstract="false" name="PremiumReceivedOnStockPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" abstract="false" name="StockIssuedDuringPeriodSharesStockPlanActivity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" abstract="false" name="PotentialCommercialMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CommonStockMaximumAmountAvailableForIssuance" abstract="false" name="CommonStockMaximumAmountAvailableForIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ZaiLabClinicalSupplyAgreementsMember" abstract="true" name="ZaiLabClinicalSupplyAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_RevenueFromGovernmentAgreementsMember" abstract="true" name="RevenueFromGovernmentAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" abstract="false" name="PotentialMilestonePaymentsAndRoyaltiesOnProductSales" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_JanssenCollaborationAndLicenseAgreementMember" abstract="true" name="JanssenCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ProceedsfromRoyaltiesPercent" abstract="false" name="ProceedsfromRoyaltiesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mgnx_StockIssuedDuringPeriodValueStockPlanActivity" abstract="false" name="StockIssuedDuringPeriodValueStockPlanActivity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IncyteMGA012AgreementMember" abstract="true" name="IncyteMGA012AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_RevenuesFromCMOAgreementsMemberMember" abstract="true" name="RevenuesFromCMOAgreementsMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" abstract="true" name="ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementTransactionPrice" abstract="false" name="CollaborativeAgreementTransactionPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenuesFromGrantsMember" abstract="true" name="RevenuesFromGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_StockIncentivePlan2013Member" abstract="true" name="StockIncentivePlan2013Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_IncyteCorporationMember" abstract="true" name="IncyteCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_NonrefundablePaymentTaxWithholding" abstract="false" name="NonrefundablePaymentTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NumberOfPerformanceObligations" abstract="false" name="NumberOfPerformanceObligations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_RevenuesFromLicenseAgreementsMember" abstract="true" name="RevenuesFromLicenseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_IncyteMGA012ClinicalServicesMember" abstract="true" name="IncyteMGA012ClinicalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" abstract="false" name="PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenuesNetOfTaxWithholding" abstract="false" name="RevenuesNetOfTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" abstract="false" name="PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mgnx_OneTimeMillstoneCredit" abstract="false" name="OneTimeMillstoneCredit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" abstract="true" name="IMabBiopharmaCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_OptInFee" abstract="false" name="OptInFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" abstract="true" name="IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_RevenueFromCollaborativeAgreementsMember" abstract="true" name="RevenueFromCollaborativeAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" abstract="false" name="CommonStockMaximumAmountAvailableForIssuanceIncrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IncyteMGA012AgreementClinicalActivitiesMember" abstract="true" name="IncyteMGA012AgreementClinicalActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_NonRefundableUpfrontFees" abstract="false" name="NonRefundableUpfrontFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_A2003StockIncentivePlanMember" abstract="true" name="A2003StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" abstract="false" name="CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" abstract="false" name="RevenueInformationUsedToAssessVariableConsiderationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" abstract="false" name="ProceedsfromStockOptionsExercisedAndESPPPurchases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_JanssenBiotechIncMember" abstract="true" name="JanssenBiotechIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" abstract="true" name="A2018ZaiLabCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" abstract="true" name="NationalInstituteOfAllergyAndInfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_IncyteMGA012SupplyAgreementMember" abstract="true" name="IncyteMGA012SupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_TotalAnnualFixedPayments" abstract="false" name="TotalAnnualFixedPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" abstract="false" name="RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" abstract="false" name="EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" abstract="false" name="NonrefundableUpfrontFeesNetOfTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" abstract="false" name="DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ZaiLabMember" abstract="true" name="ZaiLabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_A2021ZaiLabAgreementsMember" abstract="true" name="A2021ZaiLabAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_TotalPotentialValueUnderAgreement" abstract="false" name="TotalPotentialValueUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" abstract="true" name="ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_IMabBiopharmaMember" abstract="true" name="IMabBiopharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>mgnx-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:1bd791be-5155-40b4-b9a0-bccec8bc4c7f,g:90cbb752-e1e3-4609-a8e8-bbefff2b5852-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20220331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e6098b19-5832-46b8-a088-093e4336a1db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_279a46f8-21d6-4cd3-bd28-d089a8ebed67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e6098b19-5832-46b8-a088-093e4336a1db" xlink:to="loc_us-gaap_Investments_279a46f8-21d6-4cd3-bd28-d089a8ebed67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3073a723-d212-4a90-9070-37d21e105502" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e6098b19-5832-46b8-a088-093e4336a1db" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3073a723-d212-4a90-9070-37d21e105502" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f9790c85-31f9-4f3c-bf97-4403a3b49184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e6098b19-5832-46b8-a088-093e4336a1db" xlink:to="loc_us-gaap_InventoryNet_f9790c85-31f9-4f3c-bf97-4403a3b49184" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e844b849-f470-4bf4-9399-cbd3545359e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e6098b19-5832-46b8-a088-093e4336a1db" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e844b849-f470-4bf4-9399-cbd3545359e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9e5f5f4d-d313-424a-b7fe-980aae650070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e6098b19-5832-46b8-a088-093e4336a1db" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9e5f5f4d-d313-424a-b7fe-980aae650070" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8d350f1b-164b-4d49-aba4-35b0e9ea671e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_829816fc-4881-4391-bd30-41914e875c04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8d350f1b-164b-4d49-aba4-35b0e9ea671e" xlink:to="loc_us-gaap_AccountsPayableCurrent_829816fc-4881-4391-bd30-41914e875c04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4c2dddc5-dc16-458d-a024-f98979836129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8d350f1b-164b-4d49-aba4-35b0e9ea671e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4c2dddc5-dc16-458d-a024-f98979836129" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_08a3e8b5-f360-4378-bdf9-cd6de3d524e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8d350f1b-164b-4d49-aba4-35b0e9ea671e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_08a3e8b5-f360-4378-bdf9-cd6de3d524e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9091fb54-991e-471f-b1fd-a0417464c556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8d350f1b-164b-4d49-aba4-35b0e9ea671e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9091fb54-991e-471f-b1fd-a0417464c556" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d6ab9584-0d27-4e6b-b4fe-ecd5565142bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a321e693-54b4-4459-a2c3-bbc40c60a840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d6ab9584-0d27-4e6b-b4fe-ecd5565142bf" xlink:to="loc_us-gaap_LiabilitiesCurrent_a321e693-54b4-4459-a2c3-bbc40c60a840" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6b74099e-ceae-4276-afd9-b66cbe993fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d6ab9584-0d27-4e6b-b4fe-ecd5565142bf" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6b74099e-ceae-4276-afd9-b66cbe993fb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_91dc6319-3db3-4823-aca8-a1c6fd80fd30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d6ab9584-0d27-4e6b-b4fe-ecd5565142bf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_91dc6319-3db3-4823-aca8-a1c6fd80fd30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_cc427481-fa5c-4356-8a5a-21cd3de027ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d6ab9584-0d27-4e6b-b4fe-ecd5565142bf" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_cc427481-fa5c-4356-8a5a-21cd3de027ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_87cae884-6b88-4f01-8d9a-f36058c93f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c3367d2d-08e4-46fd-94c1-cc35d189d9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_87cae884-6b88-4f01-8d9a-f36058c93f8c" xlink:to="loc_us-gaap_AssetsCurrent_c3367d2d-08e4-46fd-94c1-cc35d189d9ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_dfe5e9a6-b137-440e-8487-028dc0c3ce83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_87cae884-6b88-4f01-8d9a-f36058c93f8c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_dfe5e9a6-b137-440e-8487-028dc0c3ce83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_db6abcfb-7411-4305-af7f-2da2ee917aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_87cae884-6b88-4f01-8d9a-f36058c93f8c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_db6abcfb-7411-4305-af7f-2da2ee917aba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e9d8682c-b676-4a5d-9c85-e70a69488499" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_554a6351-9823-4976-bd23-e55d4ea16eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e9d8682c-b676-4a5d-9c85-e70a69488499" xlink:to="loc_us-gaap_CommonStockValue_554a6351-9823-4976-bd23-e55d4ea16eeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b6344e2b-e2ab-466d-878f-06bdab3cd202" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e9d8682c-b676-4a5d-9c85-e70a69488499" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b6344e2b-e2ab-466d-878f-06bdab3cd202" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a9d7e4c5-1353-47db-84e1-a6762dc671ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e9d8682c-b676-4a5d-9c85-e70a69488499" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a9d7e4c5-1353-47db-84e1-a6762dc671ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b82f0f98-da15-4eb4-a6d0-d617a8612bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e9d8682c-b676-4a5d-9c85-e70a69488499" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b82f0f98-da15-4eb4-a6d0-d617a8612bc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3b8a0473-ee8e-4884-ab7a-a0f8379e6a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9a346b63-140d-4c23-a2da-c8d4ce5b3cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3b8a0473-ee8e-4884-ab7a-a0f8379e6a3d" xlink:to="loc_us-gaap_Liabilities_9a346b63-140d-4c23-a2da-c8d4ce5b3cd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e8965c41-2512-4851-9cec-74f8414a0a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3b8a0473-ee8e-4884-ab7a-a0f8379e6a3d" xlink:to="loc_us-gaap_StockholdersEquity_e8965c41-2512-4851-9cec-74f8414a0a4a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20220331.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_21b85dd0-2b8d-4eab-9757-920e717ba86b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_76b2cd9d-033e-4486-8253-5914cc57c531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_21b85dd0-2b8d-4eab-9757-920e717ba86b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_76b2cd9d-033e-4486-8253-5914cc57c531" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e976009d-b4f5-40c7-8640-0625fd624862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_21b85dd0-2b8d-4eab-9757-920e717ba86b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e976009d-b4f5-40c7-8640-0625fd624862" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ef5fc9d5-0e34-4f56-a9c8-7bd4539d54b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_21b85dd0-2b8d-4eab-9757-920e717ba86b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ef5fc9d5-0e34-4f56-a9c8-7bd4539d54b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_966cb521-d9a8-47e8-983a-1e1a03926ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_65bed59a-07d7-484b-a4b8-a58bbdb518e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_966cb521-d9a8-47e8-983a-1e1a03926ca2" xlink:to="loc_us-gaap_NetIncomeLoss_65bed59a-07d7-484b-a4b8-a58bbdb518e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d544acf3-c501-433d-b4f8-99a738a954af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_966cb521-d9a8-47e8-983a-1e1a03926ca2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d544acf3-c501-433d-b4f8-99a738a954af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_938331a4-b80c-4a7e-ba5e-4a9594d95c84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_149306fe-0fed-472f-b5af-f7b161c1982e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_938331a4-b80c-4a7e-ba5e-4a9594d95c84" xlink:to="loc_us-gaap_Revenues_149306fe-0fed-472f-b5af-f7b161c1982e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3612fb76-8397-49b6-be3d-930d4ad52975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_938331a4-b80c-4a7e-ba5e-4a9594d95c84" xlink:to="loc_us-gaap_CostsAndExpenses_3612fb76-8397-49b6-be3d-930d4ad52975" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9846fe30-f333-4272-91c7-7dc93a87a6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_dfbbf7e3-3101-4540-bc5c-1fca1c6b4e11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9846fe30-f333-4272-91c7-7dc93a87a6b0" xlink:to="loc_us-gaap_OperatingIncomeLoss_dfbbf7e3-3101-4540-bc5c-1fca1c6b4e11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_eba21448-fd93-42f5-b917-a2b83425b316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9846fe30-f333-4272-91c7-7dc93a87a6b0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_eba21448-fd93-42f5-b917-a2b83425b316" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20220331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1a5c42a0-218d-4224-8c77-5025c0a2bf82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_a2745be8-f14f-4aa9-a41e-3f389556b9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1a5c42a0-218d-4224-8c77-5025c0a2bf82" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_a2745be8-f14f-4aa9-a41e-3f389556b9dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_255ecaab-2e7c-4907-aa0c-4d01224b99b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1a5c42a0-218d-4224-8c77-5025c0a2bf82" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_255ecaab-2e7c-4907-aa0c-4d01224b99b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0798037a-3156-4a5c-9429-ed445d1abb13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1a5c42a0-218d-4224-8c77-5025c0a2bf82" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0798037a-3156-4a5c-9429-ed445d1abb13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f43f68ed-f705-4125-be3f-2e9f45484b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5c926d0e-55d7-450a-a260-5fbc90ce00c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f43f68ed-f705-4125-be3f-2e9f45484b1a" xlink:to="loc_us-gaap_NetIncomeLoss_5c926d0e-55d7-450a-a260-5fbc90ce00c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3ba45411-2e40-4c81-a779-adada7f7bd0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f43f68ed-f705-4125-be3f-2e9f45484b1a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3ba45411-2e40-4c81-a779-adada7f7bd0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b52dbdfd-a1a4-42e5-8c84-ba87749c0a64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f43f68ed-f705-4125-be3f-2e9f45484b1a" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b52dbdfd-a1a4-42e5-8c84-ba87749c0a64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_bec6ee18-cec3-410e-bf15-d5a9c6f64774" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f43f68ed-f705-4125-be3f-2e9f45484b1a" xlink:to="loc_us-gaap_ShareBasedCompensation_bec6ee18-cec3-410e-bf15-d5a9c6f64774" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3b9fe962-9ee5-4a4c-9980-2e626dee8a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f43f68ed-f705-4125-be3f-2e9f45484b1a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3b9fe962-9ee5-4a4c-9980-2e626dee8a3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_84a0b185-b056-4d16-8193-459a7f70f659" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f43f68ed-f705-4125-be3f-2e9f45484b1a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_84a0b185-b056-4d16-8193-459a7f70f659" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e9cbfb70-af2d-47a7-bd79-b2a66978df41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f43f68ed-f705-4125-be3f-2e9f45484b1a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e9cbfb70-af2d-47a7-bd79-b2a66978df41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_16035af3-e7b8-4dd4-a254-a68c401c0256" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f43f68ed-f705-4125-be3f-2e9f45484b1a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_16035af3-e7b8-4dd4-a254-a68c401c0256" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_feccb41f-16c0-447c-ad90-91ee7769d8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f43f68ed-f705-4125-be3f-2e9f45484b1a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_feccb41f-16c0-447c-ad90-91ee7769d8b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9b4a4719-44b5-40b9-9e74-08049d23ea6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f43f68ed-f705-4125-be3f-2e9f45484b1a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9b4a4719-44b5-40b9-9e74-08049d23ea6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_52491d33-d112-4966-a6eb-cac28d6ba915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f43f68ed-f705-4125-be3f-2e9f45484b1a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_52491d33-d112-4966-a6eb-cac28d6ba915" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_de307735-c83a-4ddb-ae55-b2ebc34eaa8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f43f68ed-f705-4125-be3f-2e9f45484b1a" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_de307735-c83a-4ddb-ae55-b2ebc34eaa8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_e88ab40b-ebed-47f7-9423-8d80aeca9109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f43f68ed-f705-4125-be3f-2e9f45484b1a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_e88ab40b-ebed-47f7-9423-8d80aeca9109" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_be2e9c6d-4ed5-4f42-ba06-5b51aca07cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0421b7ca-9cca-45ef-81a2-d8eceb88d64c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_be2e9c6d-4ed5-4f42-ba06-5b51aca07cfb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0421b7ca-9cca-45ef-81a2-d8eceb88d64c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_558f49bb-4411-499f-ae88-bea2713e5963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_be2e9c6d-4ed5-4f42-ba06-5b51aca07cfb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_558f49bb-4411-499f-ae88-bea2713e5963" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_82851fe5-cf39-4276-a98f-6a2e5b02ae9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_be2e9c6d-4ed5-4f42-ba06-5b51aca07cfb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_82851fe5-cf39-4276-a98f-6a2e5b02ae9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21e30345-ae4f-4552-90c8-106495651f05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2a416398-fbe7-4d11-a350-6be6d2819d79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21e30345-ae4f-4552-90c8-106495651f05" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2a416398-fbe7-4d11-a350-6be6d2819d79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_81d7a3b1-7ddc-4e9a-bdef-85467fdc4717" xlink:href="mgnx-20220331.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21e30345-ae4f-4552-90c8-106495651f05" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_81d7a3b1-7ddc-4e9a-bdef-85467fdc4717" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="mgnx-20220331.xsd#FairValueofFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_987cd3ce-c3be-47a1-8bd1-84ebdfc5a0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c27835f2-7f02-40e2-923b-0ffba1b2db98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_987cd3ce-c3be-47a1-8bd1-84ebdfc5a0eb" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c27835f2-7f02-40e2-923b-0ffba1b2db98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_289428e3-a307-4fa2-96e9-d9988b9911de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_987cd3ce-c3be-47a1-8bd1-84ebdfc5a0eb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_289428e3-a307-4fa2-96e9-d9988b9911de" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20220331.xsd#MarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d55095a7-75d2-409b-829b-a852a6120d30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b125ea03-4d60-4d38-b4b9-dc4ca112f0c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d55095a7-75d2-409b-829b-a852a6120d30" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b125ea03-4d60-4d38-b4b9-dc4ca112f0c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6e2072bf-48d7-4970-a16f-faef03daf450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d55095a7-75d2-409b-829b-a852a6120d30" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6e2072bf-48d7-4970-a16f-faef03daf450" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_70725e6f-0dfb-4f2a-b414-aa9b31393dad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d55095a7-75d2-409b-829b-a852a6120d30" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_70725e6f-0dfb-4f2a-b414-aa9b31393dad" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNetDetails" xlink:type="simple" xlink:href="mgnx-20220331.xsd#InventoryNetDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/InventoryNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_8b1008d9-b98d-4134-bc8d-735a8955c4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_0205e312-3dc1-41df-b051-ddd5c16db8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_8b1008d9-b98d-4134-bc8d-735a8955c4f5" xlink:to="loc_us-gaap_InventoryWorkInProcess_0205e312-3dc1-41df-b051-ddd5c16db8c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_084c87fb-6687-4df2-a00d-98eac48692b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_8b1008d9-b98d-4134-bc8d-735a8955c4f5" xlink:to="loc_us-gaap_InventoryFinishedGoods_084c87fb-6687-4df2-a00d-98eac48692b3" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>mgnx-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:1bd791be-5155-40b4-b9a0-bccec8bc4c7f,g:90cbb752-e1e3-4609-a8e8-bbefff2b5852-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20220331.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended" id="ic412be3bf74f4c32b75e36e69c831c00_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_968b97c7-2533-4de7-ae65-0dbf6f1939ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_3f8924e5-dbda-424f-bbcd-a54c10e8fa20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_968b97c7-2533-4de7-ae65-0dbf6f1939ce" xlink:to="loc_us-gaap_RevenuesAbstract_3f8924e5-dbda-424f-bbcd-a54c10e8fa20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_05903f9b-551f-4efa-a916-da0d0e5f4a24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_3f8924e5-dbda-424f-bbcd-a54c10e8fa20" xlink:to="loc_us-gaap_Revenues_05903f9b-551f-4efa-a916-da0d0e5f4a24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_af0705f9-2da6-4849-8bfc-e8d6785ecf47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_968b97c7-2533-4de7-ae65-0dbf6f1939ce" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_af0705f9-2da6-4849-8bfc-e8d6785ecf47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_192a851d-ae69-4606-bdd0-46f14041ddc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_af0705f9-2da6-4849-8bfc-e8d6785ecf47" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_192a851d-ae69-4606-bdd0-46f14041ddc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0610b842-b545-4359-87e0-2a175017d191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_af0705f9-2da6-4849-8bfc-e8d6785ecf47" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0610b842-b545-4359-87e0-2a175017d191" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_f96c760b-b552-481a-89f2-c9171f051b76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_af0705f9-2da6-4849-8bfc-e8d6785ecf47" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_f96c760b-b552-481a-89f2-c9171f051b76" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c3c947de-aaca-44f9-a83a-d558749d8a24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_af0705f9-2da6-4849-8bfc-e8d6785ecf47" xlink:to="loc_us-gaap_CostsAndExpenses_c3c947de-aaca-44f9-a83a-d558749d8a24" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c2d83ede-849d-4a4f-9cd9-e7977b3bc47c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_af0705f9-2da6-4849-8bfc-e8d6785ecf47" xlink:to="loc_us-gaap_OperatingIncomeLoss_c2d83ede-849d-4a4f-9cd9-e7977b3bc47c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c8c2876c-1e5a-4bdf-8fd6-421b0ba73149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_af0705f9-2da6-4849-8bfc-e8d6785ecf47" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c8c2876c-1e5a-4bdf-8fd6-421b0ba73149" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_16ea8807-b445-4d30-9e91-b43a44ad2b41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_af0705f9-2da6-4849-8bfc-e8d6785ecf47" xlink:to="loc_us-gaap_NetIncomeLoss_16ea8807-b445-4d30-9e91-b43a44ad2b41" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_848d2da0-c204-42f7-9236-1965e60257a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_968b97c7-2533-4de7-ae65-0dbf6f1939ce" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_848d2da0-c204-42f7-9236-1965e60257a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_393c3c6a-f8ca-4e3a-a717-0a3b22aa7c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_848d2da0-c204-42f7-9236-1965e60257a6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_393c3c6a-f8ca-4e3a-a717-0a3b22aa7c5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0ecbce35-a002-4e30-a22b-610468a206c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_968b97c7-2533-4de7-ae65-0dbf6f1939ce" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_0ecbce35-a002-4e30-a22b-610468a206c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e7e23e0a-94c5-41b2-a2f4-78ae8dbca229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_968b97c7-2533-4de7-ae65-0dbf6f1939ce" xlink:to="loc_us-gaap_EarningsPerShareBasic_e7e23e0a-94c5-41b2-a2f4-78ae8dbca229" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4e25e93a-01e5-45d9-9384-4896a97a6042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_968b97c7-2533-4de7-ae65-0dbf6f1939ce" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4e25e93a-01e5-45d9-9384-4896a97a6042" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_547a2622-2c46-4336-8126-e6f6d8f76d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_968b97c7-2533-4de7-ae65-0dbf6f1939ce" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_547a2622-2c46-4336-8126-e6f6d8f76d2f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_616fce1c-3c07-4653-89ce-b5962c6854a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_968b97c7-2533-4de7-ae65-0dbf6f1939ce" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_616fce1c-3c07-4653-89ce-b5962c6854a8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6426c4d9-a556-46ec-a500-da63bc511c40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_968b97c7-2533-4de7-ae65-0dbf6f1939ce" xlink:to="loc_us-gaap_StatementTable_6426c4d9-a556-46ec-a500-da63bc511c40" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0a874df6-b1b4-45d1-9709-441cd0be5870" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6426c4d9-a556-46ec-a500-da63bc511c40" xlink:to="loc_srt_ProductOrServiceAxis_0a874df6-b1b4-45d1-9709-441cd0be5870" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0a874df6-b1b4-45d1-9709-441cd0be5870_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0a874df6-b1b4-45d1-9709-441cd0be5870" xlink:to="loc_srt_ProductsAndServicesDomain_0a874df6-b1b4-45d1-9709-441cd0be5870_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_393f2e6d-b12e-4f6d-b00f-7e07fd3d0212" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0a874df6-b1b4-45d1-9709-441cd0be5870" xlink:to="loc_srt_ProductsAndServicesDomain_393f2e6d-b12e-4f6d-b00f-7e07fd3d0212" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_c9eedac0-84cb-4fab-88d1-00799896aa62" xlink:href="mgnx-20220331.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_393f2e6d-b12e-4f6d-b00f-7e07fd3d0212" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_c9eedac0-84cb-4fab-88d1-00799896aa62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_dacac038-32c8-43fa-964c-61b6480112b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_393f2e6d-b12e-4f6d-b00f-7e07fd3d0212" xlink:to="loc_us-gaap_ProductMember_dacac038-32c8-43fa-964c-61b6480112b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember_f18ace85-91cb-428f-89f3-dfa9d2f1d438" xlink:href="mgnx-20220331.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_393f2e6d-b12e-4f6d-b00f-7e07fd3d0212" xlink:to="loc_mgnx_RevenueFromGovernmentAgreementsMember_f18ace85-91cb-428f-89f3-dfa9d2f1d438" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20220331.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i3edb31859f144c5597b6fa873710339c_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2035b4c9-1d31-468d-804f-bc99d0e25dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d7ccf7e-aead-4c73-8fb5-4bb901372e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2035b4c9-1d31-468d-804f-bc99d0e25dcd" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d7ccf7e-aead-4c73-8fb5-4bb901372e77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_f510e489-1951-4a6d-b580-f90c6f9610b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d7ccf7e-aead-4c73-8fb5-4bb901372e77" xlink:to="loc_us-gaap_SharesIssued_f510e489-1951-4a6d-b580-f90c6f9610b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_19ac5f18-f8bc-47f1-89eb-7d5bba224e63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d7ccf7e-aead-4c73-8fb5-4bb901372e77" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_19ac5f18-f8bc-47f1-89eb-7d5bba224e63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_381530f2-c31c-4334-a927-678c8eb40015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d7ccf7e-aead-4c73-8fb5-4bb901372e77" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_381530f2-c31c-4334-a927-678c8eb40015" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_caec10cb-d9d9-4709-851e-c929954816a6" xlink:href="mgnx-20220331.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d7ccf7e-aead-4c73-8fb5-4bb901372e77" xlink:to="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_caec10cb-d9d9-4709-851e-c929954816a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_4e09f6e4-426c-4ce5-9944-165af9d5afa7" xlink:href="mgnx-20220331.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d7ccf7e-aead-4c73-8fb5-4bb901372e77" xlink:to="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_4e09f6e4-426c-4ce5-9944-165af9d5afa7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6d1f6881-73d0-4e74-a8b7-2e75f2883e04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d7ccf7e-aead-4c73-8fb5-4bb901372e77" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6d1f6881-73d0-4e74-a8b7-2e75f2883e04" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_50428bd1-9600-4c2a-9433-fb5af56f3e68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d7ccf7e-aead-4c73-8fb5-4bb901372e77" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_50428bd1-9600-4c2a-9433-fb5af56f3e68" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_bef965da-7083-4773-b81f-15f427c5903c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d7ccf7e-aead-4c73-8fb5-4bb901372e77" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_bef965da-7083-4773-b81f-15f427c5903c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d91a248b-c25f-424a-bb96-e6eb662ed826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d7ccf7e-aead-4c73-8fb5-4bb901372e77" xlink:to="loc_us-gaap_NetIncomeLoss_d91a248b-c25f-424a-bb96-e6eb662ed826" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_9be29cbc-4335-4155-9217-fc6eb6c0e615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_116c1611-4c05-420a-9c39-b8f9b898f63f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ead04f32-0b1c-4d3f-8be5-31b2dfcb333a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2035b4c9-1d31-468d-804f-bc99d0e25dcd" xlink:to="loc_us-gaap_StatementTable_ead04f32-0b1c-4d3f-8be5-31b2dfcb333a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bd6b6a62-aebf-4291-8dc4-3106c47e2100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ead04f32-0b1c-4d3f-8be5-31b2dfcb333a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bd6b6a62-aebf-4291-8dc4-3106c47e2100" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bd6b6a62-aebf-4291-8dc4-3106c47e2100_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bd6b6a62-aebf-4291-8dc4-3106c47e2100" xlink:to="loc_us-gaap_EquityComponentDomain_bd6b6a62-aebf-4291-8dc4-3106c47e2100_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a4017fdb-f242-4e38-a989-f8b0e383704b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bd6b6a62-aebf-4291-8dc4-3106c47e2100" xlink:to="loc_us-gaap_EquityComponentDomain_a4017fdb-f242-4e38-a989-f8b0e383704b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_96bf785d-e3de-4165-9854-83ac6ce19db6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a4017fdb-f242-4e38-a989-f8b0e383704b" xlink:to="loc_us-gaap_CommonStockMember_96bf785d-e3de-4165-9854-83ac6ce19db6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_93093d23-9a47-48e3-9486-085eaac486f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a4017fdb-f242-4e38-a989-f8b0e383704b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_93093d23-9a47-48e3-9486-085eaac486f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4f63d45c-e7d8-44f6-b142-373fa119e691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a4017fdb-f242-4e38-a989-f8b0e383704b" xlink:to="loc_us-gaap_RetainedEarningsMember_4f63d45c-e7d8-44f6-b142-373fa119e691" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_f88ff0e6-bdee-44ba-9031-da70f71ee549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a4017fdb-f242-4e38-a989-f8b0e383704b" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_f88ff0e6-bdee-44ba-9031-da70f71ee549" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="mgnx-20220331.xsd#FairValueofFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="extended" id="ib03fdf0edc98457990dbbbd32da2f196_FairValueofFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1ca59045-0f1f-4e01-89c4-2df2b0dfb683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_205e43f5-4f2e-440e-9a70-b5728186e6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1ca59045-0f1f-4e01-89c4-2df2b0dfb683" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_205e43f5-4f2e-440e-9a70-b5728186e6d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_70310cfc-de0f-4114-8c8e-265d61adc789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_205e43f5-4f2e-440e-9a70-b5728186e6d1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_70310cfc-de0f-4114-8c8e-265d61adc789" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b306047b-1a86-4501-bfa4-7da6a631d322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_205e43f5-4f2e-440e-9a70-b5728186e6d1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b306047b-1a86-4501-bfa4-7da6a631d322" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8b999a41-a66c-4e80-af06-8e0ab82341e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_205e43f5-4f2e-440e-9a70-b5728186e6d1" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_8b999a41-a66c-4e80-af06-8e0ab82341e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_971b0635-635d-4d92-b2ad-d28278fa0ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1ca59045-0f1f-4e01-89c4-2df2b0dfb683" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_971b0635-635d-4d92-b2ad-d28278fa0ae5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7092b05c-6b4f-4255-9455-874d0e2e0465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_971b0635-635d-4d92-b2ad-d28278fa0ae5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7092b05c-6b4f-4255-9455-874d0e2e0465" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7092b05c-6b4f-4255-9455-874d0e2e0465_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7092b05c-6b4f-4255-9455-874d0e2e0465" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7092b05c-6b4f-4255-9455-874d0e2e0465_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_19faa585-a79e-4873-a0ee-926bdb517e89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7092b05c-6b4f-4255-9455-874d0e2e0465" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_19faa585-a79e-4873-a0ee-926bdb517e89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d5c04d6d-a598-40a8-8d00-d9c5859b93b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_19faa585-a79e-4873-a0ee-926bdb517e89" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d5c04d6d-a598-40a8-8d00-d9c5859b93b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_87d6fa63-905f-4049-ac5d-6b2239f3116a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_971b0635-635d-4d92-b2ad-d28278fa0ae5" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_87d6fa63-905f-4049-ac5d-6b2239f3116a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_87d6fa63-905f-4049-ac5d-6b2239f3116a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_87d6fa63-905f-4049-ac5d-6b2239f3116a" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_87d6fa63-905f-4049-ac5d-6b2239f3116a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c8efb05d-71f5-47d1-81e3-a845e7324273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_87d6fa63-905f-4049-ac5d-6b2239f3116a" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c8efb05d-71f5-47d1-81e3-a845e7324273" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_249dbdfb-a4b9-4ec1-bac7-c479447b3e35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c8efb05d-71f5-47d1-81e3-a845e7324273" xlink:to="loc_us-gaap_MoneyMarketFundsMember_249dbdfb-a4b9-4ec1-bac7-c479447b3e35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_49ab7dcd-2fea-41b4-8147-8de799387afe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c8efb05d-71f5-47d1-81e3-a845e7324273" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_49ab7dcd-2fea-41b4-8147-8de799387afe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_c94953be-b40c-4058-8d78-3b24d8637af9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c8efb05d-71f5-47d1-81e3-a845e7324273" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_c94953be-b40c-4058-8d78-3b24d8637af9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_dfb61d94-5ab3-4986-ac88-545b30075ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c8efb05d-71f5-47d1-81e3-a845e7324273" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_dfb61d94-5ab3-4986-ac88-545b30075ad9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_047f01d7-6842-4ee7-a84c-a1e3e255889f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_971b0635-635d-4d92-b2ad-d28278fa0ae5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_047f01d7-6842-4ee7-a84c-a1e3e255889f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_047f01d7-6842-4ee7-a84c-a1e3e255889f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_047f01d7-6842-4ee7-a84c-a1e3e255889f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_047f01d7-6842-4ee7-a84c-a1e3e255889f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71d66af8-3f11-4422-b343-2d6fa7c90a75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_047f01d7-6842-4ee7-a84c-a1e3e255889f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71d66af8-3f11-4422-b343-2d6fa7c90a75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c9fa6a02-a93d-440b-b33f-48eed1c8efaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71d66af8-3f11-4422-b343-2d6fa7c90a75" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c9fa6a02-a93d-440b-b33f-48eed1c8efaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_dbca5586-7758-4388-a551-ebbf3b31a450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71d66af8-3f11-4422-b343-2d6fa7c90a75" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_dbca5586-7758-4388-a551-ebbf3b31a450" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20220331.xsd#MarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended" id="i716d8811235f4ae1b6b81bde8e736a54_MarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_90c7a97c-fbe5-4e2a-8ac1-b0e76b6e868d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3fd9f13a-9e44-4167-bb80-ffa4264ed412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_90c7a97c-fbe5-4e2a-8ac1-b0e76b6e868d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3fd9f13a-9e44-4167-bb80-ffa4264ed412" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c7c3da2b-e836-4bd3-a145-aced9d78936f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_90c7a97c-fbe5-4e2a-8ac1-b0e76b6e868d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c7c3da2b-e836-4bd3-a145-aced9d78936f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5339d702-c75a-458c-a023-2be47cfd8c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_90c7a97c-fbe5-4e2a-8ac1-b0e76b6e868d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5339d702-c75a-458c-a023-2be47cfd8c8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d6588877-e755-4674-b6d2-e17548ae4bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_90c7a97c-fbe5-4e2a-8ac1-b0e76b6e868d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d6588877-e755-4674-b6d2-e17548ae4bd2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_9a2d83e2-2141-4150-96e5-769729cf672b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_90c7a97c-fbe5-4e2a-8ac1-b0e76b6e868d" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_9a2d83e2-2141-4150-96e5-769729cf672b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_873aa91f-e565-4d6f-9d3e-0d96f8b1d12f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_9a2d83e2-2141-4150-96e5-769729cf672b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_873aa91f-e565-4d6f-9d3e-0d96f8b1d12f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_873aa91f-e565-4d6f-9d3e-0d96f8b1d12f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_873aa91f-e565-4d6f-9d3e-0d96f8b1d12f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_873aa91f-e565-4d6f-9d3e-0d96f8b1d12f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0c68bf70-618b-4afe-815d-321c250b7909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_873aa91f-e565-4d6f-9d3e-0d96f8b1d12f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0c68bf70-618b-4afe-815d-321c250b7909" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_cf901ef1-653c-4be0-a4ce-f7b76dd8afb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0c68bf70-618b-4afe-815d-321c250b7909" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_cf901ef1-653c-4be0-a4ce-f7b76dd8afb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_6e7739ea-0f9a-4c4f-ae99-ad928f0fb405" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0c68bf70-618b-4afe-815d-321c250b7909" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_6e7739ea-0f9a-4c4f-ae99-ad928f0fb405" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9cc52143-e053-4b8f-860f-0ca37361eab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0c68bf70-618b-4afe-815d-321c250b7909" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9cc52143-e053-4b8f-860f-0ca37361eab0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20220331.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended" id="i0f017200a0754491857d6c2229a7ad4e_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_5596a16a-f578-4b6e-85c1-51e39022c38a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_6d556dc2-c594-41c4-9138-c7bf556783d7" xlink:href="mgnx-20220331.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5596a16a-f578-4b6e-85c1-51e39022c38a" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_6d556dc2-c594-41c4-9138-c7bf556783d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f194d6d4-8781-461d-ab15-7b151c60726f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5596a16a-f578-4b6e-85c1-51e39022c38a" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f194d6d4-8781-461d-ab15-7b151c60726f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_85757598-e2b7-4ddb-9322-527129989e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5596a16a-f578-4b6e-85c1-51e39022c38a" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_85757598-e2b7-4ddb-9322-527129989e8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f0d10943-f71d-411d-82b7-301e1284976c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5596a16a-f578-4b6e-85c1-51e39022c38a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f0d10943-f71d-411d-82b7-301e1284976c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_affeb043-0181-4d8c-b30e-aacf34230206" xlink:href="mgnx-20220331.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5596a16a-f578-4b6e-85c1-51e39022c38a" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_affeb043-0181-4d8c-b30e-aacf34230206" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7e19c7a3-1d5d-4b12-a656-ab5eaf7c2052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5596a16a-f578-4b6e-85c1-51e39022c38a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7e19c7a3-1d5d-4b12-a656-ab5eaf7c2052" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5af4f54b-6271-4a23-9444-05ab8e2c9cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5596a16a-f578-4b6e-85c1-51e39022c38a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5af4f54b-6271-4a23-9444-05ab8e2c9cf1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2e542a1b-f3b7-4f74-83ba-9dd95c05d7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_5596a16a-f578-4b6e-85c1-51e39022c38a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2e542a1b-f3b7-4f74-83ba-9dd95c05d7ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b39439c1-8bce-453b-93a3-d83ec32e962b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2e542a1b-f3b7-4f74-83ba-9dd95c05d7ca" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b39439c1-8bce-453b-93a3-d83ec32e962b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b39439c1-8bce-453b-93a3-d83ec32e962b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b39439c1-8bce-453b-93a3-d83ec32e962b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b39439c1-8bce-453b-93a3-d83ec32e962b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_72dbe024-718c-49b0-bec0-910e1e9048ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b39439c1-8bce-453b-93a3-d83ec32e962b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_72dbe024-718c-49b0-bec0-910e1e9048ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember_081d4aa6-e5cc-4e39-9372-cdafed1d0622" xlink:href="mgnx-20220331.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_72dbe024-718c-49b0-bec0-910e1e9048ca" xlink:to="loc_mgnx_AtTheMarketOfferingMember_081d4aa6-e5cc-4e39-9372-cdafed1d0622" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d3d9dec4-d68f-4cb3-88b5-d79028a8ce6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2e542a1b-f3b7-4f74-83ba-9dd95c05d7ca" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d3d9dec4-d68f-4cb3-88b5-d79028a8ce6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d3d9dec4-d68f-4cb3-88b5-d79028a8ce6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d3d9dec4-d68f-4cb3-88b5-d79028a8ce6d" xlink:to="loc_us-gaap_EquityComponentDomain_d3d9dec4-d68f-4cb3-88b5-d79028a8ce6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aa874144-f2fd-424e-8e5e-773c2237a338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d3d9dec4-d68f-4cb3-88b5-d79028a8ce6d" xlink:to="loc_us-gaap_EquityComponentDomain_aa874144-f2fd-424e-8e5e-773c2237a338" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_916c84a3-b9e1-4835-8b3d-25f80cf6391b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_aa874144-f2fd-424e-8e5e-773c2237a338" xlink:to="loc_us-gaap_CommonStockMember_916c84a3-b9e1-4835-8b3d-25f80cf6391b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="simple" xlink:href="mgnx-20220331.xsd#CollaborationandOtherAgreementsIncyteCorporationDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="extended" id="i88c65bcdbf3143c595904471b1f5d4e9_CollaborationandOtherAgreementsIncyteCorporationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_c9e70601-09a5-449e-80dc-9e94eb7375b7" xlink:href="mgnx-20220331.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:to="loc_mgnx_NonRefundableUpfrontFees_c9e70601-09a5-449e-80dc-9e94eb7375b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_f68ccb31-2f2f-49a4-bb89-bef863c4a7ab" xlink:href="mgnx-20220331.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_f68ccb31-2f2f-49a4-bb89-bef863c4a7ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_aaa60a41-1e9c-4e71-992f-d2b9b057e154" xlink:href="mgnx-20220331.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_aaa60a41-1e9c-4e71-992f-d2b9b057e154" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_786e5582-247b-45d6-9111-754aecf76105" xlink:href="mgnx-20220331.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_786e5582-247b-45d6-9111-754aecf76105" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_443120b6-6ab7-45cc-abbb-2c4468d48a03" xlink:href="mgnx-20220331.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_443120b6-6ab7-45cc-abbb-2c4468d48a03" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_82785b23-f253-4bfb-8b41-ae6faeb098e7" xlink:href="mgnx-20220331.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:to="loc_mgnx_NumberOfPerformanceObligations_82785b23-f253-4bfb-8b41-ae6faeb098e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_b205a30f-e5ad-430e-b8de-ccdc2ce58d65" xlink:href="mgnx-20220331.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_b205a30f-e5ad-430e-b8de-ccdc2ce58d65" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1d08fb7b-4b93-4a8c-a756-af81cd738a30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:to="loc_us-gaap_Revenues_1d08fb7b-4b93-4a8c-a756-af81cd738a30" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_cf609a90-988d-4f35-9cf6-ec0ae8b1664a" xlink:href="mgnx-20220331.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_cf609a90-988d-4f35-9cf6-ec0ae8b1664a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_9b9757d2-aa3d-45de-a711-cbd14bdce2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:to="loc_us-gaap_ContractWithCustomerLiability_9b9757d2-aa3d-45de-a711-cbd14bdce2a2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_053ae95f-739a-481f-8afb-79870fd76dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_053ae95f-739a-481f-8afb-79870fd76dd3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_156c4522-94ea-4302-b03b-22b987c5692d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_156c4522-94ea-4302-b03b-22b987c5692d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalAnnualFixedPayments_daffb7ab-e8e1-4049-8731-78a4f3bb9b0b" xlink:href="mgnx-20220331.xsd#mgnx_TotalAnnualFixedPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:to="loc_mgnx_TotalAnnualFixedPayments_daffb7ab-e8e1-4049-8731-78a4f3bb9b0b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9a31b44-e30b-4a5b-ab62-f4acbf9792c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9a31b44-e30b-4a5b-ab62-f4acbf9792c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6d8dac16-e7fe-436e-b7e4-9d6652d9cec6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9a31b44-e30b-4a5b-ab62-f4acbf9792c5" xlink:to="loc_srt_ProductOrServiceAxis_6d8dac16-e7fe-436e-b7e4-9d6652d9cec6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6d8dac16-e7fe-436e-b7e4-9d6652d9cec6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6d8dac16-e7fe-436e-b7e4-9d6652d9cec6" xlink:to="loc_srt_ProductsAndServicesDomain_6d8dac16-e7fe-436e-b7e4-9d6652d9cec6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8d5c70cd-55d4-4132-a4ea-4298f21a2043" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6d8dac16-e7fe-436e-b7e4-9d6652d9cec6" xlink:to="loc_srt_ProductsAndServicesDomain_8d5c70cd-55d4-4132-a4ea-4298f21a2043" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_d810748f-d089-48b5-a901-d74e9509d74a" xlink:href="mgnx-20220331.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8d5c70cd-55d4-4132-a4ea-4298f21a2043" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_d810748f-d089-48b5-a901-d74e9509d74a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAgreementsMemberMember_843eea7c-60ff-4c8e-bfb5-1ca0bba97d2a" xlink:href="mgnx-20220331.xsd#mgnx_RevenuesFromCMOAgreementsMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8d5c70cd-55d4-4132-a4ea-4298f21a2043" xlink:to="loc_mgnx_RevenuesFromCMOAgreementsMemberMember_843eea7c-60ff-4c8e-bfb5-1ca0bba97d2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ccbc8c9e-260a-4138-ad9f-360210e044e7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9a31b44-e30b-4a5b-ab62-f4acbf9792c5" xlink:to="loc_srt_RangeAxis_ccbc8c9e-260a-4138-ad9f-360210e044e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ccbc8c9e-260a-4138-ad9f-360210e044e7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ccbc8c9e-260a-4138-ad9f-360210e044e7" xlink:to="loc_srt_RangeMember_ccbc8c9e-260a-4138-ad9f-360210e044e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_74132982-862e-4ee8-8732-db1417ef641e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ccbc8c9e-260a-4138-ad9f-360210e044e7" xlink:to="loc_srt_RangeMember_74132982-862e-4ee8-8732-db1417ef641e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ced4adbe-4e73-43f1-85ae-f9eb07b5b06a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_74132982-862e-4ee8-8732-db1417ef641e" xlink:to="loc_srt_MinimumMember_ced4adbe-4e73-43f1-85ae-f9eb07b5b06a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_40c31d4c-8852-44c4-8f6d-32592c1b6615" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_74132982-862e-4ee8-8732-db1417ef641e" xlink:to="loc_srt_MaximumMember_40c31d4c-8852-44c4-8f6d-32592c1b6615" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4766775f-8160-4faa-b024-2c5b3f13438b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9a31b44-e30b-4a5b-ab62-f4acbf9792c5" xlink:to="loc_srt_CounterpartyNameAxis_4766775f-8160-4faa-b024-2c5b3f13438b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4766775f-8160-4faa-b024-2c5b3f13438b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4766775f-8160-4faa-b024-2c5b3f13438b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4766775f-8160-4faa-b024-2c5b3f13438b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2de56116-2d4c-484f-8fcf-e6f30857d1d5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4766775f-8160-4faa-b024-2c5b3f13438b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2de56116-2d4c-484f-8fcf-e6f30857d1d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_5ea03e0a-47ca-477e-b373-eddec2d2ab1d" xlink:href="mgnx-20220331.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2de56116-2d4c-484f-8fcf-e6f30857d1d5" xlink:to="loc_mgnx_IncyteCorporationMember_5ea03e0a-47ca-477e-b373-eddec2d2ab1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_bf8e3c7c-410a-4ca6-91af-badaa72df61b" xlink:href="mgnx-20220331.xsd#mgnx_IMabBiopharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2de56116-2d4c-484f-8fcf-e6f30857d1d5" xlink:to="loc_mgnx_IMabBiopharmaMember_bf8e3c7c-410a-4ca6-91af-badaa72df61b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2884de77-98cc-45db-8bcd-0131f2bdee00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9a31b44-e30b-4a5b-ab62-f4acbf9792c5" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2884de77-98cc-45db-8bcd-0131f2bdee00" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2884de77-98cc-45db-8bcd-0131f2bdee00_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2884de77-98cc-45db-8bcd-0131f2bdee00" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2884de77-98cc-45db-8bcd-0131f2bdee00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a7a4357e-54be-42da-becb-7afbd79545f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2884de77-98cc-45db-8bcd-0131f2bdee00" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a7a4357e-54be-42da-becb-7afbd79545f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_b829e885-fcad-4e72-bbb2-6f9c3294b7ac" xlink:href="mgnx-20220331.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a7a4357e-54be-42da-becb-7afbd79545f4" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_b829e885-fcad-4e72-bbb2-6f9c3294b7ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_b57669cc-ec4f-4109-b588-ae3e9c156db5" xlink:href="mgnx-20220331.xsd#mgnx_IncyteMGA012AgreementClinicalActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_IncyteMGA012AgreementMember_b829e885-fcad-4e72-bbb2-6f9c3294b7ac" xlink:to="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_b57669cc-ec4f-4109-b588-ae3e9c156db5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012ClinicalServicesMember_3a3be1eb-2f43-45ec-84bb-42feca7868bf" xlink:href="mgnx-20220331.xsd#mgnx_IncyteMGA012ClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a7a4357e-54be-42da-becb-7afbd79545f4" xlink:to="loc_mgnx_IncyteMGA012ClinicalServicesMember_3a3be1eb-2f43-45ec-84bb-42feca7868bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012SupplyAgreementMember_5f65e85d-952f-4d57-b900-18043a45150f" xlink:href="mgnx-20220331.xsd#mgnx_IncyteMGA012SupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a7a4357e-54be-42da-becb-7afbd79545f4" xlink:to="loc_mgnx_IncyteMGA012SupplyAgreementMember_5f65e85d-952f-4d57-b900-18043a45150f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_93880b1f-62fa-42a0-a22a-69418a37fe0d" xlink:href="mgnx-20220331.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a7a4357e-54be-42da-becb-7afbd79545f4" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_93880b1f-62fa-42a0-a22a-69418a37fe0d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20220331.xsd#CollaborationandOtherAgreementsZaiLabDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="extended" id="i3753369143b94e95a8a02a0186f3e84c_CollaborationandOtherAgreementsZaiLabDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_880eaa91-0806-4f90-a5d3-473b1f03a066" xlink:href="mgnx-20220331.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_mgnx_NonRefundableUpfrontFees_880eaa91-0806-4f90-a5d3-473b1f03a066" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_c1d49989-ba31-4cd2-802a-6b821f7d2bae" xlink:href="mgnx-20220331.xsd#mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_c1d49989-ba31-4cd2-802a-6b821f7d2bae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding_e6d44a34-0e3f-46a6-a09d-8f61f01b6168" xlink:href="mgnx-20220331.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_mgnx_NonrefundablePaymentTaxWithholding_e6d44a34-0e3f-46a6-a09d-8f61f01b6168" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_9b02665b-13e6-4408-abb5-c79f57279266" xlink:href="mgnx-20220331.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_9b02665b-13e6-4408-abb5-c79f57279266" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_d7e79056-f167-4a9b-9be3-21e1be46093a" xlink:href="mgnx-20220331.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_d7e79056-f167-4a9b-9be3-21e1be46093a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesNetOfTaxWithholding_cfc19175-5c5e-4b16-8af0-17b457f718e7" xlink:href="mgnx-20220331.xsd#mgnx_RevenuesNetOfTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_mgnx_RevenuesNetOfTaxWithholding_cfc19175-5c5e-4b16-8af0-17b457f718e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_18670613-9f87-443a-9295-f3118775a295" xlink:href="mgnx-20220331.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_18670613-9f87-443a-9295-f3118775a295" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_05544de2-ba12-4892-bd2c-50166fca20c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_us-gaap_ContractWithCustomerLiability_05544de2-ba12-4892-bd2c-50166fca20c7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2d120d18-a54b-4b32-aa49-b6c9d75f43bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_us-gaap_Revenues_2d120d18-a54b-4b32-aa49-b6c9d75f43bf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptInFee_2d18c196-4069-4a6a-8838-a32721910900" xlink:href="mgnx-20220331.xsd#mgnx_OptInFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_mgnx_OptInFee_2d18c196-4069-4a6a-8838-a32721910900" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a8103959-7b08-4daa-9df4-6e6dd9192e03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a8103959-7b08-4daa-9df4-6e6dd9192e03" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_73ef77af-ed07-44dd-986a-b5c0d4dfb59b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_73ef77af-ed07-44dd-986a-b5c0d4dfb59b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_69926ab3-75b6-4ef7-a0a9-afdbbf816b26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_69926ab3-75b6-4ef7-a0a9-afdbbf816b26" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase_92b53ee6-fc8d-453e-ba01-e2fb0ccbcb72" xlink:href="mgnx-20220331.xsd#mgnx_PremiumReceivedOnStockPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_mgnx_PremiumReceivedOnStockPurchase_92b53ee6-fc8d-453e-ba01-e2fb0ccbcb72" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_65d112ba-e413-4e10-8dd6-7ca1d398c4ae" xlink:href="mgnx-20220331.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_65d112ba-e413-4e10-8dd6-7ca1d398c4ae" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_d65cbc25-0094-4e89-b1a4-b497d5714250" xlink:href="mgnx-20220331.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_d65cbc25-0094-4e89-b1a4-b497d5714250" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_4d5c940f-e713-4d33-adf7-4a68db4a2c44" xlink:href="mgnx-20220331.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_4d5c940f-e713-4d33-adf7-4a68db4a2c44" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d6c9df33-5c57-4abe-9d78-f6828b91abd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d6c9df33-5c57-4abe-9d78-f6828b91abd2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_90ce7108-1f59-4149-80ec-4cc3d765961a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_90ce7108-1f59-4149-80ec-4cc3d765961a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3214b8a-4ebf-4426-9a7e-74bf09cd03f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3214b8a-4ebf-4426-9a7e-74bf09cd03f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5f6f5d37-c05e-4da6-8d8e-a4acde8c069c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3214b8a-4ebf-4426-9a7e-74bf09cd03f3" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5f6f5d37-c05e-4da6-8d8e-a4acde8c069c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5f6f5d37-c05e-4da6-8d8e-a4acde8c069c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5f6f5d37-c05e-4da6-8d8e-a4acde8c069c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5f6f5d37-c05e-4da6-8d8e-a4acde8c069c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8086d4de-f1cd-475f-b667-83722dc94ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5f6f5d37-c05e-4da6-8d8e-a4acde8c069c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8086d4de-f1cd-475f-b667-83722dc94ea9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_4ffc1aa8-bf1c-43e5-b98c-40c8b7bc831b" xlink:href="mgnx-20220331.xsd#mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8086d4de-f1cd-475f-b667-83722dc94ea9" xlink:to="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_4ffc1aa8-bf1c-43e5-b98c-40c8b7bc831b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_dfbaac79-a278-423a-90b3-c498f0b8b61d" xlink:href="mgnx-20220331.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8086d4de-f1cd-475f-b667-83722dc94ea9" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_dfbaac79-a278-423a-90b3-c498f0b8b61d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_3329d801-aa65-45aa-a0d5-c7c38371b19b" xlink:href="mgnx-20220331.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8086d4de-f1cd-475f-b667-83722dc94ea9" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_3329d801-aa65-45aa-a0d5-c7c38371b19b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_ffdefa1d-9a36-4787-8345-b0c05f203164" xlink:href="mgnx-20220331.xsd#mgnx_ZaiLabClinicalSupplyAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8086d4de-f1cd-475f-b667-83722dc94ea9" xlink:to="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_ffdefa1d-9a36-4787-8345-b0c05f203164" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember_e66a64b8-6972-4f51-87b3-883f5f43c8b1" xlink:href="mgnx-20220331.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8086d4de-f1cd-475f-b667-83722dc94ea9" xlink:to="loc_mgnx_A2021ZaiLabAgreementsMember_e66a64b8-6972-4f51-87b3-883f5f43c8b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_888b42d1-ee0d-457f-85f9-e25c94463c6e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3214b8a-4ebf-4426-9a7e-74bf09cd03f3" xlink:to="loc_srt_CounterpartyNameAxis_888b42d1-ee0d-457f-85f9-e25c94463c6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_888b42d1-ee0d-457f-85f9-e25c94463c6e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_888b42d1-ee0d-457f-85f9-e25c94463c6e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_888b42d1-ee0d-457f-85f9-e25c94463c6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ab363da5-fefd-4bdb-9027-c7b73cbbba6d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_888b42d1-ee0d-457f-85f9-e25c94463c6e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ab363da5-fefd-4bdb-9027-c7b73cbbba6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_05c36fd3-1fac-49d8-84e7-ef0edc75f69a" xlink:href="mgnx-20220331.xsd#mgnx_ZaiLabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ab363da5-fefd-4bdb-9027-c7b73cbbba6d" xlink:to="loc_mgnx_ZaiLabMember_05c36fd3-1fac-49d8-84e7-ef0edc75f69a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ca6e82b2-af05-4eed-8c8d-0bbd08a25d9c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3214b8a-4ebf-4426-9a7e-74bf09cd03f3" xlink:to="loc_srt_RangeAxis_ca6e82b2-af05-4eed-8c8d-0bbd08a25d9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ca6e82b2-af05-4eed-8c8d-0bbd08a25d9c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ca6e82b2-af05-4eed-8c8d-0bbd08a25d9c" xlink:to="loc_srt_RangeMember_ca6e82b2-af05-4eed-8c8d-0bbd08a25d9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_11ddee3e-f527-435a-82e8-b98fd8371761" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ca6e82b2-af05-4eed-8c8d-0bbd08a25d9c" xlink:to="loc_srt_RangeMember_11ddee3e-f527-435a-82e8-b98fd8371761" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d15dba2c-b1bf-4c86-ac7f-c8446a4fa96b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_11ddee3e-f527-435a-82e8-b98fd8371761" xlink:to="loc_srt_MaximumMember_d15dba2c-b1bf-4c86-ac7f-c8446a4fa96b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c2d018b0-46d0-45cb-bfc1-c7ae8902774f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3214b8a-4ebf-4426-9a7e-74bf09cd03f3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c2d018b0-46d0-45cb-bfc1-c7ae8902774f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c2d018b0-46d0-45cb-bfc1-c7ae8902774f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c2d018b0-46d0-45cb-bfc1-c7ae8902774f" xlink:to="loc_us-gaap_EquityComponentDomain_c2d018b0-46d0-45cb-bfc1-c7ae8902774f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b15890e0-a45d-4e61-8383-8dd6c4fc74ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c2d018b0-46d0-45cb-bfc1-c7ae8902774f" xlink:to="loc_us-gaap_EquityComponentDomain_b15890e0-a45d-4e61-8383-8dd6c4fc74ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_25dec141-347a-4205-86ad-8e70431a71d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b15890e0-a45d-4e61-8383-8dd6c4fc74ad" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_25dec141-347a-4205-86ad-8e70431a71d9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails" xlink:type="simple" xlink:href="mgnx-20220331.xsd#CollaborationandOtherAgreementsJanssenDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails" xlink:type="extended" id="i5302794c9bf74b7fb6d3f205bc67239d_CollaborationandOtherAgreementsJanssenDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a2742017-b3fa-499f-89c1-ef797b7d2398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_4318d117-1d07-4e36-882a-30a80cfe271e" xlink:href="mgnx-20220331.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a2742017-b3fa-499f-89c1-ef797b7d2398" xlink:to="loc_mgnx_NonRefundableUpfrontFees_4318d117-1d07-4e36-882a-30a80cfe271e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_e511e063-1671-40c5-84ec-b3e1c910cd1c" xlink:href="mgnx-20220331.xsd#mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a2742017-b3fa-499f-89c1-ef797b7d2398" xlink:to="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_e511e063-1671-40c5-84ec-b3e1c910cd1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_14437eb3-498c-4170-bba8-c616749bb700" xlink:href="mgnx-20220331.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a2742017-b3fa-499f-89c1-ef797b7d2398" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_14437eb3-498c-4170-bba8-c616749bb700" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_12ddb7d1-19ce-4b47-80ed-d3a8d3649c5d" xlink:href="mgnx-20220331.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a2742017-b3fa-499f-89c1-ef797b7d2398" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_12ddb7d1-19ce-4b47-80ed-d3a8d3649c5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6730d065-7485-4330-8199-bfc29f6849a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a2742017-b3fa-499f-89c1-ef797b7d2398" xlink:to="loc_us-gaap_Revenues_6730d065-7485-4330-8199-bfc29f6849a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_eeeef6ec-8b69-49a0-bca2-667088d12ae2" xlink:href="mgnx-20220331.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a2742017-b3fa-499f-89c1-ef797b7d2398" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_eeeef6ec-8b69-49a0-bca2-667088d12ae2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1eb11049-ab52-4c0a-b793-91438c9a49d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a2742017-b3fa-499f-89c1-ef797b7d2398" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1eb11049-ab52-4c0a-b793-91438c9a49d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b1becd09-2639-4fe3-8665-c83c836c6e71" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1eb11049-ab52-4c0a-b793-91438c9a49d8" xlink:to="loc_srt_CounterpartyNameAxis_b1becd09-2639-4fe3-8665-c83c836c6e71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b1becd09-2639-4fe3-8665-c83c836c6e71_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b1becd09-2639-4fe3-8665-c83c836c6e71" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b1becd09-2639-4fe3-8665-c83c836c6e71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a378037e-c693-4705-9fcd-1a2d32d639e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b1becd09-2639-4fe3-8665-c83c836c6e71" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a378037e-c693-4705-9fcd-1a2d32d639e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember_06a30532-c014-4535-91d8-79f3f6242fb5" xlink:href="mgnx-20220331.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a378037e-c693-4705-9fcd-1a2d32d639e8" xlink:to="loc_mgnx_JanssenBiotechIncMember_06a30532-c014-4535-91d8-79f3f6242fb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bbc21563-bab7-46a1-bf7f-eeff7b47a13b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1eb11049-ab52-4c0a-b793-91438c9a49d8" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bbc21563-bab7-46a1-bf7f-eeff7b47a13b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bbc21563-bab7-46a1-bf7f-eeff7b47a13b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bbc21563-bab7-46a1-bf7f-eeff7b47a13b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bbc21563-bab7-46a1-bf7f-eeff7b47a13b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5839aadc-11d6-41ab-8535-584b66a52059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bbc21563-bab7-46a1-bf7f-eeff7b47a13b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5839aadc-11d6-41ab-8535-584b66a52059" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember_14527310-f4d3-4ed2-8f51-2299d4df6eb0" xlink:href="mgnx-20220331.xsd#mgnx_JanssenCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5839aadc-11d6-41ab-8535-584b66a52059" xlink:to="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember_14527310-f4d3-4ed2-8f51-2299d4df6eb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a89e2f6c-b14c-4508-bba6-80a64d504fba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1eb11049-ab52-4c0a-b793-91438c9a49d8" xlink:to="loc_srt_ProductOrServiceAxis_a89e2f6c-b14c-4508-bba6-80a64d504fba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a89e2f6c-b14c-4508-bba6-80a64d504fba_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a89e2f6c-b14c-4508-bba6-80a64d504fba" xlink:to="loc_srt_ProductsAndServicesDomain_a89e2f6c-b14c-4508-bba6-80a64d504fba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a960c63e-a926-496f-b99d-65bc406f09db" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a89e2f6c-b14c-4508-bba6-80a64d504fba" xlink:to="loc_srt_ProductsAndServicesDomain_a960c63e-a926-496f-b99d-65bc406f09db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_b4cf3a6b-5c95-422d-aff9-2d2882486004" xlink:href="mgnx-20220331.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a960c63e-a926-496f-b99d-65bc406f09db" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_b4cf3a6b-5c95-422d-aff9-2d2882486004" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_d21366b2-be1c-44c7-ab3c-e9c5ef9e5568" xlink:href="mgnx-20220331.xsd#mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a960c63e-a926-496f-b99d-65bc406f09db" xlink:to="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_d21366b2-be1c-44c7-ab3c-e9c5ef9e5568" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="simple" xlink:href="mgnx-20220331.xsd#CollaborationandOtherAgreementsIMabBiopharmaDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="extended" id="ibe7a32f83d5c40f982a2f430df6cde4d_CollaborationandOtherAgreementsIMabBiopharmaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2334e61f-e566-4734-b951-345e26d2417d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_c762e59d-8e54-4fa1-b709-ac8dd41f77b0" xlink:href="mgnx-20220331.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2334e61f-e566-4734-b951-345e26d2417d" xlink:to="loc_mgnx_NonRefundableUpfrontFees_c762e59d-8e54-4fa1-b709-ac8dd41f77b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_82630cc7-3366-49bc-abee-f3f1cf39ff31" xlink:href="mgnx-20220331.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2334e61f-e566-4734-b951-345e26d2417d" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_82630cc7-3366-49bc-abee-f3f1cf39ff31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_511fc137-3bb0-4837-891d-0c9cffb85e9b" xlink:href="mgnx-20220331.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2334e61f-e566-4734-b951-345e26d2417d" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_511fc137-3bb0-4837-891d-0c9cffb85e9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesNetOfTaxWithholding_3371653f-a9a2-457e-896c-95290421a5a6" xlink:href="mgnx-20220331.xsd#mgnx_RevenuesNetOfTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2334e61f-e566-4734-b951-345e26d2417d" xlink:to="loc_mgnx_RevenuesNetOfTaxWithholding_3371653f-a9a2-457e-896c-95290421a5a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_f30e5e2c-7e8a-45bc-9e74-17e3fe7ab840" xlink:href="mgnx-20220331.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2334e61f-e566-4734-b951-345e26d2417d" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_f30e5e2c-7e8a-45bc-9e74-17e3fe7ab840" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_6083831a-4383-41ed-86c8-590c95f11a6e" xlink:href="mgnx-20220331.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2334e61f-e566-4734-b951-345e26d2417d" xlink:to="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_6083831a-4383-41ed-86c8-590c95f11a6e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a171f395-f5d5-4cb6-835a-9c0d22334342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2334e61f-e566-4734-b951-345e26d2417d" xlink:to="loc_us-gaap_Revenues_a171f395-f5d5-4cb6-835a-9c0d22334342" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_ce4b768c-b7a0-435f-91ec-a2a436cf58e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2334e61f-e566-4734-b951-345e26d2417d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_ce4b768c-b7a0-435f-91ec-a2a436cf58e6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ddf3b482-c28d-4678-b483-5bff28302de5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2334e61f-e566-4734-b951-345e26d2417d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ddf3b482-c28d-4678-b483-5bff28302de5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f430e487-e20c-4acd-bf21-95992f57205c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2334e61f-e566-4734-b951-345e26d2417d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f430e487-e20c-4acd-bf21-95992f57205c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OneTimeMillstoneCredit_586c1126-864a-4b8e-a246-2ee90d93434a" xlink:href="mgnx-20220331.xsd#mgnx_OneTimeMillstoneCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2334e61f-e566-4734-b951-345e26d2417d" xlink:to="loc_mgnx_OneTimeMillstoneCredit_586c1126-864a-4b8e-a246-2ee90d93434a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1c126e74-de9d-4ef2-96d5-64edb8be8b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2334e61f-e566-4734-b951-345e26d2417d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1c126e74-de9d-4ef2-96d5-64edb8be8b9f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ad3ef95e-2a0c-4e7c-b21d-207be3ef672d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1c126e74-de9d-4ef2-96d5-64edb8be8b9f" xlink:to="loc_srt_CounterpartyNameAxis_ad3ef95e-2a0c-4e7c-b21d-207be3ef672d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ad3ef95e-2a0c-4e7c-b21d-207be3ef672d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ad3ef95e-2a0c-4e7c-b21d-207be3ef672d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ad3ef95e-2a0c-4e7c-b21d-207be3ef672d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_268ad471-eb92-4f4b-9348-cd33ed71910f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ad3ef95e-2a0c-4e7c-b21d-207be3ef672d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_268ad471-eb92-4f4b-9348-cd33ed71910f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_3286d840-e3c6-4924-a0e2-8c4af6225652" xlink:href="mgnx-20220331.xsd#mgnx_IMabBiopharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_268ad471-eb92-4f4b-9348-cd33ed71910f" xlink:to="loc_mgnx_IMabBiopharmaMember_3286d840-e3c6-4924-a0e2-8c4af6225652" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_e86ab76d-50f6-4590-b53c-a9c089341212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1c126e74-de9d-4ef2-96d5-64edb8be8b9f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_e86ab76d-50f6-4590-b53c-a9c089341212" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e86ab76d-50f6-4590-b53c-a9c089341212_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_e86ab76d-50f6-4590-b53c-a9c089341212" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e86ab76d-50f6-4590-b53c-a9c089341212_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6feb1e15-30e4-446b-9d86-705648cc65d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_e86ab76d-50f6-4590-b53c-a9c089341212" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6feb1e15-30e4-446b-9d86-705648cc65d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_3437d94c-2af0-406c-84ac-399ddbaf24b5" xlink:href="mgnx-20220331.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6feb1e15-30e4-446b-9d86-705648cc65d5" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_3437d94c-2af0-406c-84ac-399ddbaf24b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_eee8a0b4-eded-4968-9f64-3a67294d1f1c" xlink:href="mgnx-20220331.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6feb1e15-30e4-446b-9d86-705648cc65d5" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_eee8a0b4-eded-4968-9f64-3a67294d1f1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c9408460-8acf-4504-9f60-510b8302ef8a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1c126e74-de9d-4ef2-96d5-64edb8be8b9f" xlink:to="loc_srt_RangeAxis_c9408460-8acf-4504-9f60-510b8302ef8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c9408460-8acf-4504-9f60-510b8302ef8a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c9408460-8acf-4504-9f60-510b8302ef8a" xlink:to="loc_srt_RangeMember_c9408460-8acf-4504-9f60-510b8302ef8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5568fd85-70f7-4806-9341-5742918db7f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c9408460-8acf-4504-9f60-510b8302ef8a" xlink:to="loc_srt_RangeMember_5568fd85-70f7-4806-9341-5742918db7f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_05aa705e-77ce-433e-9bb8-68ca8e22ab51" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5568fd85-70f7-4806-9341-5742918db7f2" xlink:to="loc_srt_MaximumMember_05aa705e-77ce-433e-9bb8-68ca8e22ab51" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20220331.xsd#CollaborationandOtherAgreementsNIAIDContractDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="extended" id="iba4d2157da294580ab7567bebd49f171_CollaborationandOtherAgreementsNIAIDContractDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_96111cab-9446-42f8-b05c-38e130bce98d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_637044e6-903f-4632-a9c8-81859ad9c2b2" xlink:href="mgnx-20220331.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_96111cab-9446-42f8-b05c-38e130bce98d" xlink:to="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_637044e6-903f-4632-a9c8-81859ad9c2b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_88c2b06e-6ac1-4a4e-81f2-bef2265c96c4" xlink:href="mgnx-20220331.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_96111cab-9446-42f8-b05c-38e130bce98d" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_88c2b06e-6ac1-4a4e-81f2-bef2265c96c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2b9dd771-4616-4cd3-91e0-9031d5577634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_96111cab-9446-42f8-b05c-38e130bce98d" xlink:to="loc_us-gaap_Revenues_2b9dd771-4616-4cd3-91e0-9031d5577634" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0d6d61cf-7d09-4fd0-87c0-257df24b4d34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_96111cab-9446-42f8-b05c-38e130bce98d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0d6d61cf-7d09-4fd0-87c0-257df24b4d34" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_330342b6-bd14-4334-9ae7-e06ec803ae91" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0d6d61cf-7d09-4fd0-87c0-257df24b4d34" xlink:to="loc_srt_ProductOrServiceAxis_330342b6-bd14-4334-9ae7-e06ec803ae91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_330342b6-bd14-4334-9ae7-e06ec803ae91_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_330342b6-bd14-4334-9ae7-e06ec803ae91" xlink:to="loc_srt_ProductsAndServicesDomain_330342b6-bd14-4334-9ae7-e06ec803ae91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8c31692d-59a9-48a9-90ce-7b7a88ba7ffb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_330342b6-bd14-4334-9ae7-e06ec803ae91" xlink:to="loc_srt_ProductsAndServicesDomain_8c31692d-59a9-48a9-90ce-7b7a88ba7ffb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember_3afd48e8-590a-410c-adb1-e73038b91ce0" xlink:href="mgnx-20220331.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8c31692d-59a9-48a9-90ce-7b7a88ba7ffb" xlink:to="loc_mgnx_RevenuesFromGrantsMember_3afd48e8-590a-410c-adb1-e73038b91ce0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8c46674f-4547-491a-ac42-f618b720ed12" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0d6d61cf-7d09-4fd0-87c0-257df24b4d34" xlink:to="loc_srt_CounterpartyNameAxis_8c46674f-4547-491a-ac42-f618b720ed12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8c46674f-4547-491a-ac42-f618b720ed12_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8c46674f-4547-491a-ac42-f618b720ed12" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8c46674f-4547-491a-ac42-f618b720ed12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c20417ef-5002-4e50-bfa9-1ad486133889" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8c46674f-4547-491a-ac42-f618b720ed12" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c20417ef-5002-4e50-bfa9-1ad486133889" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_bc112d3a-7180-4ead-8ebc-a1b8294e6332" xlink:href="mgnx-20220331.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c20417ef-5002-4e50-bfa9-1ad486133889" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_bc112d3a-7180-4ead-8ebc-a1b8294e6332" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_baab59ec-7bca-41d9-9f6a-d3153d046fd8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0d6d61cf-7d09-4fd0-87c0-257df24b4d34" xlink:to="loc_srt_RangeAxis_baab59ec-7bca-41d9-9f6a-d3153d046fd8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_baab59ec-7bca-41d9-9f6a-d3153d046fd8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_baab59ec-7bca-41d9-9f6a-d3153d046fd8" xlink:to="loc_srt_RangeMember_baab59ec-7bca-41d9-9f6a-d3153d046fd8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b0350b56-ab18-4d1e-8bf9-e98db66d706e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_baab59ec-7bca-41d9-9f6a-d3153d046fd8" xlink:to="loc_srt_RangeMember_b0350b56-ab18-4d1e-8bf9-e98db66d706e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7b348af7-d5b4-4d94-b5ee-0d175b0c46bb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b0350b56-ab18-4d1e-8bf9-e98db66d706e" xlink:to="loc_srt_MaximumMember_7b348af7-d5b4-4d94-b5ee-0d175b0c46bb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20220331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" id="i29ca17aa06644eeda6e24c037b7ce4c7_StockBasedCompensationStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d60251c4-c5a7-4b5b-a866-c5a39eae878f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c067143d-8346-4f94-a4d0-6201140cbe8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d60251c4-c5a7-4b5b-a866-c5a39eae878f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c067143d-8346-4f94-a4d0-6201140cbe8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_be84bc97-203d-4e9d-8d4b-ea9270150de8" xlink:href="mgnx-20220331.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d60251c4-c5a7-4b5b-a866-c5a39eae878f" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_be84bc97-203d-4e9d-8d4b-ea9270150de8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_dc4db196-51cd-40ea-a024-06bbaa624b6e" xlink:href="mgnx-20220331.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d60251c4-c5a7-4b5b-a866-c5a39eae878f" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_dc4db196-51cd-40ea-a024-06bbaa624b6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_f7c796c0-f782-42dc-9001-9282bb4325e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d60251c4-c5a7-4b5b-a866-c5a39eae878f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_f7c796c0-f782-42dc-9001-9282bb4325e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_ba3c318c-269f-47b6-a6e1-c6e8e352d119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d60251c4-c5a7-4b5b-a866-c5a39eae878f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_ba3c318c-269f-47b6-a6e1-c6e8e352d119" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_82106d7f-dc52-44e8-bb3a-5f8e126af9cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d60251c4-c5a7-4b5b-a866-c5a39eae878f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_82106d7f-dc52-44e8-bb3a-5f8e126af9cb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20091cba-ed26-40d9-a646-7966a4f38bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d60251c4-c5a7-4b5b-a866-c5a39eae878f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20091cba-ed26-40d9-a646-7966a4f38bbc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_e6c7a3f9-ed3d-4fd9-b727-27eea9ec61fc" xlink:href="mgnx-20220331.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d60251c4-c5a7-4b5b-a866-c5a39eae878f" xlink:to="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_e6c7a3f9-ed3d-4fd9-b727-27eea9ec61fc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_b5aa01b5-dda2-4cd6-a9aa-543985946f82" xlink:href="mgnx-20220331.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d60251c4-c5a7-4b5b-a866-c5a39eae878f" xlink:to="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_b5aa01b5-dda2-4cd6-a9aa-543985946f82" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c7a5942-e542-48c1-b402-6f9ad27d0edf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d60251c4-c5a7-4b5b-a866-c5a39eae878f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c7a5942-e542-48c1-b402-6f9ad27d0edf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_17cfcde4-dace-4f22-9522-f26cce39cd20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c7a5942-e542-48c1-b402-6f9ad27d0edf" xlink:to="loc_us-gaap_PlanNameAxis_17cfcde4-dace-4f22-9522-f26cce39cd20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_17cfcde4-dace-4f22-9522-f26cce39cd20_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_17cfcde4-dace-4f22-9522-f26cce39cd20" xlink:to="loc_us-gaap_PlanNameDomain_17cfcde4-dace-4f22-9522-f26cce39cd20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f9525c19-89c8-40fc-bcc0-a075eb385c53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_17cfcde4-dace-4f22-9522-f26cce39cd20" xlink:to="loc_us-gaap_PlanNameDomain_f9525c19-89c8-40fc-bcc0-a075eb385c53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_845629cd-797e-41c1-903f-f9e6e6a8159c" xlink:href="mgnx-20220331.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f9525c19-89c8-40fc-bcc0-a075eb385c53" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_845629cd-797e-41c1-903f-f9e6e6a8159c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2003StockIncentivePlanMember_e0ab00b0-06cd-478f-9c1a-8cf43913b6b0" xlink:href="mgnx-20220331.xsd#mgnx_A2003StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f9525c19-89c8-40fc-bcc0-a075eb385c53" xlink:to="loc_mgnx_A2003StockIncentivePlanMember_e0ab00b0-06cd-478f-9c1a-8cf43913b6b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_28a3c4b8-50a7-4fef-b30c-71b33d4467d9" xlink:href="mgnx-20220331.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f9525c19-89c8-40fc-bcc0-a075eb385c53" xlink:to="loc_mgnx_StockIncentivePlan2013Member_28a3c4b8-50a7-4fef-b30c-71b33d4467d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_50589919-0c80-405a-af1e-119252dd4e69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b96c3f1e-8ce2-480c-9566-22ac9d12560e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_50589919-0c80-405a-af1e-119252dd4e69" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b96c3f1e-8ce2-480c-9566-22ac9d12560e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_de45d4b7-3606-4c33-97dc-196cc46dd847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_50589919-0c80-405a-af1e-119252dd4e69" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_de45d4b7-3606-4c33-97dc-196cc46dd847" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1d57e874-8dbd-4ddf-baec-b8f0d4ff247b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_de45d4b7-3606-4c33-97dc-196cc46dd847" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1d57e874-8dbd-4ddf-baec-b8f0d4ff247b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1d57e874-8dbd-4ddf-baec-b8f0d4ff247b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1d57e874-8dbd-4ddf-baec-b8f0d4ff247b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1d57e874-8dbd-4ddf-baec-b8f0d4ff247b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_197da1fd-4eff-4eb6-9c90-212beb85898e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1d57e874-8dbd-4ddf-baec-b8f0d4ff247b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_197da1fd-4eff-4eb6-9c90-212beb85898e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_16867d41-c81d-40d0-a36a-31c26e3a39c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_197da1fd-4eff-4eb6-9c90-212beb85898e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_16867d41-c81d-40d0-a36a-31c26e3a39c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d8cebd72-4e8e-43dd-a57e-a9b4649a71e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_197da1fd-4eff-4eb6-9c90-212beb85898e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d8cebd72-4e8e-43dd-a57e-a9b4649a71e8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20220331.xsd#StockBasedCompensationOptionPricingAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended" id="i8d8cf8fcfe574df98b40740093d30012_StockBasedCompensationOptionPricingAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d7d16f09-e694-4d98-839e-02529c100630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1dbdbe4a-c825-4926-96e9-aab7e81f1b91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d7d16f09-e694-4d98-839e-02529c100630" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1dbdbe4a-c825-4926-96e9-aab7e81f1b91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b90205b2-510d-4e99-81a9-a27d70fb5158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d7d16f09-e694-4d98-839e-02529c100630" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b90205b2-510d-4e99-81a9-a27d70fb5158" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6249d15c-61cb-4eed-9e48-3fd3f46a0dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d7d16f09-e694-4d98-839e-02529c100630" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6249d15c-61cb-4eed-9e48-3fd3f46a0dc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_64abafc0-218c-4afb-9775-fbdf0687189a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d7d16f09-e694-4d98-839e-02529c100630" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_64abafc0-218c-4afb-9775-fbdf0687189a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_a52655a7-9c18-4718-9628-16f423b4479d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d7d16f09-e694-4d98-839e-02529c100630" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_a52655a7-9c18-4718-9628-16f423b4479d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d367f5c8-6839-4e59-b976-dfc1d8c7a0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d7d16f09-e694-4d98-839e-02529c100630" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d367f5c8-6839-4e59-b976-dfc1d8c7a0fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_64202ac8-8bf1-428d-a0cd-1784bb3e5a34" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d367f5c8-6839-4e59-b976-dfc1d8c7a0fc" xlink:to="loc_srt_RangeAxis_64202ac8-8bf1-428d-a0cd-1784bb3e5a34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_64202ac8-8bf1-428d-a0cd-1784bb3e5a34_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_64202ac8-8bf1-428d-a0cd-1784bb3e5a34" xlink:to="loc_srt_RangeMember_64202ac8-8bf1-428d-a0cd-1784bb3e5a34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dbcd3448-0277-4471-952b-2c33e3f79261" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_64202ac8-8bf1-428d-a0cd-1784bb3e5a34" xlink:to="loc_srt_RangeMember_dbcd3448-0277-4471-952b-2c33e3f79261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3d8fa14e-b005-4544-b54b-06265394c21e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_dbcd3448-0277-4471-952b-2c33e3f79261" xlink:to="loc_srt_MinimumMember_3d8fa14e-b005-4544-b54b-06265394c21e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_70efd67d-ac90-49d8-b0cf-8dd00f7fc4e6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_dbcd3448-0277-4471-952b-2c33e3f79261" xlink:to="loc_srt_MaximumMember_70efd67d-ac90-49d8-b0cf-8dd00f7fc4e6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="mgnx-20220331.xsd#StockbasedCompensationRestrictedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended" id="i7e88811fbcb4487a8f492038a2894abc_StockbasedCompensationRestrictedStockUnitActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33b30a6b-1dcd-4fd9-8762-00ce4fdb4263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f4e67db3-0841-452b-868f-beab392434ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33b30a6b-1dcd-4fd9-8762-00ce4fdb4263" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f4e67db3-0841-452b-868f-beab392434ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c62a3c22-f4be-4638-8acd-913a08dc3805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f4e67db3-0841-452b-868f-beab392434ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c62a3c22-f4be-4638-8acd-913a08dc3805" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0f546e1f-b2ee-4a08-b92f-853bbbe77a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f4e67db3-0841-452b-868f-beab392434ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0f546e1f-b2ee-4a08-b92f-853bbbe77a80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_37d86187-ea9c-4652-8515-ccd5df8360c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f4e67db3-0841-452b-868f-beab392434ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_37d86187-ea9c-4652-8515-ccd5df8360c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cf7e62d8-7d98-460c-a703-d8e1957cafdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_77557a73-b713-477b-a59c-faf790a58611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33b30a6b-1dcd-4fd9-8762-00ce4fdb4263" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_77557a73-b713-477b-a59c-faf790a58611" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_889d2bb4-3c7c-43b0-8ec0-27575da1cf75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_77557a73-b713-477b-a59c-faf790a58611" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_889d2bb4-3c7c-43b0-8ec0-27575da1cf75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cd420378-8ae9-4b4e-8f60-8d4809fe6a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_77557a73-b713-477b-a59c-faf790a58611" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cd420378-8ae9-4b4e-8f60-8d4809fe6a7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7eccf1d7-bd8b-453d-b1b5-a73da265874d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_77557a73-b713-477b-a59c-faf790a58611" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7eccf1d7-bd8b-453d-b1b5-a73da265874d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a1154611-0b09-4fb1-8142-2d7dd61a516f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f405dc46-465d-4df2-97b7-580c38ee824a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33b30a6b-1dcd-4fd9-8762-00ce4fdb4263" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f405dc46-465d-4df2-97b7-580c38ee824a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward_0632211f-ae09-4e78-9849-7ce638219465" xlink:href="mgnx-20220331.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33b30a6b-1dcd-4fd9-8762-00ce4fdb4263" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward_0632211f-ae09-4e78-9849-7ce638219465" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d1c873a5-277a-485d-ac54-f1d35b764e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33b30a6b-1dcd-4fd9-8762-00ce4fdb4263" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d1c873a5-277a-485d-ac54-f1d35b764e2e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_72b05bb6-8f17-4a54-9405-e26fec8f570f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33b30a6b-1dcd-4fd9-8762-00ce4fdb4263" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_72b05bb6-8f17-4a54-9405-e26fec8f570f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_516692bf-2639-4349-b178-d9e0f14c5f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33b30a6b-1dcd-4fd9-8762-00ce4fdb4263" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_516692bf-2639-4349-b178-d9e0f14c5f8c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0d12657c-0e70-4f70-bef6-dc04c5de2edb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_516692bf-2639-4349-b178-d9e0f14c5f8c" xlink:to="loc_us-gaap_AwardTypeAxis_0d12657c-0e70-4f70-bef6-dc04c5de2edb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d12657c-0e70-4f70-bef6-dc04c5de2edb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0d12657c-0e70-4f70-bef6-dc04c5de2edb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d12657c-0e70-4f70-bef6-dc04c5de2edb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c541394-aa64-4eaf-a832-ee02ebe589ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0d12657c-0e70-4f70-bef6-dc04c5de2edb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c541394-aa64-4eaf-a832-ee02ebe589ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_423134f6-0256-4b30-aae0-040e62eead06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c541394-aa64-4eaf-a832-ee02ebe589ed" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_423134f6-0256-4b30-aae0-040e62eead06" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>mgnx-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:1bd791be-5155-40b4-b9a0-bccec8bc4c7f,g:90cbb752-e1e3-4609-a8e8-bbefff2b5852-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_15355039-feec-468e-8fc1-ee6fbb2627b9_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2636a7c6-529a-47df-b1d6-e1e52a3b2e52_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_a5b393d2-8bd8-403d-8176-f54c57ffc488_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_65200288-5db2-4011-a4f2-05d12a1abdde_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e19632ee-33fb-4088-98c1-e7c3a6e3e15d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_20319cf1-517e-43a9-8505-49f5f9774c4d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_2f31d3a6-ddcd-4da8-a02a-2708d2fd3f0c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_fb089066-1aa3-4e19-a33e-9c48bc796062_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_41681e89-1586-45ee-999b-7a66dba2b8a8_terseLabel_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential commercial milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PotentialCommercialMilestonePaymentsUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:href="mgnx-20220331.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_1cdd85be-0187-4d03-9f3b-871e2c48d749_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_59adc85e-33fb-43c9-9714-98820ce08b7d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_dd27361b-3b10-4562-85c6-5f8bdd1a5bef_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_c8cccb0c-1b6b-4fd1-b830-ec4b50b5d64a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_dc929d6a-ded3-4024-9328-bff947590a7b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_8df377b8-6115-45fc-baf3-6176a5444443_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d1e06919-34d1-43fe-9097-8de89b97c89f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2c0ccca0-bfd0-4ff7-9b69-3037ebfaf930_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d342232a-a66b-4d28-8bc4-70dc5d80ff67_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_5199c2c8-9b1b-4f00-b7b3-468071fb19d8_terseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential proceeds from royalties (percent)</link:label>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_label_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProceedsfromRoyaltiesPercent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent" xlink:href="mgnx-20220331.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromRoyaltiesPercent" xlink:to="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_2c116610-f7ba-4964-96c3-e9cd206fa18b_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_56dba88c-7d75-4f6c-9eca-c3f574ffd44b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9ebf2491-2087-4c9d-a92e-cd82383dcb4d_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_15494a36-13a2-438b-b13f-e8159972f4a1_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ac77613a-aa6d-4920-971f-7f03e6bb753c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_fe527ee5-7638-4d55-bd37-9ce957864456_terseLabel_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NIAID</link:label>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_label_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NationalInstituteOfAllergyAndInfectiousDiseasesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:href="mgnx-20220331.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6ea18388-7dfe-49d3-b6b4-c1bc6f6c8521_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83760ece-36c4-4be4-8614-70f1f0fa92c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_4ffab52d-ff41-4895-b6d0-ec2791df6d4d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received for options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_90b014b0-ba5f-4d31-9f20-9291e747c89a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_fdedb85a-e9b9-4224-b8b4-8703f719c892_terseLabel_en-US" xlink:label="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment, net of tax withholding</link:label>
    <link:label id="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_label_en-US" xlink:label="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Upfront Fees, Net Of Tax Withholding</link:label>
    <link:label id="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Upfront Fees, Net Of Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:href="mgnx-20220331.xsd#mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:to="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_651b6059-2d00-4c8b-856d-5718a764cba1_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_ad75eb60-2867-44dc-9101-1adb66cedf21_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c4231e10-e905-4075-898a-89ded81ecbe2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05eecb81-9df9-4ef3-9f95-b93a803495c4_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1354e942-4b67-4b30-ab9f-61863136b1f4_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_19813193-741b-4191-b8ba-11b689966efe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_eb7ee3f4-cead-489e-88a3-acbf86f5d7c6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_7598a88a-1ea6-4c02-84bd-51ed0806516c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_9a663546-964c-4eba-9c83-a5bfd52f7430_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_108a4ca0-3fa0-4522-88ca-77b2b7ce7f03_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3d17278d-8040-4aff-85a8-1f29dd4b428a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_af20f83a-1d0b-41a9-99d8-b5e6c3ce2790_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_f65176a9-e3c0-47ab-a28e-02b68c277db6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_aa855ead-018d-4282-a1b0-484372745f4c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_f7a7ef46-9971-4c31-aed1-cedb0997ec43_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_c9278346-7da9-499a-8bfc-1c645f4439bd_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0d35bdc9-8669-45d4-bb0c-e0f7b82ad600_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_3e590876-0e91-453f-b572-c5b8fbce38c4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_a0acf9f8-cc81-406b-a39f-501eb731902d_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_ad875c00-2831-4951-aea0-c2af071c7b0a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_41adc3b6-eaff-441a-a399-b5c1f3bf994f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012SupplyAgreementMember_625d8920-59f0-4a17-ab02-25c74028aeb1_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012SupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Supply Agreement</link:label>
    <link:label id="lab_mgnx_IncyteMGA012SupplyAgreementMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012SupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Supply Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IncyteMGA012SupplyAgreementMember_documentation_en-US" xlink:label="lab_mgnx_IncyteMGA012SupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Supply Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012SupplyAgreementMember" xlink:href="mgnx-20220331.xsd#mgnx_IncyteMGA012SupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012SupplyAgreementMember" xlink:to="lab_mgnx_IncyteMGA012SupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_e79578be-98f0-4b12-85e8-aabbe1265ee5_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncyteMGA012AgreementMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember" xlink:href="mgnx-20220331.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012AgreementMember" xlink:to="lab_mgnx_IncyteMGA012AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_129e1fb7-3628-44ba-8cab-9f247f36237f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_5eb65bad-027a-4697-8164-2419f1fa45e4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_647202b7-d4f0-4632-980b-3bdd7edb6f77_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8fc972ac-35a5-440f-8e70-a922f0916bdf_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_6c1d9a49-f326-41c1-bcbf-355e47b173a4_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_fc5ff19d-69b6-4e7d-a756-f810936822d7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_67a88e8b-3952-44a8-ab02-0111ee5d02be_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fad76630-cb3c-403a-b7f7-81965417ae88_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_daa076ae-11d8-476a-aa78-59331e22246b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_1a989ec8-6b21-4010-b5a1-227db26f97ee_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ff03f3d3-1dc5-4fd8-b9db-fa642161f279_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9bf46d5f-560b-41f4-9062-fa7dcf43e689_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_befa0995-b818-43bf-b2a0-4deca1255bb5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchased (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromCMOAgreementsMemberMember_130d74ae-682f-42b8-8153-76230ef252cf_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromCMOAgreementsMember</link:label>
    <link:label id="lab_mgnx_RevenuesFromCMOAgreementsMemberMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromCMOAgreementsMember [Member]</link:label>
    <link:label id="lab_mgnx_RevenuesFromCMOAgreementsMemberMember_documentation_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromCMOAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:href="mgnx-20220331.xsd#mgnx_RevenuesFromCMOAgreementsMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:to="lab_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_1ed2080a-9f6d-4276-a6c0-c7ae3a5dec9e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ea45441c-bbc5-48c0-b6a6-961d20370634_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8692cac1-b801-48fc-bc26-67959ec08aed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8b7376ba-f705-4041-98d3-5e77b95d075d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_724550ee-4949-441c-a364-248523ef9da3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_9671f020-77f0-4b26-999d-6d171cc67b02_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_a675d580-74e8-4245-98b2-ee77bfee1ed0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c4937a46-81f0-4c06-b406-137c663aef16_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_068c5e42-b207-4478-acc2-2304c59560ac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Roll Forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_3d5681ea-db8f-42cb-8e4f-2e2f06fae60e_terseLabel_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment</link:label>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_label_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NonRefundableUpfrontFees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees" xlink:href="mgnx-20220331.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonRefundableUpfrontFees" xlink:to="lab_mgnx_NonRefundableUpfrontFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_dd9ec955-5fb0-4cf3-a790-bdc566abbdc1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2b6e0543-f156-4007-816a-ee6fa60cc29c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_87904310-fe35-49ef-9835-bf422cbb1f80_terseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7b56adb6-3e68-4f6b-a093-dbbc303ff930_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c000c4ee-cae5-4ddb-8070-f7a4e9d382c5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding, Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e04884e7-afe7-4d24-9c45-fe60dc2bea5c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8491b285-1c45-4c27-9c0e-6e8e0266edb3_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2fd0c432-2397-4bfe-90ef-644c6b0fa8ed_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_a4c94417-0a78-48c0-a13c-935179f07fea_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_69be59e0-9d57-442a-96b0-38eb4c553167_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_db9121a9-45db-4bfe-8493-f6113ccfecf1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ef409582-902f-4705-827e-e46d1a3edfd2_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_97d43161-85e6-4ae2-beb3-34723b96a5e0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock percent of the fair market value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_ee266d62-301d-4a96-ad43-1348facb8410_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_6b909ac6-1eea-45e0-ac3b-bb99c8149f36_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_2c1a6852-d105-4cf6-a1ac-1d6b927c62fa_verboseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_label_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProceedsfromStockOptionsExercisedAndESPPPurchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:href="mgnx-20220331.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:to="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_9f858763-c5e8-431a-aabc-4738a2f50903_terseLabel_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Biotech Inc</link:label>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_label_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Biotech Inc [Member]</link:label>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_documentation_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Biotech Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember" xlink:href="mgnx-20220331.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JanssenBiotechIncMember" xlink:to="lab_mgnx_JanssenBiotechIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c7e593b2-b8c0-4a3c-9dee-401aab0337c5_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_437e3675-a1ca-419d-8850-1c7859c1af53_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement - Clinical activities</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncyteMGA012AgreementClinicalActivitiesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:href="mgnx-20220331.xsd#mgnx_IncyteMGA012AgreementClinicalActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:to="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_723c3b67-a585-4eed-b76f-3c00a6a3996e_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount available for issuance</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_label_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_documentation_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:href="mgnx-20220331.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:to="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_80b88b50-c649-4013-9173-1f3b7b468c47_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_9b9a9bff-15c9-46d8-9d7a-16e3d357dac4_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and software included in accounts payable or accruals</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012ClinicalServicesMember_77d39b33-294f-4380-9ce3-49b881042064_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Clinical Services</link:label>
    <link:label id="lab_mgnx_IncyteMGA012ClinicalServicesMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Clinical Services [Member]</link:label>
    <link:label id="lab_mgnx_IncyteMGA012ClinicalServicesMember_documentation_en-US" xlink:label="lab_mgnx_IncyteMGA012ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Clinical Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012ClinicalServicesMember" xlink:href="mgnx-20220331.xsd#mgnx_IncyteMGA012ClinicalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012ClinicalServicesMember" xlink:to="lab_mgnx_IncyteMGA012ClinicalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_e10ae189-995a-47be-8371-8a2ec0e69f11_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_197c3169-1659-4a19-b765-7e7ca78ee147_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b596675c-e444-4fba-ac7b-f79a363da1d1_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_a6748c6f-7748-4783-917d-a3a14e62afe2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_dcd8eb82-09ed-4f16-9d14-c1fa21453783_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_ee435fd5-dc59-44f0-b08f-fa419a0e5495_terseLabel_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock plan activity (in shares)</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_label_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Stock Plan Activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_documentation_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued due to stock plan related activity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:href="mgnx-20220331.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:to="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_24836e45-049c-4116-a2bf-86ad08ba2bd7_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_6a065cdd-22db-41fa-a81e-a0fd8e3170b0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_604a7689-479a-42f3-8f91-4269e39be72f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_2bffeb64-b842-42d3-8a0d-cc66a884ca25_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss per common share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_7cafa7f4-f395-4cb3-8e64-970b6cc9129b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_caefd707-1ff0-449f-8902-36bdf45bad9b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_90d5599a-09e1-4cf9-877e-0895db1aef56_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bd16b22b-044a-4199-89db-926582338f2e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a51a8603-43f9-4ac9-b6d4-9f825afc7c0b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_7e9986b4-5f4c-44ec-9a9a-f41daa35b1e6_terseLabel_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and regulatory milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:href="mgnx-20220331.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_71c78e1b-e26d-4be4-9f42-21f525267c3e_terseLabel_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At the Market Offering</link:label>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember" xlink:href="mgnx-20220331.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AtTheMarketOfferingMember" xlink:to="lab_mgnx_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_be108718-2ce5-44d7-8291-1c8f7fba0363_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f4d887cd-9423-4d57-90e0-8d3d36c2235b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_3ff25638-744b-4ad1-b6b8-0ca4389cccba_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_10820f9b-178d-428e-95fe-2488fe7d9640_terseLabel_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium received on stock purchase</link:label>
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_label_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PremiumReceivedOnStockPurchase</link:label>
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_documentation_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PremiumReceivedOnStockPurchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase" xlink:href="mgnx-20220331.xsd#mgnx_PremiumReceivedOnStockPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PremiumReceivedOnStockPurchase" xlink:to="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_991f1f42-82b9-4544-8841-1d2f57b6687d_terseLabel_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable payment tax withholding</link:label>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_label_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Payment Tax Withholding</link:label>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Payment Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding" xlink:href="mgnx-20220331.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonrefundablePaymentTaxWithholding" xlink:to="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_2574e693-819b-4072-82b9-c1d765a618c7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e91f6d6-8300-43c0-988e-15127e98eaa2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_22c83f18-b1a6-4abe-a515-f48fdd7b44e7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2cea1e2c-75e8-4657-8eca-7348c521cf32_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4afd5fbd-3dfa-4b1b-bb63-32fea0a2feb8_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c2a15ffa-58d5-4df1-b784-b8f4a2d04e64_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss per common share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_10c09962-c902-4345-9ed3-9c20c2aee28a_terseLabel_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering period</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_label_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_documentation_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:href="mgnx-20220331.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_77f0cd1f-eb71-4df7-839a-2430487dc911_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of stock purchase price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_eb5451b3-068b-4202-8b74-12fdfcbe5979_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_55866379-248a-4f5e-8b8c-463d1ca0a39a_terseLabel_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated variable consideration</link:label>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_label_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Assess Variable Consideration, Amount</link:label>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_documentation_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Assess Variable Consideration, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:href="mgnx-20220331.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:to="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_d7ede6ff-d438-4a2a-b14b-d5b1a3a3e55e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_7636b020-041d-43ff-8854-f0712f04b613_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from collaborative and other agreements</link:label>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenueFromCollaborativeAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:href="mgnx-20220331.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:to="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_6d5d5911-3c22-4902-849b-7a50467bd942_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember_82395a8f-4906-4902-8b8f-6afa91f5a3d1_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Clinical Supply Agreements</link:label>
    <link:label id="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember_label_en-US" xlink:label="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Clinical Supply Agreements [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Clinical Supply Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:href="mgnx-20220331.xsd#mgnx_ZaiLabClinicalSupplyAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:to="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_887cd919-e36a-4eb8-9f5a-9ef81ad25457_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_3480b9f7-f82d-4f74-b2c3-faffd1ba139f_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_cde60d70-307b-4a6b-919a-c67c406c25aa_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_ab9ee0da-3d3d-44ef-92bd-3cf01c739a39_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_7de5f1ae-7e0c-44a1-8101-99d1bb6f41a9_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_9025b855-e57d-4590-97e0-63975d2fa9a6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ecf41767-3426-4c45-afa6-2a2ac249594a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_95625db2-cfd3-4de4-b635-a5559fac43a2_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Agreement, TRIDENT molecule</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_label_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, TRIDENT molecule [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, TRIDENT molecule</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:href="mgnx-20220331.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:to="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_90300ec5-792b-4366-82e5-40b7045d949e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_19a75f11-73b3-442c-bcc2-510be72b15c3_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_539fb4c2-9784-420a-8400-ffabe517c998_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0f4b88aa-534f-4356-b8dd-ea1f8aa15142_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_9b00d4b5-86ce-47a4-8a35-db9ad0cbd302_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_7a4d97b3-3905-4d2e-bef7-251a6092f07a_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_cfb99603-97e3-4049-9a83-433a661041b5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_67bc50bc-6fb6-4227-b495-a25f2dd58bd3_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_f228873d-2134-4600-88cb-cb843c8569f4_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_e2700a08-8815-4c70-bc36-9517af564ceb_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_label_en-US" xlink:label="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Other Agreements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:href="mgnx-20220331.xsd#mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:to="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_629b2c1e-3976-4a7d-98e2-61955d49be63_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_cf65832c-ddb4-4e93-a764-2ce83f742a34_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d4d4dd83-12b1-4b98-8978-1426ebf55526_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_924d8e3f-1705-4cd6-b5af-d66e32f3af80_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_4f2e8922-a28c-4fa7-976a-344c8b35b394_terseLabel_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement Clinical Supply</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_label_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement Clinical Supply [Member]</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_documentation_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement Clinical Supply</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:href="mgnx-20220331.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:to="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_624a10ca-a844-4df3-b95f-675e9ac7686c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_728a91bd-5e13-45e3-8c03-3c13dc96557f_terseLabel_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and regulatory milestones recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_label_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_documentation_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:href="mgnx-20220331.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:to="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_8605cb3e-035f-4854-9f21-d2502b3789d1_terseLabel_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments and royalties on product sales</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_label_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments and Royalties On Product Sales</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_documentation_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments and Royalties On Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:href="mgnx-20220331.xsd#mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:to="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_c27a104c-d56f-4728-89de-dd70ec6c6e04_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9c6f3cc2-e4cc-4e80-a06a-be905eb25e1a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_32a16d3e-412f-422c-91fe-44d6c0fece0b_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Agreement, Margetuximab</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_label_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, Margetuximab [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, Margetuximab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:href="mgnx-20220331.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:to="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d02dd3c6-1b85-4906-9822-c7fa8177df83_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_bf29dca7-a096-49ac-8e4b-529baad0a530_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_f4042c06-150c-4d6a-845e-c8f2a434ca06_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of product sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_0600940a-1147-4837-b5cf-e54b9f9b58de_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_fe2889dd-4480-4766-b357-7463342b48d9_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9b0bf715-c56c-44fe-bf42-6f1ef56e4d49_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_15c13dd4-7aac-47f9-9a14-e0b16fab58de_terseLabel_en-US" xlink:label="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Zai Lab Agreement</link:label>
    <link:label id="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Zai Lab Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Zai Lab Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20220331.xsd#mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_df3e6f00-a6fe-45df-b4d2-eb4efdffcfe1_terseLabel_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TwoThousandSixteenEmployeeStockPurchasePlanMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:href="mgnx-20220331.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:to="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_becd0f9c-0866-4e57-8d44-4e4accfb5c46_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8f221d78-9139-4a4e-a3be-66613a20b3d2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c4bf669b-e350-46a0-b4c1-21cba1f2091f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward_067335e5-fe6b-4218-b034-e520dd1a5d25_terseLabel_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares per employee</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward_label_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number Of Shares Received For Each Vested Award</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward_documentation_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number Of Shares Received For Each Vested Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward" xlink:href="mgnx-20220331.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward" xlink:to="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a4ed6e62-7a3e-4ce5-b20a-659b2574f79d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OneTimeMillstoneCredit_5440be39-1763-4a77-b24e-205b0273663c_terseLabel_en-US" xlink:label="lab_mgnx_OneTimeMillstoneCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Time Millstone Credit</link:label>
    <link:label id="lab_mgnx_OneTimeMillstoneCredit_label_en-US" xlink:label="lab_mgnx_OneTimeMillstoneCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Time Millstone Credit</link:label>
    <link:label id="lab_mgnx_OneTimeMillstoneCredit_documentation_en-US" xlink:label="lab_mgnx_OneTimeMillstoneCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Time Millstone Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OneTimeMillstoneCredit" xlink:href="mgnx-20220331.xsd#mgnx_OneTimeMillstoneCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OneTimeMillstoneCredit" xlink:to="lab_mgnx_OneTimeMillstoneCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_10f8c492-43d1-4b91-8f63-d3b7fc6ddba7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_bad988ad-a452-4788-8dbe-6a66ca88a323_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b94a726f-1ffa-4f0a-8e0a-69ba49e14347_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e17652b7-29db-4d7c-98df-875fd58c7869_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteCorporationMember_dc53aaf4-fd27-40fd-b111-e258e0525509_terseLabel_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte Corporation</link:label>
    <link:label id="lab_mgnx_IncyteCorporationMember_label_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncyteCorporationMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember" xlink:href="mgnx-20220331.xsd#mgnx_IncyteCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteCorporationMember" xlink:to="lab_mgnx_IncyteCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesNetOfTaxWithholding_9c98b238-1e3c-42e4-8d9f-9f1a4960faf4_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, net of tax withholding</link:label>
    <link:label id="lab_mgnx_RevenuesNetOfTaxWithholding_label_en-US" xlink:label="lab_mgnx_RevenuesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Net Of Tax Withholding</link:label>
    <link:label id="lab_mgnx_RevenuesNetOfTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_RevenuesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Net Of Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesNetOfTaxWithholding" xlink:href="mgnx-20220331.xsd#mgnx_RevenuesNetOfTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesNetOfTaxWithholding" xlink:to="lab_mgnx_RevenuesNetOfTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_24674d51-9c74-4905-8cb9-65fbbe9e84af_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_24d90e5c-879a-449d-b191-bc3a3d2548af_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_e7c9a602-064a-445e-9ca0-8c81a0654b79_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_8c1df233-d6f9-4930-9829-97023ddb0be7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromGrantsMember_65c538da-8fe0-4e1f-92cd-ce9233ebe2d1_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From Grants</link:label>
    <link:label id="lab_mgnx_RevenuesFromGrantsMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromGrantsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember" xlink:href="mgnx-20220331.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromGrantsMember" xlink:to="lab_mgnx_RevenuesFromGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_389a80f2-b078-4e8b-afd8-a98a0f2e3ec8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_4faad575-deec-465c-a43e-b95ab79e2a34_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_010635cd-8efb-4b37-8902-07c21ca5d4a5_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bdaf88f2-77fe-47b9-a7b5-f271fdea59e4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_b9df5c18-7e5e-4fa9-9c70-8a7432c418f1_terseLabel_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential annual increase in shares reserved for future issuance as percentage of outstanding share</link:label>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_label_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:href="mgnx-20220331.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:to="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_0f89a321-9c96-4ca5-b7ed-fdfd5096f21a_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_082d0cbf-9095-4137-a1b0-2a83a3f67f12_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9ed9f97d-864c-4ac5-961b-c444fdc5060e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_80ca256a-ce23-4620-9685-b22b8de26a3f_terseLabel_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll deduction percentage</link:label>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="mgnx-20220331.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_f777edee-7f6f-4eb4-9021-c424f0f5eb25_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3ec4ad06-7217-4860-988f-ab1f9ae10847_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_e0451e43-b581-4e5a-aaa2-cfa2ee27921b_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_61392e4c-098d-4d2e-8137-8c9025b3a7d6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember_5258a0c5-e9a6-4f75-96a5-1ca6b2853530_terseLabel_en-US" xlink:label="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Collaboration and License Agreement</link:label>
    <link:label id="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20220331.xsd#mgnx_JanssenCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8021b85b-9233-4ad0-8f08-8194deb62323_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4cde6352-69e3-466f-a6ec-9e8ca3ed83e7_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_311b2e69-50e6-49e0-80b2-24a32f00a0f1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued or sold (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_fb36169c-02c3-4b3f-8a95-c4e62cd6a8c0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_ef1113ed-db40-412f-bfb6-b05c15dc2f4e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_ad8c36e7-bc20-42f7-a986-117a83ceb859_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1c8882d6-44c0-4725-a741-8f49e135c36b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price of stock options outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7a792eff-25b6-4c91-8f10-fdf29fbf8624_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_08c77922-9506-405a-9baa-1ea1a096a4cc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_f01886f8-c369-485a-b857-af4e2bc7e0da_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value -- 125,000,000 shares authorized, 61,333,074 and 61,307,428 shares outstanding at March&#160;31, 2022 and December&#160;31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_c64fa6a2-d106-4c31-b9a5-1f76a0e96eca_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f126a040-c716-432d-b1cf-699e57e3c478_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense recognition period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_040f52bc-1bcf-4761-aab1-22af467efc17_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2b93c397-6248-49d9-b6f1-c1700d05148b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6afd3b61-10f9-47ef-ae24-146084dee4ec_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TotalAnnualFixedPayments_7dd46c71-c21e-443d-b6aa-265114860b73_terseLabel_en-US" xlink:label="lab_mgnx_TotalAnnualFixedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Fixed Payments</link:label>
    <link:label id="lab_mgnx_TotalAnnualFixedPayments_label_en-US" xlink:label="lab_mgnx_TotalAnnualFixedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Annual Fixed Payments</link:label>
    <link:label id="lab_mgnx_TotalAnnualFixedPayments_documentation_en-US" xlink:label="lab_mgnx_TotalAnnualFixedPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Annual Fixed Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalAnnualFixedPayments" xlink:href="mgnx-20220331.xsd#mgnx_TotalAnnualFixedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TotalAnnualFixedPayments" xlink:to="lab_mgnx_TotalAnnualFixedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_79427b70-c038-4ad3-a925-59ef74dcc704_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_6367c434-ed3e-441d-9039-1bfd491675e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_efe478ab-2a1b-4d46-ad5e-6d3e13789d07_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1638d551-2f53-4c07-8da5-47d6bb41334b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_0400d5d5-54d8-41a7-9e4d-593b9a342626_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a6e6a010-42ac-400a-a6b4-fefc5b2317dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IMabBiopharmaMember_6320b8ce-6c8b-475e-85d4-77a42b83ea70_terseLabel_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaMember_label_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma [Member]</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaMember_documentation_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember" xlink:href="mgnx-20220331.xsd#mgnx_IMabBiopharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IMabBiopharmaMember" xlink:to="lab_mgnx_IMabBiopharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_42457524-1bf7-4f01-9ddc-f47484f1ec41_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Assumptions Using the Black-Scholes Option-Pricing Model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_aca7336c-8c30-4d94-a515-72625b5d236c_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of commercialized molecules</link:label>
    <link:label id="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_label_en-US" xlink:label="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:href="mgnx-20220331.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:to="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_ffa70ebd-dd36-4104-8220-9b75d366f59c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums and discounts on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_a2af1aa5-b5e3-4214-80e2-dbdb3b1c5a34_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_f43a8edf-b57a-4192-b1aa-e1e735bf70b1_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_bab781fe-83dd-42fd-a683-f00f5bc3882c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory valuation reserves</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_44ff3e39-fee2-47b6-8a1c-8d47186b59bb_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_56e2afa0-c9e1-4c4c-b3ff-2c3a2155ac05_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3a3dfd75-849e-4616-9eb7-a98286b19b79_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_733eb076-4f68-4a70-b882-009241337cf3_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_488e2d7b-ae90-4122-84e3-cc04d7413d61_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_832e2e8c-f346-4ec8-98f5-a9d11ddac1b8_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_76f15452-1159-4985-ad98-555c364640e3_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_17c87c09-9741-4854-bb10-01a795ee1868_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_f5f8c6aa-ce6e-4632-851c-f8ac34311e5d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit loss related to available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_98f94fdc-9a4f-4b4e-9f2c-116c7aa8411d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_cd00d3c1-83bd-409c-9a5b-58006660e715_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds of stock sale</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_136ab1fc-2305-46b1-9454-7999b4cfb4ee_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0153df5b-ecc7-4c85-8f97-47b13f8a5421_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a70194a9-4e85-4297-9021-87ae4c022da1_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7f7ba088-3011-497d-8838-b2d11c662fab_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bc888f12-8294-4b09-b688-0c4d826820d7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_1c66d98c-e29d-4723-afd8-2c547bdde6dc_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_ee998823-679c-4cb2-86e8-0909fc3f57ea_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_f7880ce0-6edd-45f4-9141-401331a87431_terseLabel_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration and License Agreement</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20220331.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_f04bb9b0-692e-4a6e-847d-a8bbf0adee1c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1115a5c5-8d99-4462-a993-8c8760262509_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_d6581c06-b171-490f-bd79-ba1074c68321_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_dd1dba4e-b03c-43c9-b9c3-f156ac00770d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_c7e0f616-4222-4147-a277-34c7e9f3a54d_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_f4268d38-bf07-4077-98fa-136f34e69165_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Performance of the Research and Development Activities</link:label>
    <link:label id="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_label_en-US" xlink:label="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Performance Of The Research And Development Activities [Member]</link:label>
    <link:label id="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_documentation_en-US" xlink:label="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Performance Of The Research And Development Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:href="mgnx-20220331.xsd#mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:to="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_5a332a54-a2a9-4486-9943-5f912ced488e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_af770bc3-41f1-4d97-9c72-bdf72ddc084a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_343c3223-a84d-4919-8246-8d2c460655ac_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_132b51a6-716a-40ea-81a2-364907b721a4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7bf853a0-2727-4f65-9c5d-637e263d5059_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_f559abb7-7532-4797-9977-abf546c6a9a1_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement transaction price</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CollaborativeAgreementTransactionPrice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice" xlink:href="mgnx-20220331.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementTransactionPrice" xlink:to="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_94a783da-a053-4e81-9fbd-f5440c8a617f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a3a5495d-55a5-4913-8086-398f91d25cab_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_96b9fd55-3394-4a9d-bcf8-87ffcd4bbaba_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_87585a36-439f-4889-99fa-5d215a8f9626_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c1e908e2-79f6-4e0f-ac40-adc285c00786_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_7b70f444-b907-4b6c-b24a-35abf02f045a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_16d0d52b-fc42-4605-ae80-3c52c9ebe6cc_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_6b4bbd2c-3afb-4c8f-9a2a-5334576a37b6_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_ef08a51a-7336-4718-9dd2-e4623ab06b19_terseLabel_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock plan related activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_label_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Stock Plan Activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_documentation_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares issued due to stock plan related activity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:href="mgnx-20220331.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:to="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_67246396-6b1b-4a1d-af0f-a28b78328a8e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_70c21e9c-c68e-44fd-9514-827bae599578_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d9b62ac-0779-41e4-b07f-d34dec30a056_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_c9461fb5-aa04-4867-b460-24a62ec30c3c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabMember_7060e609-bd7d-4919-883a-a3a3fafee080_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs</link:label>
    <link:label id="lab_mgnx_ZaiLabMember_label_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember" xlink:href="mgnx-20220331.xsd#mgnx_ZaiLabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabMember" xlink:to="lab_mgnx_ZaiLabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_a24293f3-3728-4af6-a597-086e00f9faed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_a36eeb59-2ab9-42e2-b7bc-dd9b599d3696_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d80f135b-2b00-440e-9e94-83dee9605f8c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_43d3f6a7-589e-4547-bca1-d2e6ef7fbc5f_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_2e2c9efe-74c3-4fd6-bf85-41fd402d26d4_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From License Agreements</link:label>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromLicenseAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember" xlink:href="mgnx-20220331.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromLicenseAgreementsMember" xlink:to="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_413aa3cf-834a-4423-b922-5d0e08f6ca8f_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from government agreements</link:label>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenueFromGovernmentAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember" xlink:href="mgnx-20220331.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromGovernmentAgreementsMember" xlink:to="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_81339b0d-274a-405b-9ca9-05202afd2960_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2ff1ccaa-5ceb-410c-8ba9-d8ced1c7d9ed_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_7c50aff2-055f-4089-8d5b-e5b7347717a4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7dd52576-ddbd-4744-8cb8-f8900390717e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_A2003StockIncentivePlanMember_d612835b-a03b-4f33-b573-5a52fce54138_terseLabel_en-US" xlink:label="lab_mgnx_A2003StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2003 Stock Incentive Plan</link:label>
    <link:label id="lab_mgnx_A2003StockIncentivePlanMember_label_en-US" xlink:label="lab_mgnx_A2003StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A2003StockIncentivePlanMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2003StockIncentivePlanMember" xlink:href="mgnx-20220331.xsd#mgnx_A2003StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_A2003StockIncentivePlanMember" xlink:to="lab_mgnx_A2003StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfPerformanceObligations_208e30f8-4b25-4523-bc74-2f27522c1055_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_mgnx_NumberOfPerformanceObligations_label_en-US" xlink:label="lab_mgnx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations" xlink:href="mgnx-20220331.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfPerformanceObligations" xlink:to="lab_mgnx_NumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OptInFee_7067cd10-3408-41b2-85b7-0ed51b18d9a7_terseLabel_en-US" xlink:label="lab_mgnx_OptInFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opt-in fee</link:label>
    <link:label id="lab_mgnx_OptInFee_label_en-US" xlink:label="lab_mgnx_OptInFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opt-in Fee</link:label>
    <link:label id="lab_mgnx_OptInFee_documentation_en-US" xlink:label="lab_mgnx_OptInFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opt-in Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptInFee" xlink:href="mgnx-20220331.xsd#mgnx_OptInFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OptInFee" xlink:to="lab_mgnx_OptInFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_e26c3989-14a9-4e68-801e-f2f6c142c20b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_1de05b13-1f5d-4979-8022-4f943d29b1e4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_de34a381-0f61-42a3-be9d-54f4e75b8565_terseLabel_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable consideration recognized</link:label>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_281f841b-9747-4d57-860f-0e030295f5fa_verboseLabel_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial activities selling price amount</link:label>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_label_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</link:label>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_documentation_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:href="mgnx-20220331.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:to="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_872edc64-a769-4ae9-a035-b187dd9cc6ac_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74a8132f-5963-4be3-91f8-32e01e6ce993_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_aa8dfa42-f403-462e-8be7-d993f802d60a_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_57b3a44b-1123-4574-aada-92bb70836c3f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and software</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5b70c701-27f1-4b13-a1f6-f41548a41a34_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_0c421922-686a-4519-98a4-2db9918b27d1_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_248862a0-89af-449e-92b9-088927cc3898_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_80670632-735e-4629-ad79-7f5eb07da42e_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_087f40ae-81cc-4d92-b9e1-33a65caa5f7a_terseLabel_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total potential value</link:label>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_label_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TotalPotentialValueUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement" xlink:href="mgnx-20220331.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TotalPotentialValueUnderAgreement" xlink:to="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_A2021ZaiLabAgreementsMember_edf5efba-f141-41f6-aeb2-001b811ea05c_terseLabel_en-US" xlink:label="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Zai Lab Agreements</link:label>
    <link:label id="lab_mgnx_A2021ZaiLabAgreementsMember_label_en-US" xlink:label="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Zai Lab Agreements [Member]</link:label>
    <link:label id="lab_mgnx_A2021ZaiLabAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Zai Lab Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember" xlink:href="mgnx-20220331.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_A2021ZaiLabAgreementsMember" xlink:to="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_9169c26e-b498-45bd-8f82-5f234be20fdd_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f95c8e69-1507-4954-8239-18531c94677e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c6878133-db3b-44b8-ba11-74fde0de4bda_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e90cd297-2e5d-4d11-bd78-27cdfbab9348_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding, Ending Balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c202f619-fbb6-4241-a853-8451d745b4b8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_114fdf30-d6bf-4ef3-bdd7-8dfeb64e4a01_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount available for issuance, increase</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_label_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance, Increase</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_documentation_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance, Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:href="mgnx-20220331.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:to="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_1f50bb69-878e-4518-adc1-a351da43afa0_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_49833e00-d1c3-4558-b311-bc9c99a4af88_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential annual increase in shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:href="mgnx-20220331.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:to="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_fce3d385-f84c-45c8-aa4c-02ee99ed96ec_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_423bffd6-dc0a-4d42-a53e-61ef8728abdf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_70a5e208-ce53-49b3-b84f-ac136933f127_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_7622107c-7422-4605-aaaa-8354f95a03f3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_0c546f2d-ace5-4129-8d94-2ec99f351cb3_terseLabel_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2013</link:label>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_label_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">StockIncentivePlan2013Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member" xlink:href="mgnx-20220331.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIncentivePlan2013Member" xlink:to="lab_mgnx_StockIncentivePlan2013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_97ea9660-4f69-4d97-b6e2-77b048c79156_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d270bff8-a742-42e4-a5ed-dac90a20ff6f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_0196e62d-9f11-4f2f-b466-36b24a40ac30_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:href="mgnx-20220331.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_12b86952-9b87-44c4-81da-30afbaa96c0b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9c44a894-8bb5-4f75-adb1-dadf0bc905de_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Other Agreements [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6eceb0b4-e7cf-466a-96c2-4dad8d5067e8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Vested and expected to vest (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>mgnx-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:1bd791be-5155-40b4-b9a0-bccec8bc4c7f,g:90cbb752-e1e3-4609-a8e8-bbefff2b5852-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/CoverPage" xlink:type="simple" xlink:href="mgnx-20220331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_bc58cf43-cc2e-4a3d-9a98-2fddadc555ff" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_DocumentType_bc58cf43-cc2e-4a3d-9a98-2fddadc555ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_39eced9f-1096-4662-ab45-9503c98dcd08" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_DocumentQuarterlyReport_39eced9f-1096-4662-ab45-9503c98dcd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_632bc957-28d4-4895-bd64-e35f24e795dc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_DocumentPeriodEndDate_632bc957-28d4-4895-bd64-e35f24e795dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_5b5f39cd-ee5b-4070-8844-ff4b87d8c5b4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_DocumentTransitionReport_5b5f39cd-ee5b-4070-8844-ff4b87d8c5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_25ee5aba-dabc-4d2d-beeb-20994c9293b5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_EntityFileNumber_25ee5aba-dabc-4d2d-beeb-20994c9293b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a4696016-0f11-40e8-b862-4cc37c79db33" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_EntityRegistrantName_a4696016-0f11-40e8-b862-4cc37c79db33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_90519c53-0b5c-4d12-b95f-bb432f1bba96" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_EntityIncorporationStateCountryCode_90519c53-0b5c-4d12-b95f-bb432f1bba96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_06e7625d-4841-4f7e-a121-96b5c27281be" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_EntityTaxIdentificationNumber_06e7625d-4841-4f7e-a121-96b5c27281be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_576d15b1-8f9b-4b7a-92f1-5010e09e593d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_EntityAddressAddressLine1_576d15b1-8f9b-4b7a-92f1-5010e09e593d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b09e5c56-261e-4598-a8e4-f39428a183cd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_EntityAddressCityOrTown_b09e5c56-261e-4598-a8e4-f39428a183cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c07281e6-42f1-4bd3-b342-66f35e01c782" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_EntityAddressStateOrProvince_c07281e6-42f1-4bd3-b342-66f35e01c782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_dd525149-02fa-4b5d-8179-4a656e1e1595" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_EntityAddressPostalZipCode_dd525149-02fa-4b5d-8179-4a656e1e1595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_81e35382-3ede-468f-a3dc-f258b81607cf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_CityAreaCode_81e35382-3ede-468f-a3dc-f258b81607cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_358f91c6-c264-41b2-a824-09fa145890e0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_LocalPhoneNumber_358f91c6-c264-41b2-a824-09fa145890e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a2a6b2cd-1a60-4bab-8d56-7c4a545ef2d1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_Security12bTitle_a2a6b2cd-1a60-4bab-8d56-7c4a545ef2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e4255831-4020-496f-b651-55fac740afe1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_TradingSymbol_e4255831-4020-496f-b651-55fac740afe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_3c1ae235-f0df-47d2-b598-ba1f1185e1e9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_SecurityExchangeName_3c1ae235-f0df-47d2-b598-ba1f1185e1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c2e01c57-4651-470e-b262-fd9a5942c58a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_EntityCurrentReportingStatus_c2e01c57-4651-470e-b262-fd9a5942c58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_b769e4b0-6a91-4972-97cd-ef7d9303fba0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_EntityInteractiveDataCurrent_b769e4b0-6a91-4972-97cd-ef7d9303fba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_51500a78-8864-4ba2-981d-c8434758dd6f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_EntityFilerCategory_51500a78-8864-4ba2-981d-c8434758dd6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_48c71346-9a01-4b9f-9c29-a7beddb56926" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_EntitySmallBusiness_48c71346-9a01-4b9f-9c29-a7beddb56926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_99b06961-1fc5-4471-866a-c7cce8d54f25" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_EntityEmergingGrowthCompany_99b06961-1fc5-4471-866a-c7cce8d54f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_8033c32b-a395-43e2-a930-59e628b518a5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_EntityShellCompany_8033c32b-a395-43e2-a930-59e628b518a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_92e81e41-33a2-40e2-b41a-f720e61dc9eb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_92e81e41-33a2-40e2-b41a-f720e61dc9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3dd8a719-6e48-4bb6-bd60-088fd47f205e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_AmendmentFlag_3dd8a719-6e48-4bb6-bd60-088fd47f205e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_15f2a9a9-d250-45ca-ab93-334ca9fc95da" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_DocumentFiscalYearFocus_15f2a9a9-d250-45ca-ab93-334ca9fc95da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_417d9d09-66d5-47e0-8686-47073b97357c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_DocumentFiscalPeriodFocus_417d9d09-66d5-47e0-8686-47073b97357c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_49de509f-422a-46cb-b767-96103abd7bdb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_EntityCentralIndexKey_49de509f-422a-46cb-b767-96103abd7bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_f495a65f-52b1-45fe-8b2b-2a217b8213e2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c1c7961-e320-4ed5-a9c3-0ef48c9a56ae" xlink:to="loc_dei_CurrentFiscalYearEndDate_f495a65f-52b1-45fe-8b2b-2a217b8213e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20220331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_fa205a90-fbe0-413b-a1ab-fc942b1d0794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_dcb21a09-b03d-4e3f-81e2-0e99cef24848" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fa205a90-fbe0-413b-a1ab-fc942b1d0794" xlink:to="loc_us-gaap_AssetsAbstract_dcb21a09-b03d-4e3f-81e2-0e99cef24848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_93e6beb1-19d0-4f33-ba50-cfd3106bd8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dcb21a09-b03d-4e3f-81e2-0e99cef24848" xlink:to="loc_us-gaap_AssetsCurrentAbstract_93e6beb1-19d0-4f33-ba50-cfd3106bd8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_055fe884-d278-4784-ac67-6ba509aab389" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93e6beb1-19d0-4f33-ba50-cfd3106bd8ba" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_055fe884-d278-4784-ac67-6ba509aab389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_187e5d65-0c29-4e1c-989a-26dcc3216cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93e6beb1-19d0-4f33-ba50-cfd3106bd8ba" xlink:to="loc_us-gaap_Investments_187e5d65-0c29-4e1c-989a-26dcc3216cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_81f3a3d9-1d9f-4bab-bce3-e1aef79c689a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93e6beb1-19d0-4f33-ba50-cfd3106bd8ba" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_81f3a3d9-1d9f-4bab-bce3-e1aef79c689a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a57d1819-c5da-48b2-9414-a414c6082fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93e6beb1-19d0-4f33-ba50-cfd3106bd8ba" xlink:to="loc_us-gaap_InventoryNet_a57d1819-c5da-48b2-9414-a414c6082fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_316e1f46-0010-4077-b0b0-8388b9598bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93e6beb1-19d0-4f33-ba50-cfd3106bd8ba" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_316e1f46-0010-4077-b0b0-8388b9598bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3257f5c5-e680-4515-b1a5-dc33461126ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93e6beb1-19d0-4f33-ba50-cfd3106bd8ba" xlink:to="loc_us-gaap_AssetsCurrent_3257f5c5-e680-4515-b1a5-dc33461126ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9c053293-8f38-42d3-a024-e5d1b0252515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dcb21a09-b03d-4e3f-81e2-0e99cef24848" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9c053293-8f38-42d3-a024-e5d1b0252515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3550b831-ccf8-499b-a8a7-5de78dc3cbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dcb21a09-b03d-4e3f-81e2-0e99cef24848" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3550b831-ccf8-499b-a8a7-5de78dc3cbd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_694593df-c9f8-4d7d-b5d7-321891ecfa25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dcb21a09-b03d-4e3f-81e2-0e99cef24848" xlink:to="loc_us-gaap_Assets_694593df-c9f8-4d7d-b5d7-321891ecfa25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1a4860a7-e575-45a5-9005-573ad9e4fd02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fa205a90-fbe0-413b-a1ab-fc942b1d0794" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1a4860a7-e575-45a5-9005-573ad9e4fd02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4472aee3-f5a0-409c-a6f3-57a5516b3e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1a4860a7-e575-45a5-9005-573ad9e4fd02" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4472aee3-f5a0-409c-a6f3-57a5516b3e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ee636440-3b37-4c63-96da-bebdc89e790e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4472aee3-f5a0-409c-a6f3-57a5516b3e0b" xlink:to="loc_us-gaap_AccountsPayableCurrent_ee636440-3b37-4c63-96da-bebdc89e790e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_57e7b278-5524-48b2-9053-9277dcc599a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4472aee3-f5a0-409c-a6f3-57a5516b3e0b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_57e7b278-5524-48b2-9053-9277dcc599a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_bd9485c1-475f-4f66-a8cb-1ed6bf711ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4472aee3-f5a0-409c-a6f3-57a5516b3e0b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_bd9485c1-475f-4f66-a8cb-1ed6bf711ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_44ebca0c-90d7-4a89-bef5-66fc88907542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4472aee3-f5a0-409c-a6f3-57a5516b3e0b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_44ebca0c-90d7-4a89-bef5-66fc88907542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b18743f8-28ff-4ead-890f-583c960dc9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4472aee3-f5a0-409c-a6f3-57a5516b3e0b" xlink:to="loc_us-gaap_LiabilitiesCurrent_b18743f8-28ff-4ead-890f-583c960dc9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_232cc6d7-b723-4622-b057-a5a42ba670c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1a4860a7-e575-45a5-9005-573ad9e4fd02" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_232cc6d7-b723-4622-b057-a5a42ba670c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f4d48b01-9ca9-4bca-b5ed-aa1357e61460" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1a4860a7-e575-45a5-9005-573ad9e4fd02" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f4d48b01-9ca9-4bca-b5ed-aa1357e61460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_474d602d-099f-48d2-84ab-7a40dfd2ea58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1a4860a7-e575-45a5-9005-573ad9e4fd02" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_474d602d-099f-48d2-84ab-7a40dfd2ea58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_54041b47-0a48-4c19-9fa2-df74d3852907" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1a4860a7-e575-45a5-9005-573ad9e4fd02" xlink:to="loc_us-gaap_Liabilities_54041b47-0a48-4c19-9fa2-df74d3852907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_bd7d14bc-4c37-43f7-82f6-6b59448d9386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1a4860a7-e575-45a5-9005-573ad9e4fd02" xlink:to="loc_us-gaap_StockholdersEquityAbstract_bd7d14bc-4c37-43f7-82f6-6b59448d9386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_caed4d13-bb45-4392-80ac-99278e689da1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_bd7d14bc-4c37-43f7-82f6-6b59448d9386" xlink:to="loc_us-gaap_CommonStockValue_caed4d13-bb45-4392-80ac-99278e689da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_841d7726-880b-4f1d-b049-1800a86c8f79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_bd7d14bc-4c37-43f7-82f6-6b59448d9386" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_841d7726-880b-4f1d-b049-1800a86c8f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_55064469-adf8-4545-ad52-ae9b030bb57c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_bd7d14bc-4c37-43f7-82f6-6b59448d9386" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_55064469-adf8-4545-ad52-ae9b030bb57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_06c6192d-d05e-40bc-9ed1-fb50058d602a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_bd7d14bc-4c37-43f7-82f6-6b59448d9386" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_06c6192d-d05e-40bc-9ed1-fb50058d602a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4e166db3-cee4-45f5-8c43-8e3c1b9b6876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_bd7d14bc-4c37-43f7-82f6-6b59448d9386" xlink:to="loc_us-gaap_StockholdersEquity_4e166db3-cee4-45f5-8c43-8e3c1b9b6876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9da4fa29-d9cd-4c3d-8e82-95bdebfedc38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1a4860a7-e575-45a5-9005-573ad9e4fd02" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_9da4fa29-d9cd-4c3d-8e82-95bdebfedc38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mgnx-20220331.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7ac46884-7de1-4e73-9024-79104b947c57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28e9ae02-4484-4246-a8ba-e0c3df64dcf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7ac46884-7de1-4e73-9024-79104b947c57" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28e9ae02-4484-4246-a8ba-e0c3df64dcf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_75163ec8-6c3e-4d31-8f0c-f0f59d18ea17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28e9ae02-4484-4246-a8ba-e0c3df64dcf1" xlink:to="loc_us-gaap_StockholdersEquityAbstract_75163ec8-6c3e-4d31-8f0c-f0f59d18ea17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_22086eba-c93d-438d-a565-587800cc020a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_75163ec8-6c3e-4d31-8f0c-f0f59d18ea17" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_22086eba-c93d-438d-a565-587800cc020a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_fbc3aa7f-e68a-46ea-bf68-880fea01b67a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_75163ec8-6c3e-4d31-8f0c-f0f59d18ea17" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_fbc3aa7f-e68a-46ea-bf68-880fea01b67a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e099ee0b-b16c-4fc1-9723-f7ff2b387dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_75163ec8-6c3e-4d31-8f0c-f0f59d18ea17" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e099ee0b-b16c-4fc1-9723-f7ff2b387dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20220331.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_a287b487-3102-47a1-9b99-52dc247aa4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6426c4d9-a556-46ec-a500-da63bc511c40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a287b487-3102-47a1-9b99-52dc247aa4f9" xlink:to="loc_us-gaap_StatementTable_6426c4d9-a556-46ec-a500-da63bc511c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0a874df6-b1b4-45d1-9709-441cd0be5870" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6426c4d9-a556-46ec-a500-da63bc511c40" xlink:to="loc_srt_ProductOrServiceAxis_0a874df6-b1b4-45d1-9709-441cd0be5870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_393f2e6d-b12e-4f6d-b00f-7e07fd3d0212" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0a874df6-b1b4-45d1-9709-441cd0be5870" xlink:to="loc_srt_ProductsAndServicesDomain_393f2e6d-b12e-4f6d-b00f-7e07fd3d0212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_c9eedac0-84cb-4fab-88d1-00799896aa62" xlink:href="mgnx-20220331.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_393f2e6d-b12e-4f6d-b00f-7e07fd3d0212" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_c9eedac0-84cb-4fab-88d1-00799896aa62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_dacac038-32c8-43fa-964c-61b6480112b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_393f2e6d-b12e-4f6d-b00f-7e07fd3d0212" xlink:to="loc_us-gaap_ProductMember_dacac038-32c8-43fa-964c-61b6480112b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember_f18ace85-91cb-428f-89f3-dfa9d2f1d438" xlink:href="mgnx-20220331.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_393f2e6d-b12e-4f6d-b00f-7e07fd3d0212" xlink:to="loc_mgnx_RevenueFromGovernmentAgreementsMember_f18ace85-91cb-428f-89f3-dfa9d2f1d438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_968b97c7-2533-4de7-ae65-0dbf6f1939ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6426c4d9-a556-46ec-a500-da63bc511c40" xlink:to="loc_us-gaap_StatementLineItems_968b97c7-2533-4de7-ae65-0dbf6f1939ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_3f8924e5-dbda-424f-bbcd-a54c10e8fa20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_968b97c7-2533-4de7-ae65-0dbf6f1939ce" xlink:to="loc_us-gaap_RevenuesAbstract_3f8924e5-dbda-424f-bbcd-a54c10e8fa20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_05903f9b-551f-4efa-a916-da0d0e5f4a24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_3f8924e5-dbda-424f-bbcd-a54c10e8fa20" xlink:to="loc_us-gaap_Revenues_05903f9b-551f-4efa-a916-da0d0e5f4a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_af0705f9-2da6-4849-8bfc-e8d6785ecf47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_968b97c7-2533-4de7-ae65-0dbf6f1939ce" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_af0705f9-2da6-4849-8bfc-e8d6785ecf47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_192a851d-ae69-4606-bdd0-46f14041ddc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_af0705f9-2da6-4849-8bfc-e8d6785ecf47" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_192a851d-ae69-4606-bdd0-46f14041ddc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0610b842-b545-4359-87e0-2a175017d191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_af0705f9-2da6-4849-8bfc-e8d6785ecf47" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0610b842-b545-4359-87e0-2a175017d191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_f96c760b-b552-481a-89f2-c9171f051b76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_af0705f9-2da6-4849-8bfc-e8d6785ecf47" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_f96c760b-b552-481a-89f2-c9171f051b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c3c947de-aaca-44f9-a83a-d558749d8a24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_af0705f9-2da6-4849-8bfc-e8d6785ecf47" xlink:to="loc_us-gaap_CostsAndExpenses_c3c947de-aaca-44f9-a83a-d558749d8a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c2d83ede-849d-4a4f-9cd9-e7977b3bc47c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_af0705f9-2da6-4849-8bfc-e8d6785ecf47" xlink:to="loc_us-gaap_OperatingIncomeLoss_c2d83ede-849d-4a4f-9cd9-e7977b3bc47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c8c2876c-1e5a-4bdf-8fd6-421b0ba73149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_af0705f9-2da6-4849-8bfc-e8d6785ecf47" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c8c2876c-1e5a-4bdf-8fd6-421b0ba73149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_16ea8807-b445-4d30-9e91-b43a44ad2b41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_af0705f9-2da6-4849-8bfc-e8d6785ecf47" xlink:to="loc_us-gaap_NetIncomeLoss_16ea8807-b445-4d30-9e91-b43a44ad2b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_848d2da0-c204-42f7-9236-1965e60257a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_968b97c7-2533-4de7-ae65-0dbf6f1939ce" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_848d2da0-c204-42f7-9236-1965e60257a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_393c3c6a-f8ca-4e3a-a717-0a3b22aa7c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_848d2da0-c204-42f7-9236-1965e60257a6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_393c3c6a-f8ca-4e3a-a717-0a3b22aa7c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0ecbce35-a002-4e30-a22b-610468a206c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_968b97c7-2533-4de7-ae65-0dbf6f1939ce" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_0ecbce35-a002-4e30-a22b-610468a206c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e7e23e0a-94c5-41b2-a2f4-78ae8dbca229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_968b97c7-2533-4de7-ae65-0dbf6f1939ce" xlink:to="loc_us-gaap_EarningsPerShareBasic_e7e23e0a-94c5-41b2-a2f4-78ae8dbca229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4e25e93a-01e5-45d9-9384-4896a97a6042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_968b97c7-2533-4de7-ae65-0dbf6f1939ce" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4e25e93a-01e5-45d9-9384-4896a97a6042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_547a2622-2c46-4336-8126-e6f6d8f76d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_968b97c7-2533-4de7-ae65-0dbf6f1939ce" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_547a2622-2c46-4336-8126-e6f6d8f76d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_616fce1c-3c07-4653-89ce-b5962c6854a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_968b97c7-2533-4de7-ae65-0dbf6f1939ce" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_616fce1c-3c07-4653-89ce-b5962c6854a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20220331.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_ccbb567e-12a9-4c08-aeac-bcf2a1d0de55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ead04f32-0b1c-4d3f-8be5-31b2dfcb333a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_ccbb567e-12a9-4c08-aeac-bcf2a1d0de55" xlink:to="loc_us-gaap_StatementTable_ead04f32-0b1c-4d3f-8be5-31b2dfcb333a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bd6b6a62-aebf-4291-8dc4-3106c47e2100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ead04f32-0b1c-4d3f-8be5-31b2dfcb333a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bd6b6a62-aebf-4291-8dc4-3106c47e2100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a4017fdb-f242-4e38-a989-f8b0e383704b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bd6b6a62-aebf-4291-8dc4-3106c47e2100" xlink:to="loc_us-gaap_EquityComponentDomain_a4017fdb-f242-4e38-a989-f8b0e383704b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_96bf785d-e3de-4165-9854-83ac6ce19db6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a4017fdb-f242-4e38-a989-f8b0e383704b" xlink:to="loc_us-gaap_CommonStockMember_96bf785d-e3de-4165-9854-83ac6ce19db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_93093d23-9a47-48e3-9486-085eaac486f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a4017fdb-f242-4e38-a989-f8b0e383704b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_93093d23-9a47-48e3-9486-085eaac486f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4f63d45c-e7d8-44f6-b142-373fa119e691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a4017fdb-f242-4e38-a989-f8b0e383704b" xlink:to="loc_us-gaap_RetainedEarningsMember_4f63d45c-e7d8-44f6-b142-373fa119e691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_f88ff0e6-bdee-44ba-9031-da70f71ee549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a4017fdb-f242-4e38-a989-f8b0e383704b" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_f88ff0e6-bdee-44ba-9031-da70f71ee549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2035b4c9-1d31-468d-804f-bc99d0e25dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ead04f32-0b1c-4d3f-8be5-31b2dfcb333a" xlink:to="loc_us-gaap_StatementLineItems_2035b4c9-1d31-468d-804f-bc99d0e25dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d7ccf7e-aead-4c73-8fb5-4bb901372e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2035b4c9-1d31-468d-804f-bc99d0e25dcd" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d7ccf7e-aead-4c73-8fb5-4bb901372e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_f510e489-1951-4a6d-b580-f90c6f9610b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d7ccf7e-aead-4c73-8fb5-4bb901372e77" xlink:to="loc_us-gaap_SharesIssued_f510e489-1951-4a6d-b580-f90c6f9610b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_19ac5f18-f8bc-47f1-89eb-7d5bba224e63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d7ccf7e-aead-4c73-8fb5-4bb901372e77" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_19ac5f18-f8bc-47f1-89eb-7d5bba224e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_381530f2-c31c-4334-a927-678c8eb40015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d7ccf7e-aead-4c73-8fb5-4bb901372e77" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_381530f2-c31c-4334-a927-678c8eb40015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_caec10cb-d9d9-4709-851e-c929954816a6" xlink:href="mgnx-20220331.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d7ccf7e-aead-4c73-8fb5-4bb901372e77" xlink:to="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_caec10cb-d9d9-4709-851e-c929954816a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_4e09f6e4-426c-4ce5-9944-165af9d5afa7" xlink:href="mgnx-20220331.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d7ccf7e-aead-4c73-8fb5-4bb901372e77" xlink:to="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_4e09f6e4-426c-4ce5-9944-165af9d5afa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6d1f6881-73d0-4e74-a8b7-2e75f2883e04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d7ccf7e-aead-4c73-8fb5-4bb901372e77" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6d1f6881-73d0-4e74-a8b7-2e75f2883e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_50428bd1-9600-4c2a-9433-fb5af56f3e68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d7ccf7e-aead-4c73-8fb5-4bb901372e77" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_50428bd1-9600-4c2a-9433-fb5af56f3e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_bef965da-7083-4773-b81f-15f427c5903c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d7ccf7e-aead-4c73-8fb5-4bb901372e77" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_bef965da-7083-4773-b81f-15f427c5903c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d91a248b-c25f-424a-bb96-e6eb662ed826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d7ccf7e-aead-4c73-8fb5-4bb901372e77" xlink:to="loc_us-gaap_NetIncomeLoss_d91a248b-c25f-424a-bb96-e6eb662ed826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_9be29cbc-4335-4155-9217-fc6eb6c0e615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d7ccf7e-aead-4c73-8fb5-4bb901372e77" xlink:to="loc_us-gaap_SharesIssued_9be29cbc-4335-4155-9217-fc6eb6c0e615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_116c1611-4c05-420a-9c39-b8f9b898f63f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d7ccf7e-aead-4c73-8fb5-4bb901372e77" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_116c1611-4c05-420a-9c39-b8f9b898f63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20220331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_53f45a13-516b-4e5f-b287-a2c13b3ce8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7a79f1ec-b452-4659-a9ed-d31dd5cbc999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_53f45a13-516b-4e5f-b287-a2c13b3ce8cd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7a79f1ec-b452-4659-a9ed-d31dd5cbc999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_03526ab8-f249-43a5-9104-0e7fe6c999a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7a79f1ec-b452-4659-a9ed-d31dd5cbc999" xlink:to="loc_us-gaap_NetIncomeLoss_03526ab8-f249-43a5-9104-0e7fe6c999a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_84db88b4-3469-41e1-82e6-f326fd3e8be3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7a79f1ec-b452-4659-a9ed-d31dd5cbc999" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_84db88b4-3469-41e1-82e6-f326fd3e8be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_db9a8148-914e-4381-ba46-72d9d54cd51e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_84db88b4-3469-41e1-82e6-f326fd3e8be3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_db9a8148-914e-4381-ba46-72d9d54cd51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_7876e9a5-fa3c-4043-b0ca-25b9693de327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_84db88b4-3469-41e1-82e6-f326fd3e8be3" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_7876e9a5-fa3c-4043-b0ca-25b9693de327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2e1d4a36-6894-4f72-a71d-cd31c7a19f72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_84db88b4-3469-41e1-82e6-f326fd3e8be3" xlink:to="loc_us-gaap_ShareBasedCompensation_2e1d4a36-6894-4f72-a71d-cd31c7a19f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_df827341-27d0-401c-9731-6c288bec8fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_84db88b4-3469-41e1-82e6-f326fd3e8be3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_df827341-27d0-401c-9731-6c288bec8fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b616499a-700f-4bb3-bcc1-d00abea60db5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_df827341-27d0-401c-9731-6c288bec8fa6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b616499a-700f-4bb3-bcc1-d00abea60db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_461ce0e2-cda1-4ce5-ba41-a092db61cc90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_df827341-27d0-401c-9731-6c288bec8fa6" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_461ce0e2-cda1-4ce5-ba41-a092db61cc90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e4cd72a1-3b6c-4e63-9485-7597f74edcff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_df827341-27d0-401c-9731-6c288bec8fa6" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e4cd72a1-3b6c-4e63-9485-7597f74edcff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d9ace692-5cd3-41db-a056-bc29e48be37a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_df827341-27d0-401c-9731-6c288bec8fa6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d9ace692-5cd3-41db-a056-bc29e48be37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_b760c35f-0bfe-4ddb-9d31-a93f1910e427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_df827341-27d0-401c-9731-6c288bec8fa6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_b760c35f-0bfe-4ddb-9d31-a93f1910e427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_41133157-fc18-43df-a3ad-1a88bed9d9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_df827341-27d0-401c-9731-6c288bec8fa6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_41133157-fc18-43df-a3ad-1a88bed9d9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1083bd9f-6f4e-4dca-87f7-ce10d03654d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_df827341-27d0-401c-9731-6c288bec8fa6" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1083bd9f-6f4e-4dca-87f7-ce10d03654d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b2f1ac89-97da-4f0b-a237-450130fc903e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_df827341-27d0-401c-9731-6c288bec8fa6" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b2f1ac89-97da-4f0b-a237-450130fc903e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_f9503e2a-e6e7-4c0f-8810-aca37392bcf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_df827341-27d0-401c-9731-6c288bec8fa6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_f9503e2a-e6e7-4c0f-8810-aca37392bcf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c59b092f-a12d-447e-ba00-c8045fe1f0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7a79f1ec-b452-4659-a9ed-d31dd5cbc999" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c59b092f-a12d-447e-ba00-c8045fe1f0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1b10fe5e-6d90-453d-8549-d131b044e8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_53f45a13-516b-4e5f-b287-a2c13b3ce8cd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1b10fe5e-6d90-453d-8549-d131b044e8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_0acb2559-fe70-4a44-84ac-07b27675ce9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1b10fe5e-6d90-453d-8549-d131b044e8d6" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_0acb2559-fe70-4a44-84ac-07b27675ce9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_af5b3037-0d22-4d5c-a1e5-9572add24ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1b10fe5e-6d90-453d-8549-d131b044e8d6" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_af5b3037-0d22-4d5c-a1e5-9572add24ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b2df2c3f-58be-434e-ad18-22637f7199cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1b10fe5e-6d90-453d-8549-d131b044e8d6" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b2df2c3f-58be-434e-ad18-22637f7199cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_abef706d-e3ab-4f0b-8845-7fdfea06501b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1b10fe5e-6d90-453d-8549-d131b044e8d6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_abef706d-e3ab-4f0b-8845-7fdfea06501b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d2dc1c4-85a8-4642-8815-b7b6d72bad06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_53f45a13-516b-4e5f-b287-a2c13b3ce8cd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d2dc1c4-85a8-4642-8815-b7b6d72bad06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6bd2400c-45e6-4895-9ea3-0b78e2e8a92b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d2dc1c4-85a8-4642-8815-b7b6d72bad06" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6bd2400c-45e6-4895-9ea3-0b78e2e8a92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_4560fa2e-d1eb-45fc-abd1-58182a9b54ca" xlink:href="mgnx-20220331.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d2dc1c4-85a8-4642-8815-b7b6d72bad06" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_4560fa2e-d1eb-45fc-abd1-58182a9b54ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_75b13ec1-025f-4de5-b84e-55e1535f9a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d2dc1c4-85a8-4642-8815-b7b6d72bad06" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_75b13ec1-025f-4de5-b84e-55e1535f9a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c7e1e69d-d170-4f39-88fa-6c9e6723a6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_53f45a13-516b-4e5f-b287-a2c13b3ce8cd" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c7e1e69d-d170-4f39-88fa-6c9e6723a6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bc24d476-e0ec-476d-ac15-61645d6c0dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_53f45a13-516b-4e5f-b287-a2c13b3ce8cd" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bc24d476-e0ec-476d-ac15-61645d6c0dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bb7dea2a-6802-4dc3-9945-f059cc43de0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_53f45a13-516b-4e5f-b287-a2c13b3ce8cd" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bb7dea2a-6802-4dc3-9945-f059cc43de0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_83110fea-dae1-4ace-8fd9-9fa39a6f2054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_53f45a13-516b-4e5f-b287-a2c13b3ce8cd" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_83110fea-dae1-4ace-8fd9-9fa39a6f2054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_edfad544-31fb-41cd-ac88-2fca096c5ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_83110fea-dae1-4ace-8fd9-9fa39a6f2054" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_edfad544-31fb-41cd-ac88-2fca096c5ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/NatureofOperations" xlink:type="simple" xlink:href="mgnx-20220331.xsd#NatureofOperations"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/NatureofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_092bf138-bfc3-4669-9134-b85bb74255f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_22acebe2-8c77-4314-afb3-0eccb6ffbbc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_092bf138-bfc3-4669-9134-b85bb74255f8" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_22acebe2-8c77-4314-afb3-0eccb6ffbbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="mgnx-20220331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e95f7e0d-35e5-4214-8d47-692a1495a242" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3389eb35-5dab-47b4-9106-9a7ca294dfec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e95f7e0d-35e5-4214-8d47-692a1495a242" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3389eb35-5dab-47b4-9106-9a7ca294dfec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mgnx-20220331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_663c228f-e2da-43d5-9eaf-88500009b041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a0b275e4-988c-4696-b781-189cc3671b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_663c228f-e2da-43d5-9eaf-88500009b041" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a0b275e4-988c-4696-b781-189cc3671b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7c9cf82b-84c2-4cbf-a285-bf1977b30f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_663c228f-e2da-43d5-9eaf-88500009b041" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7c9cf82b-84c2-4cbf-a285-bf1977b30f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_613a8852-22db-47de-9b8f-0d1a9ea82509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_663c228f-e2da-43d5-9eaf-88500009b041" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_613a8852-22db-47de-9b8f-0d1a9ea82509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="mgnx-20220331.xsd#FairValueofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_52c44bfd-cfae-4678-bc67-07988107fd76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_190572f6-c4f6-42b0-898c-b58ecb76285f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_52c44bfd-cfae-4678-bc67-07988107fd76" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_190572f6-c4f6-42b0-898c-b58ecb76285f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="mgnx-20220331.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f0a4cd95-137c-48a8-a42c-1cefb452eafb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_fd98a56d-cd18-44e1-9b7f-d0dbab5f0846" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f0a4cd95-137c-48a8-a42c-1cefb452eafb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_fd98a56d-cd18-44e1-9b7f-d0dbab5f0846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="mgnx-20220331.xsd#FairValueofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_34446f35-5b0d-47bf-a9e0-de67ef199f87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_971b0635-635d-4d92-b2ad-d28278fa0ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_34446f35-5b0d-47bf-a9e0-de67ef199f87" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_971b0635-635d-4d92-b2ad-d28278fa0ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7092b05c-6b4f-4255-9455-874d0e2e0465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_971b0635-635d-4d92-b2ad-d28278fa0ae5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7092b05c-6b4f-4255-9455-874d0e2e0465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_19faa585-a79e-4873-a0ee-926bdb517e89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7092b05c-6b4f-4255-9455-874d0e2e0465" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_19faa585-a79e-4873-a0ee-926bdb517e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d5c04d6d-a598-40a8-8d00-d9c5859b93b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_19faa585-a79e-4873-a0ee-926bdb517e89" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d5c04d6d-a598-40a8-8d00-d9c5859b93b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_87d6fa63-905f-4049-ac5d-6b2239f3116a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_971b0635-635d-4d92-b2ad-d28278fa0ae5" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_87d6fa63-905f-4049-ac5d-6b2239f3116a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c8efb05d-71f5-47d1-81e3-a845e7324273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_87d6fa63-905f-4049-ac5d-6b2239f3116a" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c8efb05d-71f5-47d1-81e3-a845e7324273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_249dbdfb-a4b9-4ec1-bac7-c479447b3e35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c8efb05d-71f5-47d1-81e3-a845e7324273" xlink:to="loc_us-gaap_MoneyMarketFundsMember_249dbdfb-a4b9-4ec1-bac7-c479447b3e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_49ab7dcd-2fea-41b4-8147-8de799387afe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c8efb05d-71f5-47d1-81e3-a845e7324273" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_49ab7dcd-2fea-41b4-8147-8de799387afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_c94953be-b40c-4058-8d78-3b24d8637af9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c8efb05d-71f5-47d1-81e3-a845e7324273" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_c94953be-b40c-4058-8d78-3b24d8637af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_dfb61d94-5ab3-4986-ac88-545b30075ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c8efb05d-71f5-47d1-81e3-a845e7324273" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_dfb61d94-5ab3-4986-ac88-545b30075ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_047f01d7-6842-4ee7-a84c-a1e3e255889f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_971b0635-635d-4d92-b2ad-d28278fa0ae5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_047f01d7-6842-4ee7-a84c-a1e3e255889f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71d66af8-3f11-4422-b343-2d6fa7c90a75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_047f01d7-6842-4ee7-a84c-a1e3e255889f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71d66af8-3f11-4422-b343-2d6fa7c90a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c9fa6a02-a93d-440b-b33f-48eed1c8efaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71d66af8-3f11-4422-b343-2d6fa7c90a75" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c9fa6a02-a93d-440b-b33f-48eed1c8efaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_dbca5586-7758-4388-a551-ebbf3b31a450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71d66af8-3f11-4422-b343-2d6fa7c90a75" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_dbca5586-7758-4388-a551-ebbf3b31a450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1ca59045-0f1f-4e01-89c4-2df2b0dfb683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_971b0635-635d-4d92-b2ad-d28278fa0ae5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1ca59045-0f1f-4e01-89c4-2df2b0dfb683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_205e43f5-4f2e-440e-9a70-b5728186e6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1ca59045-0f1f-4e01-89c4-2df2b0dfb683" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_205e43f5-4f2e-440e-9a70-b5728186e6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_70310cfc-de0f-4114-8c8e-265d61adc789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_205e43f5-4f2e-440e-9a70-b5728186e6d1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_70310cfc-de0f-4114-8c8e-265d61adc789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b306047b-1a86-4501-bfa4-7da6a631d322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_205e43f5-4f2e-440e-9a70-b5728186e6d1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b306047b-1a86-4501-bfa4-7da6a631d322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8b999a41-a66c-4e80-af06-8e0ab82341e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_205e43f5-4f2e-440e-9a70-b5728186e6d1" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_8b999a41-a66c-4e80-af06-8e0ab82341e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:type="simple" xlink:href="mgnx-20220331.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_36b2d27a-6699-4be9-8d79-6878395c1202" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_fffd9e27-87fe-4e72-a70d-e4116d71ddaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_36b2d27a-6699-4be9-8d79-6878395c1202" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_fffd9e27-87fe-4e72-a70d-e4116d71ddaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="mgnx-20220331.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0db6bb80-66c0-45c4-8d13-f2ffe6d96f62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1a325887-884f-4831-9d51-d8205c940dce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0db6bb80-66c0-45c4-8d13-f2ffe6d96f62" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1a325887-884f-4831-9d51-d8205c940dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20220331.xsd#MarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_66f765d6-3f90-45fd-97c9-ef9fc3bf127c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_9a2d83e2-2141-4150-96e5-769729cf672b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_66f765d6-3f90-45fd-97c9-ef9fc3bf127c" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_9a2d83e2-2141-4150-96e5-769729cf672b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_873aa91f-e565-4d6f-9d3e-0d96f8b1d12f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_9a2d83e2-2141-4150-96e5-769729cf672b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_873aa91f-e565-4d6f-9d3e-0d96f8b1d12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0c68bf70-618b-4afe-815d-321c250b7909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_873aa91f-e565-4d6f-9d3e-0d96f8b1d12f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0c68bf70-618b-4afe-815d-321c250b7909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_cf901ef1-653c-4be0-a4ce-f7b76dd8afb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0c68bf70-618b-4afe-815d-321c250b7909" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_cf901ef1-653c-4be0-a4ce-f7b76dd8afb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_6e7739ea-0f9a-4c4f-ae99-ad928f0fb405" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0c68bf70-618b-4afe-815d-321c250b7909" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_6e7739ea-0f9a-4c4f-ae99-ad928f0fb405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9cc52143-e053-4b8f-860f-0ca37361eab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0c68bf70-618b-4afe-815d-321c250b7909" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9cc52143-e053-4b8f-860f-0ca37361eab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_90c7a97c-fbe5-4e2a-8ac1-b0e76b6e868d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_9a2d83e2-2141-4150-96e5-769729cf672b" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_90c7a97c-fbe5-4e2a-8ac1-b0e76b6e868d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3fd9f13a-9e44-4167-bb80-ffa4264ed412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_90c7a97c-fbe5-4e2a-8ac1-b0e76b6e868d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3fd9f13a-9e44-4167-bb80-ffa4264ed412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c7c3da2b-e836-4bd3-a145-aced9d78936f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_90c7a97c-fbe5-4e2a-8ac1-b0e76b6e868d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c7c3da2b-e836-4bd3-a145-aced9d78936f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5339d702-c75a-458c-a023-2be47cfd8c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_90c7a97c-fbe5-4e2a-8ac1-b0e76b6e868d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5339d702-c75a-458c-a023-2be47cfd8c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d6588877-e755-4674-b6d2-e17548ae4bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_90c7a97c-fbe5-4e2a-8ac1-b0e76b6e868d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d6588877-e755-4674-b6d2-e17548ae4bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_cceffe0b-d4fc-47f8-bc2f-ca1ea8feaba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_66f765d6-3f90-45fd-97c9-ef9fc3bf127c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_cceffe0b-d4fc-47f8-bc2f-ca1ea8feaba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNet" xlink:type="simple" xlink:href="mgnx-20220331.xsd#InventoryNet"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/InventoryNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_26ef164c-c9bc-4c41-82f0-59004e7326ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_656ce93a-7078-46cf-a7ce-f778804a4360" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_26ef164c-c9bc-4c41-82f0-59004e7326ca" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_656ce93a-7078-46cf-a7ce-f778804a4360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNetTables" xlink:type="simple" xlink:href="mgnx-20220331.xsd#InventoryNetTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/InventoryNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_e57d3b02-6270-41f8-b0f0-30b47f2865ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_a6550932-59fc-4567-b3f8-1ffaec877190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e57d3b02-6270-41f8-b0f0-30b47f2865ec" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_a6550932-59fc-4567-b3f8-1ffaec877190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNetDetails" xlink:type="simple" xlink:href="mgnx-20220331.xsd#InventoryNetDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/InventoryNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_3f22b71a-6cfe-47be-b884-ffd2d4e1d7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_0b684a5d-79bc-4c01-96d5-decd008a7b32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3f22b71a-6cfe-47be-b884-ffd2d4e1d7a7" xlink:to="loc_us-gaap_InventoryWorkInProcess_0b684a5d-79bc-4c01-96d5-decd008a7b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_2ecb9467-457c-4a70-a33b-b37a42fcc85c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3f22b71a-6cfe-47be-b884-ffd2d4e1d7a7" xlink:to="loc_us-gaap_InventoryFinishedGoods_2ecb9467-457c-4a70-a33b-b37a42fcc85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9e75ca37-c991-4c3b-bc0e-835bfae3183d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3f22b71a-6cfe-47be-b884-ffd2d4e1d7a7" xlink:to="loc_us-gaap_InventoryNet_9e75ca37-c991-4c3b-bc0e-835bfae3183d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_75b79895-40f3-4bff-9f53-4d1c3e8c8de4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3f22b71a-6cfe-47be-b884-ffd2d4e1d7a7" xlink:to="loc_us-gaap_InventoryValuationReserves_75b79895-40f3-4bff-9f53-4d1c3e8c8de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mgnx-20220331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3f13a16c-908a-403a-a6f7-90c9e1d9ad00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_357b9068-3ac5-4c11-8dfc-8ff91fd9bc98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3f13a16c-908a-403a-a6f7-90c9e1d9ad00" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_357b9068-3ac5-4c11-8dfc-8ff91fd9bc98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20220331.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4f084b8c-f362-48c4-a933-a0cae44aa0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2e542a1b-f3b7-4f74-83ba-9dd95c05d7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4f084b8c-f362-48c4-a933-a0cae44aa0ce" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2e542a1b-f3b7-4f74-83ba-9dd95c05d7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b39439c1-8bce-453b-93a3-d83ec32e962b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2e542a1b-f3b7-4f74-83ba-9dd95c05d7ca" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b39439c1-8bce-453b-93a3-d83ec32e962b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_72dbe024-718c-49b0-bec0-910e1e9048ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b39439c1-8bce-453b-93a3-d83ec32e962b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_72dbe024-718c-49b0-bec0-910e1e9048ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember_081d4aa6-e5cc-4e39-9372-cdafed1d0622" xlink:href="mgnx-20220331.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_72dbe024-718c-49b0-bec0-910e1e9048ca" xlink:to="loc_mgnx_AtTheMarketOfferingMember_081d4aa6-e5cc-4e39-9372-cdafed1d0622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d3d9dec4-d68f-4cb3-88b5-d79028a8ce6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2e542a1b-f3b7-4f74-83ba-9dd95c05d7ca" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d3d9dec4-d68f-4cb3-88b5-d79028a8ce6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aa874144-f2fd-424e-8e5e-773c2237a338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d3d9dec4-d68f-4cb3-88b5-d79028a8ce6d" xlink:to="loc_us-gaap_EquityComponentDomain_aa874144-f2fd-424e-8e5e-773c2237a338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_916c84a3-b9e1-4835-8b3d-25f80cf6391b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_aa874144-f2fd-424e-8e5e-773c2237a338" xlink:to="loc_us-gaap_CommonStockMember_916c84a3-b9e1-4835-8b3d-25f80cf6391b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_5596a16a-f578-4b6e-85c1-51e39022c38a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2e542a1b-f3b7-4f74-83ba-9dd95c05d7ca" xlink:to="loc_us-gaap_ClassOfStockLineItems_5596a16a-f578-4b6e-85c1-51e39022c38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_6d556dc2-c594-41c4-9138-c7bf556783d7" xlink:href="mgnx-20220331.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5596a16a-f578-4b6e-85c1-51e39022c38a" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_6d556dc2-c594-41c4-9138-c7bf556783d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f194d6d4-8781-461d-ab15-7b151c60726f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5596a16a-f578-4b6e-85c1-51e39022c38a" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f194d6d4-8781-461d-ab15-7b151c60726f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_85757598-e2b7-4ddb-9322-527129989e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5596a16a-f578-4b6e-85c1-51e39022c38a" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_85757598-e2b7-4ddb-9322-527129989e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f0d10943-f71d-411d-82b7-301e1284976c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5596a16a-f578-4b6e-85c1-51e39022c38a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f0d10943-f71d-411d-82b7-301e1284976c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_affeb043-0181-4d8c-b30e-aacf34230206" xlink:href="mgnx-20220331.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5596a16a-f578-4b6e-85c1-51e39022c38a" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_affeb043-0181-4d8c-b30e-aacf34230206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7e19c7a3-1d5d-4b12-a656-ab5eaf7c2052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5596a16a-f578-4b6e-85c1-51e39022c38a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7e19c7a3-1d5d-4b12-a656-ab5eaf7c2052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5af4f54b-6271-4a23-9444-05ab8e2c9cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5596a16a-f578-4b6e-85c1-51e39022c38a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5af4f54b-6271-4a23-9444-05ab8e2c9cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/Revenue" xlink:type="simple" xlink:href="mgnx-20220331.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_d1f3c4b8-5057-420d-a906-d78581834296" xlink:href="mgnx-20220331.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_e52da17d-91ec-45c7-ae02-b37e83b5c0a0" xlink:href="mgnx-20220331.xsd#mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_d1f3c4b8-5057-420d-a906-d78581834296" xlink:to="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_e52da17d-91ec-45c7-ae02-b37e83b5c0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="simple" xlink:href="mgnx-20220331.xsd#CollaborationandOtherAgreementsIncyteCorporationDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_4ae49f49-2013-435e-aebb-9f7eb64f0c32" xlink:href="mgnx-20220331.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9a31b44-e30b-4a5b-ab62-f4acbf9792c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_4ae49f49-2013-435e-aebb-9f7eb64f0c32" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9a31b44-e30b-4a5b-ab62-f4acbf9792c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6d8dac16-e7fe-436e-b7e4-9d6652d9cec6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9a31b44-e30b-4a5b-ab62-f4acbf9792c5" xlink:to="loc_srt_ProductOrServiceAxis_6d8dac16-e7fe-436e-b7e4-9d6652d9cec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8d5c70cd-55d4-4132-a4ea-4298f21a2043" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6d8dac16-e7fe-436e-b7e4-9d6652d9cec6" xlink:to="loc_srt_ProductsAndServicesDomain_8d5c70cd-55d4-4132-a4ea-4298f21a2043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_d810748f-d089-48b5-a901-d74e9509d74a" xlink:href="mgnx-20220331.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8d5c70cd-55d4-4132-a4ea-4298f21a2043" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_d810748f-d089-48b5-a901-d74e9509d74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAgreementsMemberMember_843eea7c-60ff-4c8e-bfb5-1ca0bba97d2a" xlink:href="mgnx-20220331.xsd#mgnx_RevenuesFromCMOAgreementsMemberMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8d5c70cd-55d4-4132-a4ea-4298f21a2043" xlink:to="loc_mgnx_RevenuesFromCMOAgreementsMemberMember_843eea7c-60ff-4c8e-bfb5-1ca0bba97d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ccbc8c9e-260a-4138-ad9f-360210e044e7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9a31b44-e30b-4a5b-ab62-f4acbf9792c5" xlink:to="loc_srt_RangeAxis_ccbc8c9e-260a-4138-ad9f-360210e044e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_74132982-862e-4ee8-8732-db1417ef641e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ccbc8c9e-260a-4138-ad9f-360210e044e7" xlink:to="loc_srt_RangeMember_74132982-862e-4ee8-8732-db1417ef641e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ced4adbe-4e73-43f1-85ae-f9eb07b5b06a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_74132982-862e-4ee8-8732-db1417ef641e" xlink:to="loc_srt_MinimumMember_ced4adbe-4e73-43f1-85ae-f9eb07b5b06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_40c31d4c-8852-44c4-8f6d-32592c1b6615" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_74132982-862e-4ee8-8732-db1417ef641e" xlink:to="loc_srt_MaximumMember_40c31d4c-8852-44c4-8f6d-32592c1b6615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4766775f-8160-4faa-b024-2c5b3f13438b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9a31b44-e30b-4a5b-ab62-f4acbf9792c5" xlink:to="loc_srt_CounterpartyNameAxis_4766775f-8160-4faa-b024-2c5b3f13438b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2de56116-2d4c-484f-8fcf-e6f30857d1d5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4766775f-8160-4faa-b024-2c5b3f13438b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2de56116-2d4c-484f-8fcf-e6f30857d1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_5ea03e0a-47ca-477e-b373-eddec2d2ab1d" xlink:href="mgnx-20220331.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2de56116-2d4c-484f-8fcf-e6f30857d1d5" xlink:to="loc_mgnx_IncyteCorporationMember_5ea03e0a-47ca-477e-b373-eddec2d2ab1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_bf8e3c7c-410a-4ca6-91af-badaa72df61b" xlink:href="mgnx-20220331.xsd#mgnx_IMabBiopharmaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2de56116-2d4c-484f-8fcf-e6f30857d1d5" xlink:to="loc_mgnx_IMabBiopharmaMember_bf8e3c7c-410a-4ca6-91af-badaa72df61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2884de77-98cc-45db-8bcd-0131f2bdee00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9a31b44-e30b-4a5b-ab62-f4acbf9792c5" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2884de77-98cc-45db-8bcd-0131f2bdee00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a7a4357e-54be-42da-becb-7afbd79545f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2884de77-98cc-45db-8bcd-0131f2bdee00" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a7a4357e-54be-42da-becb-7afbd79545f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_b829e885-fcad-4e72-bbb2-6f9c3294b7ac" xlink:href="mgnx-20220331.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a7a4357e-54be-42da-becb-7afbd79545f4" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_b829e885-fcad-4e72-bbb2-6f9c3294b7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_b57669cc-ec4f-4109-b588-ae3e9c156db5" xlink:href="mgnx-20220331.xsd#mgnx_IncyteMGA012AgreementClinicalActivitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_IncyteMGA012AgreementMember_b829e885-fcad-4e72-bbb2-6f9c3294b7ac" xlink:to="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_b57669cc-ec4f-4109-b588-ae3e9c156db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012ClinicalServicesMember_3a3be1eb-2f43-45ec-84bb-42feca7868bf" xlink:href="mgnx-20220331.xsd#mgnx_IncyteMGA012ClinicalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a7a4357e-54be-42da-becb-7afbd79545f4" xlink:to="loc_mgnx_IncyteMGA012ClinicalServicesMember_3a3be1eb-2f43-45ec-84bb-42feca7868bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012SupplyAgreementMember_5f65e85d-952f-4d57-b900-18043a45150f" xlink:href="mgnx-20220331.xsd#mgnx_IncyteMGA012SupplyAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a7a4357e-54be-42da-becb-7afbd79545f4" xlink:to="loc_mgnx_IncyteMGA012SupplyAgreementMember_5f65e85d-952f-4d57-b900-18043a45150f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_93880b1f-62fa-42a0-a22a-69418a37fe0d" xlink:href="mgnx-20220331.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a7a4357e-54be-42da-becb-7afbd79545f4" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_93880b1f-62fa-42a0-a22a-69418a37fe0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9a31b44-e30b-4a5b-ab62-f4acbf9792c5" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_c9e70601-09a5-449e-80dc-9e94eb7375b7" xlink:href="mgnx-20220331.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:to="loc_mgnx_NonRefundableUpfrontFees_c9e70601-09a5-449e-80dc-9e94eb7375b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_f68ccb31-2f2f-49a4-bb89-bef863c4a7ab" xlink:href="mgnx-20220331.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_f68ccb31-2f2f-49a4-bb89-bef863c4a7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_aaa60a41-1e9c-4e71-992f-d2b9b057e154" xlink:href="mgnx-20220331.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_aaa60a41-1e9c-4e71-992f-d2b9b057e154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_786e5582-247b-45d6-9111-754aecf76105" xlink:href="mgnx-20220331.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_786e5582-247b-45d6-9111-754aecf76105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_443120b6-6ab7-45cc-abbb-2c4468d48a03" xlink:href="mgnx-20220331.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_443120b6-6ab7-45cc-abbb-2c4468d48a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_82785b23-f253-4bfb-8b41-ae6faeb098e7" xlink:href="mgnx-20220331.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:to="loc_mgnx_NumberOfPerformanceObligations_82785b23-f253-4bfb-8b41-ae6faeb098e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_b205a30f-e5ad-430e-b8de-ccdc2ce58d65" xlink:href="mgnx-20220331.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_b205a30f-e5ad-430e-b8de-ccdc2ce58d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1d08fb7b-4b93-4a8c-a756-af81cd738a30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:to="loc_us-gaap_Revenues_1d08fb7b-4b93-4a8c-a756-af81cd738a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_cf609a90-988d-4f35-9cf6-ec0ae8b1664a" xlink:href="mgnx-20220331.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_cf609a90-988d-4f35-9cf6-ec0ae8b1664a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_9b9757d2-aa3d-45de-a711-cbd14bdce2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:to="loc_us-gaap_ContractWithCustomerLiability_9b9757d2-aa3d-45de-a711-cbd14bdce2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_053ae95f-739a-481f-8afb-79870fd76dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_053ae95f-739a-481f-8afb-79870fd76dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_156c4522-94ea-4302-b03b-22b987c5692d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_156c4522-94ea-4302-b03b-22b987c5692d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalAnnualFixedPayments_daffb7ab-e8e1-4049-8731-78a4f3bb9b0b" xlink:href="mgnx-20220331.xsd#mgnx_TotalAnnualFixedPayments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_929be560-1558-483b-aaca-32fbb0ff6fb5" xlink:to="loc_mgnx_TotalAnnualFixedPayments_daffb7ab-e8e1-4049-8731-78a4f3bb9b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20220331.xsd#CollaborationandOtherAgreementsZaiLabDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_8a0bdd19-f69f-446f-b9fc-89f81168dd47" xlink:href="mgnx-20220331.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3214b8a-4ebf-4426-9a7e-74bf09cd03f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_8a0bdd19-f69f-446f-b9fc-89f81168dd47" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3214b8a-4ebf-4426-9a7e-74bf09cd03f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5f6f5d37-c05e-4da6-8d8e-a4acde8c069c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3214b8a-4ebf-4426-9a7e-74bf09cd03f3" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5f6f5d37-c05e-4da6-8d8e-a4acde8c069c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8086d4de-f1cd-475f-b667-83722dc94ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5f6f5d37-c05e-4da6-8d8e-a4acde8c069c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8086d4de-f1cd-475f-b667-83722dc94ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_4ffc1aa8-bf1c-43e5-b98c-40c8b7bc831b" xlink:href="mgnx-20220331.xsd#mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8086d4de-f1cd-475f-b667-83722dc94ea9" xlink:to="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_4ffc1aa8-bf1c-43e5-b98c-40c8b7bc831b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_dfbaac79-a278-423a-90b3-c498f0b8b61d" xlink:href="mgnx-20220331.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8086d4de-f1cd-475f-b667-83722dc94ea9" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_dfbaac79-a278-423a-90b3-c498f0b8b61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_3329d801-aa65-45aa-a0d5-c7c38371b19b" xlink:href="mgnx-20220331.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8086d4de-f1cd-475f-b667-83722dc94ea9" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_3329d801-aa65-45aa-a0d5-c7c38371b19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_ffdefa1d-9a36-4787-8345-b0c05f203164" xlink:href="mgnx-20220331.xsd#mgnx_ZaiLabClinicalSupplyAgreementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8086d4de-f1cd-475f-b667-83722dc94ea9" xlink:to="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_ffdefa1d-9a36-4787-8345-b0c05f203164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember_e66a64b8-6972-4f51-87b3-883f5f43c8b1" xlink:href="mgnx-20220331.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8086d4de-f1cd-475f-b667-83722dc94ea9" xlink:to="loc_mgnx_A2021ZaiLabAgreementsMember_e66a64b8-6972-4f51-87b3-883f5f43c8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_888b42d1-ee0d-457f-85f9-e25c94463c6e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3214b8a-4ebf-4426-9a7e-74bf09cd03f3" xlink:to="loc_srt_CounterpartyNameAxis_888b42d1-ee0d-457f-85f9-e25c94463c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ab363da5-fefd-4bdb-9027-c7b73cbbba6d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_888b42d1-ee0d-457f-85f9-e25c94463c6e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ab363da5-fefd-4bdb-9027-c7b73cbbba6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_05c36fd3-1fac-49d8-84e7-ef0edc75f69a" xlink:href="mgnx-20220331.xsd#mgnx_ZaiLabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ab363da5-fefd-4bdb-9027-c7b73cbbba6d" xlink:to="loc_mgnx_ZaiLabMember_05c36fd3-1fac-49d8-84e7-ef0edc75f69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ca6e82b2-af05-4eed-8c8d-0bbd08a25d9c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3214b8a-4ebf-4426-9a7e-74bf09cd03f3" xlink:to="loc_srt_RangeAxis_ca6e82b2-af05-4eed-8c8d-0bbd08a25d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_11ddee3e-f527-435a-82e8-b98fd8371761" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ca6e82b2-af05-4eed-8c8d-0bbd08a25d9c" xlink:to="loc_srt_RangeMember_11ddee3e-f527-435a-82e8-b98fd8371761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d15dba2c-b1bf-4c86-ac7f-c8446a4fa96b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_11ddee3e-f527-435a-82e8-b98fd8371761" xlink:to="loc_srt_MaximumMember_d15dba2c-b1bf-4c86-ac7f-c8446a4fa96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c2d018b0-46d0-45cb-bfc1-c7ae8902774f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3214b8a-4ebf-4426-9a7e-74bf09cd03f3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c2d018b0-46d0-45cb-bfc1-c7ae8902774f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b15890e0-a45d-4e61-8383-8dd6c4fc74ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c2d018b0-46d0-45cb-bfc1-c7ae8902774f" xlink:to="loc_us-gaap_EquityComponentDomain_b15890e0-a45d-4e61-8383-8dd6c4fc74ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_25dec141-347a-4205-86ad-8e70431a71d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b15890e0-a45d-4e61-8383-8dd6c4fc74ad" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_25dec141-347a-4205-86ad-8e70431a71d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3214b8a-4ebf-4426-9a7e-74bf09cd03f3" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_880eaa91-0806-4f90-a5d3-473b1f03a066" xlink:href="mgnx-20220331.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_mgnx_NonRefundableUpfrontFees_880eaa91-0806-4f90-a5d3-473b1f03a066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_c1d49989-ba31-4cd2-802a-6b821f7d2bae" xlink:href="mgnx-20220331.xsd#mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_c1d49989-ba31-4cd2-802a-6b821f7d2bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding_e6d44a34-0e3f-46a6-a09d-8f61f01b6168" xlink:href="mgnx-20220331.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_mgnx_NonrefundablePaymentTaxWithholding_e6d44a34-0e3f-46a6-a09d-8f61f01b6168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_9b02665b-13e6-4408-abb5-c79f57279266" xlink:href="mgnx-20220331.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_9b02665b-13e6-4408-abb5-c79f57279266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_d7e79056-f167-4a9b-9be3-21e1be46093a" xlink:href="mgnx-20220331.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_d7e79056-f167-4a9b-9be3-21e1be46093a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesNetOfTaxWithholding_cfc19175-5c5e-4b16-8af0-17b457f718e7" xlink:href="mgnx-20220331.xsd#mgnx_RevenuesNetOfTaxWithholding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_mgnx_RevenuesNetOfTaxWithholding_cfc19175-5c5e-4b16-8af0-17b457f718e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_18670613-9f87-443a-9295-f3118775a295" xlink:href="mgnx-20220331.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_18670613-9f87-443a-9295-f3118775a295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_05544de2-ba12-4892-bd2c-50166fca20c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_us-gaap_ContractWithCustomerLiability_05544de2-ba12-4892-bd2c-50166fca20c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2d120d18-a54b-4b32-aa49-b6c9d75f43bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_us-gaap_Revenues_2d120d18-a54b-4b32-aa49-b6c9d75f43bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptInFee_2d18c196-4069-4a6a-8838-a32721910900" xlink:href="mgnx-20220331.xsd#mgnx_OptInFee"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_mgnx_OptInFee_2d18c196-4069-4a6a-8838-a32721910900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a8103959-7b08-4daa-9df4-6e6dd9192e03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a8103959-7b08-4daa-9df4-6e6dd9192e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_73ef77af-ed07-44dd-986a-b5c0d4dfb59b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_73ef77af-ed07-44dd-986a-b5c0d4dfb59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_69926ab3-75b6-4ef7-a0a9-afdbbf816b26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_69926ab3-75b6-4ef7-a0a9-afdbbf816b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase_92b53ee6-fc8d-453e-ba01-e2fb0ccbcb72" xlink:href="mgnx-20220331.xsd#mgnx_PremiumReceivedOnStockPurchase"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_mgnx_PremiumReceivedOnStockPurchase_92b53ee6-fc8d-453e-ba01-e2fb0ccbcb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_65d112ba-e413-4e10-8dd6-7ca1d398c4ae" xlink:href="mgnx-20220331.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_65d112ba-e413-4e10-8dd6-7ca1d398c4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_d65cbc25-0094-4e89-b1a4-b497d5714250" xlink:href="mgnx-20220331.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_d65cbc25-0094-4e89-b1a4-b497d5714250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_4d5c940f-e713-4d33-adf7-4a68db4a2c44" xlink:href="mgnx-20220331.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_4d5c940f-e713-4d33-adf7-4a68db4a2c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d6c9df33-5c57-4abe-9d78-f6828b91abd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d6c9df33-5c57-4abe-9d78-f6828b91abd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_90ce7108-1f59-4149-80ec-4cc3d765961a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b33ea43-f688-4981-840a-14087b79e3a8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_90ce7108-1f59-4149-80ec-4cc3d765961a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails" xlink:type="simple" xlink:href="mgnx-20220331.xsd#CollaborationandOtherAgreementsJanssenDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_d7157b2e-2104-4949-ad20-e2957c0b61d3" xlink:href="mgnx-20220331.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1eb11049-ab52-4c0a-b793-91438c9a49d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_d7157b2e-2104-4949-ad20-e2957c0b61d3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1eb11049-ab52-4c0a-b793-91438c9a49d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b1becd09-2639-4fe3-8665-c83c836c6e71" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1eb11049-ab52-4c0a-b793-91438c9a49d8" xlink:to="loc_srt_CounterpartyNameAxis_b1becd09-2639-4fe3-8665-c83c836c6e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a378037e-c693-4705-9fcd-1a2d32d639e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b1becd09-2639-4fe3-8665-c83c836c6e71" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a378037e-c693-4705-9fcd-1a2d32d639e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember_06a30532-c014-4535-91d8-79f3f6242fb5" xlink:href="mgnx-20220331.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a378037e-c693-4705-9fcd-1a2d32d639e8" xlink:to="loc_mgnx_JanssenBiotechIncMember_06a30532-c014-4535-91d8-79f3f6242fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bbc21563-bab7-46a1-bf7f-eeff7b47a13b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1eb11049-ab52-4c0a-b793-91438c9a49d8" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bbc21563-bab7-46a1-bf7f-eeff7b47a13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5839aadc-11d6-41ab-8535-584b66a52059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bbc21563-bab7-46a1-bf7f-eeff7b47a13b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5839aadc-11d6-41ab-8535-584b66a52059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember_14527310-f4d3-4ed2-8f51-2299d4df6eb0" xlink:href="mgnx-20220331.xsd#mgnx_JanssenCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5839aadc-11d6-41ab-8535-584b66a52059" xlink:to="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember_14527310-f4d3-4ed2-8f51-2299d4df6eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a89e2f6c-b14c-4508-bba6-80a64d504fba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1eb11049-ab52-4c0a-b793-91438c9a49d8" xlink:to="loc_srt_ProductOrServiceAxis_a89e2f6c-b14c-4508-bba6-80a64d504fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a960c63e-a926-496f-b99d-65bc406f09db" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a89e2f6c-b14c-4508-bba6-80a64d504fba" xlink:to="loc_srt_ProductsAndServicesDomain_a960c63e-a926-496f-b99d-65bc406f09db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_b4cf3a6b-5c95-422d-aff9-2d2882486004" xlink:href="mgnx-20220331.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a960c63e-a926-496f-b99d-65bc406f09db" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_b4cf3a6b-5c95-422d-aff9-2d2882486004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_d21366b2-be1c-44c7-ab3c-e9c5ef9e5568" xlink:href="mgnx-20220331.xsd#mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a960c63e-a926-496f-b99d-65bc406f09db" xlink:to="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_d21366b2-be1c-44c7-ab3c-e9c5ef9e5568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a2742017-b3fa-499f-89c1-ef797b7d2398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1eb11049-ab52-4c0a-b793-91438c9a49d8" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a2742017-b3fa-499f-89c1-ef797b7d2398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_4318d117-1d07-4e36-882a-30a80cfe271e" xlink:href="mgnx-20220331.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a2742017-b3fa-499f-89c1-ef797b7d2398" xlink:to="loc_mgnx_NonRefundableUpfrontFees_4318d117-1d07-4e36-882a-30a80cfe271e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_e511e063-1671-40c5-84ec-b3e1c910cd1c" xlink:href="mgnx-20220331.xsd#mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a2742017-b3fa-499f-89c1-ef797b7d2398" xlink:to="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_e511e063-1671-40c5-84ec-b3e1c910cd1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_14437eb3-498c-4170-bba8-c616749bb700" xlink:href="mgnx-20220331.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a2742017-b3fa-499f-89c1-ef797b7d2398" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_14437eb3-498c-4170-bba8-c616749bb700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_12ddb7d1-19ce-4b47-80ed-d3a8d3649c5d" xlink:href="mgnx-20220331.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a2742017-b3fa-499f-89c1-ef797b7d2398" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_12ddb7d1-19ce-4b47-80ed-d3a8d3649c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6730d065-7485-4330-8199-bfc29f6849a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a2742017-b3fa-499f-89c1-ef797b7d2398" xlink:to="loc_us-gaap_Revenues_6730d065-7485-4330-8199-bfc29f6849a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_eeeef6ec-8b69-49a0-bca2-667088d12ae2" xlink:href="mgnx-20220331.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a2742017-b3fa-499f-89c1-ef797b7d2398" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_eeeef6ec-8b69-49a0-bca2-667088d12ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="simple" xlink:href="mgnx-20220331.xsd#CollaborationandOtherAgreementsIMabBiopharmaDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_16ce3e92-176e-4c10-8439-b4adedd2f157" xlink:href="mgnx-20220331.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1c126e74-de9d-4ef2-96d5-64edb8be8b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_16ce3e92-176e-4c10-8439-b4adedd2f157" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1c126e74-de9d-4ef2-96d5-64edb8be8b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ad3ef95e-2a0c-4e7c-b21d-207be3ef672d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1c126e74-de9d-4ef2-96d5-64edb8be8b9f" xlink:to="loc_srt_CounterpartyNameAxis_ad3ef95e-2a0c-4e7c-b21d-207be3ef672d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_268ad471-eb92-4f4b-9348-cd33ed71910f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ad3ef95e-2a0c-4e7c-b21d-207be3ef672d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_268ad471-eb92-4f4b-9348-cd33ed71910f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_3286d840-e3c6-4924-a0e2-8c4af6225652" xlink:href="mgnx-20220331.xsd#mgnx_IMabBiopharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_268ad471-eb92-4f4b-9348-cd33ed71910f" xlink:to="loc_mgnx_IMabBiopharmaMember_3286d840-e3c6-4924-a0e2-8c4af6225652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_e86ab76d-50f6-4590-b53c-a9c089341212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1c126e74-de9d-4ef2-96d5-64edb8be8b9f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_e86ab76d-50f6-4590-b53c-a9c089341212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6feb1e15-30e4-446b-9d86-705648cc65d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_e86ab76d-50f6-4590-b53c-a9c089341212" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6feb1e15-30e4-446b-9d86-705648cc65d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_3437d94c-2af0-406c-84ac-399ddbaf24b5" xlink:href="mgnx-20220331.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6feb1e15-30e4-446b-9d86-705648cc65d5" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_3437d94c-2af0-406c-84ac-399ddbaf24b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_eee8a0b4-eded-4968-9f64-3a67294d1f1c" xlink:href="mgnx-20220331.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6feb1e15-30e4-446b-9d86-705648cc65d5" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_eee8a0b4-eded-4968-9f64-3a67294d1f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c9408460-8acf-4504-9f60-510b8302ef8a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1c126e74-de9d-4ef2-96d5-64edb8be8b9f" xlink:to="loc_srt_RangeAxis_c9408460-8acf-4504-9f60-510b8302ef8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5568fd85-70f7-4806-9341-5742918db7f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c9408460-8acf-4504-9f60-510b8302ef8a" xlink:to="loc_srt_RangeMember_5568fd85-70f7-4806-9341-5742918db7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_05aa705e-77ce-433e-9bb8-68ca8e22ab51" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5568fd85-70f7-4806-9341-5742918db7f2" xlink:to="loc_srt_MaximumMember_05aa705e-77ce-433e-9bb8-68ca8e22ab51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2334e61f-e566-4734-b951-345e26d2417d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1c126e74-de9d-4ef2-96d5-64edb8be8b9f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2334e61f-e566-4734-b951-345e26d2417d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_c762e59d-8e54-4fa1-b709-ac8dd41f77b0" xlink:href="mgnx-20220331.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2334e61f-e566-4734-b951-345e26d2417d" xlink:to="loc_mgnx_NonRefundableUpfrontFees_c762e59d-8e54-4fa1-b709-ac8dd41f77b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_82630cc7-3366-49bc-abee-f3f1cf39ff31" xlink:href="mgnx-20220331.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2334e61f-e566-4734-b951-345e26d2417d" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_82630cc7-3366-49bc-abee-f3f1cf39ff31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_511fc137-3bb0-4837-891d-0c9cffb85e9b" xlink:href="mgnx-20220331.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2334e61f-e566-4734-b951-345e26d2417d" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_511fc137-3bb0-4837-891d-0c9cffb85e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesNetOfTaxWithholding_3371653f-a9a2-457e-896c-95290421a5a6" xlink:href="mgnx-20220331.xsd#mgnx_RevenuesNetOfTaxWithholding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2334e61f-e566-4734-b951-345e26d2417d" xlink:to="loc_mgnx_RevenuesNetOfTaxWithholding_3371653f-a9a2-457e-896c-95290421a5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_f30e5e2c-7e8a-45bc-9e74-17e3fe7ab840" xlink:href="mgnx-20220331.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2334e61f-e566-4734-b951-345e26d2417d" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_f30e5e2c-7e8a-45bc-9e74-17e3fe7ab840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_6083831a-4383-41ed-86c8-590c95f11a6e" xlink:href="mgnx-20220331.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2334e61f-e566-4734-b951-345e26d2417d" xlink:to="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_6083831a-4383-41ed-86c8-590c95f11a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a171f395-f5d5-4cb6-835a-9c0d22334342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2334e61f-e566-4734-b951-345e26d2417d" xlink:to="loc_us-gaap_Revenues_a171f395-f5d5-4cb6-835a-9c0d22334342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_ce4b768c-b7a0-435f-91ec-a2a436cf58e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2334e61f-e566-4734-b951-345e26d2417d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_ce4b768c-b7a0-435f-91ec-a2a436cf58e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ddf3b482-c28d-4678-b483-5bff28302de5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2334e61f-e566-4734-b951-345e26d2417d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ddf3b482-c28d-4678-b483-5bff28302de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f430e487-e20c-4acd-bf21-95992f57205c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2334e61f-e566-4734-b951-345e26d2417d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f430e487-e20c-4acd-bf21-95992f57205c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OneTimeMillstoneCredit_586c1126-864a-4b8e-a246-2ee90d93434a" xlink:href="mgnx-20220331.xsd#mgnx_OneTimeMillstoneCredit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2334e61f-e566-4734-b951-345e26d2417d" xlink:to="loc_mgnx_OneTimeMillstoneCredit_586c1126-864a-4b8e-a246-2ee90d93434a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20220331.xsd#CollaborationandOtherAgreementsNIAIDContractDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_8d03a139-6f69-43d8-a09d-6fdc83f584f3" xlink:href="mgnx-20220331.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0d6d61cf-7d09-4fd0-87c0-257df24b4d34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_8d03a139-6f69-43d8-a09d-6fdc83f584f3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0d6d61cf-7d09-4fd0-87c0-257df24b4d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_330342b6-bd14-4334-9ae7-e06ec803ae91" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0d6d61cf-7d09-4fd0-87c0-257df24b4d34" xlink:to="loc_srt_ProductOrServiceAxis_330342b6-bd14-4334-9ae7-e06ec803ae91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8c31692d-59a9-48a9-90ce-7b7a88ba7ffb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_330342b6-bd14-4334-9ae7-e06ec803ae91" xlink:to="loc_srt_ProductsAndServicesDomain_8c31692d-59a9-48a9-90ce-7b7a88ba7ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember_3afd48e8-590a-410c-adb1-e73038b91ce0" xlink:href="mgnx-20220331.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8c31692d-59a9-48a9-90ce-7b7a88ba7ffb" xlink:to="loc_mgnx_RevenuesFromGrantsMember_3afd48e8-590a-410c-adb1-e73038b91ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8c46674f-4547-491a-ac42-f618b720ed12" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0d6d61cf-7d09-4fd0-87c0-257df24b4d34" xlink:to="loc_srt_CounterpartyNameAxis_8c46674f-4547-491a-ac42-f618b720ed12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c20417ef-5002-4e50-bfa9-1ad486133889" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8c46674f-4547-491a-ac42-f618b720ed12" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c20417ef-5002-4e50-bfa9-1ad486133889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_bc112d3a-7180-4ead-8ebc-a1b8294e6332" xlink:href="mgnx-20220331.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c20417ef-5002-4e50-bfa9-1ad486133889" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_bc112d3a-7180-4ead-8ebc-a1b8294e6332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_baab59ec-7bca-41d9-9f6a-d3153d046fd8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0d6d61cf-7d09-4fd0-87c0-257df24b4d34" xlink:to="loc_srt_RangeAxis_baab59ec-7bca-41d9-9f6a-d3153d046fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b0350b56-ab18-4d1e-8bf9-e98db66d706e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_baab59ec-7bca-41d9-9f6a-d3153d046fd8" xlink:to="loc_srt_RangeMember_b0350b56-ab18-4d1e-8bf9-e98db66d706e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7b348af7-d5b4-4d94-b5ee-0d175b0c46bb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b0350b56-ab18-4d1e-8bf9-e98db66d706e" xlink:to="loc_srt_MaximumMember_7b348af7-d5b4-4d94-b5ee-0d175b0c46bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_96111cab-9446-42f8-b05c-38e130bce98d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0d6d61cf-7d09-4fd0-87c0-257df24b4d34" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_96111cab-9446-42f8-b05c-38e130bce98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_637044e6-903f-4632-a9c8-81859ad9c2b2" xlink:href="mgnx-20220331.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_96111cab-9446-42f8-b05c-38e130bce98d" xlink:to="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_637044e6-903f-4632-a9c8-81859ad9c2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_88c2b06e-6ac1-4a4e-81f2-bef2265c96c4" xlink:href="mgnx-20220331.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_96111cab-9446-42f8-b05c-38e130bce98d" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_88c2b06e-6ac1-4a4e-81f2-bef2265c96c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2b9dd771-4616-4cd3-91e0-9031d5577634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_96111cab-9446-42f8-b05c-38e130bce98d" xlink:to="loc_us-gaap_Revenues_2b9dd771-4616-4cd3-91e0-9031d5577634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="mgnx-20220331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_17227236-42e2-498d-9aff-52bf3aa0724c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2dcc35ea-0010-459a-a291-c89b4d13c200" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_17227236-42e2-498d-9aff-52bf3aa0724c" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2dcc35ea-0010-459a-a291-c89b4d13c200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="mgnx-20220331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bb6a5739-af91-45ff-bee7-dce4adcc3530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c047ccab-ccfd-4647-8e08-84917227d613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bb6a5739-af91-45ff-bee7-dce4adcc3530" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c047ccab-ccfd-4647-8e08-84917227d613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c924a309-88c6-415c-8336-f240bdc4f38e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bb6a5739-af91-45ff-bee7-dce4adcc3530" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c924a309-88c6-415c-8336-f240bdc4f38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_ed2d1d00-cc6d-429e-a049-9e2a2ace3263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bb6a5739-af91-45ff-bee7-dce4adcc3530" xlink:to="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_ed2d1d00-cc6d-429e-a049-9e2a2ace3263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_d958f18a-9f22-4bb5-ba76-dc79b9797a78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bb6a5739-af91-45ff-bee7-dce4adcc3530" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_d958f18a-9f22-4bb5-ba76-dc79b9797a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20220331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e4831b20-e432-4ecb-acda-efaf4245e116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c7a5942-e542-48c1-b402-6f9ad27d0edf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e4831b20-e432-4ecb-acda-efaf4245e116" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c7a5942-e542-48c1-b402-6f9ad27d0edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_17cfcde4-dace-4f22-9522-f26cce39cd20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c7a5942-e542-48c1-b402-6f9ad27d0edf" xlink:to="loc_us-gaap_PlanNameAxis_17cfcde4-dace-4f22-9522-f26cce39cd20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f9525c19-89c8-40fc-bcc0-a075eb385c53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_17cfcde4-dace-4f22-9522-f26cce39cd20" xlink:to="loc_us-gaap_PlanNameDomain_f9525c19-89c8-40fc-bcc0-a075eb385c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_845629cd-797e-41c1-903f-f9e6e6a8159c" xlink:href="mgnx-20220331.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f9525c19-89c8-40fc-bcc0-a075eb385c53" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_845629cd-797e-41c1-903f-f9e6e6a8159c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2003StockIncentivePlanMember_e0ab00b0-06cd-478f-9c1a-8cf43913b6b0" xlink:href="mgnx-20220331.xsd#mgnx_A2003StockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f9525c19-89c8-40fc-bcc0-a075eb385c53" xlink:to="loc_mgnx_A2003StockIncentivePlanMember_e0ab00b0-06cd-478f-9c1a-8cf43913b6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_28a3c4b8-50a7-4fef-b30c-71b33d4467d9" xlink:href="mgnx-20220331.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f9525c19-89c8-40fc-bcc0-a075eb385c53" xlink:to="loc_mgnx_StockIncentivePlan2013Member_28a3c4b8-50a7-4fef-b30c-71b33d4467d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d60251c4-c5a7-4b5b-a866-c5a39eae878f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c7a5942-e542-48c1-b402-6f9ad27d0edf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d60251c4-c5a7-4b5b-a866-c5a39eae878f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c067143d-8346-4f94-a4d0-6201140cbe8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d60251c4-c5a7-4b5b-a866-c5a39eae878f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c067143d-8346-4f94-a4d0-6201140cbe8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_be84bc97-203d-4e9d-8d4b-ea9270150de8" xlink:href="mgnx-20220331.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d60251c4-c5a7-4b5b-a866-c5a39eae878f" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_be84bc97-203d-4e9d-8d4b-ea9270150de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_dc4db196-51cd-40ea-a024-06bbaa624b6e" xlink:href="mgnx-20220331.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d60251c4-c5a7-4b5b-a866-c5a39eae878f" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_dc4db196-51cd-40ea-a024-06bbaa624b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_f7c796c0-f782-42dc-9001-9282bb4325e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d60251c4-c5a7-4b5b-a866-c5a39eae878f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_f7c796c0-f782-42dc-9001-9282bb4325e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_ba3c318c-269f-47b6-a6e1-c6e8e352d119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d60251c4-c5a7-4b5b-a866-c5a39eae878f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_ba3c318c-269f-47b6-a6e1-c6e8e352d119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_82106d7f-dc52-44e8-bb3a-5f8e126af9cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d60251c4-c5a7-4b5b-a866-c5a39eae878f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_82106d7f-dc52-44e8-bb3a-5f8e126af9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20091cba-ed26-40d9-a646-7966a4f38bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d60251c4-c5a7-4b5b-a866-c5a39eae878f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20091cba-ed26-40d9-a646-7966a4f38bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_e6c7a3f9-ed3d-4fd9-b727-27eea9ec61fc" xlink:href="mgnx-20220331.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d60251c4-c5a7-4b5b-a866-c5a39eae878f" xlink:to="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_e6c7a3f9-ed3d-4fd9-b727-27eea9ec61fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_b5aa01b5-dda2-4cd6-a9aa-543985946f82" xlink:href="mgnx-20220331.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d60251c4-c5a7-4b5b-a866-c5a39eae878f" xlink:to="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_b5aa01b5-dda2-4cd6-a9aa-543985946f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_de45d4b7-3606-4c33-97dc-196cc46dd847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e4831b20-e432-4ecb-acda-efaf4245e116" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_de45d4b7-3606-4c33-97dc-196cc46dd847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1d57e874-8dbd-4ddf-baec-b8f0d4ff247b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_de45d4b7-3606-4c33-97dc-196cc46dd847" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1d57e874-8dbd-4ddf-baec-b8f0d4ff247b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_197da1fd-4eff-4eb6-9c90-212beb85898e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1d57e874-8dbd-4ddf-baec-b8f0d4ff247b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_197da1fd-4eff-4eb6-9c90-212beb85898e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_16867d41-c81d-40d0-a36a-31c26e3a39c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_197da1fd-4eff-4eb6-9c90-212beb85898e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_16867d41-c81d-40d0-a36a-31c26e3a39c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d8cebd72-4e8e-43dd-a57e-a9b4649a71e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_197da1fd-4eff-4eb6-9c90-212beb85898e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d8cebd72-4e8e-43dd-a57e-a9b4649a71e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_50589919-0c80-405a-af1e-119252dd4e69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_de45d4b7-3606-4c33-97dc-196cc46dd847" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_50589919-0c80-405a-af1e-119252dd4e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b96c3f1e-8ce2-480c-9566-22ac9d12560e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_50589919-0c80-405a-af1e-119252dd4e69" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b96c3f1e-8ce2-480c-9566-22ac9d12560e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20220331.xsd#StockBasedCompensationOptionPricingAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_309a774d-4f65-47f8-93d1-68d7cae864be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d367f5c8-6839-4e59-b976-dfc1d8c7a0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_309a774d-4f65-47f8-93d1-68d7cae864be" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d367f5c8-6839-4e59-b976-dfc1d8c7a0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_64202ac8-8bf1-428d-a0cd-1784bb3e5a34" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d367f5c8-6839-4e59-b976-dfc1d8c7a0fc" xlink:to="loc_srt_RangeAxis_64202ac8-8bf1-428d-a0cd-1784bb3e5a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dbcd3448-0277-4471-952b-2c33e3f79261" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_64202ac8-8bf1-428d-a0cd-1784bb3e5a34" xlink:to="loc_srt_RangeMember_dbcd3448-0277-4471-952b-2c33e3f79261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3d8fa14e-b005-4544-b54b-06265394c21e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_dbcd3448-0277-4471-952b-2c33e3f79261" xlink:to="loc_srt_MinimumMember_3d8fa14e-b005-4544-b54b-06265394c21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_70efd67d-ac90-49d8-b0cf-8dd00f7fc4e6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_dbcd3448-0277-4471-952b-2c33e3f79261" xlink:to="loc_srt_MaximumMember_70efd67d-ac90-49d8-b0cf-8dd00f7fc4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d7d16f09-e694-4d98-839e-02529c100630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d367f5c8-6839-4e59-b976-dfc1d8c7a0fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d7d16f09-e694-4d98-839e-02529c100630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1dbdbe4a-c825-4926-96e9-aab7e81f1b91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d7d16f09-e694-4d98-839e-02529c100630" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1dbdbe4a-c825-4926-96e9-aab7e81f1b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b90205b2-510d-4e99-81a9-a27d70fb5158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d7d16f09-e694-4d98-839e-02529c100630" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b90205b2-510d-4e99-81a9-a27d70fb5158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6249d15c-61cb-4eed-9e48-3fd3f46a0dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d7d16f09-e694-4d98-839e-02529c100630" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6249d15c-61cb-4eed-9e48-3fd3f46a0dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_64abafc0-218c-4afb-9775-fbdf0687189a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d7d16f09-e694-4d98-839e-02529c100630" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_64abafc0-218c-4afb-9775-fbdf0687189a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_a52655a7-9c18-4718-9628-16f423b4479d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d7d16f09-e694-4d98-839e-02529c100630" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_a52655a7-9c18-4718-9628-16f423b4479d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="mgnx-20220331.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d897f894-d007-4786-b2fe-474fe95a1a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_68fd4823-dafd-4f88-9e0a-92ff0aad013d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d897f894-d007-4786-b2fe-474fe95a1a4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_68fd4823-dafd-4f88-9e0a-92ff0aad013d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cc3a05cf-28e3-4133-85d7-9fc70b335a66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_68fd4823-dafd-4f88-9e0a-92ff0aad013d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cc3a05cf-28e3-4133-85d7-9fc70b335a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_5d7150e6-b1de-4983-b686-a90b6e1eec96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_68fd4823-dafd-4f88-9e0a-92ff0aad013d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_5d7150e6-b1de-4983-b686-a90b6e1eec96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d0783c45-d967-4eb4-b1ec-12b6185d86e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_68fd4823-dafd-4f88-9e0a-92ff0aad013d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d0783c45-d967-4eb4-b1ec-12b6185d86e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_66f2cda3-3ece-4318-af7a-c7da667d51ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_68fd4823-dafd-4f88-9e0a-92ff0aad013d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_66f2cda3-3ece-4318-af7a-c7da667d51ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_241aced4-4989-4b20-8c0b-64fa48361978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_68fd4823-dafd-4f88-9e0a-92ff0aad013d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_241aced4-4989-4b20-8c0b-64fa48361978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_feeffeec-e477-46b8-98e0-f54df31868e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_68fd4823-dafd-4f88-9e0a-92ff0aad013d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_feeffeec-e477-46b8-98e0-f54df31868e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9f25aea7-baf4-4fed-9350-45f00c05424f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_68fd4823-dafd-4f88-9e0a-92ff0aad013d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9f25aea7-baf4-4fed-9350-45f00c05424f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a0b9e03c-d597-4c50-9376-ab4bee975842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_68fd4823-dafd-4f88-9e0a-92ff0aad013d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a0b9e03c-d597-4c50-9376-ab4bee975842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_46ce49c5-ee21-462a-b70b-d6402f946833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d897f894-d007-4786-b2fe-474fe95a1a4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_46ce49c5-ee21-462a-b70b-d6402f946833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_15273a7a-f4a9-4dfd-a8d4-fb3d9a538942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_46ce49c5-ee21-462a-b70b-d6402f946833" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_15273a7a-f4a9-4dfd-a8d4-fb3d9a538942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9afe6537-e7d8-480c-838c-e7e9b771ae55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_46ce49c5-ee21-462a-b70b-d6402f946833" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9afe6537-e7d8-480c-838c-e7e9b771ae55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_44763a16-f86e-44fb-813d-16e1e306d7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_46ce49c5-ee21-462a-b70b-d6402f946833" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_44763a16-f86e-44fb-813d-16e1e306d7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_bd7144eb-1f0f-48ef-b751-2dc8c77bd075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_46ce49c5-ee21-462a-b70b-d6402f946833" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_bd7144eb-1f0f-48ef-b751-2dc8c77bd075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_9892f611-5908-416a-9249-c31e8800ef02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_46ce49c5-ee21-462a-b70b-d6402f946833" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_9892f611-5908-416a-9249-c31e8800ef02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7f7abd3c-eae7-43c4-ad43-d19e5d7f06b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_46ce49c5-ee21-462a-b70b-d6402f946833" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7f7abd3c-eae7-43c4-ad43-d19e5d7f06b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_cfef8373-ec70-4240-ab01-a65ebe6a155a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_46ce49c5-ee21-462a-b70b-d6402f946833" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_cfef8373-ec70-4240-ab01-a65ebe6a155a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_47fb10b9-f50a-428a-8c84-c40db3ac6c17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_46ce49c5-ee21-462a-b70b-d6402f946833" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_47fb10b9-f50a-428a-8c84-c40db3ac6c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1514b978-ee5f-48e0-9470-af806e4e1d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d897f894-d007-4786-b2fe-474fe95a1a4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1514b978-ee5f-48e0-9470-af806e4e1d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8ad363a9-2222-4414-9713-10a93bcd0d73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1514b978-ee5f-48e0-9470-af806e4e1d2b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8ad363a9-2222-4414-9713-10a93bcd0d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f678246c-9435-436d-ae5e-a226574319a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1514b978-ee5f-48e0-9470-af806e4e1d2b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f678246c-9435-436d-ae5e-a226574319a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0f5a1cb8-0b07-4261-8406-3618243758af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1514b978-ee5f-48e0-9470-af806e4e1d2b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0f5a1cb8-0b07-4261-8406-3618243758af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c44c9042-1c02-439c-8191-085d9677f5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1514b978-ee5f-48e0-9470-af806e4e1d2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c44c9042-1c02-439c-8191-085d9677f5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c78a206c-54d2-4478-8b09-b171f951dfac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1514b978-ee5f-48e0-9470-af806e4e1d2b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c78a206c-54d2-4478-8b09-b171f951dfac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c4a02eca-b961-4e77-8795-f7efd90722aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1514b978-ee5f-48e0-9470-af806e4e1d2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c4a02eca-b961-4e77-8795-f7efd90722aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3a26038a-5fc0-48ed-8b45-32429d05da51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d897f894-d007-4786-b2fe-474fe95a1a4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3a26038a-5fc0-48ed-8b45-32429d05da51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6f1d0aaf-435c-418e-b188-a9e44c4d3b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d897f894-d007-4786-b2fe-474fe95a1a4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6f1d0aaf-435c-418e-b188-a9e44c4d3b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3b2f7613-bc1d-45cc-a2cb-ada38d99eff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d897f894-d007-4786-b2fe-474fe95a1a4d" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3b2f7613-bc1d-45cc-a2cb-ada38d99eff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_a2b4932b-2318-4ac8-9c83-b9b1f7b51977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d897f894-d007-4786-b2fe-474fe95a1a4d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_a2b4932b-2318-4ac8-9c83-b9b1f7b51977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6aa310d6-860c-4880-8cf8-b0237f86779b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d897f894-d007-4786-b2fe-474fe95a1a4d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6aa310d6-860c-4880-8cf8-b0237f86779b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1f659b00-d53b-4eda-94a3-8623b40202c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d897f894-d007-4786-b2fe-474fe95a1a4d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1f659b00-d53b-4eda-94a3-8623b40202c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="mgnx-20220331.xsd#StockbasedCompensationRestrictedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_85f189af-78d2-4bf2-bcf7-d27dfb13e42e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_516692bf-2639-4349-b178-d9e0f14c5f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_85f189af-78d2-4bf2-bcf7-d27dfb13e42e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_516692bf-2639-4349-b178-d9e0f14c5f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0d12657c-0e70-4f70-bef6-dc04c5de2edb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_516692bf-2639-4349-b178-d9e0f14c5f8c" xlink:to="loc_us-gaap_AwardTypeAxis_0d12657c-0e70-4f70-bef6-dc04c5de2edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c541394-aa64-4eaf-a832-ee02ebe589ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0d12657c-0e70-4f70-bef6-dc04c5de2edb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c541394-aa64-4eaf-a832-ee02ebe589ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_423134f6-0256-4b30-aae0-040e62eead06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c541394-aa64-4eaf-a832-ee02ebe589ed" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_423134f6-0256-4b30-aae0-040e62eead06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33b30a6b-1dcd-4fd9-8762-00ce4fdb4263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_516692bf-2639-4349-b178-d9e0f14c5f8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33b30a6b-1dcd-4fd9-8762-00ce4fdb4263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f4e67db3-0841-452b-868f-beab392434ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33b30a6b-1dcd-4fd9-8762-00ce4fdb4263" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f4e67db3-0841-452b-868f-beab392434ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c62a3c22-f4be-4638-8acd-913a08dc3805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f4e67db3-0841-452b-868f-beab392434ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c62a3c22-f4be-4638-8acd-913a08dc3805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0f546e1f-b2ee-4a08-b92f-853bbbe77a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f4e67db3-0841-452b-868f-beab392434ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0f546e1f-b2ee-4a08-b92f-853bbbe77a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_37d86187-ea9c-4652-8515-ccd5df8360c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f4e67db3-0841-452b-868f-beab392434ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_37d86187-ea9c-4652-8515-ccd5df8360c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cf7e62d8-7d98-460c-a703-d8e1957cafdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f4e67db3-0841-452b-868f-beab392434ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cf7e62d8-7d98-460c-a703-d8e1957cafdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_77557a73-b713-477b-a59c-faf790a58611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33b30a6b-1dcd-4fd9-8762-00ce4fdb4263" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_77557a73-b713-477b-a59c-faf790a58611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_889d2bb4-3c7c-43b0-8ec0-27575da1cf75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_77557a73-b713-477b-a59c-faf790a58611" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_889d2bb4-3c7c-43b0-8ec0-27575da1cf75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cd420378-8ae9-4b4e-8f60-8d4809fe6a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_77557a73-b713-477b-a59c-faf790a58611" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cd420378-8ae9-4b4e-8f60-8d4809fe6a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7eccf1d7-bd8b-453d-b1b5-a73da265874d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_77557a73-b713-477b-a59c-faf790a58611" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7eccf1d7-bd8b-453d-b1b5-a73da265874d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a1154611-0b09-4fb1-8142-2d7dd61a516f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_77557a73-b713-477b-a59c-faf790a58611" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a1154611-0b09-4fb1-8142-2d7dd61a516f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f405dc46-465d-4df2-97b7-580c38ee824a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33b30a6b-1dcd-4fd9-8762-00ce4fdb4263" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f405dc46-465d-4df2-97b7-580c38ee824a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward_0632211f-ae09-4e78-9849-7ce638219465" xlink:href="mgnx-20220331.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33b30a6b-1dcd-4fd9-8762-00ce4fdb4263" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward_0632211f-ae09-4e78-9849-7ce638219465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d1c873a5-277a-485d-ac54-f1d35b764e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33b30a6b-1dcd-4fd9-8762-00ce4fdb4263" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d1c873a5-277a-485d-ac54-f1d35b764e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_72b05bb6-8f17-4a54-9405-e26fec8f570f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33b30a6b-1dcd-4fd9-8762-00ce4fdb4263" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_72b05bb6-8f17-4a54-9405-e26fec8f570f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mgnx-20220331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cca27cc5-93be-4578-9db4-dad4fe8dbfbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8ef8c538-65f3-4a40-99db-c4850f530ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cca27cc5-93be-4578-9db4-dad4fe8dbfbb" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8ef8c538-65f3-4a40-99db-c4850f530ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418970992568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MACROGENICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1591613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9704 Medical Center Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">251-5172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MGNX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,333,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001125345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418971194456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 47,328<span></span>
</td>
<td class="nump">$ 123,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Marketable securities</a></td>
<td class="nump">136,658<span></span>
</td>
<td class="nump">120,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">14,905<span></span>
</td>
<td class="nump">10,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">4,598<span></span>
</td>
<td class="nump">4,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">14,712<span></span>
</td>
<td class="nump">21,170<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">218,201<span></span>
</td>
<td class="nump">279,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and software, net</a></td>
<td class="nump">36,034<span></span>
</td>
<td class="nump">37,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non current assets</a></td>
<td class="nump">17,210<span></span>
</td>
<td class="nump">18,009<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">271,445<span></span>
</td>
<td class="nump">335,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,731<span></span>
</td>
<td class="nump">15,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">32,967<span></span>
</td>
<td class="nump">33,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">25,562<span></span>
</td>
<td class="nump">20,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">4,837<span></span>
</td>
<td class="nump">4,677<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">67,097<span></span>
</td>
<td class="nump">74,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">6,364<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">19,512<span></span>
</td>
<td class="nump">20,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non current liabilities</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">93,231<span></span>
</td>
<td class="nump">95,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value -- 125,000,000 shares authorized, 61,333,074 and 61,307,428 shares outstanding at March&#160;31, 2022 and December&#160;31, 2021, respectively</a></td>
<td class="nump">613<span></span>
</td>
<td class="nump">613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,218,263<span></span>
</td>
<td class="nump">1,213,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(283)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,040,379)<span></span>
</td>
<td class="num">(973,936)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">178,214<span></span>
</td>
<td class="nump">239,618<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 271,445<span></span>
</td>
<td class="nump">$ 335,245<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418972312696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">61,333,074<span></span>
</td>
<td class="nump">61,307,428<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418971044392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 11,101<span></span>
</td>
<td class="nump">$ 16,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sales</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">61,438<span></span>
</td>
<td class="nump">53,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">16,253<span></span>
</td>
<td class="nump">15,036<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">77,739<span></span>
</td>
<td class="nump">68,174<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(66,638)<span></span>
</td>
<td class="num">(51,293)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">195<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(66,443)<span></span>
</td>
<td class="num">(51,272)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(222)<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="num">$ (66,665)<span></span>
</td>
<td class="num">$ (51,254)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (in usd per share)</a></td>
<td class="num">$ (1.08)<span></span>
</td>
<td class="num">$ (0.90)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (in usd per share)</a></td>
<td class="num">$ (1.08)<span></span>
</td>
<td class="num">$ (0.90)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding (in shares)</a></td>
<td class="nump">61,324,163<span></span>
</td>
<td class="nump">57,202,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common shares outstanding (in shares)</a></td>
<td class="nump">61,324,163<span></span>
</td>
<td class="nump">57,202,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember', window );">Revenue from collaborative and other agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 7,093<span></span>
</td>
<td class="nump">$ 15,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">3,580<span></span>
</td>
<td class="nump">887<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember', window );">Revenue from government agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 428<span></span>
</td>
<td class="nump">$ 810<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418968920776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,244,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 295,884<span></span>
</td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">$ 1,067,150<span></span>
</td>
<td class="num">$ (771,821)<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">5,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">2,458<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">2,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,622,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">98,200<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">98,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(51,272)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,272)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,011,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">350,531<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">1,173,013<span></span>
</td>
<td class="num">(823,093)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,307,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">239,618<span></span>
</td>
<td class="nump">$ 613<span></span>
</td>
<td class="nump">1,213,002<span></span>
</td>
<td class="num">(973,936)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">5,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(222)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(222)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(66,443)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,443)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,333,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 178,214<span></span>
</td>
<td class="nump">$ 613<span></span>
</td>
<td class="nump">$ 1,218,263<span></span>
</td>
<td class="num">$ (1,040,379)<span></span>
</td>
<td class="num">$ (283)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued due to stock plan related activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_StockIssuedDuringPeriodSharesStockPlanActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued due to stock plan related activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_StockIssuedDuringPeriodValueStockPlanActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418971216248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (66,443)<span></span>
</td>
<td class="num">$ (51,272)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">2,913<span></span>
</td>
<td class="nump">2,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums and discounts on marketable securities</a></td>
<td class="nump">334<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">5,274<span></span>
</td>
<td class="nump">5,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(4,520)<span></span>
</td>
<td class="nump">15,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(210)<span></span>
</td>
<td class="num">(6,172)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">6,457<span></span>
</td>
<td class="num">(1,239)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other non current assets</a></td>
<td class="nump">801<span></span>
</td>
<td class="nump">3,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities', window );">Accounts payable</a></td>
<td class="num">(11,920)<span></span>
</td>
<td class="nump">1,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(543)<span></span>
</td>
<td class="nump">855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="num">(1,119)<span></span>
</td>
<td class="num">(683)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">11,280<span></span>
</td>
<td class="num">(601)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other non current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(57,696)<span></span>
</td>
<td class="num">(29,036)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(54,077)<span></span>
</td>
<td class="num">(93,881)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sale and maturities of marketable securities</a></td>
<td class="nump">37,010<span></span>
</td>
<td class="nump">60,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and software</a></td>
<td class="num">(1,415)<span></span>
</td>
<td class="num">(626)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(18,482)<span></span>
</td>
<td class="num">(34,257)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">98,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases', window );">Proceeds from stock option exercises</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">2,458<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">100,658<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(76,141)<span></span>
</td>
<td class="nump">37,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">123,469<span></span>
</td>
<td class="nump">181,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">47,328<span></span>
</td>
<td class="nump">218,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property, equipment and software included in accounts payable or accruals</a></td>
<td class="nump">$ 151<span></span>
</td>
<td class="nump">$ 486<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418973889512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Nature of Operations</a></td>
<td class="text">Nature of Operations<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of the business</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The Company has a pipeline of product candidates being evaluated in clinical trials sponsored by MacroGenics or its collaborators.  These product candidates include multiple immuno-oncology programs, some of which were created primarily using the Company&#8217;s proprietary, antibody-based technology platforms. The Company believes its product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.  In March 2021, the Company and its commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.  </span></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biotechnology company, the Company has primarily funded its operations with proceeds from the sale of its common stock in equity offerings, revenue from its multiple collaboration agreements, and contracts and grants from the National Institute of Allergy and Infectious Diseases (NIAID).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews the Company&#8217;s available liquidity relative to its operating budget and forecast to monitor the sufficiency of the Company&#8217;s working capital.  Based on the Company&#8217;s most recent cash flow forecast, the Company believes its current resources are sufficient to fund its operating plans for a minimum of twelve months from the date that this Quarterly Report on Form 10-Q was filed. The Company plans to meet its future operating requirements by generating revenue from current and future strategic collaborations or other arrangements, and product sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support its product development activities.  If the Company is unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate one or more of its product research and development programs or clinical studies, reduce other operating expenses, and/or downsize its organization.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the other risk factors pertinent to the Company's business, the COVID-19 pandemic and geopolitical tensions, including the ongoing military conflict between Russia and Ukraine and the related sanctions imposed against Russia, might unfavorably impact the Company's ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to the COVID-19 pandemic and geopolitical tensions, the Company will continue to evaluate the nature and extent of the impact of these uncertainties on its business and financial position.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2021 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 24, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418973735672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, there have been no material changes to the significant accounting policies previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements that were issued or became effective since the issuance of the Company&#8217;s 2021 Annual Report on Form 10-K that had, or are expected to have, a material impact on its consolidated financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418973912920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value of Financial Instruments<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between levels during the periods presented. </span></div><div style="margin-bottom:15pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:15pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,007&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,308&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,699&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,348&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,334&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,014&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at March&#160;31, 2022 includes approximately $6.3 million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2021 includes approximately $23.2 million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418973735672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's marketable debt securities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.724%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,940&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(282)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,658&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.724%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,208&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,147&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All available-for-sale marketable debt securities held as of March&#160;31, 2022 and December&#160;31, 2021 had contractual maturities of less than one year.  All of the Company's available-for-sale marketable debt securities in an unrealized loss position as of March&#160;31, 2022 and December&#160;31, 2021 were in a loss position for less than twelve months.&#160; Unrealized losses on </span></div>available-for-sale debt securities as of March&#160;31, 2022 and December&#160;31, 2021 were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities.  Accordingly, no allowance for credit losses related to the Company's available-for-sale debt securities was recorded for any periods presented. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418974259544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory, Net</a></td>
<td class="text">Inventory, Net<div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's net inventory (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,724&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,598&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,388&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>Prior to U.S. Food and Drug Administration (FDA) approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA. The inventory balance as of March&#160;31, 2022 and December&#160;31, 2021 is net of a reserve of $2.0 million for unsaleable inventory.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418973931016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Company entered into a sales agreement (Sales Agreement) with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $100.0 million through an &#8220;at the market offering&#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. The shares that were sold under the Sales Agreement were issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on November 4, 2020.  During the three months ended March 31, 2021, the Company sold 3,622,186 shares of common stock at a weighted average price per share of $27.60, resulting in net proceeds of approximately $98.2 million, net of underwriting discounts and commissions and other offering expenses. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company entered into Amendment No. 1 to the Sales Agreement which increases the amount of the Company&#8217;s common stock that can be sold by the Company through its agent under the ATM Offering, from an aggregate offering price of up to $100.0&#160;million to an aggregate offering price of up to $300.0&#160;million.  The Company has not sold any shares of common stock related to Amendment No. 1 to the Sales Agreement as of March&#160;31, 2022.  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the consideration for the rights granted to Zai Lab US LLC under the collaboration and license agreement described more fully in Note 7, Revenue, the Company and Zai Lab US LLC entered into a separate stock purchase agreement (Stock Purchase Agreement) in June 2021.  Under this Stock Purchase Agreement, Zai Lab US LLC paid the Company approximately $30.0 million to purchase 958,467 newly issued shares of the Company's common stock, par value $0.01, at a fixed price of $31.30 which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418973921704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock', window );">Revenue</a></td>
<td class="text">Revenue <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborative and Other Agreements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte Corporation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte License Agreement</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for retifanlimab, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab.  Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $150.0 million in 2017. In July 2021, Incyte announced that the FDA had issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for retifanlimab as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal. Incyte&#8217;s announcement indicated that the FDA determined that additional data are needed to demonstrate the clinical benefit of retifanlimab for the submitted indication, and that Incyte was reviewing the CRL </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and would discuss next steps with the FDA. Incyte subsequently withdrew its European application for marketing authorization of retifanlimab for the treatment of squamous carcinoma of the anal canal. Incyte has stated it is pursuing development of retifanlimab in potentially registration-enabling studies beyond squamous cell carcinoma of the anal canal, including in patients with MSI-high endometrial cancer, Merkel cell carcinoma and non-small cell lung cancer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, Incyte will lead global development of retifanlimab.  Assuming successful development and commercialization by Incyte, the Company could receive up to approximately $420.0 million in development and regulatory milestones and up to $330.0 million in commercial milestones. From the inception of the Incyte License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has recognized $70.0 million in development milestones under the Incyte License Agreement.  If retifanlimab is approved and commercialized, the Company would be eligible to receive tiered royalties of 15% to 24% on any global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte License Agreement under the provisions of Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606) and identified the following two performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period.  The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience.  The Company determined that the transaction price of the Incyte License Agreement at inception was $154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed.  The transaction price was allocated to each performance obligation based on their relative standalone selling price.  The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The standalone selling price for the agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. From 2018 through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, it became probable that a significant reversal of cumulative revenue would not occur for development milestones totaling $70.0 million related to </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical and regulatory activities related to the further advancement of retifanlimab, including Incyte&#8217;s initiation of a Phase 3 clinical trial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Therefore, the associated consideration was added to the estimated transaction price and was recognized as revenue</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the $150.0 million allocated to the license when it satisfied its performance obligation and transferred the license to Incyte in 2017. The $4.0 million allocated to the clinical activities was recognized ratably as services were performed during 2017 and 2018. No revenue was recognized under the Incyte License Agreement during the three months ended March 31, 2022.  During the three months ended March 31, 2021, $10.0 million in milestone revenue was recognized under the Incyte License Agreement.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte Clinical Supply Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into an agreement with Incyte, under which the Company is to perform development and manufacturing services for Incyte&#8217;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement).  The Company evaluated the Incyte Clinical Supply Agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab.  The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services.  During the three months ended March 31, 2022 and 2021, the Company recognized revenue of $0.3 million and $0.1 million, respectively, for services performed under the Incyte Clinical Supply Agreement.  </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte Commercial Supply Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company entered into an agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#8217;s obligation to pay royalties under the Incyte License Agreement.  The Company evaluated the Incyte Commercial Supply Agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the commercial supply of retifanlimab. The transaction price is based on a fixed price per batch of bulk drug substance to be manufactured and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor costs incurred) related to the manufacturing services.  During the three months ended March 31, 2022 , the Company recognized de minimis revenue and during the three months ended March 31, 2021 the Company recognized $3.1&#160;million for services performed under the Incyte Commercial Supply Agreement.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zai Lab Limited</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Zai Lab Agreement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab)  under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#8217;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab, a bispecific DART&#174; molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development of these molecules in its territory. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2018 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0 million ($22.5 million after netting value-added tax withholdings of $2.5 million). Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, the Company could receive up to $140.0 million in development and regulatory milestones, of which the Company has earned $9.0 million through March&#160;31, 2022. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-teens to 20% for net sales of margetuximab in Zai Lab&#8217;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#8217;s territory and 10% for net sales of the TRIDENT molecule in Zai Lab&#8217;s territory, which may be subject to adjustment in specified circumstances. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2018 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and tebotelimab:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#8217;s territory and (ii) certain research and development activities. The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate. Activities related to margetuximab and tebotelimab are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract. The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule. The Company determined that the net $22.5 million upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.  From 2020 through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, it became probable that a significant reversal of cumulative revenue would not occur for development and regulatory milestones totaling $9.0 million.  Therefore, the associated consideration was added to the estimated transaction price and was recognized as revenue</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Of this </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$9.0 million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.0 million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was recognized as revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the three months ended March 31, 2022.  No revenue was recognized during the three months ended March 31, 2021 under the 2018 Zai Lab Agreement.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zai Lab Clinical Supply Agreements</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#8217;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements). The Company evaluated the agreements under ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: to perform services related to manufacturing the clinical supply of each of margetuximab and tebotelimab.  The transaction price is based on the costs incurred to manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing service. During the three months ended March 31, 2022 and 2021, the Company recognized revenue of $0.2 million and $1.1 million, respectively, related to the Zai Lab Clinical Supply Agreements. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Zai Lab Agreement</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates the Company&#8217;s DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be designated by the Company. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while the Company receives commercial rights in all other territories. Under the Lead Program, Zai Lab received an option upon reaching a predefined clinical milestone to convert the regional arrangement into a global 50/50 profit share. If Zai Lab elects such option, Zai Lab is to pay the Company $85.0&#160;million plus any research costs incurred by both parties as of the option election date. Zai Lab also obtained exclusive, global licenses from the Company to develop, manufacture and commercialize two additional molecules. Zai Lab granted the Company a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to the Company.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2021 Zai Lab Agreement, the Lead Program includes joint research and development services by both the Company and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with the Company to perform research and development services in the future. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0&#160;million. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, the Company and Zai Lab entered into the Stock Purchase Agreement whereby Zai Lab paid the Company approximately $30.0 million to purchase shares of the Company&#8217;s common stock, par value $0.01, at a fixed price of $31.30 which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful development and commercialization of the Programs, the Company could receive up to approximately $800.0&#160;million in development and regulatory milestones and $600.0&#160;million in commercial milestones. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of low double digit teens on annual net sales of certain specified products and of mid-single digits to low double digit teens on annual net sales of other specified products in Zai Lab&#8217;s territory, which may be subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, the Company may also receive reimbursements from Zai Lab for certain research and development costs incurred by the Company. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2021 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises: (i) exclusive licenses to develop, manufacture and commercialize the products in Zai Lab&#8217;s territory for each Program and (ii) certain research and development activities for the Lead Program. The Company determined that for the Lead Program, the license is not distinct from the related research and development activities, considering the early stage of development of the molecule and the Company&#8217;s significant expertise in this area and as such, the research and development services are expected to significantly modify and customize the license. Therefore, for the Lead Program, the license and the services were combined into a single performance obligation. Since the other programs each represent distinct intellectual property and there are no other services included in the 2021 Zai Lab Agreement related to these licenses, each license is considered to be a distinct performance obligation. As such, there are four performance obligations included in the 2021 Zai Lab Agreement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the estimated transaction price is $40.4 million, consisting of the $25.0 million upfront payment, the $10.4 million premium related to the purchase of the Company&#8217;s common stock, and the $5.0 million estimated reimbursement by Zai Lab for research and development activities for the Lead Program. The potential milestone payments </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were deemed to be fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company will re-assess the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price of $40.4 million was then allocated to the four performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was not directly observable; therefore, the Company estimated the standalone selling price using an adjusted market assessment approach, representing the amount that the Company believes a market participant is willing to pay for the product or service. The estimate was based on consideration of observable inputs, such as, values of other preclinical collaboration arrangements adjusted for the Company&#8217;s estimate of the probability of success for each Program. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue related to the Lead Program license and related research and development services performance obligation is being recognized over time as the research and development activities are performed. The Company will utilize a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations. The Company recognized revenue allocated to the other programs at a point in time upon transfer of the licenses to Zai Lab in June 2021. During the three months ended March 31, 2022, the Company recognized revenue of $0.3 million under the 2021 Zai Lab Agreement. As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022, $16.2 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenue was deferred under the agreement, all of which was current. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December&#160;31, 2021, $16.1 million in revenue was deferred, all of which was current.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Biotech, Inc.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company entered into a research collaboration and license agreement with Janssen Biotech, Inc. (Janssen) to develop a novel DART molecule (Janssen Agreement).  The research collaboration will incorporate the Company&#8217;s proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the Janssen Agreement, Janssen paid the Company an upfront payment of $20.0&#160;million and will be responsible for funding all research and development expenses. The Company will also be eligible to receive up to $312.0&#160;million in potential milestone payments and tiered royalties of up to 10% on worldwide product sales. </span><span style="color:#58585a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Janssen an exclusive, royalty-bearing license to develop, manufacture and commercialize the preclinical bispecific molecule and the Company will perform certain research and development activities during a specified research term. The Company evaluated the Janssen Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i)  a license to develop the preclinical bispecific molecule and (ii) performing certain research and development activities during the research term. The Company determined that the license and research and development activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as Janssen could benefit from the license on its own without the Company&#8217;s involvement during the research term.  The Company determined that the transaction price of the Janssen Agreement at inception was $22.2&#160;million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for research and development activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements as well as current market conditions. The standalone selling price for agreed-upon research and development activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. This variable consideration is fully constrained until the Company begins its work under the performance obligation.  The potential milestone payments are </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Janssen and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the $20.0&#160;million allocated to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license when it satisfied its performance obligation and transferred the license to Janssen in December 2020. The $2.2&#160;million allocated to the research and development activities is being recognized over the Company&#8217;s involvement in the research term, which is estimated to be less than two years.  The Company recognized revenue of $0.3&#160;million for each of the three-month periods ended March&#160;31, 2022 and 2021 for research and development activities performed under the Janssen Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">I-Mab Biopharma</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">I-Mab License Agreement</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the Company's proprietary Fc Optimization technology platform (I-Mab License Agreement).  I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the I-Mab License Agreement, I-Mab paid the Company an upfront payment of $15.0 million.  Assuming successful development and commercialization of enoblituzumab, the Company could receive up to $135.0 million in development and regulatory milestones, of which $5.0&#160;million has been earned from the inception of the I-Mab License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, I-Mab would pay the Company tiered royalties ranging from mid-teens to 20% on annual net sales in I-Mab's territory.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the I-Mab License Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i) an exclusive license to develop and commercialize enoblituzumab in I-Mab&#8217;s territories, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation. The Company determined that the $15.0 million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities. The Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $1.0 million. I-Mab paid the Company for the cost of this study as the costs were incurred and I-Mab received a one-time credit of eighty percent of the total amount of such costs against the milestone achieved during 2021. The Company reassessed the transaction price as it became probable that a significant reversal of cumulative revenue would not occur for a $5.0&#160;million milestone ($4.5&#160;million after netting a one-time credit as described above) related to development progress of enoblituzumab, therefore the associated consideration was added to the estimated transaction price and was recognized as revenue during 2021. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to I-Mab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Revenue under the I-Mab License Agreement is being recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations.  During the three months ended March 31, 2022 and 2021, the Company recognized revenue of $0.2 million and $0.6 million, respectively, under the I-Mab License Agreement. As of March&#160;31, 2022, $4.4 million in revenue was deferred under the I-Mab License Agreement, all of which was current. As of December&#160;31, 2021, $4.5 million in revenue was deferred under the I-Mab License Agreement, all of which was current.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">I-Mab Clinical Supply Agreement</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into an agreement under which the Company is to perform development and manufacturing services for I-Mab&#8217;s clinical needs of enoblituzumab (I-Mab Clinical Supply Agreement). The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of enoblituzumab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the three months ended March 31, 2022, the Company recognized revenue of $0.9 million for research and development activities performed under the I-Mab Clinical Supply Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing Services Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into a Manufacturing and Clinical Supply Agreement with Incyte (Incyte Manufacturing and Clinical Supply Agreement) to provide manufacturing services to produce certain Incyte bulk drug substance over a three-year period at one of the Company&#8217;s manufacturing facilities. Under the terms of the Incyte Manufacturing and Clinical Supply Agreement, the Company received an upfront payment of $10.0&#160;million and is eligible to receive annual fixed payments paid quarterly over the term of the contract totaling $14.4&#160;million. The Company will also be reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing services.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte Manufacturing and Clinical Supply Agreement under the provisions of ASC 606 and identified one performance obligation to provide manufacturing runs to Incyte, as and when requested by Incyte, over the term of the contract that is part of a series of goods and services. The Company determined that the transaction price at inception consists of the upfront payment received of $10.0&#160;million and the annual fixed payments totaling $14.4&#160;million.   The Company will recognize revenue over time on a straight-line basis as the manufacturing services are provided to Incyte, as the Company determined that its efforts in providing the manufacturing services will be incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product for Incyte will be allocated to the related manufacturing activities and will be recognized as revenue as those activities occur.  Materials purchased by the Company to manufacture the product for Incyte are considered costs to fulfill a contract and will be capitalized and expensed as the materials are used to provide the manufacturing services.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no revenue recognized under the Incyte Manufacturing and Clinical Supply Agreement during the three months ended March 31, 2022. As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$11.2&#160;million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was deferred under this agreement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.8&#160;million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was current and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.4&#160;million </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of which was non-current.  </span></div><div style="margin-bottom:6pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NIAID Contract</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a contract with National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to two DART molecules, MGD014 and MGD020 (NIAID Contract). Under the NIAID Contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.</span></div>Since the inception of the NIAID Contract, NIAID has exercised the two options contemplated in the original contract and executed modifications such that the total funded contract value as of March&#160;31, 2022 is $25.1&#160;million. In addition, the most recent modification changed the period of performance under the NIAID Contract to end in July 2023. During the three months ended March 31, 2022 and 2021, the Company recognized revenue under the NIAID Contract of $0.4 million and    $0.8 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418973787016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended (IRC), and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfMzg0ODI5MDcwNDU3Ng_27cd901d-e912-415a-9df7-55d3c46ad18f">six</span>-month offering periods ending on May 31 and November 30 of each year.  At the end of each offering period, employees are able to purchase shares at 85% of the fair market value of the Company&#8217;s common stock on the last day of the offering period.  During the three months ended March&#160;31, 2022, no shares of common stock were purchased under the 2016 ESPP.   </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Option Plans</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the IRC, or non-qualified stock options.  In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan.  Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160; As of March&#160;31, 2022, under the 2003 Plan, there were options to purchase an aggregate of 160,357 shares of common stock outstanding.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2013, the Company implemented the 2013 Plan.&#160;&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards.&#160;&#160;The number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) 1,960,168 shares, (b) 4.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Company's Board of Directors. During the three months ended March&#160;31, 2022, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to 15,816,949.&#160;&#160; If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards.  As of March&#160;31, 2022, there were options to purchase an aggregate of 10,346,223 shares of common stock outstanding.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation expense was recognized for the periods indicated (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,559&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,274&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,286&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:</span></div><div style="margin-bottom:9pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.837%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.9% -88.3%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.4% - 86.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5% - 2.4%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6% - 1.4%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the three months ended March&#160;31, 2022:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.010%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>&#160;(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,373,921&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,646)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157,197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,695)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,506,580&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of March 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,853,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,693,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of options granted during the three months ended March&#160;31, 2022 and 2021 was $7.48 and $14.23, respectively. The total intrinsic value of options exercised during the three months ended March&#160;31, 2022 and 2021 was approximately $0.3 million and $1.4 million, respectively.  The total cash received for options </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercised during the three months ended March&#160;31, 2022 was de minimis, and $2.5 million was received for options exercised during the three months ended March 31, 2021.  The total fair value of shares vested in the three months ended March&#160;31, 2022 and 2021 was approximately $5.4 million and $4.1 million, respectively. As of March&#160;31, 2022, the total unrecognized compensation expense related to unvested stock options, net of related forfeiture estimates, was approximately $38.4 million, which the Company expects to recognize over a weighted-average period of approximately 1.6 years.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants restricted stock units (RSUs) under the 2013 Plan to employees from time to time as a component of their compensation. During the three months ended March 31, 2022, the Company awarded RSUs to employees in conjunction with the annual performance review process. Each RSU vests over a two-year period and entitles the holder to receive one share of the Company's common stock when the RSU vests. Compensation expense is recognized on a straight-line basis over the vesting period. </span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the three months ended March&#160;31, 2022:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.268%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,444&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, there was $2.9 million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of approximately 1.4 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418973873336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and ContingenciesOn September 13, 2019, a securities class action complaint was filed in the U.S. District Court for the District of Maryland (District Court) by Todd Hill naming the Company, its Chief Executive Officer, Dr. Koenig, and its Chief Financial Officer, Mr. Karrels, as defendants for allegedly making false and materially misleading statements regarding the Company&#8217;s SOPHIA trial. On August 17, 2020, the Employees&#8217; Retirement System of the City of Baton Rouge and Parish of East Baton Rouge was appointed as Lead Plaintiff, and on October 16, 2020, the Lead Plaintiff filed an amended complaint. The amended complaint asserts a putative class period stemming from February 6, 2019 to June 4, 2019. The Company filed a Motion to Dismiss on November 30, 2020. On September 29, 2021, the District Court issued an Order dismissing the case, with prejudice. On October 28, 2021 the Lead Plaintiff filed a Notice of Appeal.  The appeal is now pending in the Fourth Circuit. The Company intends to vigorously defend against this action. However, the outcome of this legal proceeding is uncertain at this time and the Company cannot reasonably estimate a range of loss, if any. Accordingly, the Company has not accrued any liability associated with this action.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418973326408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2021 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 24, 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements that were issued or became effective since the issuance of the Company&#8217;s 2021 Annual Report on Form 10-K that had, or are expected to have, a material impact on its consolidated financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div>The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. There were no transfers between levels during the periods presented.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418973889512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Financial Assets Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:15pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:15pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,007&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,308&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,699&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,348&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,334&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,014&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at March&#160;31, 2022 includes approximately $6.3 million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2021 includes approximately $23.2 million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418974265144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Available-for-sale Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's marketable debt securities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.724%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,940&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(282)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,658&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.724%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,208&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,147&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418973968168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's net inventory (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,724&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,598&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,388&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418971041256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation expense was recognized for the periods indicated (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,559&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,274&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,286&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Valuation Assumptions Using the Black-Scholes Option-Pricing Model</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:</span></div><div style="margin-bottom:9pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.837%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.9% -88.3%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.4% - 86.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5% - 2.4%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6% - 1.4%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of Stock Options Roll Forward</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the three months ended March&#160;31, 2022:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.010%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>&#160;(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,373,921&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,646)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157,197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,695)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,506,580&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of March 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,853,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,693,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of RSU Activity</a></td>
<td class="text"><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the three months ended March&#160;31, 2022:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.268%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,444&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418970186232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">$ 136,658<span></span>
</td>
<td class="nump">$ 120,147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">6,300<span></span>
</td>
<td class="nump">23,200<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">143,007<span></span>
</td>
<td class="nump">143,348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">128,308<span></span>
</td>
<td class="nump">98,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">14,699<span></span>
</td>
<td class="nump">45,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">352<span></span>
</td>
<td class="nump">17,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">352<span></span>
</td>
<td class="nump">17,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Money market funds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">127,956<span></span>
</td>
<td class="nump">81,132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | U.S. Treasury securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">127,956<span></span>
</td>
<td class="nump">81,132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | U.S. Treasury securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">7,700<span></span>
</td>
<td class="nump">7,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Government-sponsored enterprises | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Government-sponsored enterprises | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">7,700<span></span>
</td>
<td class="nump">7,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">6,999<span></span>
</td>
<td class="nump">37,280<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate debt securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">$ 6,999<span></span>
</td>
<td class="nump">$ 37,280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418971136792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 136,940,000<span></span>
</td>
<td class="nump">$ 120,208,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(282,000)<span></span>
</td>
<td class="num">(61,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">136,658,000<span></span>
</td>
<td class="nump">120,147,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit loss related to available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">128,231,000<span></span>
</td>
<td class="nump">81,184,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(274,000)<span></span>
</td>
<td class="num">(52,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">127,957,000<span></span>
</td>
<td class="nump">81,132,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">7,705,000<span></span>
</td>
<td class="nump">7,739,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">7,700,000<span></span>
</td>
<td class="nump">7,734,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,004,000<span></span>
</td>
<td class="nump">31,285,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3,000)<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 1,001,000<span></span>
</td>
<td class="nump">$ 31,281,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418971053864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">$ 3,724<span></span>
</td>
<td class="nump">$ 3,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">874<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory, net</a></td>
<td class="nump">4,598<span></span>
</td>
<td class="nump">4,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory valuation reserves</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418974204552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold (in shares)</a></td>
<td class="nump">958,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,622,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember', window );">At the Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CommonStockMaximumAmountAvailableForIssuance', window );">Maximum amount available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,622,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sales of stock purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease', window );">Maximum amount available for issuance, increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockMaximumAmountAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Maximum Amount Available For Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockMaximumAmountAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Maximum Amount Available For Issuance, Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418965391144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Incyte Corporation (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1">51 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>performanceObligation</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,101,000<span></span>
</td>
<td class="nump">$ 16,881,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,562,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,646,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,562,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,364,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,364,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember', window );">Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 420,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Development and regulatory milestones recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfPerformanceObligations', window );">Number of performance obligations | performanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Collaborative agreement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount', window );">Variable consideration recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember', window );">I-Mab | I-Mab Biopharma Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Development and regulatory milestones recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | I-Mab | I-Mab Biopharma Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement - Clinical activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAgreementsMemberMember', window );">RevenuesFromCMOAgreementsMember | Incyte Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_TotalAnnualFixedPayments', window );">Annual Fixed Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TotalAnnualFixedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Annual Fixed Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_TotalAnnualFixedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementClinicalActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementClinicalActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012ClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012ClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012SupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012SupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAgreementsMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAgreementsMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418966199304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Zai Lab (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">21 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 15, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,101<span></span>
</td>
<td class="nump">$ 16,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,562<span></span>
</td>
<td class="nump">$ 20,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,364<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember', window );">2018 Zai Lab Agreement | Zai Labs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding', window );">Non-refundable upfront payment, net of tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonrefundablePaymentTaxWithholding', window );">Nonrefundable payment tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Development and regulatory milestones recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenuesNetOfTaxWithholding', window );">Revenues, net of tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember', window );">Zai Lab Agreement, Margetuximab | Zai Labs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember', window );">Zai Lab Agreement, TRIDENT molecule | Zai Labs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabClinicalSupplyAgreementsMember', window );">Zai Lab Clinical Supply Agreements | Zai Labs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember', window );">2021 Zai Lab Agreements | Zai Labs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,200<span></span>
</td>
<td class="nump">$ 16,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OptInFee', window );">Opt-in fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sales of stock purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Collaborative agreement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount', window );">Variable consideration recognized</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember', window );">2021 Zai Lab Agreements | Zai Labs | Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PremiumReceivedOnStockPurchase', window );">Premium received on stock purchase</a></td>
<td class="nump">$ 10,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonrefundablePaymentTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable Payment Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonrefundablePaymentTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable Upfront Fees, Net Of Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OptInFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Opt-in Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OptInFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PremiumReceivedOnStockPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PremiumReceivedOnStockPurchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PremiumReceivedOnStockPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenuesNetOfTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues, Net Of Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenuesNetOfTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ZaiLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ZaiLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabClinicalSupplyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabClinicalSupplyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418971226296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Janssen (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,101<span></span>
</td>
<td class="nump">$ 16,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember', window );">Janssen Biotech Inc | Janssen Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales', window );">Potential milestone payments and royalties on product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 312,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Collaborative agreement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount', window );">Clinical trial activities selling price amount</a></td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember', window );">Janssen Biotech Inc | Janssen Collaboration and License Agreement | Revenues From License Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember', window );">Janssen Biotech Inc | Janssen Collaboration and License Agreement | Revenue From Performance of the Research and Development Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payments and Royalties On Product Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418969039944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - I-Mab Biopharma (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 11,101<span></span>
</td>
<td class="nump">$ 16,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">25,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">6,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember', window );">I-Mab | I-Mab Biopharma Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Development and regulatory milestones recognized</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount', window );">Estimated variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OneTimeMillstoneCredit', window );">One Time Millstone Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember', window );">I-Mab | I-Mab Biopharma Collaboration and License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember', window );">I-Mab | I-Mab Biopharma Collaboration And License Agreement Clinical Supply</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OneTimeMillstoneCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>One Time Millstone Credit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OneTimeMillstoneCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Information Used To Assess Variable Consideration, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418966444552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - NIAID Contract (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 15, 2015 </div>
<div>Molecule</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,101<span></span>
</td>
<td class="nump">$ 16,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember', window );">NIAID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement', window );">Number of commercialized molecules | Molecule</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_TotalPotentialValueUnderAgreement', window );">Total potential value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember', window );">Revenues From Grants | NIAID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TotalPotentialValueUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_TotalPotentialValueUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418966239944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">Offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,506,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,373,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price of stock options outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,274<span></span>
</td>
<td class="nump">$ 5,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember', window );">2016 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent', window );">Payroll deduction percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock percent of the fair market value</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_A2003StockIncentivePlanMember', window );">2003 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,816,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,346,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance', window );">Potential annual increase in shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,960,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan', window );">Potential annual increase in shares reserved for future issuance as percentage of outstanding share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,392<span></span>
</td>
<td class="nump">2,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,882<span></span>
</td>
<td class="nump">$ 2,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_A2003StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_A2003StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418974203240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Option Pricing Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 11 months 12 days<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Expired (in dollars per share)</a></td>
<td class="nump">$ 21.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">87.90%<span></span>
</td>
<td class="nump">86.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">88.30%<span></span>
</td>
<td class="nump">86.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418969732408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Beginning Balance (in shares)</a></td>
<td class="nump">8,373,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares, Granted (in shares)</a></td>
<td class="nump">2,349,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised (in shares)</a></td>
<td class="num">(25,646)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Forfeited or expired (in shares)</a></td>
<td class="num">(157,197)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</a></td>
<td class="num">(33,695)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Ending Balance (in shares)</a></td>
<td class="nump">10,506,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares, Exercisable (in shares)</a></td>
<td class="nump">5,853,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Shares, Vested and expected to vest (in shares)</a></td>
<td class="nump">9,693,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)</a></td>
<td class="nump">$ 21.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Granted (in dollars per share)</a></td>
<td class="nump">10.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercised (in dollars per share)</a></td>
<td class="nump">1.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Forfeited (in dollars per share)</a></td>
<td class="nump">16.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Expired (in dollars per share)</a></td>
<td class="nump">21.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share)</a></td>
<td class="nump">19.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercisable (in dollars per share)</a></td>
<td class="nump">22.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 19.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Term, Outstanding (in years)</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Exercisable (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Vested and expected to vest (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding, Ending Balance</a></td>
<td class="nump">$ 904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">$ 903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 7.48<span></span>
</td>
<td class="nump">$ 14.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received for options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="nump">5,400<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates</a></td>
<td class="nump">$ 38,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period (in years)</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140418966240872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Restricted Stock Unit Activity (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period (in years)</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance (in shares)</a></td>
<td class="nump">21,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">309,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited or expired (in shares)</a></td>
<td class="num">(5,428)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">325,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 25.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">10.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited or expired (in dollars per share) | $ / shares</a></td>
<td class="nump">10.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward', window );">Number of shares per employee</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total unrecognized compensation cost | $</a></td>
<td class="nump">$ 2.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period (in years)</a></td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number Of Shares Received For Each Vested Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>mgnx-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mgnx="http://macrogenics.com/20220331"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mgnx-20220331.xsd" xlink:type="simple"/>
    <context id="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id9c7ce63000148a1940f679036069716_I20220429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="i48bdd36e5bfa487081b635f45c9c8141_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d6180f7949d43fd94d47d00066fc533_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia2b41ef23b1644f8bf8a1ab64aa91c4e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if51dfe4d455b420781d382a10b0128c6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8052edef0e8142a0aae1084562aec9a8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0c66c701c256418fb52b049e4ebc9d9a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i607d6d4b7a0b4a269b66b704af5c7980_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i42f32c13c8944d9ba988f770f28210b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7ab8dc2df2542edb9cf3ade797023cf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5a1fda27e1b42518702a64371c3ffbf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie29fa966142d4809926b4fce9ac47d66_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3e82a89c57234ca2a3478adaa271fec3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i21ac8ecb1ef74bb188581735307623a4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i782fb333be73427da78999262075f9f1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic759253504a2492db7e2ee3ad72992da_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i26a9072466f44863844deebde8ebd435_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iba667f5b561d48d8a13c95cd18dd77d0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0cd82a548e734c0b80d9b7adbea03f44_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i13caa53ffc1749ee85d3f04baf65b8e2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i12a5fd8f1ac64b25a36c35f490310693_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i514431b860214fa08d26900f9bc8809f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3c1fe4be954c4a76a3462acae2e52d25_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1fb34feb7d82479fa90e51ee903d7fc5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i61850671ea5c46908f41ccc8bad84475_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i765ca9da243a400f9b9eda52bf592847_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9d29335a8b4d442d847dc74d97919490_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7b13a8a2d938497f94da21f2db99b34d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i30760bd2ed9f4522bde9a72f4d193433_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i39336f55686d443a9f9bb2e7f5368a75_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5672f6e735064f58bfdfcc331c3ac673_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7646821245c2453e910c16b5b8ae12a4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia2c7a9bb638f4f09a965e4cc3541bc2b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib5da4e28ca474a05a3dd215f637ca9a6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id95d122f09ba4d2abee62f84fae879ac_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i87b87bbcaef644248cdf6ccd14a1dceb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1e70e3df18ab41f78be816bc2ec224ad_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i38dae976f1074d01ade570e63f5432e2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i11d98d66595a4e23a7412ce37ac28a09_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic38615f63b384c709ab9bb249a259668_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if1679ec57ed840b4ba3621b23001f423_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i134315721b8b4bc8b6ad9a64c9dca944_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i01b2c1f07c9a491abfb73f67bfdfee33_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i84a8b67fd745449695ca7b9bb8d32b55_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4b8362beacc0443ebef61473a9dccbea_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iec177ca29fe3450a851669d85c7c44bc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iadf67bfafee04b0e8f19076f8b5ba241_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4c87ec43f73d49438e33596695e0f16a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6211e35b2594407c9f7301938b926647_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i74c05f3a658142a898bc4958d7248bad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibc78708aeb344bafbf36d06b7e3268c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if85bdb5b035f43b884ce2ecf0893b353_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ad8e34e86da4770904f35743caf98ac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia4152da960bb40088ebf5bc56b742e61_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ec75cded8dd44b088006c06d9e3b597_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id74359d02a6a4da78e3f2fc132eb4559_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icdf424220c884f50be1e050499baaa2e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if6db79bbb4d648b889a9b1cb12bcc873_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib90bb549405247818bd658fcfc5dbb02_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id2a9ffd7eb2944f7a2b80b1417657841_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icdf1d14d8fc0481c9792632139822db0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic793e546189e40c692e374b70b7656d3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib77cf447ac3c41209a584a715a1efc6e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib1670779e18c400db0676422bc94c22e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4ce219c82bc1424b9f3d36c9e3956c15_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib3b3f430d68b497f825e77b9e6f604da_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia1f6c9125c0b45aab207a0111b790111_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia7afc4d905b84b94add195a76efd0e03_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied0c021681ab444cb45099fb32ff4b98_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i543d462b4fb941c3b7c489c116e8bf4f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee6c657f52bd4f23bd0bf6abce303d78_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i46cfcfe1a61845d48ac67642abb7f911_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if06926cd9b2147e88810d44763baa9ce_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7d0c61251f464c44a32c131af591406f_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ie0aca00030b84821a220040e1894b4ed_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i53817096bacf40229bf71a7348ab1def_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib5527acf5cf248e5ac690d183c18549f_I20210615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-15</instant>
        </period>
    </context>
    <context id="i1b909bf9e4ae42208ed813d9676eadb7_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3a2c1fb5405243d38e27f09c198a5915_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i1dabbd2bdcd948c59b80f6888528ba3b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ica1236dc56be456dadbe35007ebd92bc_D20180101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie34522f6d1964d318f94e89b4a7854b2_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i02d8186b9ed94687aa3108cc69312fbd_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i94127aa94aa2402086ac95e5ef578edd_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i54eb455b76a2472aae844a12fa08813e_D20170101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8c7b19308ad740b49d92d38c4aa6390d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i43cf385ec61546e2885724e6c7c3177a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if3c00bc643434efbbf8833b77153ad2d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0adbde0716db4da29d82fc8ba600273b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic8d7471a9a78429b9f892ec0cc71150c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012SupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifba4c7039c924aa5b223417e6cf78e36_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8a199c459cc44adc89979956653b5201_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6a9c376486b84ec3b165f5f033a1fd8d_D20200701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0c95d8da85da4d78b72fd3032fd7f680_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib9c86092c7f8459fa95d28f361b3564a_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i605a7292ff3f44c383e3d95959a523b0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i51a097abe2f346a8bea4a1a0e880968a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia36f2c15a9ed480fb6dfd60b54cdb774_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i29c3c82f97234786bc2f333cf100ce5f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3a06e176aa5944de902c9e6384aa45bf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic3025bab32fb46cd9d6da9f324ce3688_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i36440f83cc204cf1996dbfe7485383bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i76399d6c1802415b90c08bf9c69f7100_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie55d7a52498740cc96d51ad5658ea4c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibc75ade1173842ff87ee4dbbac9daeb5_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib49d110aa2b04f54ad540230e16f5db5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6925c66d0d90474cabcbca044e7bb353_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iecc8c23d2f2f46e295c148fe79e31e39_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i61fd77fcf6144f8f852769a79d64119a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia548adfe30414a9f9d0fd63c315589d5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0e56061fef8544908e67631567510f9d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1514a61deb464837bf8bb0f50659cd2b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib5ec03c4a3794d77bfafe5617533f80a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if8da3009f9f94f879c4bf206e40f1cc4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic49edb54de2c4ae4a6d757a5b491be58_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iedfb3cdeb7214224a72fce2beb8e46d1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0157b8cec1ad4b9a9b95f37868dd31e3_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="ia4e2cd3790dd4e78a153c3c1da4940aa_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaec489dac35b477286b66bb36de621fc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1337d1949d0643488c0089eab0614890_D20150915-20150915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-15</startDate>
            <endDate>2015-09-15</endDate>
        </period>
    </context>
    <context id="i7e37fc50bcd44ac683c40725c776294b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic750b1bc388a426a9377427e21e4fe52_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0ba225f70b5e431a996b967e49bfb1c8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iad1e5d2adfa44b97a1de1c2f673de3f3_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="i909599960cbd4d01a402618a5680f14c_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i950e359d634d41aeb9e7dcdaf238a1ec_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i83ac7c613bf04ee3a7d8345a36323be1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i86806d0d26194ccda0c95e062fc00349_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:A2003StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1ded582f69f04d0aaaf29d8dddc272a5_I20131031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-10-31</instant>
        </period>
    </context>
    <context id="ib91bd3b003bd40c9b8460d6c1e8f8f10_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if0a7f8632e7f42d5ad0ae052ddb56492_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i35c13a3e3a224d948c4a2fe4b9fa5d99_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i59db3d1311064ab88fb9f88769f9da7b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i010ad6f9a1c640caa25d8015911a45d6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iacae1a7b3e1f4879bf90a88d717407ae_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia47224cd15db4935927f150937cfc761_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib2e3c0ef64b149e285c3286cfaaaefa7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1675839c45fe4c938d0aaa356a3df94c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i11689de0548a42dba1fc04b3de566926_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i66614c40c0e14c88b42fd0af30436dfc_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0dc396f12757461e9c5b3a86b51821a5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifa66c46429f947848a8668ce68165b60_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id18c2d3f95654745b74930d2f8ea04b0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="performanceobligation">
        <measure>mgnx:performanceObligation</measure>
    </unit>
    <unit id="molecule">
        <measure>mgnx:Molecule</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80L2ZyYWc6YzBhYTcxMGQxZmRlNDdjMDg1M2M2ZTY2Yjk3ZmFiMzkvdGFibGU6N2UyNjZiZjlkMTQ1NDU5YThhZjFlMDc3NTg4N2NjOTQvdGFibGVyYW5nZTo3ZTI2NmJmOWQxNDU0NTlhOGFmMWUwNzc1ODg3Y2M5NF8yLTEtMS0xLTM2OTIx_c773a9e6-f346-4fa8-87c1-67717465317b">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80L2ZyYWc6YzBhYTcxMGQxZmRlNDdjMDg1M2M2ZTY2Yjk3ZmFiMzkvdGFibGU6N2UyNjZiZjlkMTQ1NDU5YThhZjFlMDc3NTg4N2NjOTQvdGFibGVyYW5nZTo3ZTI2NmJmOWQxNDU0NTlhOGFmMWUwNzc1ODg3Y2M5NF80LTEtMS0xLTM2OTIx_44765d51-3276-496b-8f6f-c7bed67fde66">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80L2ZyYWc6YzBhYTcxMGQxZmRlNDdjMDg1M2M2ZTY2Yjk3ZmFiMzkvdGFibGU6N2UyNjZiZjlkMTQ1NDU5YThhZjFlMDc3NTg4N2NjOTQvdGFibGVyYW5nZTo3ZTI2NmJmOWQxNDU0NTlhOGFmMWUwNzc1ODg3Y2M5NF81LTEtMS0xLTM2OTIx_6f37ea51-c629-474b-b67c-469d53fdde42">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80L2ZyYWc6YzBhYTcxMGQxZmRlNDdjMDg1M2M2ZTY2Yjk3ZmFiMzkvdGV4dHJlZ2lvbjpjMGFhNzEwZDFmZGU0N2MwODUzYzZlNjZiOTdmYWIzOV8xMzA_a38d055c-8b6c-4c92-bb09-e81c3d1c4e8f">0001125345</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80L2ZyYWc6YzBhYTcxMGQxZmRlNDdjMDg1M2M2ZTY2Yjk3ZmFiMzkvdGV4dHJlZ2lvbjpjMGFhNzEwZDFmZGU0N2MwODUzYzZlNjZiOTdmYWIzOV8xMzE_b8b72687-3ac1-4742-8085-23f7029aad10">--12-31</dei:CurrentFiscalYearEndDate>
    <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
      contextRef="i950e359d634d41aeb9e7dcdaf238a1ec_D20170501-20170531"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfMzg0ODI5MDcwNDU3Ng_27cd901d-e912-415a-9df7-55d3c46ad18f">P6M</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <dei:DocumentType
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGV4dHJlZ2lvbjo2ZThhZTQ0ZjQ0Y2E0NTA4OTZlYzFhNTgwY2M2ZTJjYV84Mg_9966ec78-3b97-4d35-821d-44bfa4b7227d">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGFibGU6OTY5OGQzNTk2NGQ1NDU3OWJlYTZiNjk5OGY4MGUyNTYvdGFibGVyYW5nZTo5Njk4ZDM1OTY0ZDU0NTc5YmVhNmI2OTk4ZjgwZTI1Nl8wLTAtMS0xLTM2OTIx_29e2d212-52e2-499b-840b-086c83868e09">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGV4dHJlZ2lvbjo2ZThhZTQ0ZjQ0Y2E0NTA4OTZlYzFhNTgwY2M2ZTJjYV8xMTc_c6763240-9d07-4591-a4cf-b1f3a7decf1d">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGFibGU6MTlmNjI1MDAyYmJmNDg3ODlkMmRiN2YwODUzZDZmYzkvdGFibGVyYW5nZToxOWY2MjUwMDJiYmY0ODc4OWQyZGI3ZjA4NTNkNmZjOV8wLTAtMS0xLTM2OTIx_94b19076-8320-4944-aceb-603b90707722">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGV4dHJlZ2lvbjo2ZThhZTQ0ZjQ0Y2E0NTA4OTZlYzFhNTgwY2M2ZTJjYV8yMDg_87bd563c-b5fc-4af5-8775-302655fc26b6">001-36112</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGV4dHJlZ2lvbjo2ZThhZTQ0ZjQ0Y2E0NTA4OTZlYzFhNTgwY2M2ZTJjYV8yMTE_a628ef95-b1c8-4d6e-96f0-6303727c8357">MACROGENICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGFibGU6MTBkYzBhNGEwZGIzNDg5MWJkM2MzM2NmODI5YTFmZmUvdGFibGVyYW5nZToxMGRjMGE0YTBkYjM0ODkxYmQzYzMzY2Y4MjlhMWZmZV8wLTAtMS0xLTM2OTIx_689ac431-8864-4244-8f1d-286e671f362f">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGFibGU6MTBkYzBhNGEwZGIzNDg5MWJkM2MzM2NmODI5YTFmZmUvdGFibGVyYW5nZToxMGRjMGE0YTBkYjM0ODkxYmQzYzMzY2Y4MjlhMWZmZV8wLTEtMS0xLTM2OTIx_3e3b992b-881f-450c-8f91-a459aa295cad">06-1591613</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGFibGU6MTBkYzBhNGEwZGIzNDg5MWJkM2MzM2NmODI5YTFmZmUvdGFibGVyYW5nZToxMGRjMGE0YTBkYjM0ODkxYmQzYzMzY2Y4MjlhMWZmZV8zLTAtMS0xLTM2OTIxL3RleHRyZWdpb246ZmZhOTFiOTk1OWVkNDI3ZjgxM2ZiN2Q0Y2U3NGE5YWRfNQ_f51c23a9-c4bb-4427-bea9-5ee73398bbd4">9704 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGFibGU6MTBkYzBhNGEwZGIzNDg5MWJkM2MzM2NmODI5YTFmZmUvdGFibGVyYW5nZToxMGRjMGE0YTBkYjM0ODkxYmQzYzMzY2Y4MjlhMWZmZV8zLTAtMS0xLTM2OTIxL3RleHRyZWdpb246ZmZhOTFiOTk1OWVkNDI3ZjgxM2ZiN2Q0Y2U3NGE5YWRfOA_bec6d39a-9651-40b5-9849-1b02e873d20f">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGFibGU6MTBkYzBhNGEwZGIzNDg5MWJkM2MzM2NmODI5YTFmZmUvdGFibGVyYW5nZToxMGRjMGE0YTBkYjM0ODkxYmQzYzMzY2Y4MjlhMWZmZV8zLTAtMS0xLTM2OTIxL3RleHRyZWdpb246ZmZhOTFiOTk1OWVkNDI3ZjgxM2ZiN2Q0Y2U3NGE5YWRfMTI_c15f7b90-55cc-4d99-8ac0-108da904502c">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGFibGU6MTBkYzBhNGEwZGIzNDg5MWJkM2MzM2NmODI5YTFmZmUvdGFibGVyYW5nZToxMGRjMGE0YTBkYjM0ODkxYmQzYzMzY2Y4MjlhMWZmZV8zLTEtMS0xLTM2OTIx_c745d6de-3d30-45dd-bb15-c469eea62106">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGV4dHJlZ2lvbjo2ZThhZTQ0ZjQ0Y2E0NTA4OTZlYzFhNTgwY2M2ZTJjYV8yNzA_b4541644-37fb-40cb-ab9a-c9f9d2b62002">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGV4dHJlZ2lvbjo2ZThhZTQ0ZjQ0Y2E0NTA4OTZlYzFhNTgwY2M2ZTJjYV8yNzM_5f5b7fd7-f544-4079-b74a-d5e64e987f16">251-5172</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGFibGU6NDhhM2RiYmU1ZTBhNDRmNDgyNDA2MWM4ZDFmNzhjOGUvdGFibGVyYW5nZTo0OGEzZGJiZTVlMGE0NGY0ODI0MDYxYzhkMWY3OGM4ZV8xLTAtMS0xLTM2OTIx_011da034-69e0-498d-8563-b3bcde6efb8e">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGFibGU6NDhhM2RiYmU1ZTBhNDRmNDgyNDA2MWM4ZDFmNzhjOGUvdGFibGVyYW5nZTo0OGEzZGJiZTVlMGE0NGY0ODI0MDYxYzhkMWY3OGM4ZV8xLTEtMS0xLTM2OTIx_86ef4578-0c50-41d8-9ad7-73dab1a1b140">MGNX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGFibGU6NDhhM2RiYmU1ZTBhNDRmNDgyNDA2MWM4ZDFmNzhjOGUvdGFibGVyYW5nZTo0OGEzZGJiZTVlMGE0NGY0ODI0MDYxYzhkMWY3OGM4ZV8xLTItMS0xLTM2OTIx_252e8763-e3ca-4e34-aa4a-4aa625ac576b">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGV4dHJlZ2lvbjo2ZThhZTQ0ZjQ0Y2E0NTA4OTZlYzFhNTgwY2M2ZTJjYV8xOTE1_017e62c2-b27f-45a3-a994-0622aa0ffe4e">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGV4dHJlZ2lvbjo2ZThhZTQ0ZjQ0Y2E0NTA4OTZlYzFhNTgwY2M2ZTJjYV8xOTE2_ca48009c-2be1-40f8-821e-d5d10128c85a">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGFibGU6Yjc0NzUzNDk2OWYzNGZhNjljODViM2VkYTYyM2RkMjcvdGFibGVyYW5nZTpiNzQ3NTM0OTY5ZjM0ZmE2OWM4NWIzZWRhNjIzZGQyN18wLTAtMS0xLTM2OTIx_52061ec4-1a3e-4a88-8ec0-061eff16513a">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGFibGU6Yjc0NzUzNDk2OWYzNGZhNjljODViM2VkYTYyM2RkMjcvdGFibGVyYW5nZTpiNzQ3NTM0OTY5ZjM0ZmE2OWM4NWIzZWRhNjIzZGQyN18yLTMtMS0xLTM2OTIx_1fe62421-ffed-46a3-ae30-531b96901669">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGFibGU6Yjc0NzUzNDk2OWYzNGZhNjljODViM2VkYTYyM2RkMjcvdGFibGVyYW5nZTpiNzQ3NTM0OTY5ZjM0ZmE2OWM4NWIzZWRhNjIzZGQyN180LTEtMS0xLTM2OTIx_53738ecf-bf94-46eb-9cf6-2cbb19ef549a">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGV4dHJlZ2lvbjo2ZThhZTQ0ZjQ0Y2E0NTA4OTZlYzFhNTgwY2M2ZTJjYV8xOTE3_d276b98a-d656-4614-bc8d-0c2cd8043e2e">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="id9c7ce63000148a1940f679036069716_I20220429"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xL2ZyYWc6NmU4YWU0NGY0NGNhNDUwODk2ZWMxYTU4MGNjNmUyY2EvdGV4dHJlZ2lvbjo2ZThhZTQ0ZjQ0Y2E0NTA4OTZlYzFhNTgwY2M2ZTJjYV8xODI4_752c22ce-e369-4ee7-a52f-9a27f6ed534a"
      unitRef="shares">61333500</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfNC0xLTEtMS0zNjkyMQ_c3796104-c16e-477e-b2fd-599b2b31f5ec"
      unitRef="usd">47328000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfNC0zLTEtMS0zNjkyMQ_e8e489ea-03f9-45e8-befb-964bf4a568c1"
      unitRef="usd">123469000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:Investments
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfNS0xLTEtMS0zNjkyMQ_2d86e9cb-9e94-4413-b0eb-ee1b1f529fe8"
      unitRef="usd">136658000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfNS0zLTEtMS0zNjkyMQ_437a3171-681d-4703-a886-ebab9adc75d3"
      unitRef="usd">120147000</us-gaap:Investments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfNi0xLTEtMS0zNjkyMQ_bde98caa-0bba-459a-af82-4fd4da55ebdc"
      unitRef="usd">14905000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfNi0zLTEtMS0zNjkyMQ_e83c41c9-583e-43bf-866a-43b399f22f4b"
      unitRef="usd">10386000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfNy0xLTEtMS0zNjkyMQ_b7ea1cad-0813-4295-95a0-51b780521771"
      unitRef="usd">4598000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfNy0zLTEtMS0zNjkyMQ_83630d54-4451-42ab-9d72-e110822af0cc"
      unitRef="usd">4388000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfOC0xLTEtMS0zNjkyMQ_6b7a31b5-0f5a-49a9-813f-faf2a450a95f"
      unitRef="usd">14712000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfOC0zLTEtMS0zNjkyMQ_9a9a5766-930e-47c9-a2e0-1a6462575725"
      unitRef="usd">21170000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMTAtMS0xLTEtMzY5MjE_dffa818c-479c-464a-aa18-e435c8bdcec5"
      unitRef="usd">218201000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMTAtMy0xLTEtMzY5MjE_9c813880-5a6a-4679-897b-062b038d2cad"
      unitRef="usd">279560000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMTEtMS0xLTEtMzY5MjE_eef1cf70-a3cb-44cc-b96d-6090628e2284"
      unitRef="usd">36034000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMTEtMy0xLTEtMzY5MjE_cb4305eb-e7b3-4fdc-ab7c-ba8380c9e0dc"
      unitRef="usd">37676000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMTMtMS0xLTEtMzY5MjE_c1fc2d54-7580-4c89-920a-e7b3a157cbb6"
      unitRef="usd">17210000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMTMtMy0xLTEtMzY5MjE_74eb49e8-5967-4106-b44d-267e820919b9"
      unitRef="usd">18009000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMTQtMS0xLTEtMzY5MjE_5bf711f5-c03d-4874-beba-484e3c633551"
      unitRef="usd">271445000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMTQtMy0xLTEtMzY5MjE_d0f7737d-c254-45b2-bca5-7c8a713a1160"
      unitRef="usd">335245000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMTgtMS0xLTEtMzY5MjE_28dbcccb-3de6-46a8-8684-10fa80080d34"
      unitRef="usd">3731000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMTgtMy0xLTEtMzY5MjE_a28d158f-0458-4abd-ab54-336e29af3a21"
      unitRef="usd">15500000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMTktMS0xLTEtMzY5MjE_1d1fefc2-07e4-4140-ab30-8b9d74f641b9"
      unitRef="usd">32967000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMTktMy0xLTEtMzY5MjE_973e9df4-27e8-490e-9405-12776c37b115"
      unitRef="usd">33755000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjAtMS0xLTEtMzY5MjE_d76ec88c-de29-4e45-a701-e300a322ac36"
      unitRef="usd">25562000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjAtMy0xLTEtMzY5MjE_640aae50-88f8-4906-8566-c8fa36cab9fa"
      unitRef="usd">20646000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjEtMS0xLTEtMzY5MjE_1516aa59-178b-49d5-96b2-40ffdb38f952"
      unitRef="usd">4837000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjEtMy0xLTEtMzY5MjE_d40e3be8-205c-41b6-8d11-5e3cbccb4133"
      unitRef="usd">4677000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjMtMS0xLTEtMzY5MjE_ebd6c123-7890-417b-9650-2ebec90940bc"
      unitRef="usd">67097000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjMtMy0xLTEtMzY5MjE_98b25cae-17ea-4ebe-842f-b018329700c6"
      unitRef="usd">74578000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjQtMS0xLTEtMzY5MjE_3ce20489-71ad-441a-bb82-28e5c5658097"
      unitRef="usd">6364000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjQtMy0xLTEtMzY5MjE_503bacd6-cbf5-4c55-8b7f-45a10cd4de27"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjUtMS0xLTEtMzY5MjE_4cda3893-38e7-404c-a9f7-9ac7aecc53b8"
      unitRef="usd">19512000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjUtMy0xLTEtMzY5MjE_53cce398-ca63-4b5c-a6a0-e0a0526b2b6c"
      unitRef="usd">20791000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjYtMS0xLTEtMzY5MjE_e78658ae-ace1-4970-9965-2958b8154f4c"
      unitRef="usd">258000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjYtMy0xLTEtMzY5MjE_2c5b7b1c-184f-4fe5-a315-89c4eb91cbfb"
      unitRef="usd">258000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjctMS0xLTEtMzY5MjE_17385441-cd7f-4a09-ba7e-9858cc4b8d44"
      unitRef="usd">93231000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjctMy0xLTEtMzY5MjE_2cdffe78-ef93-46f5-8abb-c522a2b43a02"
      unitRef="usd">95627000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjktMC0xLTEtMzY5MjEvdGV4dHJlZ2lvbjo5ZTgzNzk1NzZhMmE0ZmNkYTY2ODZmZmFhMjY3OTIxMF8xOA_cab2090c-c45b-4897-9cac-aecdc0f3f393"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjktMC0xLTEtMzY5MjEvdGV4dHJlZ2lvbjo5ZTgzNzk1NzZhMmE0ZmNkYTY2ODZmZmFhMjY3OTIxMF8xOA_e5dbf4e5-f90f-4c11-8b60-ca9fd9674306"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjktMC0xLTEtMzY5MjEvdGV4dHJlZ2lvbjo5ZTgzNzk1NzZhMmE0ZmNkYTY2ODZmZmFhMjY3OTIxMF8zNA_11b71daf-b4e7-4394-b9b3-9a258d840fca"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjktMC0xLTEtMzY5MjEvdGV4dHJlZ2lvbjo5ZTgzNzk1NzZhMmE0ZmNkYTY2ODZmZmFhMjY3OTIxMF8zNA_5d82cec3-27e8-41e1-bbb4-bc80e445978c"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjktMC0xLTEtMzY5MjEvdGV4dHJlZ2lvbjo5ZTgzNzk1NzZhMmE0ZmNkYTY2ODZmZmFhMjY3OTIxMF81Ng_a8f3db47-db12-403f-9aff-7fb0e2cad4e8"
      unitRef="shares">61333074</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjktMC0xLTEtMzY5MjEvdGV4dHJlZ2lvbjo5ZTgzNzk1NzZhMmE0ZmNkYTY2ODZmZmFhMjY3OTIxMF82Mw_bc87032c-aee1-476d-9a75-21787d6696d0"
      unitRef="shares">61307428</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjktMS0xLTEtMzY5MjE_a88c2979-9ab4-4939-982c-b9b21c76a217"
      unitRef="usd">613000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMjktMy0xLTEtMzY5MjE_31d67701-d7d3-4afb-ae1a-38a7e05fdc34"
      unitRef="usd">613000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMzAtMS0xLTEtMzY5MjE_848fc7cd-7b47-4a08-804f-0862863101f3"
      unitRef="usd">1218263000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMzAtMy0xLTEtMzY5MjE_af759337-e182-474e-b7b0-2a6e5c9373d8"
      unitRef="usd">1213002000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMzEtMS0xLTEtMzY5MjE_57862124-2920-4bd7-9678-8059e70a02e1"
      unitRef="usd">-283000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMzEtMy0xLTEtMzY5MjE_a722bcfb-f5a5-452d-ba31-42cba3f1d594"
      unitRef="usd">-61000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMzItMS0xLTEtMzY5MjE_edc9e84c-2ede-4ca5-8950-0a60ca61aba8"
      unitRef="usd">-1040379000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMzItMy0xLTEtMzY5MjE_86f52264-0cce-495d-945d-0a94cec00946"
      unitRef="usd">-973936000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMzMtMS0xLTEtMzY5MjE_969aa288-1f31-48cb-96aa-a548e8cad457"
      unitRef="usd">178214000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMzMtMy0xLTEtMzY5MjE_55032aeb-7f70-4429-a2ef-d12e3f89f75b"
      unitRef="usd">239618000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMzQtMS0xLTEtMzY5MjE_6e531f46-7237-45b3-863c-313d32f701cc"
      unitRef="usd">271445000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8xOS9mcmFnOmVkOTM1ODZkYWNiZjRmYzRiZDU4ZGM5ZmUzMjZhZjY1L3RhYmxlOmQxNjY3YzRlNDM4NDQ4NjFiNjU1MDExZTEyNjFjYjNhL3RhYmxlcmFuZ2U6ZDE2NjdjNGU0Mzg0NDg2MWI2NTUwMTFlMTI2MWNiM2FfMzQtMy0xLTEtMzY5MjE_0eac3eaf-d230-40d0-b385-c1e731f2f2fa"
      unitRef="usd">335245000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="i4d6180f7949d43fd94d47d00066fc533_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMy0xLTEtMS0zNjkyMQ_732e3132-78b6-431a-82e8-51b87b2c5121"
      unitRef="usd">7093000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia2b41ef23b1644f8bf8a1ab64aa91c4e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMy0zLTEtMS0zNjkyMQ_fb81854b-b088-4a09-9062-a4247fb903a5"
      unitRef="usd">15184000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if51dfe4d455b420781d382a10b0128c6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfNC0xLTEtMS0zNjkyMQ_27902a22-5bae-40b7-93d0-ddb3dfdd5875"
      unitRef="usd">3580000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8052edef0e8142a0aae1084562aec9a8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfNC0zLTEtMS0zNjkyMQ_2d68b2f1-1eaf-4425-9863-b328a75ce586"
      unitRef="usd">887000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0c66c701c256418fb52b049e4ebc9d9a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfNS0xLTEtMS0zNjkyMQ_bce2bbe1-00f2-4ef6-b077-9ef6161cf36f"
      unitRef="usd">428000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i607d6d4b7a0b4a269b66b704af5c7980_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfNS0zLTEtMS0zNjkyMQ_2a7b153a-0f9d-41b4-9af4-d10755960f9f"
      unitRef="usd">810000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfNi0xLTEtMS0zNjkyMQ_5f7968f6-b361-4769-9db3-8a11e76b155c"
      unitRef="usd">11101000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfNi0zLTEtMS0zNjkyMQ_f46ac26b-12ab-4df8-86fe-0f4e9d512956"
      unitRef="usd">16881000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfOC0xLTEtMS0zNjkyMQ_95ba5096-59b1-4611-8c4e-08b3e9716223"
      unitRef="usd">48000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfOC0zLTEtMS0zNjkyMQ_8e799efa-aaee-4193-aaf3-f2943e06e416"
      unitRef="usd">17000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfOS0xLTEtMS0zNjkyMQ_982cfc39-c519-4be0-a636-9ce342feaa97"
      unitRef="usd">61438000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfOS0zLTEtMS0zNjkyMQ_40e85584-fe75-47cf-8c58-93549fea2899"
      unitRef="usd">53121000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTAtMS0xLTEtMzY5MjE_4ca211ca-002f-46f3-bec5-014a1b99ce47"
      unitRef="usd">16253000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTAtMy0xLTEtMzY5MjE_6b2b0750-a34e-4913-a29f-bc8193ad6fee"
      unitRef="usd">15036000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTEtMS0xLTEtMzY5MjE_25655669-4d43-44b8-9e8b-0ecc09be1f0a"
      unitRef="usd">77739000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTEtMy0xLTEtMzY5MjE_659559e5-cb1a-4589-8266-fba74096eb28"
      unitRef="usd">68174000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTItMS0xLTEtMzY5MjE_cbda1aac-8262-4dc0-b3d4-844ec05fae66"
      unitRef="usd">-66638000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTItMy0xLTEtMzY5MjE_b665232a-85da-4ead-9354-37e146daf4d8"
      unitRef="usd">-51293000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTMtMS0xLTEtMzY5MjE_7a57d40b-f2aa-483f-8768-78de100d0a16"
      unitRef="usd">195000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTMtMy0xLTEtMzY5MjE_48ba2f9c-28be-472a-b4fe-35dab6390379"
      unitRef="usd">21000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTQtMS0xLTEtMzY5MjE_1cd7a942-0e43-4e5c-b52a-2c90491c5db7"
      unitRef="usd">-66443000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTQtMy0xLTEtMzY5MjE_57c266ab-f6ba-4d07-a5e7-4c38eacaf9f5"
      unitRef="usd">-51272000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTYtMS0xLTEtMzY5MjE_32646731-2d78-4aed-8f72-952aadfd4c5c"
      unitRef="usd">-222000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTYtMy0xLTEtMzY5MjE_ed7403e9-dae9-425c-84d7-bbf0a80cf440"
      unitRef="usd">18000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTctMS0xLTEtMzY5MjE_f4965456-ba05-440d-bda5-9c76b17e2256"
      unitRef="usd">-66665000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTctMy0xLTEtMzY5MjE_468f8108-11e7-42d3-a559-fff6288a4302"
      unitRef="usd">-51254000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTktMS0xLTEtMzY5MjE_839d86af-c8e4-45c9-8f87-752c5f38f89b"
      unitRef="usdPerShare">-1.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTktMS0xLTEtMzY5MjE_b8bc4af0-dea2-4fa6-a604-28832ca54d85"
      unitRef="usdPerShare">-1.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTktMy0xLTEtMzY5MjE_3a9c6df0-24b3-443f-a8b7-a26133a76d38"
      unitRef="usdPerShare">-0.90</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMTktMy0xLTEtMzY5MjE_ba972ea1-9625-4d63-8538-376580936141"
      unitRef="usdPerShare">-0.90</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMjAtMS0xLTEtMzY5MjE_028c7c7b-2377-4a7b-95c1-537ce2945182"
      unitRef="shares">61324163</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMjAtMS0xLTEtMzY5MjE_1a9f6405-12c8-4bfd-86d8-49d2041d9b01"
      unitRef="shares">61324163</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMjAtMy0xLTEtMzY5MjE_794c0189-d280-4209-a652-2fd209825c73"
      unitRef="shares">57202846</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yMi9mcmFnOjRmOGIxZmI1MjE1OTQ0ZDlhYWFmMDRhNTJmNjY0OGRiL3RhYmxlOjE4NDA1YzQ5ZmY3MDQzOTY5MmE5MzEzNmYwM2Y5Nzc5L3RhYmxlcmFuZ2U6MTg0MDVjNDlmZjcwNDM5NjkyYTkzMTM2ZjAzZjk3NzlfMjAtMy0xLTEtMzY5MjE_bbad41d7-7e48-4d0a-8c8d-8385afd5ba6d"
      unitRef="shares">57202846</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesIssued
      contextRef="i42f32c13c8944d9ba988f770f28210b3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfMi0xLTEtMS0zNjkyMQ_068fecb6-31a1-4b6d-9ea8-3d1af610104c"
      unitRef="shares">61307428</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i42f32c13c8944d9ba988f770f28210b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfMi0zLTEtMS0zNjkyMQ_cf984e2e-6805-4bfc-9fe7-7e786d29e515"
      unitRef="usd">613000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic7ab8dc2df2542edb9cf3ade797023cf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfMi05LTEtMS0zNjkyMQ_d67a51e5-045c-41df-80a5-fea372866ae0"
      unitRef="usd">1213002000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib5a1fda27e1b42518702a64371c3ffbf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfMi0xMS0xLTEtMzY5MjE_91054390-e26f-41b9-b7ec-2d9e799de745"
      unitRef="usd">-973936000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie29fa966142d4809926b4fce9ac47d66_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfMi0xMy0xLTEtMzY5MjE_41d57d60-fcc7-4622-bdea-fc0e80358b8b"
      unitRef="usd">-61000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfMi0xNS0xLTEtMzY5MjE_ed6d4163-4055-41cb-a03a-de167e946955"
      unitRef="usd">239618000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3e82a89c57234ca2a3478adaa271fec3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfMy05LTEtMS0zNjkyMQ_d7223631-ee10-458c-bbfc-3d1717b0ebf4"
      unitRef="usd">5224000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfMy0xNS0xLTEtMzY5MjE_c54c484c-eef0-454a-ae0b-4331360b2152"
      unitRef="usd">5224000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="i21ac8ecb1ef74bb188581735307623a4_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfNS0xLTEtMS0zNjkyMQ_a5b28331-30d0-4e1a-8224-76835603434c"
      unitRef="shares">25646</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i3e82a89c57234ca2a3478adaa271fec3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfNS05LTEtMS0zNjkyMQ_555c9d50-7d10-4670-97fd-87127f71ab5b"
      unitRef="usd">37000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfNS0xNS0xLTEtMzY5MjE_865e292b-2583-4a62-b508-a82d4fcb69d9"
      unitRef="usd">37000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i782fb333be73427da78999262075f9f1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfNi0xMy0xLTEtMzY5MjE_8dfcf484-44d6-4d12-9ce7-5b9c2e95e719"
      unitRef="usd">-222000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfNi0xNS0xLTEtMzY5MjE_8bdc82db-5397-4e6c-b60d-d412112fa850"
      unitRef="usd">-222000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="ic759253504a2492db7e2ee3ad72992da_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfNy0xMS0xLTEtMzY5MjE_b9e2c1fc-87af-4901-8f31-d667eda97506"
      unitRef="usd">-66443000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfNy0xNS0xLTEtMzY5MjE_c9671f5a-5a61-403a-9d17-fc45db310fb0"
      unitRef="usd">-66443000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i26a9072466f44863844deebde8ebd435_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfOC0xLTEtMS0zNjkyMQ_29dd4ed8-ed57-4585-a694-de64d93af2aa"
      unitRef="shares">61333074</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i26a9072466f44863844deebde8ebd435_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfOC0zLTEtMS0zNjkyMQ_859de3d7-13df-450d-880c-90be922daf26"
      unitRef="usd">613000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iba667f5b561d48d8a13c95cd18dd77d0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfOC05LTEtMS0zNjkyMQ_b925f17c-9a50-45fb-b284-d1834a58535b"
      unitRef="usd">1218263000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0cd82a548e734c0b80d9b7adbea03f44_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfOC0xMS0xLTEtMzY5MjE_1eb30a3d-e949-4d88-9f57-0649c20d0a13"
      unitRef="usd">-1040379000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i13caa53ffc1749ee85d3f04baf65b8e2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfOC0xMy0xLTEtMzY5MjE_eefc2b63-8596-44b3-a680-595f34cf7c13"
      unitRef="usd">-283000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOmNkYmM4MGEzZDM4ZjQ3YTZhMjlkNTE4ZTUyZjYwNjU5L3RhYmxlcmFuZ2U6Y2RiYzgwYTNkMzhmNDdhNmEyOWQ1MThlNTJmNjA2NTlfOC0xNS0xLTEtMzY5MjE_35d69b24-2419-42fb-b4ab-2e96c0f33b13"
      unitRef="usd">178214000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i12a5fd8f1ac64b25a36c35f490310693_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfMi0xLTEtMS0zNjkyMQ_8900e5cb-9818-4570-98a2-2bbecb7cbd5a"
      unitRef="shares">56244771</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i12a5fd8f1ac64b25a36c35f490310693_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfMi0zLTEtMS0zNjkyMQ_ae95475a-2d1e-4f90-9824-b11b7b8dd377"
      unitRef="usd">562000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i514431b860214fa08d26900f9bc8809f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfMi05LTEtMS0zNjkyMQ_693489b0-b7e1-47b9-9c3e-f1dfcca88de7"
      unitRef="usd">1067150000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3c1fe4be954c4a76a3462acae2e52d25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfMi0xMS0xLTEtMzY5MjE_8018c083-1a71-4940-8075-3ffff7629a92"
      unitRef="usd">-771821000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1fb34feb7d82479fa90e51ee903d7fc5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfMi0xMy0xLTEtMzY5MjE_895c2176-c4a6-4000-ae16-fe6fe55fe656"
      unitRef="usd">-7000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i61850671ea5c46908f41ccc8bad84475_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfMi0xNS0xLTEtMzY5MjE_06078917-7646-44d5-94ae-443c6aa29d28"
      unitRef="usd">295884000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i765ca9da243a400f9b9eda52bf592847_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfMy05LTEtMS0zNjkyMQ_234dc913-9060-4730-b078-b887fc3e1974"
      unitRef="usd">5243000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfMy0xNS0xLTEtMzY5MjE_8a5c70f1-6c8a-4890-ab94-7988f95798bc"
      unitRef="usd">5243000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i9d29335a8b4d442d847dc74d97919490_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNC0xLTEtMS0zNjkyMQ_2ff67551-65b5-40f1-ac07-6b6feed4510a"
      unitRef="shares">3622186</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9d29335a8b4d442d847dc74d97919490_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNC0zLTEtMS0zNjkyMQ_14ea17d4-6c10-4c35-aaa2-d8f0ae6b6520"
      unitRef="usd">36000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i765ca9da243a400f9b9eda52bf592847_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNC05LTEtMS0zNjkyMQ_ddf23747-bbde-4079-9d17-baf82115decb"
      unitRef="usd">98164000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNC0xNS0xLTEtMzY5MjE_5e366129-15eb-4e5d-91b9-b01bcca09a0d"
      unitRef="usd">98200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="i9d29335a8b4d442d847dc74d97919490_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNS0xLTEtMS0zNjkyMQ_e40c3895-a6dd-44f8-8737-f2b4087e0d8d"
      unitRef="shares">144249</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i9d29335a8b4d442d847dc74d97919490_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNS0zLTEtMS0zNjkyMQ_eb8a9deb-9f27-4d29-a4b5-943799286cec"
      unitRef="usd">2000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i765ca9da243a400f9b9eda52bf592847_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNS05LTEtMS0zNjkyMQ_851de4ff-d4b8-4cba-ad0c-75f1f83a058b"
      unitRef="usd">2456000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNS0xNS0xLTEtMzY5MjE_0b23e886-3f00-458a-8344-3bc97b5c2655"
      unitRef="usd">2458000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i7b13a8a2d938497f94da21f2db99b34d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNi0xMy0xLTEtNDExOTE_0405f719-b14e-4a19-a9e3-8fcb4d42de6b"
      unitRef="usd">18000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNi0xNS0xLTEtMzY5MjE_b6c61a78-443e-40fc-9389-529e6f8fd2e7"
      unitRef="usd">18000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="i30760bd2ed9f4522bde9a72f4d193433_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNy0xMS0xLTEtMzc4ODQ_5e073c20-2a3a-459a-9baf-6f40aab74471"
      unitRef="usd">-51272000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNy0xNS0xLTEtMzc4ODQ_0fe6fbc9-933f-4192-8e76-173ccdf2f7c2"
      unitRef="usd">-51272000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i39336f55686d443a9f9bb2e7f5368a75_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNy0xLTEtMS0zNjkyMQ_98735b54-053f-440a-ae56-e47402efd8c2"
      unitRef="shares">60011206</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i39336f55686d443a9f9bb2e7f5368a75_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNy0zLTEtMS0zNjkyMQ_7b42cda1-fc44-4dc3-87b2-af23550b9b75"
      unitRef="usd">600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5672f6e735064f58bfdfcc331c3ac673_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNy05LTEtMS0zNjkyMQ_6b965364-a104-48e3-bbdd-8624770c0164"
      unitRef="usd">1173013000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7646821245c2453e910c16b5b8ae12a4_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNy0xMS0xLTEtMzY5MjE_e1021602-775d-4236-b11a-124826ebc255"
      unitRef="usd">-823093000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia2c7a9bb638f4f09a965e4cc3541bc2b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNy0xMy0xLTEtMzY5MjE_31f1bb1b-bf20-40f5-b173-5d0c9aa2a2f7"
      unitRef="usd">11000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib5da4e28ca474a05a3dd215f637ca9a6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yNS9mcmFnOjE1YTcyMmZkYjlmNjRmZDRhZmRhNTk4N2E4ZDNkMTQyL3RhYmxlOjFjYzc0MWRlMDUyYjQ2ODA5NWUyYjEwYjJmNmFjMWYwL3RhYmxlcmFuZ2U6MWNjNzQxZGUwNTJiNDY4MDk1ZTJiMTBiMmY2YWMxZjBfNy0xNS0xLTEtMzY5MjE_e209aa8f-6ec6-449f-b39d-43aa2796af3c"
      unitRef="usd">350531000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMy0xLTEtMS0zNjkyMQ_fab4e09e-d0a7-4d86-bc71-65b41d5f681c"
      unitRef="usd">-66443000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMy0zLTEtMS0zNjkyMQ_868dfaea-6674-48a7-9e67-ff1a7d35310e"
      unitRef="usd">-51272000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfNS0xLTEtMS0zNjkyMQ_d83cc3a5-b878-451d-b2ec-61b6add9b324"
      unitRef="usd">2913000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfNS0zLTEtMS0zNjkyMQ_938b0d93-012c-4497-8d96-66cbd5ce8aa1"
      unitRef="usd">2729000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfNi0xLTEtMS0zNjkyMQ_36d458ec-8570-45c4-a302-6dc6d06c9db9"
      unitRef="usd">-334000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfNi0zLTEtMS0zNjkyMQ_4e82b425-e17e-49c7-a812-5a899c5d9ea5"
      unitRef="usd">-367000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfNy0xLTEtMS0zNjkyMQ_9a0b5857-ac75-467b-b822-f2f7cedc50c1"
      unitRef="usd">5274000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfNy0zLTEtMS0zNjkyMQ_e70f6c0d-a5a0-4e22-af4c-6f8fe8a9637a"
      unitRef="usd">5286000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTAtMS0xLTEtMzY5MjE_4b51c290-63da-4aa4-872d-ef3b7c40e006"
      unitRef="usd">4520000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTAtMy0xLTEtMzY5MjE_0d982ac2-114e-421f-9e64-e8315eb09862"
      unitRef="usd">-15934000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTEtMS0xLTEtMzY5MjE_f3b6f9a2-08a2-4727-a5a0-d403673f0048"
      unitRef="usd">210000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTEtMy0xLTEtMzY5MjE_e9af757e-ecf2-4fdc-b231-47b7fa502a84"
      unitRef="usd">6172000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTItMS0xLTEtMzY5MjE_f1cf9146-ad5f-40b6-94f3-83199654e0e4"
      unitRef="usd">-6457000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTItMy0xLTEtMzY5MjE_3675fe46-d658-487b-b2de-dc473d6109df"
      unitRef="usd">1239000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTMtMS0xLTEtMzY5MjE_8c9117b3-f9a6-40f1-8404-ddcd89860fb1"
      unitRef="usd">-801000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTMtMy0xLTEtMzY5MjE_4aa547fb-d19b-4a7b-96cd-cdcc6931bcd5"
      unitRef="usd">-3673000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTQtMS0xLTEtMzY5MjE_60b2698c-8553-4233-8041-efe1327d401b"
      unitRef="usd">-11920000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTQtMy0xLTEtMzY5MjE_649fd75e-2cc7-42ce-ad7f-6793e997a425"
      unitRef="usd">1829000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTUtMS0xLTEtMzY5MjE_a17b2569-dc3b-49dc-a7fe-d1a6cad5a2c2"
      unitRef="usd">-543000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTUtMy0xLTEtMzY5MjE_b375df4f-67ff-4d84-bbec-404146ca0eeb"
      unitRef="usd">855000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTYtMS0xLTEtMzY5MjE_adcd7cca-2e62-4d48-90bf-95fee9037be1"
      unitRef="usd">-1119000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTYtMy0xLTEtMzY5MjE_0355db91-7b73-41c5-b4bf-ff5698503c12"
      unitRef="usd">-683000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTctMS0xLTEtMzY5MjE_514c924d-521a-4075-9197-b1e814b0c6b1"
      unitRef="usd">11280000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTctMy0xLTEtMzY5MjE_216a019b-42fb-4c00-b680-03b4603d3bd8"
      unitRef="usd">-601000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTgtMS0xLTEtMzY5MjE_56fdaf43-db7a-41b2-81b6-7a5445680b23"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTgtMy0xLTEtMzY5MjE_172ee86f-7673-4101-89db-95c963cb8d81"
      unitRef="usd">258000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTktMS0xLTEtMzY5MjE_beba9931-29a3-4c0f-9f69-a401e103feda"
      unitRef="usd">-57696000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMTktMy0xLTEtMzY5MjE_4ba6e3a8-8635-44e8-b17e-63d65a51b7b6"
      unitRef="usd">-29036000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMjEtMS0xLTEtMzY5MjE_74fbb39c-5b58-4295-9561-b006330933bc"
      unitRef="usd">54077000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMjEtMy0xLTEtMzY5MjE_cc9502de-5b8c-42a5-a92d-0502b448a4ee"
      unitRef="usd">93881000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMjItMS0xLTEtMzY5MjE_97c71f61-4003-47e2-bca6-7f1f7e7cef92"
      unitRef="usd">37010000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMjItMy0xLTEtMzY5MjE_d65bbd6c-28b5-481e-821d-083c330b73bf"
      unitRef="usd">60250000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMjMtMS0xLTEtMzY5MjE_3e8a8918-aa43-4f7d-be14-2e086396ef9d"
      unitRef="usd">1415000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMjMtMy0xLTEtMzY5MjE_260ff8f1-e275-4f61-9f3e-c15496292f9f"
      unitRef="usd">626000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMjQtMS0xLTEtMzY5MjE_759eecfb-e720-47a2-8433-65b5e72cf704"
      unitRef="usd">-18482000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMjQtMy0xLTEtMzY5MjE_ca9538b5-2950-4386-82e4-1e501288dd2d"
      unitRef="usd">-34257000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMjYtMS0xLTEtMzY5MjE_6194a695-9649-4898-bef4-1f032e618415"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMjYtMy0xLTEtMzY5MjE_203a448e-b918-4659-8b52-311556eb7c31"
      unitRef="usd">98200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMjctMS0xLTEtMzY5MjE_49f983f6-fa69-432e-adab-c92b0c1edfbf"
      unitRef="usd">37000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMjctMy0xLTEtMzY5MjE_bc958e4a-4f46-488b-b272-b61e055fbcbd"
      unitRef="usd">2458000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMjktMS0xLTEtMzY5MjE_4c6619c1-9e5c-48f8-8884-278da34c68c6"
      unitRef="usd">37000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMjktMy0xLTEtMzY5MjE_5ff90320-1f65-4288-b33f-e03d07ede920"
      unitRef="usd">100658000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMzAtMS0xLTEtMzY5MjE_137e9130-d9af-4903-aaba-7d9e4d5e56a2"
      unitRef="usd">-76141000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMzAtMy0xLTEtMzY5MjE_1636368d-c238-478a-a441-c17751518b92"
      unitRef="usd">37365000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMzEtMS0xLTEtMzY5MjE_c9bad031-bfce-4d76-9dae-adc94cde39d3"
      unitRef="usd">123469000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i61850671ea5c46908f41ccc8bad84475_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMzEtMy0xLTEtMzY5MjE_4a532c95-15d4-4156-a4d5-9b63851347bf"
      unitRef="usd">181131000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMzItMS0xLTEtMzY5MjE_a0b12490-8275-4bc6-9259-5d20aeb47e2e"
      unitRef="usd">47328000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib5da4e28ca474a05a3dd215f637ca9a6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMzItMy0xLTEtMzY5MjE_07bd7e11-9dba-4669-a1ad-d9b58e297fd6"
      unitRef="usd">218496000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMzUtMS0xLTEtMzY5MjE_d28fd493-a8a4-485c-9eb2-68eb5565b211"
      unitRef="usd">151000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8yOC9mcmFnOjhmZTAzZTY3NzdlMTQyMDhiMDUzMzcyMzBlM2ZkNjYwL3RhYmxlOmY0YzE1ODVlMDdlOTQyODM5MjAwNjIzNzQyZDI1ODFhL3RhYmxlcmFuZ2U6ZjRjMTU4NWUwN2U5NDI4MzkyMDA2MjM3NDJkMjU4MWFfMzUtMy0xLTEtMzY5MjE_5eb521ee-fe09-4f33-94f2-22f2c4cee9b1"
      unitRef="usd">486000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8zNC9mcmFnOjQwZTVmNzkzNDQ1NjRlNzc4OWQ2ZDMxYTE4NzE4ZmQ2L3RleHRyZWdpb246NDBlNWY3OTM0NDU2NGU3Nzg5ZDZkMzFhMTg3MThmZDZfNTEyOQ_b4698dd6-4352-4f62-894b-9fc63cfb7e81">Nature of Operations&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of the business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The Company has a pipeline of product candidates being evaluated in clinical trials sponsored by MacroGenics or its collaborators.  These product candidates include multiple immuno-oncology programs, some of which were created primarily using the Company&#x2019;s proprietary, antibody-based technology platforms. The Company believes its product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.  In March 2021, the Company and its commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a biotechnology company, the Company has primarily funded its operations with proceeds from the sale of its common stock in equity offerings, revenue from its multiple collaboration agreements, and contracts and grants from the National Institute of Allergy and Infectious Diseases (NIAID).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management regularly reviews the Company&#x2019;s available liquidity relative to its operating budget and forecast to monitor the sufficiency of the Company&#x2019;s working capital.  Based on the Company&#x2019;s most recent cash flow forecast, the Company believes its current resources are sufficient to fund its operating plans for a minimum of twelve months from the date that this Quarterly Report on Form 10-Q was filed. The Company plans to meet its future operating requirements by generating revenue from current and future strategic collaborations or other arrangements, and product sales.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support its product development activities.  If the Company is unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate one or more of its product research and development programs or clinical studies, reduce other operating expenses, and/or downsize its organization.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Similar to the other risk factors pertinent to the Company's business, the COVID-19 pandemic and geopolitical tensions, including the ongoing military conflict between Russia and Ukraine and the related sanctions imposed against Russia, might unfavorably impact the Company's ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to the COVID-19 pandemic and geopolitical tensions, the Company will continue to evaluate the nature and extent of the impact of these uncertainties on its business and financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2021 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 24, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8zNC9mcmFnOjQwZTVmNzkzNDQ1NjRlNzc4OWQ2ZDMxYTE4NzE4ZmQ2L3RleHRyZWdpb246NDBlNWY3OTM0NDU2NGU3Nzg5ZDZkMzFhMTg3MThmZDZfNTEzMA_f1d778b3-6d2c-4366-8933-20542e6f1750">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2021 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 24, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8zNy9mcmFnOmZlNTM1MjFjYWEzMjRjMjJiZWIwNjJjZjY3NzBjOTk4L3RleHRyZWdpb246ZmU1MzUyMWNhYTMyNGMyMmJlYjA2MmNmNjc3MGM5OThfOTI3NA_23a113a2-3785-43ae-8be4-ddbaddd7e82b">Summary of Significant Accounting Policies&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, there have been no material changes to the significant accounting policies previously disclosed in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements that were issued or became effective since the issuance of the Company&#x2019;s 2021 Annual Report on Form 10-K that had, or are expected to have, a material impact on its consolidated financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF8zNy9mcmFnOmZlNTM1MjFjYWEzMjRjMjJiZWIwNjJjZjY3NzBjOTk4L3RleHRyZWdpb246ZmU1MzUyMWNhYTMyNGMyMmJlYjA2MmNmNjc3MGM5OThfOTI3Mw_2aeab123-680d-4e1d-8013-84ba3715858a">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements that were issued or became effective since the issuance of the Company&#x2019;s 2021 Annual Report on Form 10-K that had, or are expected to have, a material impact on its consolidated financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RleHRyZWdpb246YmU4YzFlNzExYzYxNGRiNGJlZjIzOTdkYmRkMzJlNjBfMzE2NQ_35b6fbd3-4ae9-4bd4-b594-890506eaa72a">Fair Value of Financial Instruments&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between levels during the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:15pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:15pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Total assets measured at fair value at March&#160;31, 2022 includes approximately $6.3 million reported in cash and cash equivalents on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Total assets measured at fair value at December&#160;31, 2021 includes approximately $23.2 million reported in cash and cash equivalents on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RleHRyZWdpb246YmU4YzFlNzExYzYxNGRiNGJlZjIzOTdkYmRkMzJlNjBfMzE2Ng_cc92de24-681b-4b33-84aa-6687548ba173">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/span&gt;&lt;/div&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. There were no transfers between levels during the periods presented.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RleHRyZWdpb246YmU4YzFlNzExYzYxNGRiNGJlZjIzOTdkYmRkMzJlNjBfMzE2Nw_025c7a06-f1cf-4015-8ce1-ce76615209d0">&lt;div style="margin-bottom:15pt;margin-top:15pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:15pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Total assets measured at fair value at March&#160;31, 2022 includes approximately $6.3 million reported in cash and cash equivalents on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Total assets measured at fair value at December&#160;31, 2021 includes approximately $23.2 million reported in cash and cash equivalents on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id95d122f09ba4d2abee62f84fae879ac_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfMy0xLTEtMS0zNjkyMQ_81fbbafc-1091-43a6-8769-018dd88b73a2"
      unitRef="usd">352000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i87b87bbcaef644248cdf6ccd14a1dceb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfMy0zLTEtMS0zNjkyMQ_e1719ba4-3d80-4521-929f-d39ea7960918"
      unitRef="usd">352000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1e70e3df18ab41f78be816bc2ec224ad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfMy01LTEtMS0zNjkyMQ_bebe9b81-eed3-4c47-b06c-e8047fcb78c6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i38dae976f1074d01ade570e63f5432e2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfNC0xLTEtMS0zNjkyMQ_0d6a70fa-7349-4299-8f35-a36f1d14c8a1"
      unitRef="usd">127956000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i11d98d66595a4e23a7412ce37ac28a09_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfNC0zLTEtMS0zNjkyMQ_8d9f4fb4-c335-48bf-bd18-313d6a3ca871"
      unitRef="usd">127956000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic38615f63b384c709ab9bb249a259668_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfNC01LTEtMS0zNjkyMQ_e91025dd-91ff-41e3-ad83-bd2279b4ef12"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if1679ec57ed840b4ba3621b23001f423_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfNS0xLTEtMS0zNjkyMQ_e1166ba8-f180-48fb-9cd9-1897004d1868"
      unitRef="usd">7700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i134315721b8b4bc8b6ad9a64c9dca944_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfNS0zLTEtMS0zNjkyMQ_c2255212-8a14-499f-bb1e-19ae8b24db21"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i01b2c1f07c9a491abfb73f67bfdfee33_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfNS01LTEtMS0zNjkyMQ_cdddce70-6fe8-4e92-b5cc-342e75b4abac"
      unitRef="usd">7700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i84a8b67fd745449695ca7b9bb8d32b55_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfNi0xLTEtMS0zNjkyMQ_710bc205-4387-495d-af8c-1683b8d80e11"
      unitRef="usd">6999000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4b8362beacc0443ebef61473a9dccbea_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfNi0zLTEtMS0zNjkyMQ_3ad99f4f-3673-49cc-9fd5-38222991b286"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iec177ca29fe3450a851669d85c7c44bc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfNi01LTEtMS0zNjkyMQ_81fb7ad0-207e-43b6-9b89-8a862ac2f9a1"
      unitRef="usd">6999000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iadf67bfafee04b0e8f19076f8b5ba241_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfOC0xLTEtMS0zNjkyMQ_39bf17b0-1282-43b5-8d38-4045661f6955"
      unitRef="usd">143007000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4c87ec43f73d49438e33596695e0f16a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfOC0zLTEtMS0zNjkyMQ_95642b6d-62d5-4e4b-bbd3-77a2f636ae68"
      unitRef="usd">128308000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6211e35b2594407c9f7301938b926647_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOjk1NDExMWYyYTYzZjRmOTFiMTEyNjg4Y2QzMjc2Yzc4L3RhYmxlcmFuZ2U6OTU0MTExZjJhNjNmNGY5MWIxMTI2ODhjZDMyNzZjNzhfOC01LTEtMS0zNjkyMQ_433bad67-53b6-4204-a0ca-0dd7215dcdc2"
      unitRef="usd">14699000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i74c05f3a658142a898bc4958d7248bad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfMy0xLTEtMS0zNjkyMQ_d14164b0-67e8-4c2f-8bcc-78bb0b934e68"
      unitRef="usd">17202000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibc78708aeb344bafbf36d06b7e3268c0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfMy0zLTEtMS0zNjkyMQ_9a57518b-3bea-4c56-b756-7b1174ccc51c"
      unitRef="usd">17202000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if85bdb5b035f43b884ce2ecf0893b353_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfMy01LTEtMS0zNjkyMQ_eff0f481-128b-403e-acc8-124766fa39fd"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2ad8e34e86da4770904f35743caf98ac_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfNC0xLTEtMS0zNjkyMQ_1a7f6c1c-2a0d-40b8-81ac-fea39acbd389"
      unitRef="usd">81132000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia4152da960bb40088ebf5bc56b742e61_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfNC0zLTEtMS0zNjkyMQ_59b8e11d-fe4d-408f-9b84-9fde1bb35e54"
      unitRef="usd">81132000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2ec75cded8dd44b088006c06d9e3b597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfNC01LTEtMS0zNjkyMQ_89d47500-b888-4141-999b-bf57cb6e71a8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id74359d02a6a4da78e3f2fc132eb4559_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfNS0xLTEtMS0zNjkyMQ_901f0420-7d01-4f3f-ab96-c62ff098d544"
      unitRef="usd">7734000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icdf424220c884f50be1e050499baaa2e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfNS0zLTEtMS0zNjkyMQ_5d5c8420-dd23-442a-9c07-322ac5f5eff5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if6db79bbb4d648b889a9b1cb12bcc873_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfNS01LTEtMS0zNjkyMQ_690b2d75-25fd-494d-9b2c-2f447e55d326"
      unitRef="usd">7734000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib90bb549405247818bd658fcfc5dbb02_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfNi0xLTEtMS0zNjkyMQ_1a78d421-c97a-4976-bfc1-8b2a28923bcf"
      unitRef="usd">37280000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id2a9ffd7eb2944f7a2b80b1417657841_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfNi0zLTEtMS0zNjkyMQ_d61e0a0d-2713-4fdc-820d-f9d7fcd8fd42"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icdf1d14d8fc0481c9792632139822db0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfNi01LTEtMS0zNjkyMQ_524bce04-9501-46b5-8ecd-4fa4034e4565"
      unitRef="usd">37280000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic793e546189e40c692e374b70b7656d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfOC0xLTEtMS0zNjkyMQ_d0cd6e9c-1e0e-467a-8866-86412f340220"
      unitRef="usd">143348000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib77cf447ac3c41209a584a715a1efc6e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfOC0zLTEtMS0zNjkyMQ_968d59b8-f67d-408b-873f-9d05658b36b5"
      unitRef="usd">98334000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib1670779e18c400db0676422bc94c22e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RhYmxlOmEzYWRjOGQ0YTBlNzQ4Mzk4OGRkM2E4ZmYyZTNkMTIyL3RhYmxlcmFuZ2U6YTNhZGM4ZDRhMGU3NDgzOTg4ZGQzYThmZjJlM2QxMjJfOC01LTEtMS0zNjkyMQ_32568477-3b0d-4f65-b3d5-d24d556805fe"
      unitRef="usd">45014000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iadf67bfafee04b0e8f19076f8b5ba241_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RleHRyZWdpb246YmU4YzFlNzExYzYxNGRiNGJlZjIzOTdkYmRkMzJlNjBfMjUwNA_b33fb832-041c-46b7-9147-0df755788f60"
      unitRef="usd">6300000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic793e546189e40c692e374b70b7656d3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80MC9mcmFnOmJlOGMxZTcxMWM2MTRkYjRiZWYyMzk3ZGJkZDMyZTYwL3RleHRyZWdpb246YmU4YzFlNzExYzYxNGRiNGJlZjIzOTdkYmRkMzJlNjBfMjY0OQ_f1a55d0e-87ee-4e33-bd26-70e5b6e0ed54"
      unitRef="usd">23200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RleHRyZWdpb246ZWVmYWRiYjY3MWU3NGJlNTgzNDBmYmRhMWI4ZDQzYzdfMTAyOQ_882918ae-fae5-43ac-82e2-b29583a16a8e">Marketable Securities&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company's marketable debt securities (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(282)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All available-for-sale marketable debt securities held as of March&#160;31, 2022 and December&#160;31, 2021 had contractual maturities of less than one year.  All of the Company's available-for-sale marketable debt securities in an unrealized loss position as of March&#160;31, 2022 and December&#160;31, 2021 were in a loss position for less than twelve months.&#160; Unrealized losses on &lt;/span&gt;&lt;/div&gt;available-for-sale debt securities as of March&#160;31, 2022 and December&#160;31, 2021 were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities.  Accordingly, no allowance for credit losses related to the Company's available-for-sale debt securities was recorded for any periods presented. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RleHRyZWdpb246ZWVmYWRiYjY3MWU3NGJlNTgzNDBmYmRhMWI4ZDQzYzdfMTAzMQ_8d17bc94-ca93-4ed6-976b-f0cba4a4da3a">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company's marketable debt securities (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(282)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4ce219c82bc1424b9f3d36c9e3956c15_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfMi0xLTEtMS0zNjkyMQ_e53e42ca-1f79-40de-9064-96dde38bac39"
      unitRef="usd">128231000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4ce219c82bc1424b9f3d36c9e3956c15_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfMi0zLTEtMS0zNjkyMQ_495ca726-f1e1-4d4e-a5ff-772c301464a1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4ce219c82bc1424b9f3d36c9e3956c15_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfMi01LTEtMS0zNjkyMQ_aeedbf50-a52a-42ba-8e75-fa38fe919099"
      unitRef="usd">274000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4ce219c82bc1424b9f3d36c9e3956c15_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfMi03LTEtMS0zNjkyMQ_41553352-2287-4f80-a485-043ad71649bf"
      unitRef="usd">127957000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib3b3f430d68b497f825e77b9e6f604da_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfMy0xLTEtMS0zNjkyMQ_ba909171-3cf9-41d4-946e-f343989f3bea"
      unitRef="usd">7705000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib3b3f430d68b497f825e77b9e6f604da_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfMy0zLTEtMS0zNjkyMQ_f54de1e0-697e-4145-9fe6-04c4ea1cbd97"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib3b3f430d68b497f825e77b9e6f604da_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfMy01LTEtMS0zNjkyMQ_5ef3d545-3328-46ee-8728-4d7ef6c22462"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib3b3f430d68b497f825e77b9e6f604da_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfMy03LTEtMS0zNjkyMQ_e5e959bd-015a-4445-8421-f2c8f1418082"
      unitRef="usd">7700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia1f6c9125c0b45aab207a0111b790111_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfNC0xLTEtMS0zNjkyMQ_897b4b0b-87d0-42f5-b5cc-ca7a15e8f052"
      unitRef="usd">1004000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia1f6c9125c0b45aab207a0111b790111_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfNC0zLTEtMS0zNjkyMQ_8656f156-6ea2-4876-a738-1a3bf7764140"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia1f6c9125c0b45aab207a0111b790111_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfNC01LTEtMS0zNjkyMQ_6d743b11-b1a6-4b2f-ad80-a9a6b4a76354"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia1f6c9125c0b45aab207a0111b790111_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfNC03LTEtMS0zNjkyMQ_a61bd5e3-351f-4a82-baee-d8ae5a3480aa"
      unitRef="usd">1001000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfNS0xLTEtMS0zNjkyMQ_a9dcff1a-51f2-4fed-a05d-48e3d201d983"
      unitRef="usd">136940000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfNS0zLTEtMS0zNjkyMQ_a74b2e06-3cbc-463a-91b8-d0be31ac50a3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfNS01LTEtMS0zNjkyMQ_3306f2ff-a77f-4894-b2c5-41e6396c3bc5"
      unitRef="usd">282000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOmJlY2FlZDVmZWYzNTRkMDY5NzY2YzYyN2Y0N2YzNmRmL3RhYmxlcmFuZ2U6YmVjYWVkNWZlZjM1NGQwNjk3NjZjNjI3ZjQ3ZjM2ZGZfNS03LTEtMS0zNjkyMQ_0c729747-5f0b-4b40-b233-ba975daebbd8"
      unitRef="usd">136658000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia7afc4d905b84b94add195a76efd0e03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfMi0xLTEtMS0zNjkyMQ_9b411349-125f-48fe-b807-621ffe7d7c24"
      unitRef="usd">81184000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia7afc4d905b84b94add195a76efd0e03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfMi0zLTEtMS0zNjkyMQ_7a464c71-1efb-4ffb-9372-174ecb551edf"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia7afc4d905b84b94add195a76efd0e03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfMi01LTEtMS0zNjkyMQ_7eaca07c-f117-4356-b836-1537c2946551"
      unitRef="usd">52000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia7afc4d905b84b94add195a76efd0e03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfMi03LTEtMS0zNjkyMQ_455130fb-d9f8-4223-80f9-dace6ae3389c"
      unitRef="usd">81132000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ied0c021681ab444cb45099fb32ff4b98_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfMy0xLTEtMS0zNjkyMQ_8e3fbc9d-0159-4c3b-a7d6-206fd196c8d9"
      unitRef="usd">7739000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ied0c021681ab444cb45099fb32ff4b98_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfMy0zLTEtMS0zNjkyMQ_6897f98c-e645-4596-8e49-92931cbfeeb7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ied0c021681ab444cb45099fb32ff4b98_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfMy01LTEtMS0zNjkyMQ_bd3cc693-cc32-42cf-8bae-29dd3e48e51c"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ied0c021681ab444cb45099fb32ff4b98_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfMy03LTEtMS0zNjkyMQ_b01f152a-1a77-4d49-a2fd-20fc9a235c81"
      unitRef="usd">7734000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i543d462b4fb941c3b7c489c116e8bf4f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfNC0xLTEtMS0zNjkyMQ_6c460eb5-46f7-495b-90ef-6b17881a45b5"
      unitRef="usd">31285000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i543d462b4fb941c3b7c489c116e8bf4f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfNC0zLTEtMS0zNjkyMQ_d216a948-e2d9-4bfa-a6a3-f40fd1aec0fd"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i543d462b4fb941c3b7c489c116e8bf4f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfNC01LTEtMS0zNjkyMQ_708ae6a4-d0cd-4ed0-8197-714643961872"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i543d462b4fb941c3b7c489c116e8bf4f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfNC03LTEtMS0zNjkyMQ_dd8d51d7-db2c-43d7-a431-eff94aac7d05"
      unitRef="usd">31281000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfNS0xLTEtMS0zNjkyMQ_4f8ad779-a514-4122-855c-0c91a28b9a4e"
      unitRef="usd">120208000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfNS0zLTEtMS0zNjkyMQ_8dd1343a-8f67-4c58-80ed-ec73a21f1853"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfNS01LTEtMS0zNjkyMQ_91753d43-1bb3-422b-96de-3234c8beae49"
      unitRef="usd">61000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RhYmxlOjg4ZDViMDIwNzZlMjQwNWFhMmYxNzgzNDFiOTlkYWVjL3RhYmxlcmFuZ2U6ODhkNWIwMjA3NmUyNDA1YWEyZjE3ODM0MWI5OWRhZWNfNS03LTEtMS0zNjkyMQ_fb9b798e-3c24-4982-b59d-d4b6e08a3430"
      unitRef="usd">120147000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RleHRyZWdpb246ZWVmYWRiYjY3MWU3NGJlNTgzNDBmYmRhMWI4ZDQzYzdfNjc2_a5592eb7-35c3-4dc2-a6d2-c1c75ec31551"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80My9mcmFnOmVlZmFkYmI2NzFlNzRiZTU4MzQwZmJkYTFiOGQ0M2M3L3RleHRyZWdpb246ZWVmYWRiYjY3MWU3NGJlNTgzNDBmYmRhMWI4ZDQzYzdfNjc2_c65dabef-596d-44ef-922d-b7a0df93dc21"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80Ni9mcmFnOjRlYTE4YWQyMmQ3NjQ2ODBhMTk3ODAzMzY3ZmNjZDIwL3RleHRyZWdpb246NGVhMThhZDIyZDc2NDY4MGExOTc4MDMzNjdmY2NkMjBfNjA5_b168b2ea-22d2-48d8-b59b-0dd71cee496b">Inventory, Net&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's net inventory (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Prior to U.S. Food and Drug Administration (FDA) approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA. The inventory balance as of March&#160;31, 2022 and December&#160;31, 2021 is net of a reserve of $2.0 million for unsaleable inventory.</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80Ni9mcmFnOjRlYTE4YWQyMmQ3NjQ2ODBhMTk3ODAzMzY3ZmNjZDIwL3RleHRyZWdpb246NGVhMThhZDIyZDc2NDY4MGExOTc4MDMzNjdmY2NkMjBfNjA4_7ed6bca3-5f72-4ce7-bb6b-b1526e72a24c">&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's net inventory (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryWorkInProcess
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80Ni9mcmFnOjRlYTE4YWQyMmQ3NjQ2ODBhMTk3ODAzMzY3ZmNjZDIwL3RhYmxlOjVlYTViZjE1ZjJiZDQyMjU4NzI3ODkyZGM0MTM3YmQwL3RhYmxlcmFuZ2U6NWVhNWJmMTVmMmJkNDIyNTg3Mjc4OTJkYzQxMzdiZDBfMy0xLTEtMS0zNjkyMQ_81e140b4-a398-4af4-a8d8-fffea26d0a45"
      unitRef="usd">3724000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80Ni9mcmFnOjRlYTE4YWQyMmQ3NjQ2ODBhMTk3ODAzMzY3ZmNjZDIwL3RhYmxlOjVlYTViZjE1ZjJiZDQyMjU4NzI3ODkyZGM0MTM3YmQwL3RhYmxlcmFuZ2U6NWVhNWJmMTVmMmJkNDIyNTg3Mjc4OTJkYzQxMzdiZDBfMy0zLTEtMS0zNjkyMQ_79eb708b-1c3a-45de-9c4f-c684289dde4c"
      unitRef="usd">3929000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80Ni9mcmFnOjRlYTE4YWQyMmQ3NjQ2ODBhMTk3ODAzMzY3ZmNjZDIwL3RhYmxlOjVlYTViZjE1ZjJiZDQyMjU4NzI3ODkyZGM0MTM3YmQwL3RhYmxlcmFuZ2U6NWVhNWJmMTVmMmJkNDIyNTg3Mjc4OTJkYzQxMzdiZDBfNC0xLTEtMS0zNjkyMQ_b7707c24-f4c6-4fd6-9b85-f2696745275f"
      unitRef="usd">874000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80Ni9mcmFnOjRlYTE4YWQyMmQ3NjQ2ODBhMTk3ODAzMzY3ZmNjZDIwL3RhYmxlOjVlYTViZjE1ZjJiZDQyMjU4NzI3ODkyZGM0MTM3YmQwL3RhYmxlcmFuZ2U6NWVhNWJmMTVmMmJkNDIyNTg3Mjc4OTJkYzQxMzdiZDBfNC0zLTEtMS0zNjkyMQ_42c60680-fe70-48c0-9cf5-8be104fe4f37"
      unitRef="usd">459000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80Ni9mcmFnOjRlYTE4YWQyMmQ3NjQ2ODBhMTk3ODAzMzY3ZmNjZDIwL3RhYmxlOjVlYTViZjE1ZjJiZDQyMjU4NzI3ODkyZGM0MTM3YmQwL3RhYmxlcmFuZ2U6NWVhNWJmMTVmMmJkNDIyNTg3Mjc4OTJkYzQxMzdiZDBfNS0xLTEtMS0zNjkyMQ_c1b51d8e-96fb-48d4-affa-585b3405defb"
      unitRef="usd">4598000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80Ni9mcmFnOjRlYTE4YWQyMmQ3NjQ2ODBhMTk3ODAzMzY3ZmNjZDIwL3RhYmxlOjVlYTViZjE1ZjJiZDQyMjU4NzI3ODkyZGM0MTM3YmQwL3RhYmxlcmFuZ2U6NWVhNWJmMTVmMmJkNDIyNTg3Mjc4OTJkYzQxMzdiZDBfNS0zLTEtMS0zNjkyMQ_2912b86d-2328-4c01-a0fd-ddabf5792348"
      unitRef="usd">4388000</us-gaap:InventoryNet>
    <us-gaap:InventoryValuationReserves
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80Ni9mcmFnOjRlYTE4YWQyMmQ3NjQ2ODBhMTk3ODAzMzY3ZmNjZDIwL3RleHRyZWdpb246NGVhMThhZDIyZDc2NDY4MGExOTc4MDMzNjdmY2NkMjBfMTA5OTUxMTYzMDE2MQ_3cf3f404-66cb-452d-aa9b-5072aa1e40a9"
      unitRef="usd">2000000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80Ni9mcmFnOjRlYTE4YWQyMmQ3NjQ2ODBhMTk3ODAzMzY3ZmNjZDIwL3RleHRyZWdpb246NGVhMThhZDIyZDc2NDY4MGExOTc4MDMzNjdmY2NkMjBfMTA5OTUxMTYzMDE2MQ_5a2e173f-debd-46ab-b0b0-b31fd7975c99"
      unitRef="usd">2000000</us-gaap:InventoryValuationReserves>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80OS9mcmFnOjI1MmZiMWNiODMwNzRkMDY5MjIyYzI3Yjc1ZGU0NmU1L3RleHRyZWdpb246MjUyZmIxY2I4MzA3NGQwNjkyMjJjMjdiNzVkZTQ2ZTVfMTgxNA_745da55b-ccf1-4874-b277-c626aa7cd45e">Stockholders' Equity&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, the Company entered into a sales agreement (Sales Agreement) with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $100.0 million through an &#x201c;at the market offering&#x201d; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. The shares that were sold under the Sales Agreement were issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on November 4, 2020.  During the three months ended March 31, 2021, the Company sold 3,622,186 shares of common stock at a weighted average price per share of $27.60, resulting in net proceeds of approximately $98.2 million, net of underwriting discounts and commissions and other offering expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Company entered into Amendment No. 1 to the Sales Agreement which increases the amount of the Company&#x2019;s common stock that can be sold by the Company through its agent under the ATM Offering, from an aggregate offering price of up to $100.0&#160;million to an aggregate offering price of up to $300.0&#160;million.  The Company has not sold any shares of common stock related to Amendment No. 1 to the Sales Agreement as of March&#160;31, 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the consideration for the rights granted to Zai Lab US LLC under the collaboration and license agreement described more fully in Note 7, Revenue, the Company and Zai Lab US LLC entered into a separate stock purchase agreement (Stock Purchase Agreement) in June 2021.  Under this Stock Purchase Agreement, Zai Lab US LLC paid the Company approximately $30.0 million to purchase 958,467 newly issued shares of the Company's common stock, par value $0.01, at a fixed price of $31.30 which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <mgnx:CommonStockMaximumAmountAvailableForIssuance
      contextRef="iee6c657f52bd4f23bd0bf6abce303d78_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80OS9mcmFnOjI1MmZiMWNiODMwNzRkMDY5MjIyYzI3Yjc1ZGU0NmU1L3RleHRyZWdpb246MjUyZmIxY2I4MzA3NGQwNjkyMjJjMjdiNzVkZTQ2ZTVfMjE4_ed2161e6-f7e4-4805-9ef1-dac4f700b205"
      unitRef="usd">100000000</mgnx:CommonStockMaximumAmountAvailableForIssuance>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i46cfcfe1a61845d48ac67642abb7f911_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80OS9mcmFnOjI1MmZiMWNiODMwNzRkMDY5MjIyYzI3Yjc1ZGU0NmU1L3RleHRyZWdpb246MjUyZmIxY2I4MzA3NGQwNjkyMjJjMjdiNzVkZTQ2ZTVfNTk0_d065b0bb-1be0-4764-b557-62e167966e05"
      unitRef="shares">3622186</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="if06926cd9b2147e88810d44763baa9ce_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80OS9mcmFnOjI1MmZiMWNiODMwNzRkMDY5MjIyYzI3Yjc1ZGU0NmU1L3RleHRyZWdpb246MjUyZmIxY2I4MzA3NGQwNjkyMjJjMjdiNzVkZTQ2ZTVfNjYx_bd6c58dc-63ed-4736-84b6-b4c5c45fde2a"
      unitRef="usdPerShare">27.6</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i46cfcfe1a61845d48ac67642abb7f911_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80OS9mcmFnOjI1MmZiMWNiODMwNzRkMDY5MjIyYzI3Yjc1ZGU0NmU1L3RleHRyZWdpb246MjUyZmIxY2I4MzA3NGQwNjkyMjJjMjdiNzVkZTQ2ZTVfNzA4_8e74dab5-de3b-4a65-8760-bd40eb8bc54e"
      unitRef="usd">98200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <mgnx:CommonStockMaximumAmountAvailableForIssuance
      contextRef="iee6c657f52bd4f23bd0bf6abce303d78_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80OS9mcmFnOjI1MmZiMWNiODMwNzRkMDY5MjIyYzI3Yjc1ZGU0NmU1L3RleHRyZWdpb246MjUyZmIxY2I4MzA3NGQwNjkyMjJjMjdiNzVkZTQ2ZTVfMTA0MA_f616cf45-6bc4-402b-b663-73b0f15da22e"
      unitRef="usd">100000000</mgnx:CommonStockMaximumAmountAvailableForIssuance>
    <mgnx:CommonStockMaximumAmountAvailableForIssuanceIncrease
      contextRef="i7d0c61251f464c44a32c131af591406f_D20210401-20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80OS9mcmFnOjI1MmZiMWNiODMwNzRkMDY5MjIyYzI3Yjc1ZGU0NmU1L3RleHRyZWdpb246MjUyZmIxY2I4MzA3NGQwNjkyMjJjMjdiNzVkZTQ2ZTVfMTA4Mw_9b461833-af04-4796-bda4-036174d94e83"
      unitRef="usd">300000000</mgnx:CommonStockMaximumAmountAvailableForIssuanceIncrease>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ie0aca00030b84821a220040e1894b4ed_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80OS9mcmFnOjI1MmZiMWNiODMwNzRkMDY5MjIyYzI3Yjc1ZGU0NmU1L3RleHRyZWdpb246MjUyZmIxY2I4MzA3NGQwNjkyMjJjMjdiNzVkZTQ2ZTVfMTU3Mg_13da2f7f-c8b7-4eee-86ab-7a8bab3042c3"
      unitRef="usd">30000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i53817096bacf40229bf71a7348ab1def_D20210601-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80OS9mcmFnOjI1MmZiMWNiODMwNzRkMDY5MjIyYzI3Yjc1ZGU0NmU1L3RleHRyZWdpb246MjUyZmIxY2I4MzA3NGQwNjkyMjJjMjdiNzVkZTQ2ZTVfMTU4Nw_17dc35f7-957d-49b1-a846-6d9dd4613fa7"
      unitRef="shares">958467</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80OS9mcmFnOjI1MmZiMWNiODMwNzRkMDY5MjIyYzI3Yjc1ZGU0NmU1L3RleHRyZWdpb246MjUyZmIxY2I4MzA3NGQwNjkyMjJjMjdiNzVkZTQ2ZTVfMTY1MQ_56024c2b-b020-47c8-86c1-8a9eb7f763e1"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ib5527acf5cf248e5ac690d183c18549f_I20210615"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80OS9mcmFnOjI1MmZiMWNiODMwNzRkMDY5MjIyYzI3Yjc1ZGU0NmU1L3RleHRyZWdpb246MjUyZmIxY2I4MzA3NGQwNjkyMjJjMjdiNzVkZTQ2ZTVfMTY3NQ_76bcf053-9a6a-49e6-af12-6b505178d5fb"
      unitRef="usdPerShare">31.3</us-gaap:SaleOfStockPricePerShare>
    <mgnx:PremiumReceivedOnStockPurchase
      contextRef="i1b909bf9e4ae42208ed813d9676eadb7_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF80OS9mcmFnOjI1MmZiMWNiODMwNzRkMDY5MjIyYzI3Yjc1ZGU0NmU1L3RleHRyZWdpb246MjUyZmIxY2I4MzA3NGQwNjkyMjJjMjdiNzVkZTQ2ZTVfMTcwOQ_380086a2-6639-44dc-b429-2fe69d0ddcdc"
      unitRef="usd">10400000</mgnx:PremiumReceivedOnStockPurchase>
    <mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMzA3Mjg_11b979ca-833d-43c4-b994-9428c0b9d01c">Revenue &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaborative and Other Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incyte Corporation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Incyte License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for retifanlimab, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab.  Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $150.0 million in 2017. In July 2021, Incyte announced that the FDA had issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for retifanlimab as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal. Incyte&#x2019;s announcement indicated that the FDA determined that additional data are needed to demonstrate the clinical benefit of retifanlimab for the submitted indication, and that Incyte was reviewing the CRL &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and would discuss next steps with the FDA. Incyte subsequently withdrew its European application for marketing authorization of retifanlimab for the treatment of squamous carcinoma of the anal canal. Incyte has stated it is pursuing development of retifanlimab in potentially registration-enabling studies beyond squamous cell carcinoma of the anal canal, including in patients with MSI-high endometrial cancer, Merkel cell carcinoma and non-small cell lung cancer.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Incyte License Agreement, Incyte will lead global development of retifanlimab.  Assuming successful development and commercialization by Incyte, the Company could receive up to approximately $420.0 million in development and regulatory milestones and up to $330.0 million in commercial milestones. From the inception of the Incyte License Agreement through &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company has recognized $70.0 million in development milestones under the Incyte License Agreement.  If retifanlimab is approved and commercialized, the Company would be eligible to receive tiered royalties of 15% to 24% on any global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Incyte License Agreement under the provisions of Accounting Standards Codification Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 606) and identified the following two performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period.  The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience.  The Company determined that the transaction price of the Incyte License Agreement at inception was $154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed.  The transaction price was allocated to each performance obligation based on their relative standalone selling price.  The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The standalone selling price for the agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. From 2018 through &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, it became probable that a significant reversal of cumulative revenue would not occur for development milestones totaling $70.0 million related to &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;clinical and regulatory activities related to the further advancement of retifanlimab, including Incyte&#x2019;s initiation of a Phase 3 clinical trial&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  Therefore, the associated consideration was added to the estimated transaction price and was recognized as revenue&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized the $150.0 million allocated to the license when it satisfied its performance obligation and transferred the license to Incyte in 2017. The $4.0 million allocated to the clinical activities was recognized ratably as services were performed during 2017 and 2018. No revenue was recognized under the Incyte License Agreement during the three months ended March 31, 2022.  During the three months ended March 31, 2021, $10.0 million in milestone revenue was recognized under the Incyte License Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Incyte Clinical Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company entered into an agreement with Incyte, under which the Company is to perform development and manufacturing services for Incyte&#x2019;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement).  The Company evaluated the Incyte Clinical Supply Agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab.  The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services.  During the three months ended March 31, 2022 and 2021, the Company recognized revenue of $0.3 million and $0.1 million, respectively, for services performed under the Incyte Clinical Supply Agreement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Incyte Commercial Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company entered into an agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#x2019;s obligation to pay royalties under the Incyte License Agreement.  The Company evaluated the Incyte Commercial Supply Agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the commercial supply of retifanlimab. The transaction price is based on a fixed price per batch of bulk drug substance to be manufactured and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor costs incurred) related to the manufacturing services.  During the three months ended March 31, 2022 , the Company recognized de minimis revenue and during the three months ended March 31, 2021 the Company recognized $3.1&#160;million for services performed under the Incyte Commercial Supply Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Zai Lab Limited&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2018 Zai Lab Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab)  under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#x2019;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab, a bispecific DART&#xae; molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development of these molecules in its territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2018 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0 million ($22.5 million after netting value-added tax withholdings of $2.5 million). Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, the Company could receive up to $140.0 million in development and regulatory milestones, of which the Company has earned $9.0 million through March&#160;31, 2022. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-teens to 20% for net sales of margetuximab in Zai Lab&#x2019;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#x2019;s territory and 10% for net sales of the TRIDENT molecule in Zai Lab&#x2019;s territory, which may be subject to adjustment in specified circumstances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the 2018 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and tebotelimab:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#x2019;s territory and (ii) certain research and development activities. The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate. Activities related to margetuximab and tebotelimab are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract. The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule. The Company determined that the net $22.5 million upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.  From 2020 through &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, it became probable that a significant reversal of cumulative revenue would not occur for development and regulatory milestones totaling $9.0 million.  Therefore, the associated consideration was added to the estimated transaction price and was recognized as revenue&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Of this &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$9.0 million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$5.0 million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was recognized as revenue &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;during the three months ended March 31, 2022.  No revenue was recognized during the three months ended March 31, 2021 under the 2018 Zai Lab Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zai Lab Clinical Supply Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, the Company entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#x2019;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements). The Company evaluated the agreements under ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: to perform services related to manufacturing the clinical supply of each of margetuximab and tebotelimab.  The transaction price is based on the costs incurred to manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing service. During the three months ended March 31, 2022 and 2021, the Company recognized revenue of $0.2 million and $1.1 million, respectively, related to the Zai Lab Clinical Supply Agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Zai Lab Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Company entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates the Company&#x2019;s DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be designated by the Company. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while the Company receives commercial rights in all other territories. Under the Lead Program, Zai Lab received an option upon reaching a predefined clinical milestone to convert the regional arrangement into a global 50/50 profit share. If Zai Lab elects such option, Zai Lab is to pay the Company $85.0&#160;million plus any research costs incurred by both parties as of the option election date. Zai Lab also obtained exclusive, global licenses from the Company to develop, manufacture and commercialize two additional molecules. Zai Lab granted the Company a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2021 Zai Lab Agreement, the Lead Program includes joint research and development services by both the Company and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with the Company to perform research and development services in the future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0&#160;million. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, the Company and Zai Lab entered into the Stock Purchase Agreement whereby Zai Lab paid the Company approximately $30.0 million to purchase shares of the Company&#x2019;s common stock, par value $0.01, at a fixed price of $31.30 which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assuming successful development and commercialization of the Programs, the Company could receive up to approximately $800.0&#160;million in development and regulatory milestones and $600.0&#160;million in commercial milestones. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of low double digit teens on annual net sales of certain specified products and of mid-single digits to low double digit teens on annual net sales of other specified products in Zai Lab&#x2019;s territory, which may be subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, the Company may also receive reimbursements from Zai Lab for certain research and development costs incurred by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the 2021 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises: (i) exclusive licenses to develop, manufacture and commercialize the products in Zai Lab&#x2019;s territory for each Program and (ii) certain research and development activities for the Lead Program. The Company determined that for the Lead Program, the license is not distinct from the related research and development activities, considering the early stage of development of the molecule and the Company&#x2019;s significant expertise in this area and as such, the research and development services are expected to significantly modify and customize the license. Therefore, for the Lead Program, the license and the services were combined into a single performance obligation. Since the other programs each represent distinct intellectual property and there are no other services included in the 2021 Zai Lab Agreement related to these licenses, each license is considered to be a distinct performance obligation. As such, there are four performance obligations included in the 2021 Zai Lab Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that the estimated transaction price is $40.4 million, consisting of the $25.0 million upfront payment, the $10.4 million premium related to the purchase of the Company&#x2019;s common stock, and the $5.0 million estimated reimbursement by Zai Lab for research and development activities for the Lead Program. The potential milestone payments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;were deemed to be fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company will re-assess the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price of $40.4 million was then allocated to the four performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was not directly observable; therefore, the Company estimated the standalone selling price using an adjusted market assessment approach, representing the amount that the Company believes a market participant is willing to pay for the product or service. The estimate was based on consideration of observable inputs, such as, values of other preclinical collaboration arrangements adjusted for the Company&#x2019;s estimate of the probability of success for each Program. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue related to the Lead Program license and related research and development services performance obligation is being recognized over time as the research and development activities are performed. The Company will utilize a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#x2019;s judgment, is the best measure of progress towards satisfying the performance obligations. The Company recognized revenue allocated to the other programs at a point in time upon transfer of the licenses to Zai Lab in June 2021. During the three months ended March 31, 2022, the Company recognized revenue of $0.3 million under the 2021 Zai Lab Agreement. As of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2022, $16.2 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; revenue was deferred under the agreement, all of which was current. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; December&#160;31, 2021, $16.1 million in revenue was deferred, all of which was current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Janssen Biotech, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company entered into a research collaboration and license agreement with Janssen Biotech, Inc. (Janssen) to develop a novel DART molecule (Janssen Agreement).  The research collaboration will incorporate the Company&#x2019;s proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the Janssen Agreement, Janssen paid the Company an upfront payment of $20.0&#160;million and will be responsible for funding all research and development expenses. The Company will also be eligible to receive up to $312.0&#160;million in potential milestone payments and tiered royalties of up to 10% on worldwide product sales. &lt;/span&gt;&lt;span style="color:#58585a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the terms of this agreement, the Company granted Janssen an exclusive, royalty-bearing license to develop, manufacture and commercialize the preclinical bispecific molecule and the Company will perform certain research and development activities during a specified research term. The Company evaluated the Janssen Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i)  a license to develop the preclinical bispecific molecule and (ii) performing certain research and development activities during the research term. The Company determined that the license and research and development activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as Janssen could benefit from the license on its own without the Company&#x2019;s involvement during the research term.  The Company determined that the transaction price of the Janssen Agreement at inception was $22.2&#160;million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for research and development activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements as well as current market conditions. The standalone selling price for agreed-upon research and development activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. This variable consideration is fully constrained until the Company begins its work under the performance obligation.  The potential milestone payments are &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Janssen and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:42pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized the $20.0&#160;million allocated to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;license when it satisfied its performance obligation and transferred the license to Janssen in December 2020. The $2.2&#160;million allocated to the research and development activities is being recognized over the Company&#x2019;s involvement in the research term, which is estimated to be less than two years.  The Company recognized revenue of $0.3&#160;million for each of the three-month periods ended March&#160;31, 2022 and 2021 for research and development activities performed under the Janssen Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;I-Mab Biopharma&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;I-Mab License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Company entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the Company's proprietary Fc Optimization technology platform (I-Mab License Agreement).  I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the I-Mab License Agreement, I-Mab paid the Company an upfront payment of $15.0 million.  Assuming successful development and commercialization of enoblituzumab, the Company could receive up to $135.0 million in development and regulatory milestones, of which $5.0&#160;million has been earned from the inception of the I-Mab License Agreement through &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2022. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In addition, I-Mab would pay the Company tiered royalties ranging from mid-teens to 20% on annual net sales in I-Mab's territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the I-Mab License Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i) an exclusive license to develop and commercialize enoblituzumab in I-Mab&#x2019;s territories, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation. The Company determined that the $15.0 million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities. The Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $1.0 million. I-Mab paid the Company for the cost of this study as the costs were incurred and I-Mab received a one-time credit of eighty percent of the total amount of such costs against the milestone achieved during 2021. The Company reassessed the transaction price as it became probable that a significant reversal of cumulative revenue would not occur for a $5.0&#160;million milestone ($4.5&#160;million after netting a one-time credit as described above) related to development progress of enoblituzumab, therefore the associated consideration was added to the estimated transaction price and was recognized as revenue during 2021. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to I-Mab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Revenue under the I-Mab License Agreement is being recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#x2019;s judgment, is the best measure of progress towards satisfying the performance obligations.  During the three months ended March 31, 2022 and 2021, the Company recognized revenue of $0.2 million and $0.6 million, respectively, under the I-Mab License Agreement. As of March&#160;31, 2022, $4.4 million in revenue was deferred under the I-Mab License Agreement, all of which was current. As of December&#160;31, 2021, $4.5 million in revenue was deferred under the I-Mab License Agreement, all of which was current.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;I-Mab Clinical Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the Company entered into an agreement under which the Company is to perform development and manufacturing services for I-Mab&#x2019;s clinical needs of enoblituzumab (I-Mab Clinical Supply Agreement). The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of enoblituzumab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the three months ended March 31, 2022, the Company recognized revenue of $0.9 million for research and development activities performed under the I-Mab Clinical Supply Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Manufacturing Services Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incyte &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the Company entered into a Manufacturing and Clinical Supply Agreement with Incyte (Incyte Manufacturing and Clinical Supply Agreement) to provide manufacturing services to produce certain Incyte bulk drug substance over a three-year period at one of the Company&#x2019;s manufacturing facilities. Under the terms of the Incyte Manufacturing and Clinical Supply Agreement, the Company received an upfront payment of $10.0&#160;million and is eligible to receive annual fixed payments paid quarterly over the term of the contract totaling $14.4&#160;million. The Company will also be reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Incyte Manufacturing and Clinical Supply Agreement under the provisions of ASC 606 and identified one performance obligation to provide manufacturing runs to Incyte, as and when requested by Incyte, over the term of the contract that is part of a series of goods and services. The Company determined that the transaction price at inception consists of the upfront payment received of $10.0&#160;million and the annual fixed payments totaling $14.4&#160;million.   The Company will recognize revenue over time on a straight-line basis as the manufacturing services are provided to Incyte, as the Company determined that its efforts in providing the manufacturing services will be incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product for Incyte will be allocated to the related manufacturing activities and will be recognized as revenue as those activities occur.  Materials purchased by the Company to manufacture the product for Incyte are considered costs to fulfill a contract and will be capitalized and expensed as the materials are used to provide the manufacturing services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was no revenue recognized under the Incyte Manufacturing and Clinical Supply Agreement during the three months ended March 31, 2022. As of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2022, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$11.2&#160;million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in revenue was deferred under this agreement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$4.8&#160;million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of which was current and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$6.4&#160;million &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of which was non-current.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Government Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;NIAID Contract&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a contract with National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to two DART molecules, MGD014 and MGD020 (NIAID Contract). Under the NIAID Contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;Since the inception of the NIAID Contract, NIAID has exercised the two options contemplated in the original contract and executed modifications such that the total funded contract value as of March&#160;31, 2022 is $25.1&#160;million. In addition, the most recent modification changed the period of performance under the NIAID Contract to end in July 2023. During the three months ended March 31, 2022 and 2021, the Company recognized revenue under the NIAID Contract of $0.4 million and    $0.8 million, respectively.</mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i3a2c1fb5405243d38e27f09c198a5915_D20180101-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNzE0_af82bfc4-bbda-4917-8624-7c7a02820f8c"
      unitRef="usd">150000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i1dabbd2bdcd948c59b80f6888528ba3b_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTY0Nw_b525e32a-c340-4b42-90a3-d527f1384a88"
      unitRef="usd">420000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="i1dabbd2bdcd948c59b80f6888528ba3b_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTcwMQ_7f95c03d-0d34-43eb-b96d-e79e4b885545"
      unitRef="usd">330000000</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="ica1236dc56be456dadbe35007ebd92bc_D20180101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTgyMA_26f2052f-7f4e-466e-8f8a-41ca7e42d84e"
      unitRef="usd">70000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="ie34522f6d1964d318f94e89b4a7854b2_D20180101-20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTk5NQ_0a535f7f-b426-42a0-9ffa-d3c1f1cd6817"
      unitRef="number">0.15</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i02d8186b9ed94687aa3108cc69312fbd_D20180101-20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjAwMQ_c824c480-e7cf-4586-bea4-0f3df712669d"
      unitRef="number">0.24</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:NumberOfPerformanceObligations
      contextRef="i1dabbd2bdcd948c59b80f6888528ba3b_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjU0Mw_003efec8-927f-4ad2-877f-7bfcd66f163e"
      unitRef="performanceobligation">2</mgnx:NumberOfPerformanceObligations>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i1dabbd2bdcd948c59b80f6888528ba3b_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMzMzMA_7ce9937d-58c0-468c-994e-9fcae09eb7e5"
      unitRef="usd">154000000</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="ica1236dc56be456dadbe35007ebd92bc_D20180101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNDkwOQ_26f2052f-7f4e-466e-8f8a-41ca7e42d84e"
      unitRef="usd">70000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues
      contextRef="i94127aa94aa2402086ac95e5ef578edd_D20180101-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNTE4NQ_bab0350c-58ed-436e-94a9-aa931dd25995"
      unitRef="usd">150000000</us-gaap:Revenues>
    <mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
      contextRef="i54eb455b76a2472aae844a12fa08813e_D20170101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNTMxMA_a3636d75-96bd-49f8-92a8-0eebaee3af88"
      unitRef="usd">4000000</mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
    <us-gaap:Revenues
      contextRef="i8c7b19308ad740b49d92d38c4aa6390d_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNTcyNA_2ef9230e-badf-43cb-810e-44e82f746b29"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8c7b19308ad740b49d92d38c4aa6390d_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNTcyNA_8c0ee3c8-ccab-4291-9a1e-9e881b240157"
      unitRef="usd">0</us-gaap:Revenues>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i43cf385ec61546e2885724e6c7c3177a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNTgzNg_45859cff-6d85-47fd-bb86-dc4be67b92c5"
      unitRef="usd">10000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i43cf385ec61546e2885724e6c7c3177a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNTgzNg_bd0bc0c0-60f9-4ff9-8dc6-8c50bff58648"
      unitRef="usd">10000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues
      contextRef="if3c00bc643434efbbf8833b77153ad2d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNjk5MQ_b4ed1642-dde9-4137-9f73-bd93305432bc"
      unitRef="usd">300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0adbde0716db4da29d82fc8ba600273b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNjk5OA_663d114f-8fd5-4910-8843-f346fa9076d3"
      unitRef="usd">100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic8d7471a9a78429b9f892ec0cc71150c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTA5OTUxMTY2MzQyMg_63ad2ec1-357d-4d1b-b245-d581deb8c284"
      unitRef="usd">3100000</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees
      contextRef="ifba4c7039c924aa5b223417e6cf78e36_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfOTQxOA_a861e5a8-7463-4495-80a6-6ce7b4735c43"
      unitRef="usd">25000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding
      contextRef="ifba4c7039c924aa5b223417e6cf78e36_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfOTQyMg_c7c23e43-19bb-436b-b7d8-3c7f48c98851"
      unitRef="usd">22500000</mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding>
    <mgnx:NonrefundablePaymentTaxWithholding
      contextRef="ifba4c7039c924aa5b223417e6cf78e36_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfOTQ3MQ_aba8ceb3-1dd2-45ad-9abd-960949d9aa9b"
      unitRef="usd">2500000</mgnx:NonrefundablePaymentTaxWithholding>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i8a199c459cc44adc89979956653b5201_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfOTYxNw_83251b24-58c1-4988-9adc-28f181ca19ee"
      unitRef="usd">140000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i6a9c376486b84ec3b165f5f033a1fd8d_D20200701-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfOTY2Mg_7db23f76-95c4-4380-8c6e-56cbefb207fb"
      unitRef="usd">9000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i0c95d8da85da4d78b72fd3032fd7f680_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfOTg4MQ_f471d8ed-d5af-49e3-b2ce-573d24b1f27f"
      unitRef="number">0.20</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="ib9c86092c7f8459fa95d28f361b3564a_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTAwMDQ_a1770e87-9c0b-4107-af6e-509cae4da3bb"
      unitRef="number">0.10</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding
      contextRef="ifba4c7039c924aa5b223417e6cf78e36_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTEzMDk_c7c23e43-19bb-436b-b7d8-3c7f48c98851"
      unitRef="usd">22500000</mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i6a9c376486b84ec3b165f5f033a1fd8d_D20200701-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNDM5ODA0NjU5ODk2MA_7db23f76-95c4-4380-8c6e-56cbefb207fb"
      unitRef="usd">9000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i6a9c376486b84ec3b165f5f033a1fd8d_D20200701-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNDM5ODA0NjU5OTcxMA_7db23f76-95c4-4380-8c6e-56cbefb207fb"
      unitRef="usd">9000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues
      contextRef="i605a7292ff3f44c383e3d95959a523b0_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNDM5ODA0NjU5OTcxOA_f8a94e09-9e38-456d-a50b-4fe08de7f975"
      unitRef="usd">5000000</us-gaap:Revenues>
    <mgnx:RevenuesNetOfTaxWithholding
      contextRef="i51a097abe2f346a8bea4a1a0e880968a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTA5OTUxMTY2NjYxMw_02f7a468-8c96-44d0-95b4-3794cdb83a10"
      unitRef="usd">0</mgnx:RevenuesNetOfTaxWithholding>
    <us-gaap:Revenues
      contextRef="ia36f2c15a9ed480fb6dfd60b54cdb774_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTQ0MjQ_ffc58507-40bc-46ae-ab67-741aa5514ef6"
      unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i29c3c82f97234786bc2f333cf100ce5f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTQ0MzE_a4a2ad4e-e8cf-420c-a390-d5dbc16584d5"
      unitRef="usd">1100000</us-gaap:Revenues>
    <mgnx:OptInFee
      contextRef="ib5527acf5cf248e5ac690d183c18549f_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTU2Mzc_b569c591-7178-4a28-9a1f-ead118417de4"
      unitRef="usd">85000000</mgnx:OptInFee>
    <mgnx:NonRefundableUpfrontFees
      contextRef="ie0aca00030b84821a220040e1894b4ed_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTYzOTc_f504cddb-a8bd-4c78-8f2a-2e72b166fe52"
      unitRef="usd">25000000</mgnx:NonRefundableUpfrontFees>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ie0aca00030b84821a220040e1894b4ed_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTY2MjU_13da2f7f-c8b7-4eee-86ab-7a8bab3042c3"
      unitRef="usd">30000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTY2ODg_eb1ec008-c6b3-46ab-b812-0408c7c9c119"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ib5527acf5cf248e5ac690d183c18549f_I20210615"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTY3MTI_76bcf053-9a6a-49e6-af12-6b505178d5fb"
      unitRef="usdPerShare">31.3</us-gaap:SaleOfStockPricePerShare>
    <mgnx:PremiumReceivedOnStockPurchase
      contextRef="i1b909bf9e4ae42208ed813d9676eadb7_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTY3MzU_380086a2-6639-44dc-b429-2fe69d0ddcdc"
      unitRef="usd">10400000</mgnx:PremiumReceivedOnStockPurchase>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="ib5527acf5cf248e5ac690d183c18549f_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTY5MjM_9a4c038d-4891-4bee-811d-87a6735aab43"
      unitRef="usd">800000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="ib5527acf5cf248e5ac690d183c18549f_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTY5NzE_c7cd5534-9d53-401b-bd6b-e325c56fb156"
      unitRef="usd">600000000</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="ib5527acf5cf248e5ac690d183c18549f_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTg3MjQ_f62f4703-c6a1-4f8c-91e6-cc32d245a03e"
      unitRef="usd">40400000</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:NonRefundableUpfrontFees
      contextRef="ie0aca00030b84821a220040e1894b4ed_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTg3NDY_f44bd440-0417-4c28-9086-50af09ac2801"
      unitRef="usd">25000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:PremiumReceivedOnStockPurchase
      contextRef="i1b909bf9e4ae42208ed813d9676eadb7_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTg3NzA_4437a49a-7422-42a2-9c0c-e5f0345606f0"
      unitRef="usd">10400000</mgnx:PremiumReceivedOnStockPurchase>
    <mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
      contextRef="ie0aca00030b84821a220040e1894b4ed_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTg4NTQ_4f60626e-fda5-4057-b2e5-0dad5485b2ad"
      unitRef="usd">5000000</mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="ib5527acf5cf248e5ac690d183c18549f_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTk3Mjg_64c0bae8-eb2a-4a74-89e3-7d268da519f0"
      unitRef="usd">40400000</mgnx:CollaborativeAgreementTransactionPrice>
    <us-gaap:Revenues
      contextRef="i3a06e176aa5944de902c9e6384aa45bf_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjEwMzQ_2902fd2e-b525-4a31-97d9-b621d5bc0bd6"
      unitRef="usd">300000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ic3025bab32fb46cd9d6da9f324ce3688_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjExMTQ_55ab3d41-3004-445b-b26c-b41fe7b6e5d1"
      unitRef="usd">16200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i36440f83cc204cf1996dbfe7485383bc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNDM5ODA0NjU1NjI1Nw_fa8ff00e-90d3-4f67-bbed-87eb316c4933"
      unitRef="usd">16100000</us-gaap:ContractWithCustomerLiability>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i76399d6c1802415b90c08bf9c69f7100_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjE2OTQ_f5a7f711-4fa2-4170-970a-b617462c4f08"
      unitRef="usd">20000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialMilestonePaymentsAndRoyaltiesOnProductSales
      contextRef="ie55d7a52498740cc96d51ad5658ea4c5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjE4MjM_b02bf858-2933-4226-ac20-2fd6fabd9e2f"
      unitRef="usd">312000000</mgnx:PotentialMilestonePaymentsAndRoyaltiesOnProductSales>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i76399d6c1802415b90c08bf9c69f7100_D20201201-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjE4ODg_2bd3dde2-ff88-4916-a80a-9cd8485a4df9"
      unitRef="number">0.10</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="ie55d7a52498740cc96d51ad5658ea4c5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjI5Njc_adee61a0-752a-47e1-bc08-ce4e91fdd703"
      unitRef="usd">22200000</mgnx:CollaborativeAgreementTransactionPrice>
    <us-gaap:Revenues
      contextRef="ibc75ade1173842ff87ee4dbbac9daeb5_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjQ1ODI_6f1f846c-8a9e-4b8b-9d5e-342139e32cd5"
      unitRef="usd">20000000</us-gaap:Revenues>
    <mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
      contextRef="i76399d6c1802415b90c08bf9c69f7100_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjQ3MTY_359547c0-969b-4961-8309-3ca7c0362895"
      unitRef="usd">2200000</mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
    <us-gaap:Revenues
      contextRef="ib49d110aa2b04f54ad540230e16f5db5_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjQ5NTA_286e4511-1bac-4f52-b157-9ee1116d5021"
      unitRef="usd">300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6925c66d0d90474cabcbca044e7bb353_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjQ5NTA_3d27a6bf-634b-49c8-9d0a-2a6797f8f726"
      unitRef="usd">300000</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees
      contextRef="iecc8c23d2f2f46e295c148fe79e31e39_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjU3MTk_3b13d44d-285c-411a-be53-8cfdff6b01c3"
      unitRef="usd">15000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i61fd77fcf6144f8f852769a79d64119a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjU4Mjg_46b5e836-b146-46dd-968f-99cbf91177d4"
      unitRef="usd">135000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="ia548adfe30414a9f9d0fd63c315589d5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTA5OTUxMTY2MzQ4NQ_c3fcde91-fb1b-4e71-88a8-de872ed4a773"
      unitRef="usd">5000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i0e56061fef8544908e67631567510f9d_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjYwNDk_674fb337-5f81-4647-9a21-c5e9a9d859f4"
      unitRef="number">0.20</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:NonRefundableUpfrontFees
      contextRef="iecc8c23d2f2f46e295c148fe79e31e39_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjY4NTA_3b13d44d-285c-411a-be53-8cfdff6b01c3"
      unitRef="usd">15000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount
      contextRef="iecc8c23d2f2f46e295c148fe79e31e39_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjcyNjU_178c03af-b1e8-43a4-be00-3b7d61c8d175"
      unitRef="usd">1000000</mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i1514a61deb464837bf8bb0f50659cd2b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNDM5ODA0NjU1MTU5MA_11ae6530-519e-4091-9688-3695296337cf"
      unitRef="usd">5000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:OneTimeMillstoneCredit
      contextRef="ib5ec03c4a3794d77bfafe5617533f80a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNDM5ODA0NjU1MTYwNQ_e61cc15e-fb19-4a9f-91c6-feffbc47ba16"
      unitRef="usd">4500000</mgnx:OneTimeMillstoneCredit>
    <us-gaap:Revenues
      contextRef="ia548adfe30414a9f9d0fd63c315589d5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjg4MTk_e89785b1-6dc1-4f2d-819b-16241535e213"
      unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if8da3009f9f94f879c4bf206e40f1cc4_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjg4MjY_988bbd83-c470-49a3-8fbc-46b4139eee7b"
      unitRef="usd">600000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ic49edb54de2c4ae4a6d757a5b491be58_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTA5OTUxMTY2MzYxNw_08bf238b-4cf3-4a29-94b7-fa787112df5c"
      unitRef="usd">4400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ib5ec03c4a3794d77bfafe5617533f80a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfNDM5ODA0NjU1NjQ4NA_0ccc3106-aa9d-4a73-9ef3-3d0db41a14ac"
      unitRef="usd">4500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:Revenues
      contextRef="iedfb3cdeb7214224a72fce2beb8e46d1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTA5OTUxMTY2MzY0Mw_c911c791-6e7e-4a57-a6ca-1d6ed089e63e"
      unitRef="usd">900000</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i0157b8cec1ad4b9a9b95f37868dd31e3_D20220101-20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTA5OTUxMTcxNjc2MQ_45b28e16-767f-443d-9083-cbb5714be7dc"
      unitRef="usd">10000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:TotalAnnualFixedPayments
      contextRef="ia4e2cd3790dd4e78a153c3c1da4940aa_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTA5OTUxMTcxNjc2OQ_ce1bd774-926f-4b22-89dd-b79e6c162565"
      unitRef="usd">14400000</mgnx:TotalAnnualFixedPayments>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i0157b8cec1ad4b9a9b95f37868dd31e3_D20220101-20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMzg0ODI5MDc4NjI4MQ_4ee1170c-68e4-4b75-8999-ec1c6d177d33"
      unitRef="usd">10000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:TotalAnnualFixedPayments
      contextRef="ia4e2cd3790dd4e78a153c3c1da4940aa_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMzg0ODI5MDc4NjI5Ng_d299dce3-4be7-433b-ba62-07a1a506f825"
      unitRef="usd">14400000</mgnx:TotalAnnualFixedPayments>
    <us-gaap:Revenues
      contextRef="iaec489dac35b477286b66bb36de621fc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMzg0ODI5MDc4NzMyOQ_3015badf-4863-40db-bae7-90c717779af0"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ia4e2cd3790dd4e78a153c3c1da4940aa_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTA5OTUxMTcxNjc3OQ_cc2b3378-75e3-4e99-8b36-687673518316"
      unitRef="usd">11200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia4e2cd3790dd4e78a153c3c1da4940aa_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTA5OTUxMTcxNjc4Nw_b9c80d93-ca23-4744-8f78-b13783b4fa82"
      unitRef="usd">4800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ia4e2cd3790dd4e78a153c3c1da4940aa_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTA5OTUxMTcxNjgyMw_f76413f8-82eb-4a64-a56c-e9ee1c46059c"
      unitRef="usd">6400000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement
      contextRef="i1337d1949d0643488c0089eab0614890_D20150915-20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMjk2NDg_fd05a877-32be-4cf2-bcfd-753ad7f9891b"
      unitRef="molecule">2</mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement>
    <mgnx:TotalPotentialValueUnderAgreement
      contextRef="i7e37fc50bcd44ac683c40725c776294b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMTA5OTUxMTY2MzY1Ng_58930f79-68d9-45dd-9372-9ab57b2af267"
      unitRef="usd">25100000</mgnx:TotalPotentialValueUnderAgreement>
    <us-gaap:Revenues
      contextRef="ic750b1bc388a426a9377427e21e4fe52_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMzA3MDA_2208fa48-522a-4a3f-aa2b-37fe8cae64cb"
      unitRef="usd">400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0ba225f70b5e431a996b967e49bfb1c8_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81Mi9mcmFnOjFlZjA1ZDMyNzkwOTRiNDhiMTgyMTVkNDg4MGY3ZDlhL3RleHRyZWdpb246MWVmMDVkMzI3OTA5NGI0OGIxODIxNWQ0ODgwZjdkOWFfMzA3MDc_a4e7a85f-c92e-424d-806b-126670016b7a"
      unitRef="usd">800000</us-gaap:Revenues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNTQ3Mw_50cd4d43-a455-4b6b-91a8-59cabd658b9f">Stock-Based Compensation&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2017, the Company&#x2019;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended (IRC), and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfMzg0ODI5MDcwNDU3Ng_27cd901d-e912-415a-9df7-55d3c46ad18f"&gt;six&lt;/span&gt;-month offering periods ending on May 31 and November 30 of each year.  At the end of each offering period, employees are able to purchase shares at 85% of the fair market value of the Company&#x2019;s common stock on the last day of the offering period.  During the three months ended March&#160;31, 2022, no shares of common stock were purchased under the 2016 ESPP.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Option Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the IRC, or non-qualified stock options.  In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan.  Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160; As of March&#160;31, 2022, under the 2003 Plan, there were options to purchase an aggregate of 160,357 shares of common stock outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2013, the Company implemented the 2013 Plan.&#160;&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards.&#160;&#160;The number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) 1,960,168 shares, (b) 4.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Company's Board of Directors. During the three months ended March&#160;31, 2022, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to 15,816,949.&#160;&#160; If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards.  As of March&#160;31, 2022, there were options to purchase an aggregate of 10,346,223 shares of common stock outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following stock-based compensation expense was recognized for the periods indicated (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:15pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:15pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.9% -88.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.4% - 86.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5% - 2.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6% - 1.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during the three months ended March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;&#160;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,373,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,349,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,646)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(157,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,695)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,506,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of March 31, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,853,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,693,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value of options granted during the three months ended March&#160;31, 2022 and 2021 was $7.48 and $14.23, respectively. The total intrinsic value of options exercised during the three months ended March&#160;31, 2022 and 2021 was approximately $0.3 million and $1.4 million, respectively.  The total cash received for options &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;exercised during the three months ended March&#160;31, 2022 was de minimis, and $2.5 million was received for options exercised during the three months ended March 31, 2021.  The total fair value of shares vested in the three months ended March&#160;31, 2022 and 2021 was approximately $5.4 million and $4.1 million, respectively. As of March&#160;31, 2022, the total unrecognized compensation expense related to unvested stock options, net of related forfeiture estimates, was approximately $38.4 million, which the Company expects to recognize over a weighted-average period of approximately 1.6 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company grants restricted stock units (RSUs) under the 2013 Plan to employees from time to time as a component of their compensation. During the three months ended March 31, 2022, the Company awarded RSUs to employees in conjunction with the annual performance review process. Each RSU vests over a two-year period and entitles the holder to receive one share of the Company's common stock when the RSU vests. Compensation expense is recognized on a straight-line basis over the vesting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity during the three months ended March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2022, there was $2.9 million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of approximately 1.4 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="iad1e5d2adfa44b97a1de1c2f673de3f3_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNDI3_e8b81636-ff05-4394-a424-fe6f3e94f396"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i909599960cbd4d01a402618a5680f14c_D20170501-20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNjI2_f33a287f-1143-44bd-a9c0-03f87ca62509"
      unitRef="number">0.10</mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i909599960cbd4d01a402618a5680f14c_D20170501-20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfODcz_4e09d451-88bc-4879-8aae-95eb96c220fd"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i83ac7c613bf04ee3a7d8345a36323be1_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfMTAwMw_c1463417-bff9-4a3a-a54b-e9aeb544e349"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i86806d0d26194ccda0c95e062fc00349_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfMTkyNQ_389c5072-0b92-484d-9550-bcbd214fe85c"
      unitRef="shares">160357</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance
      contextRef="i1ded582f69f04d0aaaf29d8dddc272a5_I20131031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfMjQxNQ_ca874aab-f1eb-42f4-aacd-6636f1c3e46a"
      unitRef="shares">1960168</mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance>
    <mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan
      contextRef="ib91bd3b003bd40c9b8460d6c1e8f8f10_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfMjQzMA_77bf5ceb-cfb6-4ba6-be7c-91137705b212"
      unitRef="number">0.04</mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="if0a7f8632e7f42d5ad0ae052ddb56492_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfMjc4Mg_f751fc65-1a79-41a1-8ee8-d1411a3464dc"
      unitRef="shares">15816949</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if0a7f8632e7f42d5ad0ae052ddb56492_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfMzM1OA_834b61ca-dcd8-433a-8a0c-9de325b7aa77"
      unitRef="shares">10346223</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNTQ3MQ_2e7ac549-4c3b-4129-99db-f28b83c607e1">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following stock-based compensation expense was recognized for the periods indicated (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i35c13a3e3a224d948c4a2fe4b9fa5d99_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmYzYmI0YzkxMDhjMDQ0ZTU4NmE0OTYwNWE4NmMyMjhlL3RhYmxlcmFuZ2U6ZjNiYjRjOTEwOGMwNDRlNTg2YTQ5NjA1YTg2YzIyOGVfMi0xLTEtMS0zNjkyMQ_ddaaab7e-8e6b-4d12-9717-cea6cd1e5360"
      unitRef="usd">2392000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i59db3d1311064ab88fb9f88769f9da7b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmYzYmI0YzkxMDhjMDQ0ZTU4NmE0OTYwNWE4NmMyMjhlL3RhYmxlcmFuZ2U6ZjNiYjRjOTEwOGMwNDRlNTg2YTQ5NjA1YTg2YzIyOGVfMi0zLTEtMS0zNjkyMQ_84f6eaf8-cacb-46a0-92fb-1403a8cdad10"
      unitRef="usd">2727000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i010ad6f9a1c640caa25d8015911a45d6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmYzYmI0YzkxMDhjMDQ0ZTU4NmE0OTYwNWE4NmMyMjhlL3RhYmxlcmFuZ2U6ZjNiYjRjOTEwOGMwNDRlNTg2YTQ5NjA1YTg2YzIyOGVfMy0xLTEtMS0zNjkyMQ_c1f046e1-6fd7-48c1-a701-e349a75dfe32"
      unitRef="usd">2882000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iacae1a7b3e1f4879bf90a88d717407ae_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmYzYmI0YzkxMDhjMDQ0ZTU4NmE0OTYwNWE4NmMyMjhlL3RhYmxlcmFuZ2U6ZjNiYjRjOTEwOGMwNDRlNTg2YTQ5NjA1YTg2YzIyOGVfMy0zLTEtMS0zNjkyMQ_f9b5bd1a-a5f4-423c-987a-2e0c426da350"
      unitRef="usd">2559000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmYzYmI0YzkxMDhjMDQ0ZTU4NmE0OTYwNWE4NmMyMjhlL3RhYmxlcmFuZ2U6ZjNiYjRjOTEwOGMwNDRlNTg2YTQ5NjA1YTg2YzIyOGVfNC0xLTEtMS0zNjkyMQ_24a91346-45f6-4e9b-8f3e-c302eabdd0b9"
      unitRef="usd">5274000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmYzYmI0YzkxMDhjMDQ0ZTU4NmE0OTYwNWE4NmMyMjhlL3RhYmxlcmFuZ2U6ZjNiYjRjOTEwOGMwNDRlNTg2YTQ5NjA1YTg2YzIyOGVfNC0zLTEtMS0zNjkyMQ_75473bbf-e40d-475f-8503-9ea4aca61107"
      unitRef="usd">5286000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNTQ3Ng_291a4652-c11c-4f82-92ea-c45004ebe704">&lt;div style="margin-bottom:9pt;margin-top:15pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:15pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.9% -88.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.4% - 86.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5% - 2.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6% - 1.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjlkMDk3ZDFjZDE3OTRiNzU5MGFmODA3YzU3OTAxMDg0L3RhYmxlcmFuZ2U6OWQwOTdkMWNkMTc5NGI3NTkwYWY4MDdjNTc5MDEwODRfMi0xLTEtMS0zNjkyMQ_6afbdd35-f582-4f1e-bc95-2a9f03af77c3"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjlkMDk3ZDFjZDE3OTRiNzU5MGFmODA3YzU3OTAxMDg0L3RhYmxlcmFuZ2U6OWQwOTdkMWNkMTc5NGI3NTkwYWY4MDdjNTc5MDEwODRfMi0zLTEtMS0zNjkyMQ_a8070723-09e1-4cbe-9c7a-82c4dfbd2cbb"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia47224cd15db4935927f150937cfc761_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjlkMDk3ZDFjZDE3OTRiNzU5MGFmODA3YzU3OTAxMDg0L3RhYmxlcmFuZ2U6OWQwOTdkMWNkMTc5NGI3NTkwYWY4MDdjNTc5MDEwODRfMy0xLTEtMS0zNjkyMS90ZXh0cmVnaW9uOjg3YmM5MTcwNjg1MzQ4MjZhNmE0MzY5MTgxYWY4MjA0XzEwOTk1MTE2Mjc4MzQ_74872302-cc01-4e8d-8744-85cd53f05ab1"
      unitRef="number">0.879</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ib2e3c0ef64b149e285c3286cfaaaefa7_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjlkMDk3ZDFjZDE3OTRiNzU5MGFmODA3YzU3OTAxMDg0L3RhYmxlcmFuZ2U6OWQwOTdkMWNkMTc5NGI3NTkwYWY4MDdjNTc5MDEwODRfMy0xLTEtMS0zNjkyMS90ZXh0cmVnaW9uOjg3YmM5MTcwNjg1MzQ4MjZhNmE0MzY5MTgxYWY4MjA0XzEwOTk1MTE2Mjc4MDg_f0ae5370-6fe2-4cf1-83e8-4a1b7d72615e"
      unitRef="number">0.883</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i1675839c45fe4c938d0aaa356a3df94c_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjlkMDk3ZDFjZDE3OTRiNzU5MGFmODA3YzU3OTAxMDg0L3RhYmxlcmFuZ2U6OWQwOTdkMWNkMTc5NGI3NTkwYWY4MDdjNTc5MDEwODRfMy0zLTEtMS0zNjkyMS90ZXh0cmVnaW9uOjY4ZmFhYTExY2RjNjQ0YTJhMjlhZjkxMDM5MGM0OGU2XzQ_15aa9277-30c5-44be-9703-7009c75e1dd0"
      unitRef="number">0.864</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i11689de0548a42dba1fc04b3de566926_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjlkMDk3ZDFjZDE3OTRiNzU5MGFmODA3YzU3OTAxMDg0L3RhYmxlcmFuZ2U6OWQwOTdkMWNkMTc5NGI3NTkwYWY4MDdjNTc5MDEwODRfMy0zLTEtMS0zNjkyMS90ZXh0cmVnaW9uOjY4ZmFhYTExY2RjNjQ0YTJhMjlhZjkxMDM5MGM0OGU2Xzk_7bed92f6-f05d-4d82-b33d-44cc8cb29ce1"
      unitRef="number">0.867</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia47224cd15db4935927f150937cfc761_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjlkMDk3ZDFjZDE3OTRiNzU5MGFmODA3YzU3OTAxMDg0L3RhYmxlcmFuZ2U6OWQwOTdkMWNkMTc5NGI3NTkwYWY4MDdjNTc5MDEwODRfNC0xLTEtMS0zNjkyMS90ZXh0cmVnaW9uOmYwMjJjOTMyMmRmNTRjNWJiNzliZWM1ODc2NDA0ZWVhXzQ_589ad9e6-2b2a-43f6-a369-91a4fbdceb87"
      unitRef="number">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ib2e3c0ef64b149e285c3286cfaaaefa7_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjlkMDk3ZDFjZDE3OTRiNzU5MGFmODA3YzU3OTAxMDg0L3RhYmxlcmFuZ2U6OWQwOTdkMWNkMTc5NGI3NTkwYWY4MDdjNTc5MDEwODRfNC0xLTEtMS0zNjkyMS90ZXh0cmVnaW9uOmYwMjJjOTMyMmRmNTRjNWJiNzliZWM1ODc2NDA0ZWVhXzk_b9910dff-cc05-44a7-9b91-2632a7175184"
      unitRef="number">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i1675839c45fe4c938d0aaa356a3df94c_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjlkMDk3ZDFjZDE3OTRiNzU5MGFmODA3YzU3OTAxMDg0L3RhYmxlcmFuZ2U6OWQwOTdkMWNkMTc5NGI3NTkwYWY4MDdjNTc5MDEwODRfNC0zLTEtMS0zNjkyMS90ZXh0cmVnaW9uOjdjY2VmM2M0ZGZiYjQwNDM4ZDk5MzE1OTIzNDBiMjZlXzQ_67aa602c-1c92-4bdb-a37e-ff4e45d234c3"
      unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i11689de0548a42dba1fc04b3de566926_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjlkMDk3ZDFjZDE3OTRiNzU5MGFmODA3YzU3OTAxMDg0L3RhYmxlcmFuZ2U6OWQwOTdkMWNkMTc5NGI3NTkwYWY4MDdjNTc5MDEwODRfNC0zLTEtMS0zNjkyMS90ZXh0cmVnaW9uOjdjY2VmM2M0ZGZiYjQwNDM4ZDk5MzE1OTIzNDBiMjZlXzk_d8d136a6-537b-4231-9ec0-c3714ab75e79"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjlkMDk3ZDFjZDE3OTRiNzU5MGFmODA3YzU3OTAxMDg0L3RhYmxlcmFuZ2U6OWQwOTdkMWNkMTc5NGI3NTkwYWY4MDdjNTc5MDEwODRfNS0xLTEtMS0zNjkyMQ_1388b050-4068-49ef-9569-81aafb676823">P5Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjlkMDk3ZDFjZDE3OTRiNzU5MGFmODA3YzU3OTAxMDg0L3RhYmxlcmFuZ2U6OWQwOTdkMWNkMTc5NGI3NTkwYWY4MDdjNTc5MDEwODRfNS0zLTEtMS0zNjkyMQ_55110493-9a10-410d-b3de-48d5d1451adf">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNTQ3OA_fde801f1-1ecc-4d81-bc2f-e6bc0e7b0b1f">&lt;div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during the three months ended March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;&#160;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,373,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,349,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,646)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(157,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,695)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,506,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of March 31, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,853,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,693,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfMS0xLTEtMS0zNjkyMQ_c395ef94-1cfe-4005-a86d-774b5404fdc8"
      unitRef="shares">8373921</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i63fbc95e39fe4d1b91328a28079b6e2f_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfMS0zLTEtMS0zNjkyMQ_072c2889-db79-42d3-afba-74dca3a34af2"
      unitRef="usdPerShare">21.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i66614c40c0e14c88b42fd0af30436dfc_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfMS01LTEtMS0zNjkyMQ_65be54fc-645f-4431-b0b3-9f348376d1df">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfMi0xLTEtMS0zNjkyMQ_5433da44-d480-4ec7-96f0-7c1b2b5f79c0"
      unitRef="shares">2349197</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfMi0zLTEtMS0zNjkyMQ_ed08a85a-b729-483c-8e7a-21955306edcb"
      unitRef="usdPerShare">10.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfMy0xLTEtMS0zNjkyMQ_76e4c781-cef8-44fe-84a6-cb14ca425090"
      unitRef="shares">25646</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfMy0zLTEtMS0zNjkyMQ_3d34c25b-502a-43d3-b9d8-504a659a61d6"
      unitRef="usdPerShare">1.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfNC0xLTEtMS00MzU2MA_7d69e0af-5727-44e9-90d9-d096d57ce45e"
      unitRef="shares">157197</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfNC0zLTEtMS00MzU2MA_d5867045-a16c-4cfa-86bc-692381e192a9"
      unitRef="usdPerShare">16.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfNC0xLTEtMS0zNjkyMQ_346d2fdc-71d3-472d-9c0a-25a5a0413dc7"
      unitRef="shares">33695</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfNC0zLTEtMS0zNjkyMQ_24a8b526-4a15-49b8-8683-cda0b89f9b61"
      unitRef="usdPerShare">21.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfNS0xLTEtMS0zNjkyMQ_da840f7a-c3a8-45c5-97eb-69b8f79be9d4"
      unitRef="shares">10506580</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfNS0zLTEtMS0zNjkyMQ_fdca0ee2-622a-455d-a442-9f89e9aca0f6"
      unitRef="usdPerShare">19.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfNS01LTEtMS0zNjkyMQ_1b4b13a6-c523-4f46-83e5-3213202d69ae">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfNS03LTEtMS0zNjkyMQ_fd0c376d-bd70-4ed5-be97-e67bb14b5e86"
      unitRef="usd">904000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfNy0xLTEtMS0zNjkyMQ_4ead658f-1f9a-425e-8dca-91615058f8ab"
      unitRef="shares">5853827</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfNy0zLTEtMS0zNjkyMQ_af25b1c9-fa00-475b-a9f1-272e410921f3"
      unitRef="usdPerShare">22.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfNy01LTEtMS0zNjkyMQ_993c4377-9a9d-4085-a9a7-a44500ecd2e2">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfNy03LTEtMS0zNjkyMQ_29ebb8ed-233a-4405-93cf-bbbc1ab27e8f"
      unitRef="usd">898000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfOC0xLTEtMS0zNjkyMQ_55eba5d8-ee34-40bd-9f55-8cb9fdc41b82"
      unitRef="shares">9693151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfOC0zLTEtMS0zNjkyMQ_1c46d758-8c86-4202-b32c-79ff9ae021df"
      unitRef="usdPerShare">19.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfOC01LTEtMS0zNjkyMQ_8df43233-c92e-4abc-b356-faa612f11b66">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOmM5Zjc0NjNmYTQwMjRmM2I5YjU5YWY2YmIxOGQ3ZGZiL3RhYmxlcmFuZ2U6YzlmNzQ2M2ZhNDAyNGYzYjliNTlhZjZiYjE4ZDdkZmJfOC03LTEtMS0zNjkyMQ_8886dc4c-fa18-4afd-8ae8-6f7e5a57177e"
      unitRef="usd">903000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfMzk3Mg_8c017583-949c-4b61-af3f-e85744eb9b9d"
      unitRef="usdPerShare">7.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfMzk3OQ_0c5f8340-c59e-4efc-8722-93d9180b301c"
      unitRef="usdPerShare">14.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNDA5OQ_0879cbb6-f1d6-4884-9cec-d29289d3448e"
      unitRef="usd">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNDEwNg_2494de2a-422e-4a45-a548-531c7ca9ab9d"
      unitRef="usd">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNDIzMw_14bcc18e-d51a-46f8-ac58-0577799b699d"
      unitRef="usd">2500000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNDM0MQ_d9c08261-20bb-4b29-9058-799485d8abbe"
      unitRef="usd">5400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="ibffd39c9932942498eb61c70d23217bc_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNDM0OA_4db7962c-7bdb-4137-b566-bef65fbc97b6"
      unitRef="usd">4100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i48bdd36e5bfa487081b635f45c9c8141_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNDUxMA_cb97d24a-c596-47f5-94b4-dd81e45f2559"
      unitRef="usd">38400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNDYwMQ_512704fa-efba-43db-ab93-81fd66f6c694">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i0dc396f12757461e9c5b3a86b51821a5_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfMzg0ODI5MDcwNDYwMA_1daa5e50-3dd4-4983-9109-72486bf0e9ae">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward
      contextRef="i0dc396f12757461e9c5b3a86b51821a5_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfMzg0ODI5MDcwNDU4NQ_cf19c22f-ffd3-4c6a-9851-02d156f95633"
      unitRef="shares">1</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNTQ3Mg_b980e999-53c1-47b6-9342-0489d0742ed8">&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity during the three months ended March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ifa66c46429f947848a8668ce68165b60_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjE4ZDdhYzA5MDAxNzQ3NThiMjk5MDZjMTIxNTRkNDM5L3RhYmxlcmFuZ2U6MThkN2FjMDkwMDE3NDc1OGIyOTkwNmMxMjE1NGQ0MzlfMS0xLTEtMS0zNjkyMQ_dd614cf0-ea44-4fa6-9b41-0699da8ff5a1"
      unitRef="shares">21500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ifa66c46429f947848a8668ce68165b60_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjE4ZDdhYzA5MDAxNzQ3NThiMjk5MDZjMTIxNTRkNDM5L3RhYmxlcmFuZ2U6MThkN2FjMDkwMDE3NDc1OGIyOTkwNmMxMjE1NGQ0MzlfMS0zLTEtMS0zNjkyMQ_d16ff12c-26fa-4afe-b832-eadb879958dc"
      unitRef="usdPerShare">25.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i0dc396f12757461e9c5b3a86b51821a5_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjE4ZDdhYzA5MDAxNzQ3NThiMjk5MDZjMTIxNTRkNDM5L3RhYmxlcmFuZ2U6MThkN2FjMDkwMDE3NDc1OGIyOTkwNmMxMjE1NGQ0MzlfMi0xLTEtMS0zNjkyMQ_3ed51ae8-e559-4091-9595-dfb1c0548b7e"
      unitRef="shares">309372</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0dc396f12757461e9c5b3a86b51821a5_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjE4ZDdhYzA5MDAxNzQ3NThiMjk5MDZjMTIxNTRkNDM5L3RhYmxlcmFuZ2U6MThkN2FjMDkwMDE3NDc1OGIyOTkwNmMxMjE1NGQ0MzlfMi0zLTEtMS0zNjkyMQ_be9ee6f3-b44c-40a2-874b-eba2a0b90828"
      unitRef="usdPerShare">10.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i0dc396f12757461e9c5b3a86b51821a5_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjE4ZDdhYzA5MDAxNzQ3NThiMjk5MDZjMTIxNTRkNDM5L3RhYmxlcmFuZ2U6MThkN2FjMDkwMDE3NDc1OGIyOTkwNmMxMjE1NGQ0MzlfNC0xLTEtMS0zNjkyMQ_bf16a194-abcd-40b8-9c35-5a7681aad2bd"
      unitRef="shares">5428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i0dc396f12757461e9c5b3a86b51821a5_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjE4ZDdhYzA5MDAxNzQ3NThiMjk5MDZjMTIxNTRkNDM5L3RhYmxlcmFuZ2U6MThkN2FjMDkwMDE3NDc1OGIyOTkwNmMxMjE1NGQ0MzlfNC0zLTEtMS0zNjkyMQ_52f4a564-d285-4039-984f-a78d6e73b805"
      unitRef="usdPerShare">10.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id18c2d3f95654745b74930d2f8ea04b0_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjE4ZDdhYzA5MDAxNzQ3NThiMjk5MDZjMTIxNTRkNDM5L3RhYmxlcmFuZ2U6MThkN2FjMDkwMDE3NDc1OGIyOTkwNmMxMjE1NGQ0MzlfNS0xLTEtMS0zNjkyMQ_b9e7b859-e782-4e0e-9c7c-8736cb278e07"
      unitRef="shares">325444</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id18c2d3f95654745b74930d2f8ea04b0_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RhYmxlOjE4ZDdhYzA5MDAxNzQ3NThiMjk5MDZjMTIxNTRkNDM5L3RhYmxlcmFuZ2U6MThkN2FjMDkwMDE3NDc1OGIyOTkwNmMxMjE1NGQ0MzlfNS0zLTEtMS0zNjkyMQ_e6e43f01-41df-4c53-bc21-faf1f7b8435c"
      unitRef="usdPerShare">11.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="id18c2d3f95654745b74930d2f8ea04b0_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNTMwMg_7c651423-9f63-48c6-ab1b-1c5b30c6bab5"
      unitRef="usd">2900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i0dc396f12757461e9c5b3a86b51821a5_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81NS9mcmFnOjM3ZGNhOGFlMDY5OTRjM2FhMTBlYmNmZDdkZTQwOTI2L3RleHRyZWdpb246MzdkY2E4YWUwNjk5NGMzYWExMGViY2ZkN2RlNDA5MjZfNTQ2OA_55cece12-2701-49d6-9c2a-1d9d45f6cbb4">P1Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzA5ODExZWY2MDRkNWVhNzcyYTE5YThhOWMxZGZkL3NlYzpkYTcwOTgxMWVmNjA0ZDVlYTc3MmExOWE4YTljMWRmZF81OC9mcmFnOjU2OThkNDlmODY4YjQ1OWM4ZGRkZGJiYWUxZGMyZjhkL3RleHRyZWdpb246NTY5OGQ0OWY4NjhiNDU5YzhkZGRkYmJhZTFkYzJmOGRfMTA2Mg_2c7f9602-85ca-4bc2-b8b1-197a8ba10079">Commitments and ContingenciesOn September 13, 2019, a securities class action complaint was filed in the U.S. District Court for the District of Maryland (District Court) by Todd Hill naming the Company, its Chief Executive Officer, Dr. Koenig, and its Chief Financial Officer, Mr. Karrels, as defendants for allegedly making false and materially misleading statements regarding the Company&#x2019;s SOPHIA trial. On August 17, 2020, the Employees&#x2019; Retirement System of the City of Baton Rouge and Parish of East Baton Rouge was appointed as Lead Plaintiff, and on October 16, 2020, the Lead Plaintiff filed an amended complaint. The amended complaint asserts a putative class period stemming from February 6, 2019 to June 4, 2019. The Company filed a Motion to Dismiss on November 30, 2020. On September 29, 2021, the District Court issued an Order dismissing the case, with prejudice. On October 28, 2021 the Lead Plaintiff filed a Notice of Appeal.  The appeal is now pending in the Fourth Circuit. The Company intends to vigorously defend against this action. However, the outcome of this legal proceeding is uncertain at this time and the Company cannot reasonably estimate a range of loss, if any. Accordingly, the Company has not accrued any liability associated with this action.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>46
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MX[8-(]?UA=:C-$;F]6,B.-"N /!^):5Y;U1W9,V=Z.)_4$L#!!0    ( (N
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MI+Q1?%><.SQSI7A67&X9C9G0!O!^S;EZO=$#U$=7D_\ 4$L#!!0    ( (N
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MVSBXJ,1RMC@XF.(%GVL=)HO=U.4"BF@@"5G;RH)<;)UG%:#E$T<A%&VLE.C
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M](U!QP&T7U@;#A,FZ+]:BS]02P,$%     @ BX"C5):9XRR\!@  4A(  !@
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M@ QSU@A[JS9?<#O/R/&E2AC_A4V;&T<!I(VQJMJ"J8.*RW9ES]MSV .,!^\
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MNS?FHGE:/9HW#U0B[UK26%*8D6L8'.Z/&F[N%DY7_J&UTHZ>;?YG3N]D-&Q
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M^*+"H!=3%)%-PQ$J@$7T38%^,H*!\.FB(4B@[8>Q;&@8$8:L& COG'.31,(
M=6'Q:4=5 )5K%@3*%Q!.V.Q$[V,+(GN 1^N9\Y#$VQ77_L".10,E,DT;B(V8
MTC[FEJ,'"8R:-,\#;1Q"*H!0%*@:#EHY7\(B#'TNOZ$1:L5!4L%7$ LH@MJ=
M#S'^/-'JR-6 D44+AR)><0)EJ%K&EI=F]2@%"%)6$C%#4P.R,HX8MAU]!Z4S
MM+QK4ZEAK*C2ID#532W#3'PQ.Y\^'@X;P&>B_RZX%U MSOV2A6ZF*1ICZJS(
M:F"/HDD3DZ$8B#%J63,R*7%0$LB.MRBQJ@8&IJ4BBZ8B=IA\3U\4&0;DK:2.
M0!5TN0F6O &CPI.+%@Q(:*>MH) 55$H"X-7F*]0#\B)9YNFS/BOK$0C:]SA<
MTSD;8FQ;O-PS.&PKE1<YKLB5H%@)#)AJH0C94BC4[]7(.AF<49F)[$!><5S:
M$,D[O!RCHL]!M!8,? /!(PBG>'4C4())Q[T+,2@()R424:A/DW](+X+QD-M#
MV0A8K>!#3&!C!81C!:2E**?)R]V?AG\/IZV(VUOQ>Q/LLCPO+$>O=:35+A$\
M'B\1].;])X: +D 3Y,_-3G1<J0\T"6O8W4,#T%(S)P>]D:5+^@\N[GB'.'*8
M,WIU)M)K!WKD_OO5H3>R"_CA5MPR2>-\LMC5DFM"YD[FJQ^EPHZ$V)/ $YHQ
ML+R5S2KKE$<\,U!5-4N7VL,OZ0-,[I+?T'A 1'(I;W#]HN#&^_H5HTNBX#S#
M/(_Y-F3C?!,)4B;A)?01*69Z.8DBYD.T&.)O.0AJJ3U+HW@GHX)@#R. $F9(
M.;DJE_"P%0X+44,Z4E.AT*R!J<<8RW5BQ^NE ZNB7$,X5W (Z] O+:@2;;YK
M;<&1=S;HM)L*^85.HBE,FHR@> (!8J4(!:,5.>Y OU[EVLL6S8RU1*-4][L2
M:Y"P.'1^>N$M.;P('TQ]@ =K0;P.^Y-O)L1J)PS>4G<,V:!2>H/FDT?])FUV
M?@^3IK/@B%YZ T\1Q)UC&3-\9TN6K%.Q.MJ^L&/,GH-/4(F&L;3OG%6YP"J
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M2#J!]:@@]/?MTM/GEBWK9"?E)O^?E.F"$3)8F_/HG2R<_8F,*OQ8O#7%!-H
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M*9&;E,-4P,4A9/&'8,\*H$K;AH:K0!&K*NYQ;^ TJ>=H68G<K/P-[9\N'B[
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M^\1RD PVPBZXV')!%0,K]JS.:VJ(91_I.]02RRW2YZ<[TAQ*]>1Z/+JV6.$
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MN30X/]RRP D/RCK@^4)*LS'L$.G^,]*_4$L#!!0    ( (N HU1YLG%]L ,
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M1D$%K1U6P1=E<.],<!<>1:IC!:LTHE$+?M6-]SOP-AI1N^$=W5AXG81_YND
M?.<*/,=S6_3<=<-O,]D)7W;#/XE]#7?:W.B&KVG6&?V^&_Y("O'N6?@?_>%>
M"_RA&[ZDX;GH;U;2K_>U;_C\,WQWG"@%8@MF@\._?V$_?-0T4?]UL ]K]J%A
M'YYC%TF"%Z\JN*\@(Q+VA.<4+O X1()S(A5D5)8'YK+-S))_;/B+]V4_=P8.
M3GS?M.P'@]Y(']721WVD&ULZG AJNN 7^#RNV<>=8C_ER09M1/KCU:-43B,0
M:"W>6<;OLJ?-Y$5)/FKX=SV:#(/Q6YOOWP_S \]S)T&[TY-:_*13_*T&'5/
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M)LEE18O,I%P;H3&!,\48/RRH+ 9@_U8(?:P4 >I/E?G_4$L#!!0    ( (N
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M+2]?RBEO!$N+UR]F3 @6%Y<K2N:4YP/D]PLF-PGJ)C=0O1IU\3]02P,$%
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MA- "";!&HNS8;F ;\$N*96A7(UFW#\,^T-+9(BJ1&DG9#; ?OR,E2TXM:\:
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ML@8XOI&8057#3E _SJ;_ E!+ P04    " "+@*-4Q;C^MUP$  "M$   &0
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M,<;8A3"MM]/;,2L<#)I9.[2"FE9@I36C"RHEC4'5#;^/(!(P3G47S])4L,7
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MT2XFP/>%@)*L!H6#^C\4XY]02P,$%     @ BX"C5/ ,-!B\ @  .P@  !D
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M8C1ET@R ]PL!JE7?F F:4]_I/U!+ P04    " "+@*-4QF/(@6(#  #J"P
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MU:;57U0-;KN]^DXP?9P10X48K(UI-!B9O,JJ]:XF6NQ<N_LLM&F>W7!K/E=
MV@WF^5H(?9Y8@.8#:/XO4$L#!!0    ( (N HU3\F9 +#P,  "P1   -
M>&PO<W1Y;&5S+GAM;-U8;6^;,!#^*XA.4RM-)825A35$VI J3=JF2NV'?:N<
M8(@E8S-CNJ2_?CY,R$M]5=</6SJB%/L>WW./[XX:9=KH-:<W2TJUMZJX:%)_
MJ77],0B:Q9)6I#F7-14&*:2JB#93509-K2C)&W"J># >C>*@(DSXLZEHJZM*
M-]Y"MD*G?C28/'O[DJ=^&+_W/4N7R9RF_MWIVY^MU)=O/'L_>7=R,KH[NSRT
MGW; F1\X22^>07H^PGD-AE''SZ)^@KDC#OKDS*:%%/LY H.)3"KJW1.>^AGA
M;*X8>!6D8GQMS6,P+"27RM.F.$9*");FP<*AG4'=>IZ*":FZV#:"_3OOEQ\
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
M   ( (N HU3&\@+H4@,  ) 6   /    >&PO=V]R:V)O;VLN>&ULQ9A;;]L@
M%(#_"O++.FE;8KM-+VHJI;FLD=HXJJ.^3L0^25 P9(#;M;]^V%XTW*5'>Z%]
M<GP@^./8\ &73U)MEU)NR:^""]T/-L;L+CH=G6V@H/J;W(&P)2NI"FKLK5IW
M]$X!S?4&P!2\$W6[O4Y!F0BN+O=MS57'O9$&,L.DL,$J\,#@2?\MKV[)(]-L
MR3@SS_V@_LTA( 43K& OD/>#;D#T1C[=2,5>I#"4IYF2G/>#L"EX &58]D\X
MK2 7=*GKB*'+>VI!^D&O:QM<,:5-7:-NGUK&1["5F[O2R GC!M2(&OBN9+EC
M8ETU8WO1<;I1YV%_;9)XH?XGC7*U8AF,9%86($R31P6\ A1ZPW8Z(((6T ^&
M\A$4F=,U5)VR3YGF30>-)7/2I2Z8+5#3O&;TR)/,TN1V.AHLQB-R/;@=S(9C
MDMZ,QXO4 8P0P.C# ,G1G#J0,0(9OR-DNK"7N_', B83DLS']P[D,0)Y_&&0
MZ2(9.I G".3)AT$.!^F- ]E#('M^(6?4E J(7)%D!ZHI=\A.$;)3OV1I6114
M/5=H*5L+9O]&A2&#+).E,,R!/$,@S_Q"3BA3Y('RLD[AA DJ,D8YF0IM5%DX
MD.<(Y+E?R#NJMF EPX&DD)6*&0;N2PZ[V*3=]0LW%8^V@E3/7\@,C$N%JL2S
M2U(CL^U&\AR4_D3&/TN[ G#9,(N$GC5R#S9C94NZF"]"S\*H4_7UFFK(R5 6
MMB5=5W+Y,%6$OETABX*9JI(F5%2,=O80:[ #M3T*,%6$GEV!3G8_(A<3DT7H
MV1;H=-?&Q,P1>E;'P0F/'"VJB/[L4F+J"#V[HSWS'<3#I!%ZML9;X_H/J+ND
MQOP1>?8'_DG&+B8FE,BS4-[X)$<VQGCKI4?H#L6S6UY_DX?X,-E$[R&;5UX^
M3(DI)_*N',[I4C;+Z5HZB=G8O?)@K0"*UM#!I!/YWJ!@F*W9/,*D$WF6#H[9
M&N&8="+/TL$QCUU,S#J19^O@F"<N)F:?Z*/L\Y541>Y9"6:?V+-]$,QDU]JD
MQIA]XO?8SKR5S=9(CS'[Q)[MTV N#V'>@W8WAS%Z0E9+J+,_ <UAQ03D,_L(
M;>,9Y=E<D>K2;.6.3ZIUUJKD?&ACB;B5--\?J.X/@Z]^ U!+ P04    " "+
M@*-4X#T)5V@!  !*%   &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
MS=C-CH(P%(;A6R&] ,LY5=2)N)J-VXDW0+" D;_03D;O?@@N\".SF(WI69%"
M.'T7Y GIX<O6F;]VK:NNO8ON3=VZ5%7>]Q]:N[RR3>9676_;\4G1#4WFQ^50
MZC[+;UEI-<=QHH?7&>IX>)T9G1^]_<_$KBBNN?WL\N_&MOZ/P?JG&VZNLM:K
MZ)P-I?6ITO=ZONWT=*'5.%E%ITNJAM.%E X=Q!#$X8,,!)GP06L(6H</VD#0
M)GQ0 D%)^* M!&W#!^T@:!<^: ]!^_!!%*.,L8"D!=8"M";DF@1X30@V"1";
MD&P28#8AVB1 ;4*V28#;A'"3 +D)Z28!=A/B30+T9M2;!>C-J#<+T)L7/]L"
M]&;4FP7HS:@W"]";46\6H#>CWBQ ;T:]68#>C'JS +T9]68!>AO4VPC0VZ#>
M1H#>!O4V O0VB\.2=^KM_*.V;NYYKG'_=U+MQW?MO/VT?-Y<?"H3SAJ.#H^_
M4$L#!!0    ( (N HU0<F@E=C $  .<4   3    6T-O;G1E;G1?5'EP97-=
M+GAM;,V8S6[",!"$7R7*%1%CIZ4_ BYMKRV'OH";;(A%$ENVH?#V=<*/U(I&
M("IU+K$2[\Z,O=)WR.1]:\A%F[IJW#0NO3>/C+FLI%JZ1!MJPDZA;2U]>+4+
M9F2VE MB8C0:LTPWGAH_]*U&/)L\4R%7E8]>-N&S4[J9QI8J%T=/N\+6:QI+
M8RJ521_VV;K)?[@,]PY)Z.QJ7*F,&X2"F)UT:'=^-]CWO:W)6I53-)?6O\HZ
M5+%-Q9S?5N22?HD3&751J(QRG:WJT)(X8TGFKB3R=97L1 ?]SC[<,.V>_&K_
M3J;/,%3.K38N3,S2Y7:'D;3=0Q.$R'K5?\2C8Y"^^GS43CNG_$SO<+V?VBZ[
M>3C6+=??\?<9'_4OS"% <J0@.6Y <MR"Y!B#Y+@#R7$/DN,!) <?H01!(2I'
M02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M (:M (:M (:M (:M
M(:M (:M (6N*0M84A:PI"EG3_R3KA];+O_[UUJY)+55S\&?=_\W9%U!+ 0(4
M Q0    ( (N HU0'04UB@0   +$    0              "  0    !D;V-0
M<F]P<R]A<' N>&UL4$L! A0#%     @ BX"C5+:VWFKN    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ BX"C
M5)E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " "+@*-41))+LCD%  !G%0  &
M@($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ BX"C
M5(8)H]5K!0  'Q4  !@              ("!? T  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( (N HU1"@!( 8@(  /L%   8
M      " @1T3  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" "+@*-43B^<6>X$  #&$@  &               @(&U%0  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ BX"C5&8W,U,H!0  \Q0  !@
M             ("!V1H  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( (N HU3++7?_/ 8  &P8   8              " @3<@  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "+@*-4Y2Y0 ;\)   8
M%P  &               @(&I)@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ BX"C5.^*ZK3K @  P08  !@              ("!GC
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( (N HU26F>,L
MO 8  %(2   8              " @;\S  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " "+@*-4Q$Q/(6X#  !,"   &0
M@(&Q.@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( (N
MHU3M/'8JB0(  '$%   9              " @58^  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ BX"C5&"!1#3C!   A0L  !D
M         ("!%D$  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " "+@*-4.L3,(,@;  #8A   &0              @($P1@  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( (N HU1.$1U#< H  'T<
M   9              " @2]B  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ BX"C5#0<BXQ=!   >@D  !D              ("!UFP
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " "+@*-46NN>
M[4H'  #U$@  &0              @(%J<0  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( (N HU1#6*$2<@,  -0(   9
M  " @>MX  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
MBX"C5*Q;^(X+ P  YP8  !D              ("!E'P  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " "+@*-4BNKX]YD"  !R!0  &0
M            @('6?P  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( (N HU2%<E1?Y00   @,   9              " @::"  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ BX"C5*4V77K2!
M AL  !D              ("!PH<  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " "+@*-4S9G)>?4#  !=$0  &0              @('+
MC   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( (N HU0P
M_CKS90(  #\&   9              " @?>0  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ BX"C5'FR<7VP P  M@P  !D
M     ("!DY,  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (N HU3P##08O (  #L(   9              "
M@6.M  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ BX"C
M5#!X>U1(!0   18  !D              ("!5K   'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " "+@*-4QF/(@6(#  #J"P  &0
M        @('5M0  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( (N HU1_UDWP\@4  +L9   9              " @6ZY  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ BX"C5.TT6VNY P  # T
M !D              ("!E[\  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " "+@*-4_)F0"P\#   L$0  #0              @ &'PP
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( (N HU27BKL<P    !,"   +
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4!08     *0 I !8+  "&S@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>146</ContextCount>
  <ElementCount>202</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>47</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/NatureofOperations</Role>
      <ShortName>Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104103 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/FairValueofFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2107104 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110105 - Disclosure - Inventory, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/InventoryNet</Role>
      <ShortName>Inventory, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2113106 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2115107 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2121108 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2127109 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/FairValueofFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/FairValueofFinancialInstruments</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecurities</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2311303 - Disclosure - Inventory, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/InventoryNetTables</Role>
      <ShortName>Inventory, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/InventoryNet</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockBasedCompensation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2406401 - Disclosure - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails</Role>
      <ShortName>Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/FairValueofFinancialInstrumentsTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Inventory, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/InventoryNetDetails</Role>
      <ShortName>Inventory, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/InventoryNetTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2414404 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockholdersEquity</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2416405 - Disclosure - Collaboration and Other Agreements - Incyte Corporation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails</Role>
      <ShortName>Collaboration and Other Agreements - Incyte Corporation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2417406 - Disclosure - Collaboration and Other Agreements - Zai Lab (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails</Role>
      <ShortName>Collaboration and Other Agreements - Zai Lab (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2418407 - Disclosure - Collaboration and Other Agreements - Janssen (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails</Role>
      <ShortName>Collaboration and Other Agreements - Janssen (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2419408 - Disclosure - Collaboration and Other Agreements - I-Mab Biopharma (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails</Role>
      <ShortName>Collaboration and Other Agreements - I-Mab Biopharma (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2420409 - Disclosure - Collaboration and Other Agreements - NIAID Contract (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails</Role>
      <ShortName>Collaboration and Other Agreements - NIAID Contract (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2423410 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - Stock-Based Compensation - Option Pricing Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Option Pricing Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="mgnx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Stock-based Compensation - Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock-based Compensation - Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="mgnx-20220331.htm">mgnx-20220331.htm</File>
    <File>ex101spitznagelemploymenta.htm</File>
    <File>exhibit31-1q12022.htm</File>
    <File>exhibit31-2q12022.htm</File>
    <File>exhibit32-1q12022.htm</File>
    <File>exhibit32-2q12022.htm</File>
    <File>mgnx-20220331.xsd</File>
    <File>mgnx-20220331_cal.xml</File>
    <File>mgnx-20220331_def.xml</File>
    <File>mgnx-20220331_lab.xml</File>
    <File>mgnx-20220331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="371">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>52
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mgnx-20220331.htm": {
   "axisCustom": 0,
   "axisStandard": 13,
   "contextCount": 146,
   "dts": {
    "calculationLink": {
     "local": [
      "mgnx-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mgnx-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mgnx-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mgnx-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mgnx-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mgnx-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 321,
   "entityCount": 1,
   "hidden": {
    "http://macrogenics.com/20220331": 1,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 6
   },
   "keyCustom": 30,
   "keyStandard": 172,
   "memberCustom": 27,
   "memberStandard": 17,
   "nsprefix": "mgnx",
   "nsuri": "http://macrogenics.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://macrogenics.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107104 - Disclosure - Marketable Securities",
     "role": "http://macrogenics.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110105 - Disclosure - Inventory, Net",
     "role": "http://macrogenics.com/role/InventoryNet",
     "shortName": "Inventory, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113106 - Disclosure - Stockholders' Equity",
     "role": "http://macrogenics.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115107 - Disclosure - Revenue",
     "role": "http://macrogenics.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121108 - Disclosure - Stock-Based Compensation",
     "role": "http://macrogenics.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127109 - Disclosure - Commitments and Contingencies",
     "role": "http://macrogenics.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "role": "http://macrogenics.com/role/FairValueofFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Marketable Securities (Tables)",
     "role": "http://macrogenics.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311303 - Disclosure - Inventory, Net (Tables)",
     "role": "http://macrogenics.com/role/InventoryNetTables",
     "shortName": "Inventory, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i48bdd36e5bfa487081b635f45c9c8141_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i48bdd36e5bfa487081b635f45c9c8141_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://macrogenics.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i48bdd36e5bfa487081b635f45c9c8141_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406401 - Disclosure - Fair Value of Financial Instruments (Details)",
     "role": "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
     "shortName": "Fair Value of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "iadf67bfafee04b0e8f19076f8b5ba241_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i48bdd36e5bfa487081b635f45c9c8141_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409402 - Disclosure - Marketable Securities (Details)",
     "role": "http://macrogenics.com/role/MarketableSecuritiesDetails",
     "shortName": "Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i48bdd36e5bfa487081b635f45c9c8141_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i48bdd36e5bfa487081b635f45c9c8141_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWorkInProcess",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412403 - Disclosure - Inventory, Net (Details)",
     "role": "http://macrogenics.com/role/InventoryNetDetails",
     "shortName": "Inventory, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i48bdd36e5bfa487081b635f45c9c8141_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWorkInProcess",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i48bdd36e5bfa487081b635f45c9c8141_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414404 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://macrogenics.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i53817096bacf40229bf71a7348ab1def_D20210601-20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416405 - Disclosure - Collaboration and Other Agreements - Incyte Corporation (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
     "shortName": "Collaboration and Other Agreements - Incyte Corporation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i3a2c1fb5405243d38e27f09c198a5915_D20180101-20180630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417406 - Disclosure - Collaboration and Other Agreements - Zai Lab (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
     "shortName": "Collaboration and Other Agreements - Zai Lab (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "ifba4c7039c924aa5b223417e6cf78e36_D20190101-20190630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418407 - Disclosure - Collaboration and Other Agreements - Janssen (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
     "shortName": "Collaboration and Other Agreements - Janssen (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i76399d6c1802415b90c08bf9c69f7100_D20201201-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419408 - Disclosure - Collaboration and Other Agreements - I-Mab Biopharma (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
     "shortName": "Collaboration and Other Agreements - I-Mab Biopharma (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "iecc8c23d2f2f46e295c148fe79e31e39_D20200101-20200630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420409 - Disclosure - Collaboration and Other Agreements - NIAID Contract (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
     "shortName": "Collaboration and Other Agreements - NIAID Contract (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i1337d1949d0643488c0089eab0614890_D20150915-20150915",
      "decimals": "INF",
      "lang": "en-US",
      "name": "mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "molecule",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i48bdd36e5bfa487081b635f45c9c8141_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i48bdd36e5bfa487081b635f45c9c8141_I20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i48bdd36e5bfa487081b635f45c9c8141_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423410 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "role": "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - Stock-Based Compensation - Option Pricing Assumptions (Details)",
     "role": "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Option Pricing Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i63fbc95e39fe4d1b91328a28079b6e2f_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "role": "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Stock-based Compensation - Restricted Stock Unit Activity (Details)",
     "role": "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails",
     "shortName": "Stock-based Compensation - Restricted Stock Unit Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "ifa66c46429f947848a8668ce68165b60_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i12a5fd8f1ac64b25a36c35f490310693_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i12a5fd8f1ac64b25a36c35f490310693_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Nature of Operations",
     "role": "http://macrogenics.com/role/NatureofOperations",
     "shortName": "Nature of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104103 - Disclosure - Fair Value of Financial Instruments",
     "role": "http://macrogenics.com/role/FairValueofFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220331.htm",
      "contextRef": "i4fd1d28bba7b43529bf97d53588b6192_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 47,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mgnx_A2003StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "A2003StockIncentivePlanMember",
        "terseLabel": "2003 Stock Incentive Plan"
       }
      }
     },
     "localname": "A2003StockIncentivePlanMember",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Zai Lab Collaboration And License Agreement",
        "label": "2018 Zai Lab Collaboration And License Agreement [Member]",
        "terseLabel": "2018 Zai Lab Agreement"
       }
      }
     },
     "localname": "A2018ZaiLabCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_A2021ZaiLabAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Zai Lab Agreements",
        "label": "2021 Zai Lab Agreements [Member]",
        "terseLabel": "2021 Zai Lab Agreements"
       }
      }
     },
     "localname": "A2021ZaiLabAgreementsMember",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At the Market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Collaboration and License Agreements [Abstract]",
        "terseLabel": "Collaboration and License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://macrogenics.com/20220331",
     "xbrltype": "stringItemType"
    },
    "mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration And Other Agreements Disclosure [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "CollaborationAndOtherAgreementsDisclosureTextBlock",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mgnx_CollaborativeAgreementTransactionPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "CollaborativeAgreementTransactionPrice",
        "terseLabel": "Collaborative agreement transaction price"
       }
      }
     },
     "localname": "CollaborativeAgreementTransactionPrice",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance",
        "terseLabel": "Potential annual increase in shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_CommonStockMaximumAmountAvailableForIssuance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Maximum Amount Available For Issuance",
        "label": "Common Stock, Maximum Amount Available For Issuance",
        "terseLabel": "Maximum amount available for issuance"
       }
      }
     },
     "localname": "CommonStockMaximumAmountAvailableForIssuance",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Maximum Amount Available For Issuance, Increase",
        "label": "Common Stock, Maximum Amount Available For Issuance, Increase",
        "terseLabel": "Maximum amount available for issuance, increase"
       }
      }
     },
     "localname": "CommonStockMaximumAmountAvailableForIssuanceIncrease",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development And Regulatory Milestone Payments Under Agreement, Recognized",
        "label": "Development And Regulatory Milestone Payments Under Agreement, Recognized",
        "terseLabel": "Development and regulatory milestones recognized"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent",
        "terseLabel": "Payroll deduction percentage"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I-Mab Biopharma Collaboration And License Agreement Clinical Supply",
        "label": "I-Mab Biopharma Collaboration And License Agreement Clinical Supply [Member]",
        "terseLabel": "I-Mab Biopharma Collaboration And License Agreement Clinical Supply"
       }
      }
     },
     "localname": "IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I-Mab Biopharma Collaboration And License Agreement",
        "label": "I-Mab Biopharma Collaboration And License Agreement [Member]",
        "terseLabel": "I-Mab Biopharma Collaboration and License Agreement"
       }
      }
     },
     "localname": "IMabBiopharmaCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IMabBiopharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I-Mab Biopharma",
        "label": "I-Mab Biopharma [Member]",
        "terseLabel": "I-Mab"
       }
      }
     },
     "localname": "IMabBiopharmaMember",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IncyteCorporationMember",
        "terseLabel": "Incyte Corporation"
       }
      }
     },
     "localname": "IncyteCorporationMember",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012AgreementClinicalActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IncyteMGA012AgreementClinicalActivitiesMember",
        "terseLabel": "Incyte MGA012 Agreement - Clinical activities"
       }
      }
     },
     "localname": "IncyteMGA012AgreementClinicalActivitiesMember",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IncyteMGA012AgreementMember",
        "terseLabel": "Incyte MGA012 Agreement"
       }
      }
     },
     "localname": "IncyteMGA012AgreementMember",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012ClinicalServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte MGA012 Clinical Services",
        "label": "Incyte MGA012 Clinical Services [Member]",
        "terseLabel": "Incyte MGA012 Clinical Services"
       }
      }
     },
     "localname": "IncyteMGA012ClinicalServicesMember",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012SupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte MGA012 Supply Agreement",
        "label": "Incyte MGA012 Supply Agreement [Member]",
        "terseLabel": "Incyte MGA012 Supply Agreement"
       }
      }
     },
     "localname": "IncyteMGA012SupplyAgreementMember",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_JanssenBiotechIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Biotech Inc",
        "label": "Janssen Biotech Inc [Member]",
        "terseLabel": "Janssen Biotech Inc"
       }
      }
     },
     "localname": "JanssenBiotechIncMember",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_JanssenCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Collaboration And License Agreement",
        "label": "Janssen Collaboration And License Agreement [Member]",
        "terseLabel": "Janssen Collaboration and License Agreement"
       }
      }
     },
     "localname": "JanssenCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NationalInstituteOfAllergyAndInfectiousDiseasesMember",
        "terseLabel": "NIAID"
       }
      }
     },
     "localname": "NationalInstituteOfAllergyAndInfectiousDiseasesMember",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_NonRefundableUpfrontFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "NonRefundableUpfrontFees",
        "terseLabel": "Non-refundable upfront payment"
       }
      }
     },
     "localname": "NonRefundableUpfrontFees",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NonrefundablePaymentTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonrefundable Payment Tax Withholding",
        "label": "Nonrefundable Payment Tax Withholding",
        "terseLabel": "Nonrefundable payment tax withholding"
       }
      }
     },
     "localname": "NonrefundablePaymentTaxWithholding",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonrefundable Upfront Fees, Net Of Tax Withholding",
        "label": "Nonrefundable Upfront Fees, Net Of Tax Withholding",
        "terseLabel": "Non-refundable upfront payment, net of tax withholding"
       }
      }
     },
     "localname": "NonrefundableUpfrontFeesNetOfTaxWithholding",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement",
        "terseLabel": "Number of commercialized molecules"
       }
      }
     },
     "localname": "NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_NumberOfPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Performance Obligations",
        "terseLabel": "Number of performance obligations"
       }
      }
     },
     "localname": "NumberOfPerformanceObligations",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_OneTimeMillstoneCredit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Time Millstone Credit",
        "label": "One Time Millstone Credit",
        "terseLabel": "One Time Millstone Credit"
       }
      }
     },
     "localname": "OneTimeMillstoneCredit",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_OptInFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opt-in Fee",
        "label": "Opt-in Fee",
        "terseLabel": "Opt-in fee"
       }
      }
     },
     "localname": "OptInFee",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan",
        "terseLabel": "Potential annual increase in shares reserved for future issuance as percentage of outstanding share"
       }
      }
     },
     "localname": "PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_PotentialCommercialMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "PotentialCommercialMilestonePaymentsUnderAgreement",
        "terseLabel": "Potential commercial milestone payments under agreement"
       }
      }
     },
     "localname": "PotentialCommercialMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement",
        "terseLabel": "Potential development and regulatory milestone payments under agreement"
       }
      }
     },
     "localname": "PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Milestone Payments and Royalties On Product Sales",
        "label": "Potential Milestone Payments and Royalties On Product Sales",
        "terseLabel": "Potential milestone payments and royalties on product sales"
       }
      }
     },
     "localname": "PotentialMilestonePaymentsAndRoyaltiesOnProductSales",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PremiumReceivedOnStockPurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PremiumReceivedOnStockPurchase",
        "label": "PremiumReceivedOnStockPurchase",
        "terseLabel": "Premium received on stock purchase"
       }
      }
     },
     "localname": "PremiumReceivedOnStockPurchase",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ProceedsfromRoyaltiesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ProceedsfromRoyaltiesPercent",
        "terseLabel": "Potential proceeds from royalties (percent)"
       }
      }
     },
     "localname": "ProceedsfromRoyaltiesPercent",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ProceedsfromStockOptionsExercisedAndESPPPurchases",
        "verboseLabel": "Proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsfromStockOptionsExercisedAndESPPPurchases",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenueFromCollaborativeAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RevenueFromCollaborativeAgreementsMember",
        "terseLabel": "Revenue from collaborative and other agreements"
       }
      }
     },
     "localname": "RevenueFromCollaborativeAgreementsMember",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueFromGovernmentAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RevenueFromGovernmentAgreementsMember",
        "terseLabel": "Revenue from government agreements"
       }
      }
     },
     "localname": "RevenueFromGovernmentAgreementsMember",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Performance Of The Research And Development Activities",
        "label": "Revenue From Performance Of The Research And Development Activities [Member]",
        "terseLabel": "Revenue From Performance of the Research and Development Activities"
       }
      }
     },
     "localname": "RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Information Used To Assess Variable Consideration, Amount",
        "label": "Revenue, Information Used To Assess Variable Consideration, Amount",
        "terseLabel": "Estimated variable consideration"
       }
      }
     },
     "localname": "RevenueInformationUsedToAssessVariableConsiderationAmount",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount",
        "label": "Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount",
        "terseLabel": "Variable consideration recognized",
        "verboseLabel": "Clinical trial activities selling price amount"
       }
      }
     },
     "localname": "RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenuesFromCMOAgreementsMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RevenuesFromCMOAgreementsMember",
        "label": "RevenuesFromCMOAgreementsMember [Member]",
        "terseLabel": "RevenuesFromCMOAgreementsMember"
       }
      }
     },
     "localname": "RevenuesFromCMOAgreementsMemberMember",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenuesFromGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RevenuesFromGrantsMember",
        "terseLabel": "Revenues From Grants"
       }
      }
     },
     "localname": "RevenuesFromGrantsMember",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenuesFromLicenseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RevenuesFromLicenseAgreementsMember",
        "terseLabel": "Revenues From License Agreements"
       }
      }
     },
     "localname": "RevenuesFromLicenseAgreementsMember",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenuesNetOfTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues, Net Of Tax Withholding",
        "label": "Revenues, Net Of Tax Withholding",
        "terseLabel": "Revenues, net of tax withholding"
       }
      }
     },
     "localname": "RevenuesNetOfTaxWithholding",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number Of Shares Received For Each Vested Award",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number Of Shares Received For Each Vested Award",
        "terseLabel": "Number of shares per employee"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period",
        "terseLabel": "Offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mgnx_StockIncentivePlan2013Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "StockIncentivePlan2013Member",
        "terseLabel": "Stock Incentive Plan 2013"
       }
      }
     },
     "localname": "StockIncentivePlan2013Member",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_StockIssuedDuringPeriodSharesStockPlanActivity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued due to stock plan related activity.",
        "label": "Stock Issued During Period Shares Stock Plan Activity",
        "terseLabel": "Stock plan activity (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockPlanActivity",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_StockIssuedDuringPeriodValueStockPlanActivity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued due to stock plan related activity.",
        "label": "Stock Issued During Period Value Stock Plan Activity",
        "terseLabel": "Stock plan related activity"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockPlanActivity",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_TotalAnnualFixedPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Annual Fixed Payments",
        "label": "Total Annual Fixed Payments",
        "terseLabel": "Annual Fixed Payments"
       }
      }
     },
     "localname": "TotalAnnualFixedPayments",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_TotalPotentialValueUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "TotalPotentialValueUnderAgreement",
        "terseLabel": "Total potential value"
       }
      }
     },
     "localname": "TotalPotentialValueUnderAgreement",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TwoThousandSixteenEmployeeStockPurchasePlanMember",
        "terseLabel": "2016 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandSixteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabClinicalSupplyAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Lab Clinical Supply Agreements",
        "label": "Zai Lab Clinical Supply Agreements [Member]",
        "terseLabel": "Zai Lab Clinical Supply Agreements"
       }
      }
     },
     "localname": "ZaiLabClinicalSupplyAgreementsMember",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Lab",
        "label": "Zai Lab [Member]",
        "terseLabel": "Zai Labs"
       }
      }
     },
     "localname": "ZaiLabMember",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Labs Collaboration And License Agreement, Margetuximab",
        "label": "Zai Labs Collaboration And License Agreement, Margetuximab [Member]",
        "terseLabel": "Zai Lab Agreement, Margetuximab"
       }
      }
     },
     "localname": "ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Labs Collaboration And License Agreement, TRIDENT molecule",
        "label": "Zai Labs Collaboration And License Agreement, TRIDENT molecule [Member]",
        "terseLabel": "Zai Lab Agreement, TRIDENT molecule"
       }
      }
     },
     "localname": "ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember",
     "nsuri": "http://macrogenics.com/20220331",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r38",
      "r40",
      "r84",
      "r85",
      "r181",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r180",
      "r191",
      "r228",
      "r229",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r345",
      "r369",
      "r371",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r180",
      "r191",
      "r228",
      "r229",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r345",
      "r369",
      "r371",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r127",
      "r216",
      "r218",
      "r348",
      "r368",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r127",
      "r216",
      "r218",
      "r348",
      "r368",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r180",
      "r191",
      "r219",
      "r228",
      "r229",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r345",
      "r369",
      "r371",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r180",
      "r191",
      "r219",
      "r228",
      "r229",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r345",
      "r369",
      "r371",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r39",
      "r40",
      "r84",
      "r85",
      "r181",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r27",
      "r314"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r6",
      "r14",
      "r130",
      "r131"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization of premiums and discounts on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r262",
      "r263",
      "r264",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r230",
      "r232",
      "r268",
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r232",
      "r258",
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r43",
      "r46",
      "r52",
      "r53",
      "r54",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r82",
      "r116",
      "r119",
      "r125",
      "r146",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r279",
      "r282",
      "r302",
      "r312",
      "r314",
      "r350",
      "r360"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r37",
      "r82",
      "r146",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r279",
      "r282",
      "r302",
      "r312",
      "r314"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r135",
      "r153"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r133",
      "r136",
      "r153",
      "r352"
     ],
     "calculation": {
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value",
        "verboseLabel": "Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r233",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r75",
      "r76",
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property, equipment and software included in accounts payable or accruals"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r25",
      "r74"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r69",
      "r74",
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r69",
      "r303"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaboration And Other Agreements [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r87",
      "r88",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r13",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r13",
      "r314"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value -- 125,000,000 shares authorized, 61,333,074 and 61,307,428 shares outstanding at March\u00a031, 2022 and December\u00a031, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r48",
      "r50",
      "r51",
      "r57",
      "r354",
      "r366"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r214",
      "r215",
      "r217"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r214",
      "r215",
      "r217"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r214",
      "r215",
      "r217"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r220",
      "r227",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r61",
      "r348"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of product sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r137",
      "r153",
      "r156",
      "r157"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit loss related to available-for-sale debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Available-for-sale Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r72",
      "r115"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r58",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r100",
      "r102",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r288",
      "r289",
      "r355",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per common share (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r58",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r102",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r288",
      "r289",
      "r355",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per common share (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r259"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense recognition period (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r259"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r52",
      "r53",
      "r54",
      "r87",
      "r88",
      "r89",
      "r91",
      "r97",
      "r99",
      "r109",
      "r147",
      "r205",
      "r212",
      "r262",
      "r263",
      "r264",
      "r274",
      "r275",
      "r287",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r372",
      "r373",
      "r374",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Financial Assets Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r290",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r182",
      "r184",
      "r185",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r291",
      "r318",
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r290",
      "r291",
      "r293",
      "r294",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r182",
      "r220",
      "r221",
      "r226",
      "r227",
      "r291",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r182",
      "r184",
      "r185",
      "r220",
      "r221",
      "r226",
      "r227",
      "r291",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r182",
      "r184",
      "r185",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r318",
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r296",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value Measurements, Recurring Basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r300",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r140",
      "r141",
      "r143",
      "r144",
      "r145",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r154",
      "r155",
      "r158",
      "r159",
      "r183",
      "r203",
      "r286",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r163",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.",
        "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r71",
      "r346"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r71",
      "r311"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "terseLabel": "Other non current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other non current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory, Net"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/InventoryNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://macrogenics.com/role/InventoryNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r5",
      "r36",
      "r314"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://macrogenics.com/role/InventoryNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory, net",
        "totalLabel": "Total inventory, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r36",
      "r160"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Inventory valuation reserves"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://macrogenics.com/role/InventoryNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r142",
      "r349",
      "r358",
      "r378",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r28",
      "r82",
      "r120",
      "r146",
      "r169",
      "r170",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r280",
      "r282",
      "r283",
      "r302",
      "r312",
      "r313"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r19",
      "r82",
      "r146",
      "r302",
      "r314",
      "r351",
      "r362"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r30",
      "r82",
      "r146",
      "r169",
      "r170",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r280",
      "r282",
      "r283",
      "r302",
      "r312",
      "r313",
      "r314"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r69",
      "r70",
      "r73"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r47",
      "r49",
      "r54",
      "r56",
      "r73",
      "r82",
      "r90",
      "r92",
      "r93",
      "r94",
      "r95",
      "r98",
      "r99",
      "r103",
      "r116",
      "r118",
      "r121",
      "r124",
      "r126",
      "r146",
      "r169",
      "r170",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r289",
      "r302",
      "r353",
      "r365"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r116",
      "r118",
      "r121",
      "r124",
      "r126"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r3",
      "r86",
      "r112",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Nature of Operations"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/NatureofOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r41",
      "r42",
      "r44"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r64",
      "r66",
      "r134"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, equipment and software"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r233",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r7",
      "r23",
      "r24"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r64",
      "r65",
      "r134"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sale and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r68",
      "r261"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash received for options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product revenue, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r162",
      "r314",
      "r359",
      "r363"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, equipment and software, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r272",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r272",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r271",
      "r347",
      "r382"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r16",
      "r212",
      "r265",
      "r314",
      "r361",
      "r375",
      "r376"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r87",
      "r88",
      "r89",
      "r91",
      "r97",
      "r99",
      "r147",
      "r262",
      "r263",
      "r264",
      "r274",
      "r275",
      "r287",
      "r372",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r55",
      "r82",
      "r113",
      "r114",
      "r117",
      "r122",
      "r123",
      "r127",
      "r128",
      "r129",
      "r146",
      "r169",
      "r170",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r302",
      "r356"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds of stock sale"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sales of stock purchase price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "License And Collaboration Agreements [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r232",
      "r257",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r232",
      "r257",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r20",
      "r21",
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r233",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Valuation Assumptions Using the Black-Scholes Option-Pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r32",
      "r80",
      "r110",
      "r111",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r194",
      "r198",
      "r203",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in stock options.",
        "label": "Schedule of Stock Options Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Roll Forward"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]",
        "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]"
       }
      }
     },
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited or expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending Balance (in dollars per share)",
        "periodStartLabel": "Beginning Balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Share-based compensation, number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Shares, Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Shares, Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Shares, Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r260"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding, Ending Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r239",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Shares, Outstanding, Ending Balance (in shares)",
        "periodStartLabel": "Shares, Outstanding, Beginning Balance (in shares)",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share)",
        "periodStartLabel": "Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)",
        "terseLabel": "Weighted-average exercise price of stock options outstanding (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Shares, Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Common stock purchased (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r231",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r253",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r260"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Vested and expected to vest (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock percent of the fair market value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r79",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r33",
      "r52",
      "r53",
      "r54",
      "r87",
      "r88",
      "r89",
      "r91",
      "r97",
      "r99",
      "r109",
      "r147",
      "r205",
      "r212",
      "r262",
      "r263",
      "r264",
      "r274",
      "r275",
      "r287",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r372",
      "r373",
      "r374",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r109",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r12",
      "r13",
      "r205",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of shares issued or sold (in shares)",
        "verboseLabel": "Issuance of common stock, net of offering costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r12",
      "r13",
      "r205",
      "r212",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Shares, Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r12",
      "r13",
      "r205",
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r13",
      "r17",
      "r18",
      "r82",
      "r132",
      "r146",
      "r302",
      "r314"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r53",
      "r82",
      "r87",
      "r88",
      "r89",
      "r91",
      "r97",
      "r146",
      "r147",
      "r212",
      "r262",
      "r263",
      "r264",
      "r274",
      "r275",
      "r277",
      "r278",
      "r284",
      "r287",
      "r302",
      "r304",
      "r305",
      "r309",
      "r373",
      "r374",
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r81",
      "r190",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r140",
      "r141",
      "r143",
      "r144",
      "r145",
      "r183",
      "r203",
      "r286",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r220",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "Government-sponsored enterprises"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r83",
      "r220",
      "r227",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r101",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted weighted average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r100",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic weighted average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r383": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r384": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r385": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r386": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r387": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r388": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r389": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r390": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r391": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r392": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r393": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r394": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r395": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r396": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>53
<FILENAME>0001125345-22-000047-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001125345-22-000047-xbrl.zip
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M3$@P:$87AM)0\K!ZBW88B;D'L^>BL($PU)JBO]JZS9Q00=FO56K1.CGF+=U
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MM"(X!LZ<FR,L=$MF.B^96M04%V7.0#W59@2)6Y0%W)&^78)" 74+XAM^FMF
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M>?'+^>D_3X:GV?I;K*.;"^GS1;D$4\PG?R;)V>+@Y>VVC3XB.QK.PG6C&;9
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M31^HC-.QX9QV/MI8U6I21O^NBIQX:^JP6^4SWWDTU_3)2?SXY>P_4$L#!!0
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M>E]$V*R26:T?B_S-S7#U;"^IS75Y]!E02P,$%     @ BX"C5/"RQG_= P
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MQ"N\C/"9*RQUY165D#^ED-\AHN/P#SCK-J1;QM!<>N1%?.A"'_3ZE2WWA/9
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M7AZV3FTEIT+16:!HO;66$+2TC,[W>/UH\[./T2BL'""HAG\$,YDQ6&6!4>Z
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M+4[;S6D$F(LQD]&BD(ZN9T$MK0J\3"E=1O)VDG)1;')>%&S%=?//=:3^]3.
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M 4@!851;JK$R3D9:S.,UQL'6P7R*>1DXD0QQ+ 0P0.^0Q<S"^!*IHN'2"&"
ME)FF7%J>^8=%Q)>08;#:ZD3.#F.HZC3%WM#F"7EA1;W_O_]'4T)_6[62L*6,
M\S.?IA7?ZWCFR^D.3(9%3:TV7BC*N+?4,JZT#=9215+T[!95#*Y2FLLB-\/#
M_F6$<0XNWNU-PHHK<*ZP^=4,-+^/P("&[5$\B(,O;1__@I?OA_?1]S_UJKO\
MC^V,8R$[2R,[9XM[ 8I2)AE!,1*,N- ^5]+Q.6Y%$>5P=(EO;(DFI8LIP)\/
M>#U/4'AV.J9,4YFF=5"Q2R@45%3LVJK8!7^"%]QSS3WHV)1U++?(1NP0AWEG
M$CM*!%T]'?L=G\%JL_S2\N6T? DG+"JW<0->O=>H\L7DA*, $%_FCXO=\8C%
M<U+#UQZDH,1Z';TC,2GN'-%::**88%A)RBS_CB:>.5'1_=3[M_;>UZ<I=L:#
M[+.OU&E]RJ*Z^!=,T?9D9LJ!BV5IU0N->FFX6N&HANE"# =0JI%8I$&!(B4U
M$Q(SSO*!"RJ:\IJL7ZN6Y*LDA%R&2;3"T[3*^O/Y+Z>G\(Y^2U]4-M<UZJ+8
M67?1"/.N3"&$-T%@I$)V94J%D5$Y>; B5"5%K!-N8XNIH@W63'R?G38HTU2F
M:1V4X=+\F$49/KAY-.]TU%)$:JA#5&B&N)44.8$ULIH&GKR3)I@5TX8O(4KI
M0V\0H1OG,=3%3T$ V[TO<>+<+[%*9>>K3%.)52K+:9V64YFF,DUK<7!+:9H<
M8\Q%Q3A5P2IM\NDMBI5()I%;\/D;3G!=TIJWMMW+^1[W>[N7O*:P^;NP^6N.
M9NF0?.*:(\Z#1#P0BHR/"@EG/(U&1$6 S5.Z>%A_A6I6%M']<=%=@BE>1/=1
M1'?!$'?!@\WMD&!&(1ZE1T[B@ (G^<!8LEK@%1+=EQ!-T8JCROI^8:$3Q4%;
MIJEL?K^TS>]GMYR>YS3=A0QZ)0P%[H>YI=P MU"1QLAL4!3,N6!_G R"9JR3
M]F<>6*+"E\8+SQ;S##D3J2?)(ZUL0MS 9.G$" I2JABL40++C2TIFYPO9L^\
M<\:-(L@%;\LTK9SQ7?#VP?!VX12.D8HD89&PDB">$WJ80!1*GHO@&,')X=7"
MVY>P'WY1.F+/#OSQM&X$O<]&^"25RJ24)(/!#_UQ+DQ9I5-YP54EJ+0&*\JE
M3)QKR33G(487HH8?@&M5#J-OG8$H524>$K3V7RT<<J F!!Z#1C$(E4_G"V2E
MX3"\D@?#;*+6UE4E&&MBM:SC@\N0H"?>.G@RD%@YA+U]:K=E#LV:XN8B]_LQ
MT"SU*E8#4.?K56AA0F1!(<("&-T"!Z0U]LA@%PVE 1!5+J5>Q?-!TA5QSOYX
M-8N"^ 7Q[X+XSDJIDG!"DL!UT)8P;X0/1(>@5,"/C?C%*; T=3!_9,P9*A)1
M@/]6Y,P<R2%'-?!KHAFW0+=9/C*6*V'H)I5%*12P+6"[9-\J]D%3*[C.,8D>
M.XV#<<H&%RUF0+EO1MM28V-=8'=A[XM$Q[!E 47##>)!:V224 A+;CS% 8/.
MS;B+.6XR9>X?&54@MT!N@=P)Y *?M5:PE#Q1W,2H16 )<V>3%$Y'^F206U#U
M;J@Z%R0>8_+428:T,!)Q[ABR4F,DC$B@6Y/R&56IOL_V5L'3@J<O 4_O$AV@
M70A,1N&2Y5IA34 &1>+"&Z\))\5?L+X0.Q]$P$20QE&.*"= 7&EV&'#K$(U&
M>IP8<Q5Q5;I)R7/8C2M)0$O+M6A9%FIIN18MRT(M+=>B95FHI>5:M"P+M;1<
MBY9EH9:6:]&R+-32<BU:EH5:6JY%R[)02\NU:%D6:FFY%BW+0BTMUZ)E6:BE
MY5JTK!;J+U5P"?P;VE^V_E/]R-_=^H\;_+)U$;EPJXO39\U$'/B8HU0VOG//
MJ@O3;T_B&^ =.O9T&'^=_O+;]!7:O2IZI_K2;UT[^-3N36,EQ.E">$/5F?KR
M;U_;873\JS&;6LC_=^-"2"</KJ^2S2H::#J45ZXQM<DEN?$RWKSYVK=NJS<%
MO_GJM^[Z[6M,B:7W56Y2II^VKVLA6W>;?TV?>$SOT%>I^0/T51"S]+X2O$FE
M7).!-=#7VPWLA%],&TRB&"FN@EVO7Z'?/>IK%II>$\=:@_GC1&WJN:!-=6W0
MYJM^M]OO-:I RALSR-QA&!X()P;]K_7O=#V'^;( ?:7!<Q5ZM-NK?I_4HE_2
MX*_]0'D_[HZK<LW5Z.S$U/;M41F=:T=G?W0<!_4JZG=/!_$X]H;M+[%1)TAK
M_)13I"T<5'BA8W?8'TVD;S9J_+^J3^K8\2L#=;V.(.H^.N*RZ:U#D+\_IMUV
M")WX-&-:9[6ZQ0+[_ON^G$';[O;'O64AVBK3]_N]TGV;OH2L_!>I '>BCUT7
M!]-L@/@^>?I?<+X_0JU(02=BO>2."LNDSP>3#&8$2\.J@TF8T)+O[^KYHI,W
M)T?G'L.].GL['\Z.3M[1_9UMT?H[__[ZZ]')']U6]PT\Z^CK_/FBO;];)ZWS
M=]#O#U];AW^T6SM'?&_G,_D(O^\=_M[>ZQ[1H_Q>)[^GO?9"OC]M,([".V0T
MT8B+7,):6XJH<]$[Y5T0=F-+R";EO*D465+QSM4XK_F=?,0/*.@K!X6W/Y%Y
MMY=?4W2[Y@C[#T%;R<JW&K WGY7/1B.X$A;10"+BR638HQPY0IQR.@2F5(:]
MQ1))SQCO5H[N?MNO77"YX/)&6Q#.&7%:8DIXLE@'*H'3)..\UMBDQ\;E9W\6
M_O% >SYW'FA9KHW#R*E($%?.(.-91(F$Y+W5.D15Y7"2JDD$?DG072#QN4/B
M7=(M,4]2Y"YS',^MDI9Q2:VWD49! Q4W8V+)<+<NX+B0X4YCHCW6#!&K !T-
MQTAC)1#+*3V4I,8:NK$%)GQ3TT4S_L[E1@HL%EA<@;>^4Q:ZY!A/T:D IIXR
MR1H<!8D13/B@DG\Z6"S(=S?DFR]5;H2G1$D$RDXB6"<8V4@D2E&F* 3\(R0@
M7\&\@GG/ O/N 'F2: 'F$(E6> YVL4Z<>.^ULT%SKKX!>84 KCH,SF>*PQ(K
M;8A"2O*<C#,(9+B-\!OSTEIJ M4;6]2(IM;WSA3W*(CX$LK153N=R-EAS._8
M/8V]H<T3<I]Z=&NXS_QC-4ROG^^5J%U3IFDMIFG%MSJ>^7*Z Y-14GAK@J6<
M65[Y]TT,5E"7A*&:JZHB+IE6Q"7?3WZ['4[&PU$W]D;#P_YE@'&.+=[M3:**
M*W"NL/G5##2_C\" ANU1/(B#+VT?_X*7[X?WT?<_]:J[_(_MC&,A.TLC.V<+
M6P&4\> -8<@ ZT%<,8P<L!_DM 9+GD5B%-_8$DUZ367=YP->SQ,4GIV.*=-4
MIFD=5*Q+*3#CC6'4<,J-CDX2KW"@C!+E?%&QSUG%+O@3M!4P^8D@Z;5%7!N,
MK#,<*:-U,@+^<7[U=.Q+B%O/<=$Y<+W13]EGD$\@#K.#KMGHQ5'^L)\2W+GW
M":X.1S<?,+E%,/MS0KQK0]9-H(8Q8;7C@7,:P)0(7O%@E"&&&_P=T+LN=CU/
M11VZOC/.LU"#5QW2#N]871J6J/9E85?KFBKV*4DE!$"7< +Q#&+68X6DDRG&
MP 7!=F.+-26E3:+EDIRA*[0)]%)%?)'4W%.^;]@*613OBI#,2'<A'W<1X/GX
M;,*C)2IPX!X$['O/!++64A1TPC:"& N*08"?L^0^!\_DBT"8I7LF;XDPQ?99
M&OS,NQ=#2)0IKI!S(0)_4 :90.!/FS0E1, PNXTMHYM$+FLG=14AZ'F*]H\Y
MKLHTE6DJT[1:_L6B*!_=T)YW$HK(I"34("*B0SR*@ QQ!CE,G/<6&XM#I2DI
M7M:!G!)9=,O(HBP=#>#NO<8@5DF/&GG<O\RGZGG!>R /[!'L?NK]^VUW8'7Q
M+YBB[<G,%+?@TM#J8,$M&#GV3!N!K P!<9XTTHHIE*CC6*N(@P:P(IPW03NM
MT)Y&V>E<5:?@MR2\HB'7"'AA''>1X7G/8'3:F@!<PR2J$(>)1):['.K,E#%4
M2Q_]QM:]\S:LL/0^!\?@BT"9I3D&?P1EBM&S- B:]PYJ04+D*:' G4;<.XML
MP!XID4C2S&*A'4!0DXM[[T^L, P]3_$N46UEFLHTK;-SL"C+I[6Y%XXE.LJB
MUA*QA#'B0END&>>(.6^4$YY*(6IMJ5=(6[Z$,,(/O4&$;IS'T/ADV[T&"&B[
M]R5.(G9?6-1@V6XJTU3"?%Y:F,^S6TYEFLHTK0/=5XXPJRT-AFEN5#(\6$H2
M#<X8QWBX<RS )9EY"UPF5V[9[^U>LIE"X^]"XV>2++5@'/8/@<9S+)(B!CG"
M(^(6?K,F,J23SYLH-$3I-K;(O3E\$=K5%=JE!_ 4H5VNT,[;WDYZ2:S2.0=0
MCF--'@'>&B2HB3+I%&B5,7>5A/8E1.:TXJC1@<7^PL)PBM.V3%/9,']I&^;/
M;CD]SVFZ4WYQK"1V0!Z"25Q0ZD(T5M'$ S&,,W8+'GA#1EW0C'7QS<P%R[[,
MTKCAV6R^<,_W=][](R)6S%.,J&46<6$L,LXF)!/'UCK%N2(;6X(TJ5J,IKI]
MZMPBR 5ORS3=#V^78'<7O'ULO&W-X2W.Z<B=-V"!LX0X,13IJ"0B@,(^))J4
MIZN%MR]A#_RB!.R>'?CC:?U7LH3ZK_5K_<I@\$-_[#JQSHO\@JO#,ECY,@DA
MM0R<,VN2<8Y&E023VDZ2D=\JPTZI#OM H#47Z6JT8L()CK#(F 7$$-DH)(I<
M<4QC"CICEL1-3 "W\++2<2Q#@M:C"L/R06+E$/9':S3<;VC6%#>OL;5_"#1+
MW=G5 -3YTTO*<>J#)2AYSA$/GB&M'$4V428$=L8ID0%UR<4+UQE)5\0YNZRJ
MM 7Q"^)_IZ*M5#3)",P+2YZ$=BF7-P6 ]\QZJ=AC(WYQ"BQ-'2Q4M'5&@A[G
MR!(,ZD!'EC-.!:0EY4IACXGDN:(M40PH]KW3[#X?I5# MH#M<GRKN5A6=IAS
MX>'_+!J"/9%..&TCH9;?C+:E5NZZP.Y"K=Q(8$XEID@I$1"G3")'B$6P##25
MT7F:SR1I"JAK%E'W1^M&%L M@/L\ ?<.>&NI5]8X)YE./&%C@0%%#OQ6< )R
MYXH_8[61=*[V+B.).$<<<HGB'&$J $D50R)@;ZREEJ8<8;I8<+Q0UX*D!4GO
M%8TO@N61:F^YXA8+RT*@1"3)E+?&RN(G6%^8G0_DCQ0TI=4)R>AS;5^3D&,&
MJ"L#C%5&VL3\QA83N"G8<\#:[X0>K*0#N+1\@2W+0BTMUZ)E6:BEY5JT+ NU
MM%R+EF6AEI9KT;(LU-)R+5J6A5I:KD7+LE!+R[5H619J:;D6+<M"+2W7HF59
MJ*7E6K0L"[6T7(N69:&6EFO1LEJHOU114/!O:'_9^D_U(W]WZS]N\,O618C-
M'2Y.G^B7%V%6W?'7]LAVVO[;,6>T*A0;8Z/7'\$C1GT8BUX5RU/5BTWMGNWY
MMNU )^&#*BGKYL)[3-]@<E-%H1^G_6$[QQ[]6I6>;7^)OWUMA]'Q-,IMYEN3
M^")\^17KH ?CT<U?F8DE\C''GVT\>K!>-7#LZE#,_LR]K2/=K,)&$Q*3Q#R(
M:)6BEABKK?$DI/ /U1O3+QT/IF]P:C]%Y ;1?D8VP0O^:CM?[=EPXY<KX]!M
M]Z8=X@)Z/#]>/[@T%R;V\<=;73O>>]NOWN^_?=W:?770;.RV7MV\%%>EQZ_V
M6P?[?^[N;!^^WFD<',(_>Z];AP>-_3>-5]L'_]UX\^?^WP<K_Q8_C7MV'-J
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MZ;3\5<_*U$2Z@*X_+^.M"GXM#[_>+5 4B1V51N>S5X(A3AE#&G."P(0EC*K
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MJ$L$T;)EG6B!I2+1"@]3C77BQ'NO87EHSI6H9!T765\G69_/\6D%HX#GB(C
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MO[1RYL;@@O]GIM\#FV$XS!JF)O/)M@=Y;"[6S?3;]8'GX?3:A)X/XS7O#"W
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M0IICAA@F!$G.+<JLPG"W1FGFG[S )-LCV8^+*-/ <S5"]8<6JDU0ZRZ%[,(
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M^K@/!G148Z$?=6G\73GAQ8,R 54"5O?L&WI^5'O+4S#^1V?],6S$#9_]LBG
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M%@GJP5_*J4"2&8$,L]PR'IPG&ORE_+E8E-U[,18R[HZ*($V*D*1>$>\2^:0
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M@5Z3X-/:OU6,"!;)X;PQ."S1/\J>N;HUXMTLE18^D_$ML )/.['_'K1%98^
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M;$XL8(>B?3\<%MP8+?>XY.I84HZE U>D!]O4G@TWK;&ZE?0-A\:7_14*:?;
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M;"YZVXM^M7\B!'48LX!D<#PBH61(2D91H$P$K;)<.!HO>A$7=%HO!,(GUGZ
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MK MI2&4K4J'M-R?::&F] 5)QCB#&M4-*&_A#9"J6$&JM#)#*&DH!A?QMH)]
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ML0C<E6*^F4AS@_3+CX[W3X@4GG&,$0:%BN#@"3*8YTAYT+A8. YG_>3%+H.
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M] ;<W=NM/7UGS[P;=\'&G-1_% U4*^BJ (2"O[T*T['"13HLU:G^U%6I;TZ
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M,QLV$ M1F&T&(=<U5)V.LR1V?#HE>&\TYK7((_,95P&RZ%P-L0;."UV%.4X
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MSXWO_8]=H,>/<^WD\NCRJW)^]D>W<]GK?K_$PV!0 9\ZRO&G;]I_P$"I)F,
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MV\=8T8'"YJ.[0O8?AN]FK'I+E/K.V@$>)L(<4N/;?<I^$:I9G#C7\ZC*'6I
MW,K4]O2-9[;%#=]V5-GGH0.>:\AEQV"6['NJX3-#,Q4709S9LHSI8HRI(]R'
MJ(EU1[)>IIR_!/!6:( &OSV!(IC$;WJ@&[YF>K*I4$%QH,N>&SCP3U 'ILLL
M-;"HM&55E]QLHB[8]C%>37#N8Y*&/'I]X;GUP[='QN?RC1NEO G2K5RMUXKU
ME<[/;UIG]Q\[L%RNL% V;<T&?,==V54"5PX4UPI,V^<&=F!337MFB&YQ@+?!
M/OG+U 0O >#-4 8-Q%N=+O@YH0L"T[%LQ3!EIEH^=F-DLF-YOFRYFNZH'#B
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M9%</7-51/%U1??#,C+8VK?M;4LHS--31->_=MB54E,-DR'I25%CG:;W(B_;
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MC6?XTIXDS_!7*OK[L'B)Z5+=:#>LH#/(BT\DZK G0NK8)P'4=-F[X+X:SK+
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M,M/+[!SC+-UVLVGN\]SV5FOV:-/W:,=H*TL7H33;\WPE0DMT#&U:8S5/OM8
MZ<=>,N03UU2_$I?)?&@'_<:K?:XM<IM699N^10"$GKTY=[,]2VR/U?3!VE2
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MJC.@Z8I$_-VV]'6$%3-#4<Z+UA\^Z!7_QIS\'BTQDW:]9#1$6N#[3W"96 C
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M\>*=57'? .B?!)&/96'43V<&5M@I I##+B @P#<I&!S 8M/@Y.O;JN$B>:%
M:>&%IMQ'XQ"TQ/*R#/\JJL]@VX.\"P^.E[\=YD>>,G!-/LE,R@;<C\)(S#Z?
MW;\!QM'EWGG+E'Y>>$O4H(G7R0'S9[X_ZH]Z99$W-@\9820Q1X+)T[$6=OG
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MX:0OW?8^9E>P22-Y1TLU\PE;JKT@F=+5MMJ(U$:*%,U'5V7UORJ=>I(DG8S
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M)R>M^>V0<!GTC"*HX)#_G3ST[CJ#2;(BHQ.5'8M9!JNDFOZ4:C#W5 '7-MX
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M8S],VU^.8=S#QCCM30^ANSE 08WPA@N2.)H0Z1TECAI*A,$W@%&E*&^B_CG
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M>UPVC\LN4<J@P'F-^8:8[0T!L=(:0KE-D481P8I&N[0/HUJE"*D"!ZHIH&[
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M/W-A95]TYNR L&D4R-T8]]0BM1^EWG*ETJ-&]L,=*W)$)A183N:W\I%!Q,3
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MM1ZUCD*2,S[/M"F1W.?:2AI-"1B9=\M]NU=9W;>.\UAIT:/T>PS66D0C7I7
MQ49V9?[S@.>3*)@.DM6<Z9!!U=##Z#)"2CF)A-KEY>[%*T,^NXSW6(G20!L-
MPK;>T>DXJE&&/#-78CW?HB?BAEHVR]8HP^)XRE8Z MGD'N,"P2/DR59*N$X&
MN]7NL0#Q^HP.NL^U^-J0ICVI-PQ71?,<9S@Y'8SFV]UQ>8_#80U<K50^#WT^
M2<4P'SP#[QP1ND@-M60-8&(!7>3&J-!I>^D)T"/DU=[T>9V3;OOWE]%L0E+Y
M^V#VZ=D9&>SD-EXT\?AVXJ.WVF9!,JF5Q#5MG,&2:9YBYBKFA"*TB5*_%=8C
MI%S_ZKK.)=^42\_.)I-JVC,M WI=P,I:]<#Q K7T!ECO+"NYEN)HTVRS"[HG
M9O6GO!MN(+>.-[H59!77 B?7)BDM!'A56^E))B RDH80D9 F;;QH$WG4$> 3
MSWI5X0U4V^ZV^\-X%H9'H]%9&+X<?,5\<8=UDD,A S+4$LWU\;RVLG56<K N
MT-$=ZY5IMT>452,\0F;T)_$;>+!]XO!EV%X/@CJ/]BL^2!Z5 I2LEH'1)*1H
M!!054BS>>I':O&GW/Y>=I?GLFZ0'0H=])Q5-)[-Z<YO/TNQX<EX/">>!:2:[
M'!(GO\46I.W:($2+"GPV1HOL$R;3A=,TP!4^TW?+7%Z%8/]AO?LAQ+A'Q?3X
M:'P%S_?267A1"*L+J'4"@-=AS74XNPW\[4=3U]7>DYAWQ@&7=;(L9= ZU\)"
MDMS6N:DGO"N"!\%4)T?P$'6_(L9WAZI?1[I]QXI<W+>^I(G_1IA&T^\7])=]
M?QUG5KD"F3E/9W#4$#SI+%M%#B;S]-^UKC%O&VQW-G6/.KGAKK$W@?8=FW85
MW[/7Q\O8%@B=DHC!)C!D8X%*CDA.EA;P%%B,P=LLUE?YRN$>E-+[$6K/6_N[
M:L',MZ^48G+)(PC#0IVCJT5,"TA#.S%#IM3RF_@66_GEL$\6WX8JZ#&,ZQ+$
M19'E#C!Z-^RN -B]*;>A"I:5N(7\6BSK!1Q;]ROO!#@CL+8V=O7R14".7'&+
MQ2C>J43>8:CQ%JNL7RVN([:>M?>:)'5Z=GI!)\PJY%@Q6$EV9>'@=$ H'B.S
M44=F.N7A=]+?#T/O]OC=6/CC/B37HSDU!W)>ZFP!1+$D>58)G-,"E$H*7#&U
M9K2F4X%'8WBGR\)N*KPZ]#U4X<:2ZWD5/JM/^SCY'":S;[4:P'QG4=88:W4!
MQPT#54* 6*L!T-D>B5]22=<IL;&3)F]"\&0P;:^8'@.0YZS'SV>3]"E<<>B6
M(2[\B"X@^[>LNL+;O=VUO2;'NU)#WP9:9[ BHS:<&Q!U&U1.$>R2"J IDM62
M]3SW=W;LF2NW&'=[HLHZTN_["NY::N_B3-08F,1JV-I4_[ (49*!@SEC$EF$
MR)<"(U;<P:P88,<V0QM=C'L69-_7;:]>A_CK8/SY4YB<A@6>6!S*9&ENO()*
MH2;1A (QY!"LR,4L5TU8I=CK'_[PE+JE !O4P7B'4Z0/_$2&T-6,JN\VT$7<
MS(?Q(C7BY7@RS^>?_OJM=IZ9;VK".9716O"NEH/2N:9'I$P[M>1%Q(S(6D69
M]P#_D=NG^Z-"@S+86TRB3N%BA7>81--"4;U,8S^%I?9 H_Z(O"4'#FN#OC*9
M8(.2FHP%K>K=DLBAE@",8$.)V7JM=%&/C<AW%,1Z*#Q>1_5MW('7?SUB7%Q:
M51>&CQ,>G=-04LV00RL@QBC %)^D\"K:D-9P"6X<9/=1K7O0V76W87N!]^XZ
MW(3K&?WJ((7A$5DP7ZYV%8R:G&1/ZP5K<THRC#U$[1P$E.@3UR8O%U]:AQJK
MAMT=6?I5U9WZ[T7.+;>&"X 7(0P+>#+(B!PCB*(D[9V8P*E(9JTHF()UM:GE
MVC2X>:Q'O5'T(/Z6['A_]OGS\-OR$M'%:'0Z@]>U*%'6%J)G#+AC2@:EN6;K
MD^/&H1XU-[87?M_%>WZX1/FATB"):SE*[:+VI'2.15[ B%)#H *#($0 XQ5W
M0=J"K./UX_J#/S[Z-%;0RJ>P'18'_;]A\%N([2J"_OCYS<N WC*=I=J?TFHI
MC>=*1E\#/(,+C+3%G2D2G4IWU?[\<:1#*O@9I<106_P9LH"4=YQ..Q: *^9L
MM!YE:%,"^O +?M+2Q! \@7?,@"J>%J?.9!)824N6R<!,MV:"#[7@YQK4Z5;P
M<QV)]^VJ$:C)3:#>U"80'\+7FD!;&XP/1A]/$L^J]E"%&"0'E;( Q^JV30X,
M+S:+&.[<"=<=]!&3I8E>^C;=?\"Y2*==@H<F*Q6D H:2S$<3# 3F<PV3(G;S
M:+AQZ]/FQK&>V-*+%OHVXK>N2>LC$\;H"%PB[9 DCEJI3T.ROF@KK!<=SZ3'
M7E5X4X+M5(-]E]_<OGAHMF@]TP8*-Q94\!%\1 F"(X^H#/.R6U+1HR\ NRD!
M=ZO#OJM]7F19W7AZE\0]MQITTE@[ YM:[88!MU%I6RSO6NKSED$>*VOZDGO?
M13YO+4M+WK5EADOPQ1%1E0S@A==0).?.6AWHFVZ'W0,N"+SQ0=:7Y!N4\;R]
M[!K36JF,@JQ\+D Y3U]ED4 S;DQ)0;#4*?WQJ4K>ECSJ7UT]5@&]5HU49"Y8
MYF1NU;;B*M;,X*#(5S3)9ZN+DLO/:D\E8?MBR$9*Z+'\YGS'._X\>S5ZB5A!
M.#KRR/IFQI,!9 (X5Q,/I;""CD+FE\,V5YPK%Y_X"#6[N40;5,*\T@R6]J+I
M@#YU?@]/1B^2 /+QZ,K$3X+C3'KMP49ROE0.M?%G46#0Y.RY%[C<9Z#_;LEW
MPWR$G&JOSC9%,B];_KT-D^/)O*-D_EL8GB&94^\_A0F>6(G%VE  ,ZOV5,[@
M'2V2J!/+*I>H??,FBZO /6*B]:VZ/@MCWK 8YG6L+X$9[X4)48+5D39>0@F!
M!0^AY!B+XR:*3B7@MMG&?D#TB(G4BY+Z+*>Y</'P='!V^GW;/ >X2/<Y\2)J
MB6B@I%H*G;XF$YW4C:)$5NLR1-NM+?SMXSQ"6O0M_1N8L64?IO4;EQF=.1<Q
M "HNB<F<@<O9@$V!9^E=4AW?/!]?>[FMWQK::.D&5FUWN=NQ1TPVFN@M-##F
M%6&L[[6\-E=4WF9MN1*ZF_OU.#KV;,J>!MJX@3';7?_VU=5#99V\JFV';*5]
MEA)"+O5QP[@<5:B-S-9Y.GCL75JV?&;8J3YO(&7;"^B+[@RYWED5@J:3KM B
MDN-I716:<-'S$/,>NK4\D-8:K:ZC-U'>#0S;^EJZ:U\&SQ*M >: %^U!\5J/
MGV$"E9+,UFAO>*>28D^M-7;+LPU5> /5MNXYU2#?/DK!572![(580"EAP >+
M8%4LS*?,9&ETA?K44F'KNXK]TF'?+17ZS7/6Q12=I87$:NQ$#H;\+8<05$@9
M76+&IR8+X:D"R!84;%(!9!TJ'&S!A"Z3>*H <C.K]T"C)I43-N' P1+:,6>R
MR@B%IPRJ5J"+QEAPT@J14^UVYA\;D7=2 63_/%Y']7UG@QP)QMUYTE_'5%!5
M2N(A.(@$%Y1$#=$[^HHE%VU,3G:L*+?VT/<U4W<M_8YWIIR^$]/.@4[O1!HF
M'W%V]G5P&N)%CY(20TC60Q"6O 11HSA9E)#(82@LNF@Z5I_<&,*CH]9NE-7W
M;M41]8=WKYZ_>//A-:DCD?5^42]#"I\='8 A& U*AP"!Y9K0DB3)BT>^'-NR
M'<MN1/%$M%8JZSL%;K'O#A>U5WZLLW%1@Z64:E_R3#Z<-"065R6B:--E9$T4
MX@TWW=YSNHSV2+G3HPKZSE,[JC;U.<IKN-"88,C3!^.M %4T!V=IGW1.EAH_
M3 <R[VHGK1KDT3&B+X'WF"ZVLI*X<RXJD3D@LAHX8PLX73R@J&^&RLAD^FN2
M\\#[.FQR:]:+8OKNB=6YB'47D(^^K\-:FMRH6/\F:MA;7X<0I9$Y:"A8"&S,
MD4QS8<E<BE:F&&,P^:%P9=V^#NVILH[TVSA&BX.0Z21-R1)X">3ZDP4-3J$%
M+ QSHL/6^&ZY[U<_]5"+_:\E]>O&Y08BZ[FMU[OO+>:"02>B@%"8KNVM,K@:
M<\MBS,P%H7.W-[I'VRYS4RMA,Q7TW?+I:KO'#C >;+O,=52PJEWF!O+K^]2^
M H?SG!$EN3N:=B8E=0 GT-6KV9+K/88U_/ZHL5N[S!ZTN([8>M;>CQT#,]<Y
M!I$@\CAOIFP@)#(@DB/#(:@2O.FO0]^!]%I<2_@K>RVN([D>S]7+,Z;FR=6S
MXL5_G=68RO'IY_%H?K+,.2HRXRXR4";3'SI%B"5Q,AT"NFI$6-4FT?Y66(_\
M/.Y?=0VZV"QA6IBB74 UC4FY$=9^8DQZ5-^XE>P;Q(+<#"YR31B005"ZM@LP
M')QT<I[QE%1)5H5.?ODA$^*.6(U=\V$=D3?@P5'.<YF&X=LPR*]&S\+GP2P,
M%Z<B63^8N")U*5NK:9.%Y$P@"PDM4Y('RW.;6)];8>W^,:$'U8U;R7VE-;+#
M*N;_BP[4*8[:E3%?&J!Y'?/;)K14R%Q+6O9>)1\+F0NV1)-E(8W%9*R0/M]5
MR'QIJ .J9!Z$)>IQ"U'66OK>%W">-CLLUMMH,\WNL58RIT7H,B?1\'D-"Y0&
MG!,!) N.I8+"\L[UJA]B)?-UJ-.MDODZ$N\[8.PR;?Q:LG@M&'I1ZN]X]'8R
MSF=I5FM73$]0<X[,2.#&\AK7INM-+3F8$GGRG*7,N[4EVV3TQTJ?YIKJ^SWD
M]J*12DF+4=9\I-K7US*(,3A(AI J'Z/M6%;M 9?KW)PJ?4F^[WBNCF4&N,B9
MYL>!^U2+S"I;DR S9!E<ED;YI+O%HCZ*H@\;TZ2!-GI\C[E6#M)8R3(S&JQR
M&I24#!SWOGJIPA?CE&_4?>:!U.3<A"=;*:%1/?"M"T8@_4\QM55?K 4H?: =
M, 4!QECFR!(3 ;O5LGHJ ++5_K,/??98D[SAI3W'R#E3'D+4 E1B :+U$FI/
M,9=\J,$1;5Y%GE+FM]TJ]TR'?:?,KPS^BCQBRLR#,))6:4$)SM!!DIRD_S/)
MH.WO ?Z!A^*N18B[0G'74<S>PBJ[@'STH;AK:7*C^,I-U+"_4%QI'2-?EUQ;
M7_L",@V^I P\B"Q%IAE@IU/T/G!EW5#<]E191_I]7STM'AY^'8QGF#Z]&J6+
M$%,3)--20&)<U3JJA(EG!]8768Q0HL1N36)6#'"P ;KKZ&+<LR ;Q!3U4W4@
MQB2X-A)BB+8V]^/DQMH"Y$T4&Y4-7+8IM/Y4CV=[<V9_5.CQ4K3?C+XNDWBJ
MQW,SJ_= HR9U3#;AP,'6X]%.^A!R LZS <5#!%>/&NU4-"9HP?13/9Z'R>-U
M5-_(>NQ8[H4K+:SD#(JJW<>Q]I&N><]">%][?AB,W5XRUQKVOF:=KZ77&RS1
M!DKI.9=L\?Y^/'F/DR_UDKHNJ. \BF)J#+Y*9"\S5Q]=#3@6C,J:J1([5>;M
MY(K>A."16XN]**;G9+,%GCK_!:+IA;O6 53OEUTKX>S^<FM[35U7>T]B[ODR
MZQ9PWK!D)$+P@C9*;PI$VKO Z)@4,X7YW%^^TXYU?\MEU:Y4OX9T^S8O+M[2
M7]+$EX^OBSHJ4:4B@XF@D]>@A,@02O$@LG!.*&<86ZM'Q6V#[?;2JB>=W-2O
MNB^!]AUCN<!7X2TLHS!*=")^^(0KC"HZ[KX,:M#610J?X-*8*"!B+2FHDJ7#
M3R9 GS06CUH;MPX=-H?R4,BR(V6LW#MVF,'PZG6(OP[&GS\%FFN[/(8;AVF>
MS7#WY)9R&B+:($5Q,FLB2O%.!%&49.03I(SJSIR&&P<\H,P&(65-UR%?79M:
MBDTJ6ABZIMMH%"8+Q6V;/+?#SVQ(U@C4ON8::06JU%L-R\B/2"YGQ8NU'3WU
M!YK9L YUNF4VK"/Q9ID-5_9R6L[O\./9L/Z[;W>UQW/"2)9H=Y>RBL/'1/L\
M(A19.!D3OA39K7C@MD@>*ZUVJL&^K?RK%L0:F-]A&G\<#?X;\XGFO"0N"7VL
M6;F.OG*>9V#)IU*BT]BQ5N[64!XK 7>KP[Z3+2[<HC<X(_,V?*VMISZ-AWDP
M^G@BI>5&RT+F<Q"U$AL2+G*PO1:>*<&##F8M__*&01XK:_J2>]^%<F_-"BJ2
M(<TK@<5:*X2\*/!H%7"+LI#)')UZ]/E8FQ]D?4F^44;%J]'<#Z[3_7V*^</X
M:#K%Z?1O83*H%MTSDL* 1CM_<SF/N3>LU@/@!+B6!5"\UI8RR8'VM+7IPGE8
M+JQ[^P:R/H3'2J;=Z*Q!GL1E#E'@EI/UI:'HK$&E:,#5VE8^L2RJ7*1JTPOU
M@21R;4*=K91PG0QMF^:>)%31&I?(6PRL%CXKX#F2]2Z"DB85[= T8<BML!XQ
M;?I3UW4NM6V/>]G#-Q<9E1.0A,N@C'5 WTK0L13A)!,9]>XI]3 :,#=CUB;*
MNTZPK9OB=FW>6^^143D+*%B"VKL,8B%2>.V]*-H*IMLT^'P<_9>;T6Q#%5YG
MFM_*&C\>X8?!*;X>#(?SVX5G$\R#V8DF(XUS0>>S462[Q=H73R@# M&S[.M)
MW:V4^,V?_PA)T9>T;[@SW+Y<:H. J43SJ2YE1E^+N14!WI#19Q3FZ"*ZZ!O5
M6'W*)MYVW]HS'0XVFSADB<5K!!'J/HV6C$_!,S'11J0?&2OZ:[/QT+.)UR'$
M7=G$ZRAF?YFA'4 ^^FSBM32Y68KH!FK8&V>$<2$KRP&CKZW-5 2R!ARD+"5F
MRSUGG4[1^\"5=;.)VU-E'>GW_93[0\C/15=,X4QVB@'*5)^6A8+ 4(!+*A0C
MA#:Z6PVA&S[\4+.(U]+!N$<!'FP&,3H3HC49-"LT">T91"T3!)^8(]EPP5O=
M9#]E$&]KPNR/"@>;0=QE$D\9Q#>S>@\T:I)YN0D'#C:#V!2,'+F&>JL'2ADZ
MLK(S8)DVRJ5D=&YSZW_ 1-Y)!O'^>;R.ZIM:C!U35J62-GN5R(8N#!0S"9P*
M":3W.<=0A.I8FV:#P>]K-O%:.EYID3904-_!S&OA_;%9^T5G;D076%2 &7--
MF''@BU$@ SEG7F5>.M9LWQK*$]F:*J]%#\7S!D%>,:<, Q=2J5F8JH)@H#F+
M]0T6B^LOA_URV$?NI&RN@IZSU=]=;>W9 <:#;8VZC@I6M4;=0'XMEO4"3DU8
M+-EIVLF*!>68J?<Z'+15PG.7HRV=;C$.0XW=6J/VH,5UQ-:S]GYL\,ET"'0(
M(5A;"_1+B>!C=&!<"@Z%"%'W5UGW0%JCKB7\E:U1UY'<(30C>_/JZ-7S"V.E
M72KOC<,T3^6]>W++J;Q!9<&US8%L(.T8.9S:V(@Q*U^XY7>E\MXXX &E\GK#
M.4^!S$PR-D&)XB R30Z'0RY93.C=0T_E/:O+]+B\)OHD,L:F'\:_XL*$QTQH
MGHU/3\FF&X1A3;=:2O\STC*ED'8&)FF3-U+4ZP<'CCOM0_9)Q&YO-%O!N.?Q
M5>N0\,>DX)WIKF]G^\-X%H:7R:=_"\,S7$XL=30^,P@F) XJ*"1@I5:$*$(8
MG;Q)W<JSW#G48V5/OSIH<C^]2*00T>=L:W<UPVF**==*9,@J<7G6VEHC59-=
M^H%DLVQ"D:V4T.#UK<%E <LF&T[.B:U5VE7)Y*O8Q$"0O5.O&E5N1*NGH,VM
M:;EG.AQ"T.:-==RD9%*):"#F6C5>2O*Z UI VL:38S*@[\]1?>!5,-<BQ%U5
M,-=1S,XJ('8!]>BJ8*ZEJ4ZE$#<1\\XXX)+DQHL,9/03RQW]X5E"L-$&YV*P
MI3R:*IC]JWX=Z;:L@OE7VMTN*S7*4+)R.$]+#Z X2Q!RY("6YN^BYPF[5:)8
M-<*AE#!<2_JKZEUN++J>JU[?&!;LDC+&JGK!KBPHSP.$I 04PUVT@F'N%A[Y
ME*2Q^7F_M6)Z=)?6"S?N O+1)VFLI<F-(N\W4</>DC228(I;+* 9$Z!0,XB%
M-E8>:&,T7$KG.G4,N0]<63=)HSU5UI%^W_;$F_-'GN&KT70VF)W-:.\]&@YQ
M\O$;[;2O1@7K9GHV?3Z8(LWDLBQTS?7-,H#ECA'B4$M5UC*!/#KA%1HI.SX1
M;#+\H29ZK*7'\4Z5T+/9\CTB((80M<=$YE>JME/V-2(@0)9<R\R4*=U:+C_:
MZ*9-#93-5- PNJD+C(<:W;26"E;$Q6PBOX;139%)S:(V$")WH#)'<+%XJ!>X
MT9ALV7*END-68Z?HIEZTN(;8FD8WV2C)-RX6LHZ*@'@%42,"R]SJR,BHB?U=
M 1U(=--:PE\9W;2.Y'82W?1^-D[_^)5._OKV_YDH/3<7;O[;%U_KE[A%D-,6
MHVT?Z]375)="GH1/@=L0F#%*(>9@4*C$I(TVH4KV9(MQMWP"_10F>&V(*Q;#
MK]^^_\JB;O+1'V&2OS^Y9<.$YDE!TH$<E*@C!&=,_59Z#.BL:U2G9FOL6S\@
M;XK@(LIF_M/IT=GLTW@RKSR=F+%<23*E97V_++3X@R*;S C&N6*IAIL?EC!7
M367W\0T[YO*UY^.]DJ'O:*H7M%>/OR'.]Z"W"P_T[3",%H?5T6AT%H;S,,Q!
M/)L[%&]Q<O&O+JHD$T(5D[?$.EES)VI/B:PB8/#",JY9QFX=D'J!\V@HN2<-
M]GTYM+'TCDO!R6#TD28Q&.>3G%2.W!L@.=(<& 8(3"A@9$F%8,C+[5CUNB=
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MUM,6-&OU8-YDGJ2%@H/9E1+#TF9GN+.U44&BG4,+FB77D%+6N3AI6.ITXWQ
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M\T<F\TE"J. X:3Q],2>09"&"!.,HX#+ ++/R].VU.S92*$5S=-;M0]4^W2\
MH.>I;5Z?:;&<<FVX;9\,^O.MG="];1KK1[:FL/YM?_KNMSG(5#VA2#,M3_VY
MV_K]42XU_%*\IOE\.G\H;CE?/:YF)N+SE513/EU.A(BR. T9C%D8Z+U(&D&<
MF$ EA9D0(=4KO')9QL]W.;:)NR4A$)6(;@NX!<IVZ[A?['J>\XVPH)$6_+B-
M9"WP3_Y6=7MTO"[N%MT.NL;;P["_U#L\V95NBF4^Y;J]3\L%__.W^719?/ST
M6[VX<<PY9P&'(4NU':!$"!F. R@Y8DG $I$BZL8T+;V-C60VPH)26E"*Z\HS
M;?#:4HPGT'IGEV-X@1^UK,5/X(]*7H];!BM<//-*6X\#4XJ%\H=L8O-0-R)9
M;T?N5=GXE\5,/UR\_FLU73Z[WCVP:6M$;_YF?[Q08%OB_PXJF?NY>.""DM]K
M!U8]#WOIP 6,@RL'3@^[S0\AIY/7\Z5NZ,UT)O.7NJ>'1?X\$9Q$1*04"BEB
MB()([Z[C"$.F%$%90@*:,9NE]43[8UM,*Q%!*2-HA+1;2T\AV,XE'G#IF37<
M(+&FAS.*'R&"0O*?'Q9??]%/EASP%S(_PNK'<N*?:G.0*7Y&H68RG_N:^[3]
M)/DJU^V]_L:_F/W]>SV8$RQ4G&4,PS0,$[WY5APRJF+]:Y;2!)G_BVWG[;$.
MQC9Q&QE!(R0P4MK/W*,@GI^ZET+3]XKOAHK3Y&U3O?/L/=KH8-.W3:7M^=OZ
MO:[KKG&7YT^+O'22ETO]R\5JOLR?7RZ$G(A0!BD)"8R1WMVB6$E( I)!+"0F
MC&0<$RMGFF5_8YO>]2*T(_--=>"C80:UY,"([KI:M^-NNWI[0W.8U?PB(#NL
M\5;P7+CFM_<QL U@I?"A36#W6,>M[Q>:RQ>TD.+EXO%)SHOJ."[/#869;<6+
MY\U7ZD/_V[]I+M;AK[=%L7I\,D\5'Z?%GV]R*>_F>OKK_?I'+>HDX@'GW.3_
M42* 2*D,$I9JS@KB3#)%%8D#I^0)?4L\-IHS,D*EA0336DJ@7P5+2AMNG"W=
M(V,:O;X-+:,(-(F<!-C6%FRI"]@SV/Y>K3(H=;X!6U<)MO2^ 49S<Q%2@D9W
M\+'MG7!WT PU3GZ=.[U+/:QC:*A!.' J#=;QP*M6Y1:[FQ?+O,QY5]POO\C\
MLS;8[RMAWRQR):?+E1;T=VF2W$EQ^U7F]$'^JAM?OM*RKW6<B!A%41Q12%-S
MQ"0B#$U^.Y@%@B<"!TJEV2!+FU>UQK;^U;)K<M2VJ/SV-,WUCS].YT L9C.:
M%^!)YJ PN)P^_1WS6]3SPGFU=V/\JVM]P+&%#2C! 4N-#KAO%MLM@&Y  Q&H
M,0(E2,"@M+5:CV A[F7<Q[%:^U7M^UC2>QE.;^M^/])UN1YC[I9+41CD/RZ>
MZ<PD?_H@->?,EY-$DPJ/.-8;T-"$A 1Z4YHQDWP6!UFH6$B$PT68EI[&MH1N
MKKP\U5)7F7WS1F[PXU,EN>42>A[K]E7-*X(]+S1M8OJZI&*!1/MUE+8&!KQX
M8J''[A43FP>Z[1%^^_0Y+V.#GVO/O&ZYCEV*>!BF:1A E3$*$4D1)"F/H21<
M1$&J:(BMSJ_/=S4V(OCMYT\_@T984*RE=3.<6Z"U,V;] -;SO/_MTP:IC9@]
M!(.=1\.KV=72W:"FT'FU]\T3BR>\7#QS#/DZ\?2(7N6#NU!]Q'2=@:'/*U#7
MB=LZH_"9JT^>DL'>"C$U%C:=?:!3<3=_29^FR^K*ICDL6O _)XFYY8TQAYG(
M$FWVIAP2R2GDL4HRI)1 R&FY.]_EV):]C<3@28L,IW/ *Z'=%CX+L.THPR^$
M/;/'%GI&6I-&K9;W!E025X&C_JC$'AZOK&+1[: $8P_#/M<X/#FP!_[0'W W
MK\HM3(AD*D(DU,-CKGAS(B ED81<X"C&L> ,B<EVO8/^G*:GI;2:EV>K/WAW
MA&[<E(=^\M(W7@SE'&\9X)X]W1<.VG?CMC[FF"YS6Y:ZCL#U?'X@QN%';I'S
M^W *GP?:FX?7HJNN08X?Y</4V,+S91E@&R:((!JG,(QI!%&,&61AK*#$84)(
M%BE$0[>HQMT.QF:<UM%W&R$=HY2/@MA.M3Z@Z9DG'5'I$'YX7/4+XPWW&ATX
MP/"X2H<1A2>^=V$V[E?3@L\6)AN#LP/E9 LC>B/74H*-F#TY4L["T4]"Z2/]
M72>K]&G%3Z:6;GGDPOS2MT4AET6=9T3<SS\:WV,^G3_H-7):_#9?L$+F7TWJ
MQ+OYTVJI_ZRUG<ZFY<KZXKE\_.6,%D53'H-G6:K7-DAI*B B46 2U"B8J2"6
MJ:F)&3NE*.U+T+&MDZ5\H!3PTB35OH?4CN;&,%!]NXI<QJA[INN> .PG*;9O
M8:^3/[LGR$^FVNZKOPXQ)>]IY4HSX2UZZ[.4]^IV-I/YP_/M7-S-E>3Z[ZM"
MKT"FYE)S$JID$F52)C!+8PR12!+(1)Q!PB5),IPBE*36P2:=1!@;@;^_N[U[
MY1!?T@WW=BX>!LV>6;:3_)Y"52["KC6&I5O+PP6W7*3Y3M3+92UU+!II O(J
M4MTJ5YA*&N(88Y@));4M*F+(4H8@#QE/5<IQ$EGY6EI[&1L/53&^\\5\70R2
MEA([UH(\"JB=)7@Q3#T33(50)6!/51[;$/!;V?%H3\-6<VQ3]J""8^N7.Y[6
M\2]2K&::9\[Z?XM3#N#/QM::X#A+ \DEC%..(&(209R&YLJ+"E6@*(FX$V%X
MDVQL)-,H5J95LCCS*5H/?< ?I9*N5;6]#;OER=TU!K/O\[IAQ]']D,XWYGZ/
MYKQ)-^R!G&]0#X[AO'?0;6%HXJ_?: C*L)#ZF._U-Y/O7W<X04I1ED0"*H5"
MB##1V]A4F#2:449"H5*!G KGG>UQ;$1NZKB#7"]YTZ]Z-JM%#A:5Q$ V(KNQ
M\GG,[=C6*Y(]L^B'G6LG58K-6ESP^BR,SJ1H#8U7LCO?ZZ D9@W"/CG9/SB"
MG".OOSU)DQ7TU?3K5,BY*'-1D( %(6*!7H(3!9&(0TB4.6>)2"@S9!(C.>7^
M[5WBL9%>(R,0M9#@>2IGCD37_SA;FJ5C&KV^S=7^<HZLWXE&]3&G'&D;IG$$
MGUE+_7V$HKD.0J\I1UH[[G("M)CK=V8U%\;D_NU)PS9?OI&R>"^7]^HS_?;[
M=/G%)-Z=SA\F2DC!<$*A)(Q %$4(,LP0Q%D0JRPD>NV)[,]][#L>VQ*B18<;
MV<&J$KXIKW<#YK),.;VDW\#?&RU<CH<<!L7F4*@?J/L^"MJ6&M1B R/W#3!U
M/N\5T+*#WWM'6"QX>?._G+9707I'@N\"<<>3-W?8VL_;'-H;\)3-7<O=L[4.
MSW?;QAC'@/E_D_OB*YT95\VF2('YPZU>>'8^V/IF%3I]-^?F0JM\):O_ZM]G
M*R-:DT36+%ROE3D0G*1)R-(@(3 200 1QPSB)!4PR4),LQ1Q9L*B[4N!#RN^
MT^HT4*WQ.OMQ>1FP^ *HMFC+'^1&3[<-S\!OA-WN9[SCW//2:%2Y :7[;DNC
M&[!5Z^5E,^[[G^T\4($ &A3 CPT./]V -12;;-H&#%"AX6]S=)U1]+I3&EB%
M0;=-UQF>_3W4E:2XI*C(^U49M$5%EDB]O,$(IQE$2'!(0OT*A52P-.52*+LX
ME&.-CVUC]'I3.P-4$G:I)5(#U[X&7 I'SPSM@$3'$B*[*GNH'U(W>(7B(;NJ
M'*\<LO>=GMSS)T\D3]\1W,OYUIPD?-!,)"<<17$HPP!*$B00!5D",<%4_R.D
MP*'D3%IY3*ZEP-@(II$5KG-4-N*"4M[MJ^*#Y%'U_<)X<OM?\348P2E >Z#*
MN5OF1Q*A[KYD YX+]#2.PQX3^%9B7*<&/0V1\R%"7W)TK3NY7[!O;6Y_6.2E
MZ$MMK+/5TCBS/B],/.ABOM0CHQM]:/*I3X)$ZC42AY (12"2*H9$F3@=$E,<
MQ(@D'$V>2F4^+6F^M%Q%O0CG0HK[(O;'CR_DPW1NBA(#1O4?6MBJSW$+XP1)
M@B*(F-GTL#B E!$%TQ"G<1BG+%3-N+V>VV:\N=*H-0+VN5D0UQXP2[MC\"'H
MVYHX4A5VV_-5:P6VU0++!=A5;%VIQ&<569](>RXSZT6T@>O0^H3SL%"MU]9'
M%'KVS\5,-S,S>35,4%)(<!B')(89,EG&0V(*SS,*PY"EF) TE4I>/?AL5^:Q
M[6#7H49?UV*.(/1L;YRO&'S6??1&L/&\-/QLH_SW$(!V?*C&'X*V)_>XMI/^
M!F*0,+0377=-^/L?JV)9;F8_+T[D^2Q%9/M:?#0'V\5T*3_)_*O>O5;[6Y,Y
MX6%>ME+5(Y(LDS)6"'))A;GQ(2'&-(:4,X53E8B,6R4N&$K@L2U>V]S&M[1Q
M337<\S#;+5]C&KR>UZ[;#W<O;XZO3)OI?[,) U!E:5Q3>7&CD\\4R,, [SF!
M<L]"#YQ^>9@A.$S>/%"_'1<@SDWYX>)C>2?.;-;>R^7+.O]!EA!,]7(!0TE3
MB'@008R8@$DH18"#- E3I^1F;9V-C?@;6>O;@D981\YO0]:2KSWAU3?7-E!M
MY+P!5"U-UHG9;/&W<?%5!)M+_?Z#MXM";P%>^LY"88.67X)LZW!8<K-0_8"8
M;)YQCP:ZU50G#-V]F=&'":%I&B<HA21%'")-<I!PK,W/A"F11"I#=O7"#UH>
M'5TTP@$CG7T,T"Y<YP. .H/0-P?8Z>\4^7-4U\YA/[NM#1;S<U2)[8"?XU^X
M3B&'YCQT?5[ZV41OW\V7^71>3'FUUP@#3!&G 8R5_@<ED;8*,*<PRUC$,BY-
MZM-!7*(.0H^-+M;2@:^E<VRA+DU$,,C0]^PE[6E Q^\FO=_X16O5MX-S-B_+
M6,H1=QBH<3A)703_/KRD'8;"=QD)I[Z[!M?4A=:JPT8CYV)N]M2WWZ;%)!9A
M%F580!P@O2)1I2!.*(:ABH@0B*$(NV6(:.MM;$M)7?=\(R3XPXCIFEVL%6#;
M6 E/L/5,V,Z(=8AEL$#"<XA"6X\#1QY8*'\84&#S4-?+*9_IMSNA6YNJ*2_)
MK;FIHJ) X9C"4 3F=)\22(C D"4RY3&744:LMZ>M/8V.-*K+&N9N\ZZX'2^Q
MG +X_(;6&VQ]DT97Q#I<=CF#QH4W7TZU/O UF#-*'MZ).?= -\OBE63+30'B
MVZ]T.C.^L#>+_!.=R3(MWV?Y;?EB9NJ!JC0)LU2SA(RY-C0RRB"-L(1!Q%+,
MHRP3S.DTU:7SL5'(6EJH%CDLM+S@'<W_E%7$X*>.U<B=AL/.+.D+Y)X)QXB]
M!>,-. )XE8 4&/%!*;]'&Z8+;%Y-&B<!!K5PND"S;_!T:N/"XD>;LDJ%8U&O
MMB9&-&>VPLVV!.VEKI<-(OV4H#G6X77*R+2H?K(43-LS[N;]JSI-T!O=*IU5
MWH<W^K-B0BE.$A/S%(180!3A"-*0Z44;HSB+,I0H9'5VW=K+V-;D1E!02=HD
MNRAEM3?I3X-ZWISW E7?*VL7E)S,^+,H=#;A3[<\F/E^5KEMT_W\ESO&K90U
M%9IP"I713"ISS$RR$"(>AY!*$4(N!0OT9Y*CV"6=TD[K3I-\@&Q'I7?UHFHG
MN^#960"=(>EY,C=U3?R'DQQ3V&_\R$X/PP:,'%/N($+DZ)<Z.O!IF1_?7!LR
M56KOU>><S@MJ:B/-Z[J+G$09CO4DSH3>82-"*,1,<1CRU*S6*";,*3G]^2['
MMGP;B<O2%&5*]6YE,2V MO3F>X6O9Q9P1,[=H6\-AE^O_OENAW7M6\-PX-^W
M?W+@T)?F^J+>BY262E'6;/K\A<YWTPA(T1QO3@(1)TQP G&::J9*!(*,!1S*
M0&4,1U2D03"9RP>J'[+DJN&DMYJUI)JUVSKTN&M?)[!9Y$!^>YKF=2Z;,G]-
MX3N!C<<7P9))1S:XWTU83'U0NP4 J(K9+34$!SEM]//KH)D1Q,AT'[QQA,IT
MD/_[B)CI/C#> F<N$*';ZG@W_ZJ[6>3/[^5R$LN$!#A+82")WBTGL8(LR2+(
M$X85XS+&'+D8VMN-C\VD7LM6YJAW6TEV0*,!Y8HH##G'&K0@99#&1,$D""7+
MXI $D7!Q,70&;3 /P]07=':K9%= >E[&MEZ@]RTH.*\KQ]3U2OP['0S*S,=4
MVZ?.H]^Y3M#[K_J+RW7LXH0*G"4\,-EK8SW126)\B32 /*(JR$*>L6"8<E-'
MQ1L;OY:B:QNLE/(J9OOQ4>S9,K]X;,9O?*_-ZTK)[8#T]U6UEZW\>B.PMUN'
M9!PF]7$1OP^KN15>WQ'E)WJYN%ZV<3^]>'XYHT51E4)&(14\9BF4)F@<Z5^-
M54>T/<Q#%3-%"%(=*V#O]S4ZYMZNA5RZ334?E.)>7)_Z &9+-O8#7M_4VAVW
M2^I!GT*DKPK/!_U=JV;S*<5;JC"??*0;@=SG#W0^_<^2PUYJ=EK,IJ(BM+GX
MH%\M69>INE=OIG,ZYU,Z6X>SNP9:>>EK1+-E6Y\;L*-16:ME6Z?2IFBT ANU
M>HG?\@JTUTGH1[)!IZM7,/<GMM_&.Q2,O)OSYZ5\]^MM$$:?5D]/L^?;AUR6
M[;^3Y36'-$H$)E$ $Z+,!;0P@Y0%$8P2GJ$@PE0RJXHG=MV-S9*H! :5Q* 2
M&:QE=BA1>![H=A+U#U_OSJ4VY, ?E<"6AI@EA ZU';U".5!%QXXOHUOU1FM@
M6FLVGF]EN$J-UAKMU&>T?^I"VMU_B65&D@PS"0DVA,O"".)$8D@I8S*,TD3*
MI!/A?E=4>RG'7LBN8^?5HU+VP "7SOUQS'K7^>YGIA_<#ZB"#K5I]W9*F4FS
M.I7%.TG-A0%Q/_]H;LSDT_F#_D)9'+;^]04MIL7;Z5S>:;NOF(01D:%B&8S3
M"$.$&(684P:)BE"F](=QYN36\2K=V#AE<VGF!E3ZE3NS+0U!HR+0F[2UDN6W
MMM4$I9[@#Z,I*%5U="'Y?0GL-MQ7&]J>*? JH]K]%I5/]/NY=N5%PNO<T_()
M[LF+75X[N3!+S)8KX,.B*).E.OKA;)H:T6Q?B[OK0VLD[L6#Y@)1/[E.VCJ^
M3LH3"RA.9CZQ>?9*14!?FZ#<\B&[FHZF_&_"S.7+**,0I22#.$P1C%!(5*@H
M2J13A-G0"HS-1#M?!/3U5MCTU4N NKXNGH(UKO@2C""<P[H$Z!8,WV<)T([C
M.*X2H*Y*C"M*I*<A\EX"M*L<ET::K,,;Z]N3>XEK4I3I]XIE4"#CODSC"!(<
M,!@S(3(I6*JRK%O827O'8UO7MF,IUI)W#3LY@[EK#(H_) <,2-F*5J[%[C5'
MD"M:/06KG.G\2I$K=I"<#F.Q?+X;57V4A=0/?=';\5?RJYPMGLKDB]\,R<KZ
M.  K3K*(<A@G-($(!0IBF060DBA2 0E3)IR\J!9]CHV@&I%+K]B6T&X<90.V
M'3UYAK!G9CJ%'J@%/G_ [<Q(#@!Y)2.;?@?E(0<@]BG(Y5$W]BGRY>1#OA K
MOKS/Z[)&98+AE(>"4$2@BJ,4HI"'D'&F-/,D$F4LS&)JY3 XU<'8>*66L9P8
MM9A.:9M/ ME.(S[@Z9DS.B!C31+GU&]C!/WL%AOHW_:9X&3C@TS[<ZHU<_SL
M]SKN?%:LF(HIS9^W$CV4+Z3BB5(A$3 E3,]LF0E(LR2%"H<!B5,<1<)MJW.J
MI[%-\;V4)%URLI\$U7(OXP.JOC<O+BBY[T_.(>!W0W*RMV%W(.>4/MARG'V@
M&RF\?GR:+9YE4[_PN#/G_4)O<PKCCS%NFZ*\>KS]=U.4\_UB^7_DLJY\^)]2
M;%JJ'MJ_/3]),XJQQ S&)(GTSH7B*AXW",-0RD0$$7.JVGXU3<9&:M7-\)4Y
MOZTUV*F*JW\I'/=&UWM)[$CTNQCZ 8\?CI;17>N_SMSRC<]6PD2/5-K<5,5U
M-0;@6:Z+[&H4;L#MHRE#Z(_SKSY@7M>4ZVDSZ)IU]4';7Q.O+]#8TJ#MWLG=
M.T4I__B*+N4Z'&BBJ,C2- X@9S&'*(@I9)DR@0 D35"848GQ('D4?&LVMC5Y
M._5"[T?_@[T^GF("QOA2C"!8P$_BM</,$ =!!.57@($*;")21Y MHJ_Q'T>B
M">_:C2OZ8.A!'2[O6U<!QY YZ3RG"TJ#+*42AJ' $.D?(:49A@F)XU!&4812
M=KW42M_=PK^."J0UV3X8D:$P9*L,V1[4%GX8@ZDP3H/@_U_V6U,^?3<+^W^%
MY?N_]"(]DJ7X*@ON7G'3.A]_2 DFDF.8LLBD%@T#R!(:PBC*!(M213+IYJT^
MULO8%J_](KP=RQT<1]32M7LI3CTSNCM$[L[2-@C\.C*/]C2LD[%-V0,'8.N7
M?0;=;9'5R\6\O._S>:'Y2"WRQS>+O-PB%)]UC_7+K500JUC$,!0\@4B9>L5$
M,*AHBJ(P#564D<O#\ARE&AN]G P]VSFW:#0#RP6H=0/ZG\K9H>T@HU]'8O(S
MUI=$!?8X@M>*&^QA\#Q%&'8$>X 81%?)1A"EV!%,NSC&KHT/??6R_,?(8=*<
MZ>EARN;4K$"80JE(%$S2LFR]0I $::17@$QPA6*98J<5H \AQ[8@E))>0NB]
MC*0GIT;/X],SW;L,S8"W#<]C-Y(;A2V"CLLE< '4_FX&6O0UL#>]RJ%_5Q2K
MK=)23"H:$)) AD,,4<P49!$-(!*2TS!*$L:L,ISU(MW8R%VK]+B8@Z(,(GW2
MK7XIW9O#%R,X.I0]>ZXO':#Q^Z4K#4&EXJB*?+5A/PY?\E$)Q[4L= '7FQ^X
MM9,.62L_ZIW&?"6+-QJ'E^_NUUGRBNKB5'W;+XP#D2$J88HC!5'$,,1A$L,L
MC>) JBB)N-752OLNQT;99X1VR&AIAW@["?>#8^]NDE9YNZ0/ML/2(86P=TP'
M2B/<]?5TRR+JA$YK/E&[EH;++.JDV4Z.4;<GW1A:R.GDK1Z2V8<OB[E\OZJX
M6(HHP &%1*5"<W&60IKR /*,RI@FVMXF5L=OQQH?&^N6\H%20%!):$<.1X%K
MI]1+X>B9/!V0L)[3;2H?L08+R7]^6'S]13]6&H)_(?,CK'XLI_;1!@>9Q&VJ
M--.U]3O=]M!U$LDF5Z.D*$$HY) Q<]2%]:QD*4TA24,]9^,L2&.G/'*[S8]M
M<E;2N>U4]P"SVVIVAZ%O3V"5J+:/;)7'=?:Z1]OK8M!-UG'U]G=))[YUG>C1
M6R'*))=T]FI:\-G"9(K=O,DX)1&G)@\$UD@CK#0)\"B%:482(GF J11#QHJV
M2CLV)O$9"[A1'&QI;C-'K_#6].QJ\_TNC-_UYN$U&#SVTVIXQN&=LY+X^_#6
MN8#O.XK3KM/K+'-U@DF3O*W>-V&6Q5G**%19H*W: (608!'#1&89(XD(LF30
MI>U PE$N9V7FVK6@URLT?3B>PRPZ%XW2=[30;.EYXVUGWOL@C&HY.93RNUI"
M3H+L>]DXW=&%]2?>KHO09!%*DD!*B @BL/1ET+C,A(^3*):*"!H[<?U!%Z,C
MZW4IBNZ%@(X :4FR%\'3-TNZ(=.](,>!\OV4WWA[G;(VI]4\65KC\)O7L07_
M664+F0N33)/K'S\OS$?WJV6QI'.3+Z>U3@))LU %40"SK*QZ&*60$)-:3X19
MR'F:L2 :TG"\3)VQ$=?Y(AN5OF54NJPU-L'G)@?,**[47OAZ#6/'#O?2?$=&
M[]:;]7KKS3(?ZV]MH!E3F8Y!QGE4=O6%*GU71KB?X?-ML7N2JMOJ?S?GN=2"
MO9+5?^_FY661.CW_5MF["4VS1"18+]1(8HCT'@ 2S"(HC8='21E*$;@LU-8]
MCVU-K;(&S4UFR+H<Q6PCK-OB:(^^W3K6"Z8]+SF-S.#'1NJ?3#ALA7)3\..M
M!<+.JX$S6EZ)V[[W03G6&91].G1OP!=S-5???I\NO[Q<%<O%H\R;_IXG')$X
MHRB%.#0;#1ZDD"']3QAG/$UC*E687L9?K?V/C<5>225S4UTOKV+3+B6N=O"[
MTI<W2*]#8NOKO']K^4&CP,V:SD[7A?) 9E;8]4QI[3)<F=BL #I/;W;-7%I]
MK4Q@7EN,'_6>_,TB+R]][18$"U+,$XDBR*(@@PAE&%+.(QC% >()2=* \FY%
MV*SZ'QO);9<1J[+QUQH HP*H=>A:G,UN2"P]$/T!W;?+P KC@4JV.8'74^4V
M.QFN5,#-":#3==S<FNEPY>C]8OY1JM5<F!9_>](JS9=OI-X(Q2))<2@I% R;
M6T:<02R1@I&,5) J*M/ *K*]M9>Q\9B6$^9K0<&JDA0\5<X$A[LP)V%M9REO
M8/7,1:=$]'2UY1P"K;=93CX\W 66<_+OW%DY^^5Q)W.?"$$D)TD"$\7,?D_%
MD&8D@$SP)$TIT_\-QYBK?6S<LYV*?=C@)-<1[_FLI\=Q'/^I3L?LZ2,XNNDX
M;.,XI'$5_OLXCNDX)-=*67[E  O+@R!CAJO*#)]$+)5!@F*HPB2%* A,B9*4
M0BFUA9P&G$?$S0TPN IC6P7/!5(,&Q31X948)A"BWX$>_S*Y7@A=XAM&>>&D
M^TB.8^7LKL;WL89>/$R^PQ@ND*3K : )4BO7[PG6.SL4AP%4,DX@(E)!@O5/
M3*$HXHR%"CL&)ZS;'MM*]([F?\IEZ0<J)%_EG<(.-LC9GLQUPJ/W4[>U5#X/
MT@Y4]7Q(MFE_X .P \4.#[<.OW)UH[>^D92Q)*6"I="D@H5(I0S2@,10,,;C
M(%:*Q$Y3W+N$8R.*YAAFL1'T>C?,#L>3!T' D9204ZDI6P@&<9!I!L\HDD3$
M..+)Y*G<@'U:TGSY'8SJOK0]FZK[9N8+^3"=S\TPOZ#ZV_R*%PH/AUL&"&,D
M,TB5_@>)"$'"4:(7[#00/&*2)KP>[M=S\=T,=B/KP$/]NIK.(QSGP?>9_Z4O
MCNX,^M@NCIX<A+'N +_'BZ,G0>YQ_^8G[=57.IV9;<J;1?Z)SN2G]6;EE63+
MS6\3C$C((IS T*P'B$>97AD""5.)91"EJ10LGNB=)%M8I\2R[-J%-+8%Z)$[
M.N[HK,&.E-!65VPBPHA>AIF2D 1ZMYPBQ%,6*(K=4A#U ?40QK%%?;_+@+9;
M!_N K^?ES0@&-I+=@+4.4"UR6&@M/&8X<\3';^XSV\Z'S8KF",E!OC37Y[O6
M!5O2Z5R*US0W6Y(ZT^F$(DX0"C,8F"*Y9?9#&L8<DC@),Z*"3$GJ5NCK6#=C
M8YM;SE>/JQDU9P"OI)KRJ670UADT[4CF<HQZII1&0-!(>#[-<X<25VT@>*Y9
M=;2K@8M0M:E[6%6J]=MN#%#D2]U@4[%BG>OXY6(UUW/MB>;+YZUJ02EA,B$R
M@$0D)F(]HI!H0P3&6#+$DR0.T\R&$)QZ'1L_;$L)C)B.]9S<(&]GC=Z [)E$
M.F!H32*=,&GC%-W@%I_HW_:YQ*W'0:BE$P@-TW1[V-?-P ^Y?*)3T=QY,Q>M
MYX4IEE0&_E099">"D3 **8$H$:S:&NFM:0Q5&FH+A2O)53B9RP>SBMN>(G81
MQ&I.D6I.;8O3W]2JI2X3A&AQBS*GPZ(,_VNN0-,.>9X[CI/MB65OV%_U2F$S
M%K7XY5!4D9AG4FU[N%'H@F#/%PNM1+GR_4(7N,Y?,W1JK1MQFI)CT^KX5[=K
M[C5J8U#.N=D;KG.0;FZV284"DN (DL 4_#&)/W&422A1*D(:2Z&$4^HFM^['
M9\.MI2\GY8[\;L3H. YVA-@?NKT;=BW ;B5N!G_T<KFP&VY>Z<]1A$%IKQL\
M^W37L94+8E/8^9,2MG]2\J$V7\M MGM556@LKT)^D/IEGR\G)!-([UA#B!.9
M0D1E!)ED,8Q1%L6,I#21[D$JO8@Z-OIL! 9/94CL0@&^4P"SDMI\KI<[H(S[
M_K&,A -?W;WX/;X!#N??5Q_7\1^$K]^*#\U;49=%+56^ ;72GL_$>QT8_X?C
M_8@[_"EYK[ ?/2[OM\=NJY,YF2P/)N_F3ZME\59^E;.H]O=+&:6I2",8!Z'0
MRPM)(=4+#@QCA!7E#*/0:7EIZ6MLZT,I&XC<>+X-2SNB]H10STR[.<V^ 96@
M-Z &K(>C% M,O))<6W^#LI2%XOLT8_-(U\UZ2]JA]UJARC,W21D)".4I#*6D
M$&D#%%(>,\@8(1R'B*C8*>^99;]CXX_]?&<W8"Y+<[+Q8#XM<K,"N.[4[0;!
M=HON'=K>]^9G$IS=@(W</O?D3D!YWHS;]3WP+MP)D,/MM]OC'1+Z?,@77$I1
M&-FWLP<UE\/*!+B?/GQHS*MB$O&0ICB)H A-22&NM+$34@Y#H2DMRG@:*6H7
M%]A-@/%%!S8J *-#O3%>E%H 66MAZ6GL."3M--8_S#VSF;/LGO(*=<:L->&0
M>ZO#92+JK/%.BJ+NK70@L/]%YT4AYR^FBZ7D7^[FO-Y'$(43G*4QY(G)BQV'
M%%+*.$19C&FDDH $5M5PVCH9FS%5BPEJ.?6>@SOPSBDD+=C% SX]<\@1:,YO
MP>PQ$@M>IBPIO16]8[73VSA>)S=F/8-!*W^>>G8XECPC_0X7GONNGTL<NR'"
MMX]FS_2?QH56+%_08EI,>"83$K,(,A/:BZ@)[16F5%@0:E;4 &<\F2P72SJS
MVVVZ"N#$E&LQ^GNUUQ("(^)E=PW.@F^WR^P3TI[)U>+N@?[,#O*+[R+8XM;K
MG82S0ESU;H(M1.?N*%BWT\&NTU3YO)3O?KT-PF@3EZB_/>5T=LN7TZ]EI_7Z
MB^),QFF6Z*THIQ"%1$",DP"&/,,)T3M6E=A;>TY=C\T&K(0'E?1@+3Z H-$
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M2GNPI3XH]0=+#0"H$2AKN548Z!]7?M).7VW@_-?A'43ZX<OR#CDH1ZOT#BI
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MZ0U8R^J3-2P@\<P;;3T.S!P6RA]RA\U#GC<\$\J(E(&@,!:Q,#7%%22120;
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MZ1O1>@EW/Z6WU^E]T,F@D_J4BOM3^>3WW"9PD2\G[Z;SZ>/JL?:#*AEA3(2
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MJ#=@7IUX+^DW\/=&7H=IW0:OQ=3V!%K/TWN#EXD0N"\C!,#OWO%R.$CSA-M
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M%@#IG2]@(I,@U\P)4TRHB+%M>G3/.%,CPUK4J)4UJH6-&FGMLZ3[H.VG,X^
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MB<.85H>#W+0)\5D#Z-QU VT:5F4^F!R'-J"W2Q;OS5'7LF2\RHW$N8(9RA(
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M%*)#CAQ\'T_I.WK(1[G>O)A V8U);-:?/II+9ADN4H90 2!,-/=E6.^$F6"
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M3C]^6O\BF!"W_W;YCSQFZWE$T%QK4"PJB#XPB"EA<C&I9,M___B/GJ48K1:
M'"4HPSP$APYBQ%**B-K1W]4/G4WG?_O'^D<,*_R%F)NO-M_^\Y\^K=>?__'7
M7__XXX\_?XW+V9\7RX^_"L;DKY>__:>+7_]ZY_?_D)O?YM[[7S=_>_6KJ^E]
MOT@?RW_]/[^]>I\^X6F Z7RU#O-4%UA-_W&U^>&K10KKC<Q_2-<O6W^C?@>7
MOP;U1\ %2/[GKZO\IW_YAU]^.1?'<C'#=UA^J?_]_=W+JR5/0UHN/N)\FE9_
M3HO37^O?__IT06AX&SY6:C?_>OWM,_[SGU;3T\^SJY]]6F+YYS^=?IQ_A:I6
M)L_7_&_?__&OWY?_O,05(6;#[BOZP<5GU-7V(@6_KG&>\9S#RT5FBW3CEV95
MOHOEY;^<A8BSS4\G&:>3S2>?Q-5Z&=)ZHA)/UAL.* 4#A5E#\$D"PZ)<\D&;
M<(OS2O6*R-ZH8X7ISQ\77WZE#R:U"/X?JGX)YU]NQ')GR7/Q[$?[Y0[\0+\[
MB4F[5)2$E 2""C*##]Z!*#F'G+36I1Q,^O45;U)^7;4GR_3+8IEQ26;D<LFP
M3#?4?!?"%[_QZ^>PI ^"]&DZRY?_NMJ3/G2V7O0@O7/5$+E_^H6X+KA<8GYU
MKIFMS&TX6Y-QQ<UO]J'U_WT6EO2)LV_O\/-BN9Y(CPFS+\"9-V08C8 0E0:O
MF4S>Y929ZPT MQ;OA 71/A8.D6DCL'B+R^DB/Y_G9W0H3XP4,7EM0;BL0#FO
M(6:C2#ZZ"(76ZYQZ \6-I3M!0K8/B?WEV0@@/BS#?#6M@K\ M8ZZ2)\R(.I(
MCI9EX)Q24(J*SF:7=%3]G12W5N\$"]4^+ Z2ZLC(>#Y?3]??7DQG^/KL-.)R
M(C01'6* '&("E46&B!A)I]ZKY(6741^,B-NK=D*";A<)!TFQ"02\PX_3*H3Y
M^G4XQ4E0QAO&#;#".2&X!E6.3CR5DK0DHARE[ D%-U?NA 33.A(.D&83:'A)
MP?Z23-E&\.])_OAT<39?+[\]762<>*:Y3YJ$$74%-T67T>M"8;>2HO 8@S<]
M@>-!0CIAQ;:.E?YDW01T/H2O+S.);UJFYW<9%Q:1&;1&Z$R.DJ(]4"Q"X(*#
M-\28L,+Q>'@X_2 )G>#B6H=+'_)M B@G.9,*5A?_>36=(Y]H:S+7D8,KGARG
M: -X0CEHQADRC]K+W!-([EF^$T!\ZP Y5*XM@>,I??EF^6'QQWP2*YE)&Q"&
M(RCM7;WK)9]:>B5<X$ZFGJ'Q??%NUUOLD2!C3Z&VA(O-,?EF^7:Y^#*=)YPD
M5@T<&E 5U2IF"5$J <84J9&1T)SH%QRW*.B&D(9O0'L3;TLP>;M8K</L_TX_
M;URIG+707'E@H@3B@LY*QZT'%8PVR)%KWU=D>]_ZW2#2\,5H3Z(=&2#5^ITL
M,6SH)E!++9T B9GLGW$%@LP)BM N.FZ838<_E%Q?L1L(&KX*W5M\(ZN]OJS.
MWGY:S"]O:*0F7X@G TD8!8I'04>?4,!\"5QIY\DQ.ECUMU?MIOZ&KSP/$N/(
M$'B/Z6Q)\.4B?IBN9S@)(I@H4@8># DAA@@NDS-DDPI::2PB\X,A<'O5;A!H
M^*[S(#&.#($/RU!S6-Y_.XV+V025T-K)>B-7)>!-@6@T146ZA&05"P4/U_^-
M);LIO^'KS?T%V,CF?_XU?0KSC[BYEY6)!Q120V&Y@+)90*PQ4 R\<.XT>2Z^
M-P-P?>5N.&CXZO)@<381)CP]6U9QG;_:55B3#LY6DR1J3*,M>30$9F490A1&
M0,DD$ J,DW:AIT#A?@JZP:/YJ\H>Q-L$3%[.Z=-('-,O^"RLPP5;DVB-1Q49
MF.")#V\%>%L??8O-7C)98CC<@WR(@FXP:?["L@?Q-@&3^OR[?!K6^'&Q_#;1
M7#,6K /GJF,< Y'O>(;DE%16NYS-X:'E/0MW2[]J_JYR?V$V@87WIV$V>W*V
MFLYQM9H0OY9+9< '5N_/? &?A(=@(^8<M?&BKP?3&PMWPT+SMY+["[,)+#P_
MQ>5'.O[^LES\L?[T=''Z.<R_3;R/S%21\)(T*&4Y.&,"))L24ORDBNCK-O)>
M KIAH_GKR,.%VP1&WG_"V>R2>L>D3%)$"-(3]1(%240RT!Z-<%%S%_J"QO5U
MNR&BX;O) T79!!"(\-.:!K)(?WO_B>2V>G.VKG4B->J>>(&.H^(@)9V BA$W
M4?$ Q0J&AN?D,?85F#Q 1S>@-'R+V;.H1P;.R2G.<\U#?3$+'R<R9Q<L]V!0
M.3H>HZE9R0R8<R4K6P33A^?9W%BR&QP:OM'<7X"-I'6_F*Y2F/T[AN4+^LEJ
MPG41P0</66@2A$X!0O22L*Q2\"5YG0^_P-BR>#<T-'S%V8=0F\+%>=7".1.*
M4_"<&8';D#R414:.D3/U%L;*Z*W4MK\:D#O+=\-&P]>>_0BV#4>#V%B&V<MY
MQJ__"[]-E,^H&0532H@ RJ0(T1H+)"4F0\PVYMY\BYM+=T-%^[>=!PAT[)R(
M\RNW[Q;OLL2I**^#T06TB!1KZX+@(GG3(@ANHQ.<'.K#\R.VK-X-%PU?;_8B
MUMZ@\4^_WI'C*_K!O@7A;UZ_?_/JY;.3#\^?/3EY=?+ZZ?/W__K\^8?W-^GN
M6""^]<-Z*1CO1NJ!!>1G*_@8PN?))G>NGA%ORHOI/,S3E Z*Q7EYV!6B2B O
M,G@&)=)!H;BD )6'".1%*()$9M8_5'97PBINM'VQZ&9S_8JS]>KR)YL]!HQ?
ME/W_MUVHV]>27*YQLEKA>G7%:TY1\$ G8V0RT^Z1!2BR$K1[O$]8A'+JH5KD
M_7F]2<<X)>J#H>+2SO0@]!$/GYO47]C+*R:\1!.1+"0GSPI4D1)B(-\[E2PY
M,S&[^% 8<RAR;I$S+H .T>^]4#E$V T@YFE8?3J9Y_J?Y_]Q-OT29L3,ZF3]
M-"R7WZ;SC_\69F<X89K.5N<4Q6R68GE+7X5$/IBIK/D0HG0/)7CLCZ!.Y+6
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M7>/KMDNHE!4!44+1H7KZ/D$P11(G06MNHD3V4/)$+Y!KZKEB& QL!]HA"FD
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MAX,>>OIF9MQ8<B@8CZST)F[\W^$Z3.>8GX?EG +IU36A/,,R3=/UA)EDN*=
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MD:/QF39MO2,KTI,22@"3/!HK9# XT C!H_(Y;N TF$_:,%@>^U::Q"145M8
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M>;2(VU??=YW)PX7?)(B>TJ].4YB=T*GTY?JDYZ@I3/.T-[$.&R<7R4/4SD%
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MK=0KC^E-'QD!CQGSE^G2F[]=G9RM/RV6F\;]B1G+E<S@9,U3+%Y!4)F!(</
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MOA*\WSVXW8WQ\,5'QT%.]8$=184%HF"W(JJ@<C9:6=JK<=UQCDH7F6:N2!W
M8YD?*J.0YIB-N/797EU??R!\M=E9C,Q!O):A@'*Q@O'907(DH3@*I*U"*??J
M:O1\#OUC8LP[U6@$:LP"B"6S89>\]O.'F^LV>9'/T-O89A64% Y]!2R6S8&A
M #GK!+8&DLJE&LM@(>ZW1)EWQ-)263$),,Z+&?]-Z[?O;@A??*2K])9>_KM5
MRN^.U!6O/<J2$Q JCOP%1C88Q@&?J2ZUE.2<^]08/I. \TZ,.A\630:BN</O
M!R[D7])OZYMT<7N0_GV]:?<-KS;EJG6/>[6Y_?9K!LS51\(?+Z]^_'#SX8K:
M@9LV+#2YXI-NK86PW3E4%CI[Y4%YHA2I.%GW>]B>:D7S3JJ:,P"?94_G!O(N
M &(R?KK0O4VX2YO?KQ\HY &'6=XG5/%)"=O^%K<AUD7:K+)-2<AL ;$-:"WH
MVJA6/C>-CL%&XVK8KPO.\ZQWWL%8<Y)@0#R,X$=-7=NX?<A$,A9-]J"=:+TZ
MM(;HL8",KA3C$(/Q?;RF'N(LNL!OFH3AN< Q $/8!%R^IU]XP[<6ZF\[$6^S
M'-%ZMC@& F8^#Q$KY$0%<J@"3:W*^#[1]!.+&B6U>#;(7/;9OW&AN$N$DJR2
M)%L=.=7*7[*#6*( )56F'&R(G<JIGUS6O'"<;//W ]41.S$ K)I3PPMX]V*#
MNZ:!3:9=+=<N'TZZX#R:UC1&MK<W%)"T2PR%HAQI]KU*GP+//18W),2.@<)7
MK<^FW9<!H/97VM!5NF")7N![CCZ;D]*R+S\7"D.AC+ZY*X':F#.$Q%QE1SH;
M9V+R\LODDXG MM?RYG4'^\%M^KT9 '#3>"'WX:<5K,,H(XC2IB4(FR!522!E
M5%8A&G)]7A0G%F24E-E1O,0Y<3( 37:2$3XN^,X$K#)K4C<QV BT!&51(+;Y
MO$JE$E$JZT0?%W._]<WK",P*H<ON^[FH7@RW#S3M]66]>?N@Y=#D;1B^]T']
M.C <).(8S1>T8/_ F_9RX"P87P-$C1)<0%\2!6=R'_-Q+LT74#M?;0FL,1W;
M:*@(.;;>*;5(=LQ\$E^^J?W9?&$F_/9KOG ("$88N;2];'&&D97:5(%<)1@5
M.&P0!4'Z8'+69--^[=0[#.Q:0)N%@[;\T3E=A^A_!-!\BC9S06U, *&\!V.\
M;&T$,BAV[DE7'Y6;;D+W8'.Z#MJR;\SI.D1_<\_INDU&^#3#%T--TA!D(6R;
MM]DF3)D,PBEG=31%R>D&M'WVT6/,Z3IHXRZGT.+<V__Y@#%!%9UGQ+?;*Q.Q
M38PH%0*B$-77PL'/=-M_\)BVR2]&)MO^H[4XP"7$%-DA'J6K(@+'QMO!=&P]
M=216HU6Q2"%<IS;F?Q:QG^*KS(2 )6/^Q[2^VLY;>A#ZMVN=UH/SA_7'-7*\
M_YJ#FI7$C)E,@A(4GP%L.2 ZBI!2]A1DE3EVK!7K*=KRB]P/P>I45.D"G'-E
MTJ^7%_S/7*QO?M^J)$>AA,T*K!3;.NH(0296B?+H1<U6VDYMCOL+M_P:^]'8
M= )XSHU/K]?7__KQBNA5&WA/US=;A3C%+FEK\^]DR:P00HC$/J^NJ*MQ26"Q
MX[/I,=&67^L_"I=.!LXH3#JFNOLIX_*&KM[+E3,II]KF'+>B5I-JANB]A9JQ
M"A>\##'UHU 7F9;?".!4[LP/E5%(<U08^O.=].NK[5^Z_E3^_6217K+*V593
MPGL4P+ ^V-U5 7@OC=+9&!_[S'5_;DF7WTZ@Y^$T)ZP6E6+Q8$C.ITD??89<
M//X9G4=;["'8&#D5&**O@7F 0OC6N=9!5I7X5Z92M$DFT\=LS9Q3,5WI]H,)
M3RL7*IJ@-&!J2;0U,%M))(BJ5I$2"JEG.@2.DF?1V1:'(+MC9?^Q\%B"#W5P
MEY!2=!*V5%"!-!BI-02+?+C5XD76VB;79WS./.UCQKL\GA"?W5O*' *6H]GR
MV]8%^^4F7=T,P9F_\A^\N7,-5RROM(+8=$FD-O=;0W:AU82+[$@2E3@F83Z7
M8Z&7P^.RY028C'"P;%OG;UNK_?#AOD/G;8^$A],S/\5"N$+A@R[& D;G6V62
M85FI@%39238+P>V7T7$X$0Y>ZT)O;SN"O>]V'P[H> OH#;UMCN00=I_U7&G=
MNN7<L]JYJ@HF#9K:$"3-L7^J/D'QR$>?1\L:&=+X/R+,0J]EQST!3@7,6;#F
MD=NTE3(R%4+3CL$(IO4N"45D<*8F$[23L=<LX>F%6>A=Z[BL.14PI[+FS<#!
M>26J_'\!,BUIU&7>ET "JC58V9:X0)VZ+LT2G(_7VW5<VIP&EA.#\Y>;40Z;
MK7?:LE1W2HA5V43)0T[5M"E?"%%;T<:E"U&$-<H,-O/J6Z(LM(_KN(PY#2PC
MQ.@G*N!7NFYOFAN\2R.X;-_ZVI(DD7E7= &TD2U)895$[1VD;#)1]#88-22)
M]I5PH8UCQ^56%VB= >7V["?=MK'NMM&X0B86"T3,$>-4@NS9]T5GA*K1N*#[
M3)Y^?ED7W89SD,?,'K#ZXQ!O):WR.OD$U22.-)$M9PH<>-:L,2:K>8/'/.JF
MG :PA$?1+CB?:7K (:!;SC/J]_+L/G\@>U)!,55R5GL@C^&VBU'0@2-;3S%[
M+Q/9F>H(IA/R;!Y@AV#F3.!;PDGY_?S76^GWTXXQWNDD'=3@V-DQ-4/@P )D
M>]36;>!0F:D>>U(YS^;%>!'L[ ?!<R#H(^^*3^HGHY?&4 99164#1I6WTDI0
M6$+Q/J/P@YZ>!TIZ-B_8BR!I3QB> TT/K2.)(:KJI 0;!?L9TK6K.A.A:$DA
M"$%5S!1Z_EF>M&":]H3A$F@Z48SNJT\9-;O]B3P870PD-!I01K+HJW#Y_"^&
MEO @/P0I9P#=^3WA/ZF:4JD&[350\0*,,@)29O8D9RF32]+:CG7Q_04\F^?^
M)?"Q!^C.X&S\_BONTW&YKUF*'*%:D5I[TP2A! /%",PZ%5?DF-EJI\E]-LD$
M2V#N,T+T# C] G'=?I$N[A^[[U^PI94F1Q]X'^TV0!<0#=NY5(-P9$BBZC/K
ML*M8\][<+CBI8#JPC,*<_'UEY(/-XFMJ<[GX^W^YW&Q5\R%=M'X\:A42:J=3
M!,7_@3'20/12@Q0IZEQ0H.^8N?.\PBX[KV!"J$_5[NF9<'<&U/RV\_XM%<E5
M=3XH]EMX([7EP-HA)+($22EGO=$RIHZNZ?,*N^S$@G&IV1MW9T#-@[WS;VM.
M5/9V2@X@<O.$E),0C'"@G62-:F]#ZEC(,80.EIV#,"Z19T+I*/R>YK+@%6MB
MO;E>EVV/RE4QID1A%,@BV ?1L4"0D?D5;.L7X*O%X=ML?2[2LI,+.K-O=@R-
M0J9I_(G/%2%7Q8>D!+L-UF#SZ'T;&24B9.EEC59B31W;3'21:=E) .,>9A.A
M:!0^=;T:?O'V[=6VZ/\KPY.$HI(@1S[ #7D/P4<+U5/%*+Q2:<RWQ:-%7O;K
M_[B'V_-@\ S(^F0^_O:'/[".[GJ@KW123NB0P+:&Y[RIR+;,6-#*J(C"8K*#
MS3PZ3M!YO<X%OU[T!-09\.VK#/LWES?IX@L;Y*I$D1(;36T+&!F(?840($5B
MU]R@SG;HYAE/2C>O [I@9DT.G0'H](^KRT*$US_R1CW>[E"S?KV3&G*1",:6
M DF5# F3#A@CU=KG,>^[2YO7=YL1R--NV@ HG.8B\Q,M[\XVN4HJFZC;=-G6
M<-"TD=.QM ZT,<OJLY71C_G<]2V)YLV.G-MXSPV1 :CR\OUO%Y>_$_U"5Q_7
MA1X_TWZZW'R\#<":!JZWY]3#G[>-^NGRYG_HYC65R[>;]?^QS7 I:2G007""
M3ZX06J_!VN8J*\W;YKR/?;*@NHDT;T+BC&09 R3GS):=&;F\VGVK_3FYDM79
MF(4 M+I-[\,$T23-RFKSD 3CO_3QE9Y7SKUX%?_DU7/":>0!6U\=VZ]9/U?K
M=BVX_?D_6>"I!FT=\UF3#=PZ6= Q!F\%6]O(Q H^M/>27!7'$=4#*H\U2TU&
M41<S-O/@K?*.\,,%?_;QM:=OVOO3RDKGHLH5E-,1C#;;MZ8 &$E4:8JMH=.S
MY50B+'J\UB'X_2K.F 4$ [A*MROG/_SBW^OKE4#9$O,*"&H%7Y6_9*H.L A>
M.9(B[!,,?+:,F9.KYX'"Y53[,@"HCE?<O=@;_,=%VOR4WM,/ERW];*6+-5*S
M!Y>2,^P6,=%3T J(A*),-D0:;9SMMZ69%^(G@&NR=@T3[?0 :'_$V[M^_<L_
M_T[;CK]&::D-JU,HZ_A4TH+%(@'""'****'H,R;JR64-7K_2'367O;9P #P>
M_>#UM[N!U%JSD,EED%A:+VV,$+Q3($0A_ETV?**-]1)ZM_:9RS^&<!Z>&0%+
MQOS+__W 4?FK#?/_PW97?KYY1U=OWJ7-[@7A[E[G8:_Y:LAYS!I$,!*,51F"
M"Y7/S91U5+Q;U"=4?EXY!S\E)D;Q5"3J#ZD_!N$^#=UU*NFB%%23"8S3 4+B
MW8Q2)Q&PZ"!F:N<XE8@+I=DSX/SY*7D$Z);3HOQH]7PQW%=4:QQ)WC3V?L&P
M1B!'52%8G7,F[U.8J0GR1!(NM(;XG!AY N3.^GC<M:&]3VI9:8_!R>"!4BQL
MJZQBK4@+I:#%&K03Q2R,C5\)N=!:X',BY&G 6_9PW\/]A^K)*0S@,096C2B0
MO-" @62TOJ2*@Z62=W%:QZL//B=&G@*ZI;=/W5\YWZV%>;C1WEOKD]>06P<A
MXWV&9-FXU51]%,FRO1NLSJJ/(A;J "_FYJ<;*,_:]]U??:L0(JJ<#>CBV3?1
M64"@(D!YZRTFR;9RL;=&TU11+OE"J1]]!C0%!V'Y#W<9]7WU%31*Z-;](5$$
MDPU!J(YUB":(6,DE/UA[@ZE5L-#3_ ]E#WJB^JR=@@=SF;ZO-4^E5(D>,H;,
M@9Q&R#);CI,T)N5L\&:F)+)GD?_LK]'.P!!TP_-96X$#W*DDI35MXI-HW:!,
MS1*"- H4>D0GDY5NL7=S@S=8&4$#XUN 3EA>^I7?]DLKZ%YOWMYZ27)5C;!8
MC&NO#]A&B2N(/GNP010=B((R@_GVCTBQT%-YYLNV4^$PXW'8BAB/%_SVMG^7
M87K]F@JM/U*K(GV9RKM?[VM05\)II:2LD*@9!^)@(083P1=R.B@964O?JZY\
MGJ4N]%0ZC0$#HF  %[%;L?7]OW3[E[X\=5<H2_ Z65#>)S"!+4@JU@#[U]IF
M[PQUJG^=3>2%-J6=YN!9!M#.F9&/MS_P*@N;LX-0I0>36#&1CW4@Y2J54*T7
M?<*S ;MIC->"=G#NG0ZI03MJL.#OUS?;<#%ML UB8+>7-F5-1S7->.J?FZ(O
MQM[+G:CUQ8//>_'%Y]UW%;CK%%!*4KX4"U&W[&[;7"(&+&!"4RE@KKE/F?M!
MRSS5;N_U86]X _Z+_]:_5H%J*%8'<+9J)HD1$%DK4/B $M4RU['/Q._#UCGO
MVW8_G'UI(CON7G\3M_M!^Y+9K/_G?_P_4$L! A0#%     @ BX"C5)5(;W*-
M4   +1," !X              ( !     &5X,3 Q<W!I='IN86=E;&5M<&QO
M>6UE;G1A+FAT;5!+ 0(4 Q0    ( (N HU1P#XCS/ <  %<C   5
M      "  <E0  !E>&AI8FET,S$M,7$Q,C R,BYH=&U02P$"% ,4    " "+
M@*-4+HA!GS<'  !9(P  %0              @ $X6   97AH:6)I=#,Q+3)Q
M,3(P,C(N:'1M4$L! A0#%     @ BX"C5,9-)AGM P  B0\  !4
M     ( !HE\  &5X:&EB:70S,BTQ<3$R,#(R+FAT;5!+ 0(4 Q0    ( (N
MHU3PLL9_W0,  .0.   5              "  <)C  !E>&AI8FET,S(M,G$Q
M,C R,BYH=&U02P$"% ,4    " "+@*-4[C,G9K-# 0"I 0T $0
M    @ '29P  ;6=N>"TR,#(R,#,S,2YH=&U02P$"% ,4    " "+@*-4;N+Y
MM?<,  #Y>@  $0              @ &TJP$ ;6=N>"TR,#(R,#,S,2YX<V10
M2P$"% ,4    " "+@*-4!D2Z'Y,1  #:G0  %0              @ ':N $
M;6=N>"TR,#(R,#,S,5]C86PN>&UL4$L! A0#%     @ BX"C5+LKG7^+/
M:;8" !4              ( !H,H! &UG;G@M,C R,C S,S%?9&5F+GAM;%!+
M 0(4 Q0    ( (N HU29B@BR;9$  -=B!@ 5              "  5X' @!M
M9VYX+3(P,C(P,S,Q7VQA8BYX;6Q02P$"% ,4    " "+@*-4ZA4J>/M>  "$
M?P0 %0              @ '^F ( ;6=N>"TR,#(R,#,S,5]P<F4N>&UL4$L%
3!@     +  L X@(  "SX @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
